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Preface to ”Stem Cell Research on Cardiology”
At present, stem cell research in cardiology ranges from fundamental research over translational
preclinical experiments up to promising clinical trials, to investigate a putative new medicinal
product. The aim of all these efforts is to improve treatment opportunities for cardiac patients and to
prevent severe disease courses.
In this context, new technologies are constantly emerging, and offer new impressive possibilities
to analyze data and to generate testing capacities suitable for clinical application.
This Special Issue of Cells comprises highly relevant original articles and brief communications,
as well as informative reviews analyzing the current situation of cardiac stem cell research.
Here, also new elementary aspects of several myocardial diseases and cardiac remodeling, with
respect to physiological and pathological events, e.g. arrhythmia and inflammation, are lit up.
Furthermore, programming approaches, maturation strategies and the characterization of cardiac
cells for translational research are addressed, and the reader will be informed about prospective
approaches in 3D cell aggregate application in the field.
We expect this collection of articles to provide valuable input for future research and further
discussions in the wide field of cardiac regenerative medicine.







Stem Cells in Cardiovascular Medicine: Historical
Overview and Future Prospects
Mostafa Samak 1,2 and Rabea Hinkel 1,2,*
1 Department of Laboratory Animal Science, Leibnitz-Institut für Primatenforschung, Deutsches
Primatenzentrum GmbH, Kellnerweg 4, 37077 Göttingen, Germany; MSamak@dpz.eu
2 DZHK (German Centre for Cardiovascular Research), Partner Site Göttingen, 37075 Göttingen, Germany
* Correspondence: rhinkel@dpz.eu
Received: 22 October 2019; Accepted: 23 November 2019; Published: 27 November 2019
Abstract: Cardiovascular diseases remain the leading cause of death in the developed world,
accounting for more than 30% of all deaths. In a large proportion of these patients, acute myocardial
infarction is usually the first manifestation, which might further progress to heart failure. In addition,
the human heart displays a low regenerative capacity, leading to a loss of cardiomyocytes and
persistent tissue scaring, which entails a morbid pathologic sequela. Novel therapeutic approaches
are urgently needed. Stem cells, such as induced pluripotent stem cells or embryonic stem cells,
exhibit great potential for cell-replacement therapy and an excellent tool for disease modeling, as well
as pharmaceutical screening of novel drugs and their cardiac side effects. This review article covers
not only the origin of stem cells but tries to summarize their translational potential, as well as potential
risks and clinical translation.
Keywords: iPSC; PSC; ESC; cardiovascular disease; regeneration
1. Introduction
Cardiovascular diseases (CVDs) remain a plight to modern-day humans, accounting for over
one-third of all deaths worldwide, according to recent World Health Organization (WHO) estimates [1].
In the US alone, one person dies of CVD-related complications every 40 s, mostly ischemic attacks [2].
To this day, catheter-based or surgical interventions, e.g., coronary bypass and implantation of assist devices,
are by far the most widely applied clinical measures—albeit with several complications [3,4]. Despite great
improvements, most surgical interventions available are mere preservatives, i.e., attempts to sustain
the functionally intact heart tissue for as long as possible without structural compensation. Howbeit,
due to the progressive nature of CVDs, heart failure (HF) is, in most cases, inevitable [5]. Regardless of
etiology and severity, many end-stage HF patients will eventually need cardiac transplantation [6].
With very few treatment options, not to mention the paucity of available donor hearts, the need for
alternative therapeutic measures is indispensable.
In recent decades, stem cell (SC) technologies have emerged with a great promise that could be
envisaged for almost all human ailments, most importantly for noncommunicable diseases characterized
by organ dysfunction and/or degeneration. In this regard, CVDs are certainly the most attractive target
for SC-based therapeutic approaches [7–10]. From a mere improvement of cardiac microenvironment,
to partial regeneration and/or compensation of lost functional tissue, and ending with a complete
fabrication of a surrogate heart, SCs have set the hopes high. Moreover, SC-based technologies have
enabled great in-depth understanding of the pathogenesis of CVD entities and served as a platform to
test novel therapeutic approaches at minimal risk of adverse events to patients and much lower costs.
This article aims at reviewing the available knowledge on SCs and their applications for cardiovascular
research, highlighting milestone achievements in both basic and translational research, and expanding
in particular on pluripotent SCs.
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2. Adult Stem Cells
The body’s regenerative capacity is a well-ingrained piece of knowledge from ancient times.
Modern science attributes this phenomenon to the presence of resident SC niches in different organs
and tissue, i.e., adult SCs. These cells are undifferentiated, but they are capable of self-renewal and
differentiation to one or more cell type, which sets them apart on a potency spectrum, e.g., multipotent
SCs. Adult SCs’ regenerative potential becomes even more conspicuous in organs and/or tissues with
high turnover rates, but, more importantly, as a response to tissue injury. A wealth of knowledge is
now available on different adult SC populations, and efforts have been made to reap the benefits of
these cells to treat CVDs. We highlight below a few examples of adult SCs, which declared themselves
as powerful research targets for cardiovascular medicine and made their way to the clinic.
2.1. Skeletal Myoblasts
Intuitively, due to embryonic and morphologic commonalities between skeletal and cardiac muscle
tissues, skeletal myoblasts have been among the early attractive research targets for cardiac regeneration.
Skeletal myoblasts (SM) constitute a group of satellite cell-derivatives residing within skeletal muscle
fibers, which are activated upon injurious insults to migrate, proliferate, and differentiate, forming new
muscle fibers, i.e., myogenesis [11]. Facilitated by their being readily accessible from autologous muscle
biopsies, rapid in vitro expansion, ischemic tolerability, and low risk of tumorigenicity, the cardiac
regenerative potential of SMs has been the subject of several preclinical investigations in both small and
large animal models of CVDs [12–17]. Indeed, results from these studies have demonstrated positive
outcomes by reducing infarct size, as well as myocardial fibrosis, thwarting ventricular remodeling
and improving overall cardiac function. Consequently, several clinical trials were initiated to verify
their efficacy [18–22]. Despite initially reported improvements in cardiac parameters of patients
transplanted with SMs, many have experienced ventricular arrhythmias, which were later attributed to
the lack of electromechanical coupling between the transplanted SM-derived myotubules and resident
cardiomyocytes where they failed to form gap junctions [23–26]. Furthermore, larger randomized,
placebo-controlled, double-blinded clinical studies not only failed to show any therapeutic benefits of
SMs in patients with severe ischemic heart disease at both short- and/or long-term follow-up, but also
reported postoperative arrhythmic events even upon prophylactic pharmacological treatment [27–31].
As a result, SMs have lost their popularity as SCs for cardiac applications.
2.2. Bone-Marrow-Derived SCs
Since the mid-20th century, the BM has long been praised for its SC abundance. BM transplantation
has been a clinical practice since the mid to late 1960s, intended for correction hematologic, as well as
immune disorders. However, reports from the late 1990s first demonstrating the ability of BM-derived
cells to migrate to injured tissues and support regeneration have instigated a wave of research on their
therapeutic potentials for CVDs [32,33]. Indeed, early studies in animal models of MI corroborated the
aforementioned expectations. The first tentative clinical translation of this finding was reported in 2001
in Düsseldorf, Germany, where a MI patient received autologous BM-derived nucleated cells upon
catheter angioplasty and reported positive outcomes [34]. This was followed by several controlled
clinical studies, albeit with inconsistent findings [35,36].
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Generally speaking, BM-derived SCs can be sub-grouped into two large cell populations;
hematopoietic (HSCs) and nonhematopoietic SCs. HSCs give rise to all blood-cell types and include
a subpopulation of pro-vasculogenic endothelial progenitor cells (EPCs), which can be found in
the circulating blood among others [37]. Of the nonhematopoietic BM-derived SCs, mesenchymal
stromal/stem cells (MSCs) are the most studied, due to their greater multipotency, manifested in their
ability to differentiate into osteoblasts, adipocyte, and chondrocytes under defined in vitro conditions,
adding to their reported immune-modulatory and anti-inflammatory properties [38]. With better
characterization of these cells based on surface-marker expression, studies were led, examining the
therapeutic potential of each BM-derived SC type.
For example, BM-derived CD133- and/or CD34-positive HSCs were utilized for phase I and II
clinical trials, where patients of MI received intramyocardial transplantation or intracoronary injections
of these cells. Despite short-term follow-ups showing positive outcomes, characterized by enhanced
left-ventricular ejection fraction (LVEF) along enhanced myocardial perfusion, these studies failed
to show any long-term benefits [39,40]. Most recently, results from randomized, placebo-controlled,
double-blinded phase III clinical trials also showed a congruent trajectory [41].
On the other hand, MSCs (CD73-, CD105-, and CD90-positive) have been a subject of greater
scrutiny in both basic and translational research. Adding to their paracrine- and exosome-mediated
immunosuppressive properties, MSCs are unique in their ability to evade the immune system [42].
This is largely due to their moderate levels of HLA class I expression, while lacking the expression
of HLA class II, B7, and CD40 ligand conferring privilege to the immune system of their host, thus
enabling allogenic transplantation without the need of concomitant immunosuppression [42,43].
Indeed, studies in large animals have shown improvements in LVEF upon MSC therapy in the setting
of myocardial ischemia. Nevertheless, results from translational attempts of these findings in clinical
studies fall into a wide spectrum of significance with regard to their benefits, notwithstanding their
mode of transplantation (i.e., autologous vs. allogenic) [44]. Despite some showing significant
improvements in patients with acute MI, other randomized controlled studies concluded no significant
differences [45–48]. Nonetheless, two randomized pilot studies were conducted in 2012 and 2017 in
patients with ischemic cardiomyopathy (ICM) and nonischemic dilated cardiomyopathy (NIDCM),
respectively, comparing autologous to allogenic MSC therapy [49,50]. Results from these studies, also
known as POSEIDON, alluded to the efficacy of MSC therapy in these patient cohorts, with superiority
given to allogenic transplantation. However, these studies were limited to the small sample size and
lack of a placebo control group.
2.3. Cardiac Progenitor Cells and Stem Cell Niches
Indeed, the heart’s endogenous regenerative capacity has been an area of extensive research
over the past decades. Contrary to the long-held dogma of being a postmitotic organ, studies have
challenged this notion, claiming that the mammalian heart is indeed capable of self-regeneration, albeit
exiguously. Studies using mitotic index, as well as DNA labeling, have conveyed the finding that
cardiomyocytes can self-renew during adulthood. However, debates have flared as to what extent this
self-renewal takes place, and even to the reliability of the methods used to quantify it. Herein, nuclear
labeling is not reliable, due to the characteristic polyploidy that human CMs undergo during growth or
disease [51–54]. Radiocarbon (14C) dating, on the other hand, has provided more accurate estimates of
cardiomyocyte turnover in the adult heart [55]. Interestingly, studies have shown a significant increase
in cardiomyocyte count and/or ploidy in neonatal and preadolescent life in both rodents and humans,
which contributed to heart growth [56,57].
Furthermore, the existence of SC niches harboring cardiac progenitor cells (CPCs) has also been
reported and highlighted by research as evidence of the heart’s regenerative capacity, notwithstanding
another yet-unresolved debate [51,58]. CPCs are multipotent as was shown by their ability to
differentiate to cardiac cell lineages, including cardiomyocytes; they were claimed to confer cardiac
tissue repair and regeneration. As a heterogeneous population of cells, they are each identified
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by expression of distinct markers. Of these cells, c-kit-, Isl1-, or epicardial Tbx18-positive (also
WT1-positive) cells are three heavily studied cell populations due to their cardiomyogenic differentiation
potential attributed during development, neonatal life, and even in adult hearts.
The c-kit-expressing cells are the most studied CPCs, however, with contradicting reports regarding
their significance for cardiac cell repair the in adult postinjury [59–61]. Despite their demonstrated
contribution to cardiac regeneration in the neonatal hearts, c-kit-positive CPCs’ role in the adult
setting of myocardial injury is largely debated [60,62,63]. A recent report alluded to the role of
c-kit-positive cells in cardiac adaptation to injury, where c-kit was shown to be upregulated in response
to pathological stress [64]. Furthermore, a RNA-sequencing study recently showed that c-kit-positive
cells transiently adopt a cardiomyocyte-like pattern of gene expression upon myocardial infarction
in vivo [65]. Contrary to these findings, more recent studies by Li and colleagues refuted the myogenic
potential of these cells in the adult by using a new genetic-lineage tracing system [66]. Furthermore,
the same group has shown that early segregation of myocytes and nonmyocytes during embryonic
development (E10.5 to E11.5) is the cut-off line beyond which no contribution to new cardiomyocyte
formation occurs, even during neonatal life [67]. Moreover, a study published earlier this year
by Elhelaly and colleagues argued that c-kit-positive cells do not contribute to cardiomyogenesis,
even during neonatal life [68]. Howbeit, the commonly agreed-upon consensus in the field is that
CPCs are remnant SCs from developmental stages whose role in the adult heart, if any, confines
to maintaining cardiac tissue homeostasis, and their cardiomyogenic potential in the context of
injury is inexistent [69,70]. Importantly, however, the repercussions of the aforementioned findings
instigated a wave of research endeavors to exploit the heart’s endogenous regenerative capacity
for novel therapeutic interventions. In summary, the field of cardiac progenitor cells is controversy
discussed, and the regenerative potential (and existence) of the cells in the adult human heart need
further investigations.
3. Pluripotent Stem Cells
Despite the efforts that have been made with adult SCs, none of these cells could meet the
expectations as a reliable treatment for CVDs. That is because not even the most potent adult SC could
provide an appreciable source for myocardial tissue regeneration and/or functional compensation for
the lost contractile element of the heart, e.g., as a result of infarction, let alone cardiomyopathies or
congenital heart disease [71]. In this regard, the pursuit after functional CMs calls for a different type
of SCs, i.e., pluripotent SCs (PSCs).
3.1. Embryonic Stem Cells
The ability of a cell to give rise of all three germ layers of the developing embryo, i.e., pluripotency,
is the most vivid and sought-after character of SCs, not only in the context of regenerative medicine,
but also for basic research purposes. Pluripotency of embryonic blastocyst inner mass cells was first
shown in the mouse as early as 1981 by Evans et al. [72]. In 1998, Thomson et al. first reported
the generation of pluripotent embryonic stem cells (ESCs, Figure 1) from human blastocysts, which
are capable of self-renewal and differentiation to all three germ layers [73]. Nevertheless, ethical
considerations have long hovered over human ESCs (hESCs), as their derivation entails destruction of
an embryo. This has prompted legislative issues, in that many countries have imposed bans on their
use and/or research funding [74,75]. To add insult to injury, ESCs’ ability to form teratomas (tumors of
mixed germ layers) when transplanted undifferentiated has further flared the argument against their
clinical application, despite efforts to enhance differentiations and purifications protocols [76].
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Figure 1. Differentiation of cardiomyocytes derived from pluripotent stem cells.
3.2. Induced Pluripotent Stem Cells
It was not long until the not-so-bright picture of SC research changed. Inspired by the preexisting
knowledge of master regulator genes capable of imparting cellular identities, Takahashi and Yamanaka
developed the first technique of somatic cell reprogramming in 2006 [77,78]. In their Nobel Prize
experiment, induced pluripotent stem cells (iPSCs, Figure 1) could be generated from somatic cells,
such as skin fibroblasts, by expression of four transcription factors that were found to be crucial
for cellular reprograming to ESC-like inner mass cells, namely Oct3/4, Sox2, c-Myc, and Klf4 [78].
Ever since, scientist have raced to improve the reprogramming efficiencies of iPSCs by manipulating
the transcription-factor cocktail and selecting for expression of other transcription factors, such as
Nanog and Lin28 [79–81]. Generation of viable and tumor-free whole organisms with iPSCs that were
capable of germ-line transmission was also made possible [82]. Unsurprisingly, human iPSCs (hiPSCs)
were generated as soon as one year after their first generation in a mouse, and by the same pioneering
group of scientists, as well as others [83,84].
3.3. Embryonic Stem Cells Versus Induced Pluripotent Stem Cells
The primary intended purpose of reprogramming of somatic cells and generation of iPSCs was to
wipe the initial cellular identity and drive them back to the embryonic inner mass state, and hence serve
as a surrogate for embryonically derived cells, i.e., ESCs. Indeed, iPSCs greatly resemble conventional
ESCs in terms of growth characteristics, gene-expression profiles, epigenetic status, and developmental
potential, which were shown in earlier studies by Yamanaka and colleagues, as well as others [79,84–86].
However, upon comparison of various undifferentiated cell lines, reports argued that iPSCs may
not be perfectly identical to conventional ESCs. This is largely attributed to the unique epigenetic
signatures of their parent somatic cells. Despite previous studies showing that somatic cells undergo
epigenetic remodeling upon reprogramming, studies have shown that iPSCs indeed retain epigenetic
5
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patterns of their donor cells, e.g., CpG island methylation [86–90]. Furthermore, gene and miRNA
expression signature were also shown to trail along with iPSCs (reviewed in [91]). Upon differentiation
to CMs, further comparison of mature CMs differentiated from ESCs and iPSCs can be insightful.
In this regard, CMs of either origin were reported to display similar ultrastructural phenotypes, upon
electron microscopic examination [92]. In line with these findings, a study by Gupta et al. revealed
that global transcriptional profiles of mature CMs derived from either human iPSCs or ESCs are highly
similar [93]. However, iPSC-CMs were more likely to share some somatic cell signature with their
undifferentiated iPSC-parents. Thus, identification of these variations between iPSC- and ESC-CMs,
as well as the interline variability of either type of PSCs, is essential before they are utilized for disease
modeling or clinical application.
Unlike ESCs, iPSCs derivation does not involve destruction of embryos, and hence does not fall
into the same ethical pitfalls. However, other ethical considerations arose with hiPSCs, especially
with regard to the possibility of reproductive cloning, the risk of generating genetically engineered
human embryos, and, more extremely, human–animal chimeras [94]. Furthermore, and like ESCs,
iPSCs are subject to safety concerns due to their ability to form tumors, even with rigorous protocols of
differentiation and selection [95].
In recent years, substantial developments in stem cell technology in terms of reprogramming
efficiency and enhancing their clinical applicability have prompted scientist to utilize pluripotent stem
cells (PSCs), not only to regenerate, but also to model the human heart for basic research purposes.
Furthermore, some countries have tentatively started to loosen their tight regulations, especially on
hESCs; a step that coincided with the establishment of stem-cell registries in the US and Europe [96–98].
This has led to several initiatives on stem cell therapy for many disease conditions, including CVDs [99].
As promising as this may sound, several challenges, however, preclude the full realization of PSC-based
therapy. In the following, we shall focus on PSCs by addressing efforts made over the past decades
to optimize their generation, differentiation, and maturation for CVD research, as well as efficient
delivery methods for late clinical and/or translational purposes.
4. Cardiac Stem-Ness
Embryology is the fundament for generation of cardiac cells from PSCs in the laboratory. The heart
is the first organ to develop and function during embryogenesis [100]. In the lateral mesoderm, cardiac
specification takes place, a process initiated by two T-box transcription factors, Eomesodermin and
Brachyury(T), which have been shown to induce the expression of yet another critical factor, namely
mesoderm posterior 1(MesP1) [101,102]. MesP1 is a basic helix-loop-helix (bHLH) transcription factor
considered to be the master regulator orchestrating the differentiation and commitment of cardiac
precursors [101,102]. Cardiac precursors then assume a crescent-shaped structure known as the cardiac
crescent, at which cells are irreversibly committed to the cardiac lineage. This is marked by the
expression of key transcription factors, namely Nkx2.5, GATA4 and Tbx5 [103]. Two waves of Nkx2.5
expression ensue, depicting the formation of two regions known as the first and second heart fields,
which subsequently give rise to different heart chambers, as well as the cardiac outflow tract [76,103].
After all, heart development is a dynamic three-dimensional process governed by an intricate
network of signals and gene transcription [104,105]. Howbeit, three major signaling pathways
converge to drive the process, from early cardiac tissue specification of mesoderm progenitors to
subsequent differentiation into cardiac progenitors, namely BMP (bone morphogenic protein) and
Nodal/Activin, both being members of the TGF-β (transforming growth factor beta) cytokine family,
and the Wnt/β-catenin [106,107]. Paracrine signals responsible for the fine-tuning of those pathways
is crucial for heart development. For example, signals activating the Wnt/β-catenin pathways are
essential for early mesoderm induction, whereas inhibitors of the same pathway are subsequently
required for precardiac specification [76].
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4.1. Generation/Differentiation of Pluripotent Stem Cells
Protocols for in vitro generation of cardiac stem cells (CSCs) from PSCs, either from ESCs or iPSCs,
rely primarily on simulating the signaling microenvironment, which induces the aforementioned
rudimental pathways, starting by initial epithelial to mesenchymal transition, mesodermal specification,
and subsequent cardiogenic differentiation, followed by selection for cardiac markers [108–110].
The initially reported protocols relied simply on serum in culture medium as a source of inducing
factors, observing spontaneous formation of aggregates called embryoid bodies (EBs) when cells are
plated in suspension [111]. These EBs would later show contractions and positive staining for cardiac
markers. This method was first reported in ESCs, however, with very low efficiency [111]. Nevertheless,
the EB-based differentiation remained a standard protocol and was also the first differentiation method
applied to generate CMs from mouse iPSCs only a couple of years after their first introduction in
2006 [112,113]. The first CMs generated from iPSCs were reported by a team of researchers from Leibniz
institute in Germany, with few refinements introduced to the protocol, which led to the differentiation
of typical CMs comparable to those generated from ESCs [112]. Interestingly, precisely at the same
time and in the same journal issue, the iPSCs-founding team from Kyoto also published a systematic
differentiation protocol of mouse iPSCs into cardiac lineages [113]. Nevertheless, and as mentioned
before, the efficiency of the EB-based protocols was low, mainly due to the uncontrolled differentiation
cues in the supporting media. One of the earliest and most cited protocols to differentiate ESCs to
beating CMs was reported by Mummery et al. in 2003, where they delegated the differentiation cues
to paracrine signaling of murine visceral endoderm-like cells (END-2) [114]. They compared their
generated CMs to primary human fetal CMs, as well as primary human adult CMs, and reported
comparable structural and functional properties. Improvements to differentiation protocols by temporal
application of cytokines, as well as small molecule inhibitors (e.g., inhibitors of the Wnt pathway) to
simulate the developmental processes have also been successful introduced to generate CMs from
PSCs [108–110,115–117]. Furthermore, several groups have sought to simplify the differentiation
protocols by using chemically defined culture media consisting of only a few components [115–117].
Nevertheless, differentiation of PSCs by using standard protocols usually yields a mixed
population [118]. Thus, identification of selection markers is crucial for the purification of cardiomyocyte
progenitors. Pioneering studies by Moretti and colleagues have greatly contributed to the refinement
of selection protocols for cardiac organogenesis from PSCs [119]. From an embryological standpoint,
myocyte progenitors are distinguished from nonmyocytes (vascular progenitors) by consistent
expression of Isl1-1 transcription factor, along with Nkx2.5, whereas co-expression of Isl-1 and
CD31 is a marker for endothelial progenitors [119]. Among myocytes, cardiomyocytes can be
further distinguished from smooth muscle cells (SMCs) by expression of vascular cell adhesion
molecule 1 (VCAM 1) and signal regulator protein alpha (SIRPα), both of which were reported to
be reliable selection markers in culture conditions, yielding as much as 98% pure-cardiomyocyte
populations by antibody-based sorting from PSCs [120,121]. Successful differentiation can be
further confirmed by expression of other cardiomyocyte markers, such as cardiac troponins, e.g.,
TNNI1 [121,122]. Using lentiviral vectors, expression of selection markers, e.g., antibiotic-resistant
genes or fluorescent proteins, under control of cardiomyocyte-specific promoter, has also been reported
to purify cardiomyocytes [123,124]. Importantly, documented biochemical disparity between CMs
and non-CMs in energy metabolism was also exploited for the so-called “metabolic purification” of
CMs. In this regard, manipulation of culture conditions by altering the composition of the culture
medium (e.g., glucose depletion, lactate, and glutamine supplementation) was found to be crucial for
such nongenetic purification of CMs [125].
Finally, studies have pointed out the important role of MicroRNAs (small, noncoding RNAs that
regulate gene expression by degradation of messenger RNAs) in CM phenotype differentiation [126–128].
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4.2. Maturation of Pluripotent Stem Cells
To be utilized for disease modeling or regenerative medicine, one might expect PSC-CMs to
recapitulate the structural and functional characteristics of adult CMs (Figure 1). Nevertheless,
CM differentiation of PSCs usually yields immature cells, resembling the embryonic or fetal
state [129]. This manifests in their morphology, gene expression, and electrophysiology. More recently,
single-cell-transcriptomic analyses have proven to be a powerful tool to understand the transcriptional
roadmap of in vitro CM differentiation, and therefore enable a better design of differentiation and
maturation protocols [130,131]. The following highlights the major differences between immature
PSC-derived CMs and mature and/or adult ones.
Morphologically, PSC-CMs are significantly smaller in size, compared to their adult or matured
counterparts. Upon maturation, cells assume an elongated shape, reminiscent of adult CMs [132].
Sarcomeres are much less organized in immature PSC-CMs and become much more organized
upon maturation, which usually correlates with isoform switch of sarcomeric proteins. A good
example is troponin I, wherein different isoforms distinguish embryonic CMs from adult ones [133,134].
Stoichiometric replacement of the fetal troponin TNNI1, encoding slow skeletal troponin I (TnIs), gene
with the adult TNNI3, encoding adult cardiac troponin I (TnIc), gene was reported in a study by Bedada
et al. as a quantifiable marker for maturation in PSC-CMs [135]. Another well-characterized hallmark
of mature CMs is the isoform switch of myosin heavy chain (MHC). Two isoforms exist, the alpha
isoform (encoded by MYH6), also known as the faster isoform, and the beta isoform (encoded by
MYH7), also known as the slower isoform [136]. Importantly, differences exist between rodents and
humans in this regard. In small rodents (mice and rats) with faster heart rates, alpha-MHC isoform
predominates and increases upon maturation, whereas, in bovine and human hearts, despite the
presence of the alpha-MHC isoform, the beta MHC isoform usually predominates, regardless of the
state of development, and increases with age [136,137]. However, most differentiation protocols of
human PSC yield CM with both isoforms, but studies have shown that long-term cultures, especially
on stiff substrates, lead to a greater shift toward the beta-isoform, reflecting maturation [138]. Titin is
another key component of the sarcomere that undergoes isoform switch during maturation. Fetal
titin isoforms N2BA 1 and 2 are more compliant, but they switch to the N2B isoform in postnatal and
adult cardiomyocytes [139]. Genes encoding structural and force-generating myofibrillar proteins
are much poorly expressed in in vitro maturated PSC-CMs when compared to adult- and fetal-heart
samples [140]. This might be attributed to the absence of biomechanical stresses in vitro, which are
normally present upon heart development in vivo [141].
Electrophysiological, and similar to contractile components, ion-transport related genes, such as
those for voltage-gated potassium channels, e.g., KCNJ2 and Ryanodine receptor RYR2, were poorly
expressed in immature CMs [142]. The lower expression level of the KCNJ2-encoding membrane protein
of the inward-rectifier current, as well as genes encoding beta-subunit members of the voltage-gated
potassium channels, such as KCNIP2, KCNAB1, and KCND3, all affect both the inward-rectifier (Ik1) and
the transient-outward (Ito) currents, respectively, leading to the characteristic “less negative” resting
membrane potential in PSC-CMs (~–60 mV) compared to adult CMs (~–90 mV) [129,132,142,143].
Furthermore, studies have shown that PSC-CMs have few to no T-tubules, which are key components
of excitation–contraction coupling (ECC) and a hallmark of mature and/or adult CMs; this is typified
by unsynchronized Ca2+ transients in immature CMs [144].
Metabolically, immature CMs have few and underdeveloped mitochondria, accounting for a small
fraction of the cell volume. Adult CMs, on the other hand, show highly developed, well-distributed,
and dense mitochondria, accounting for ~20–40% of the adult myocyte volume. During development,
hypoxia is an early trigger for mesoderm cardiac specification [145]. The growing heart, thus, resorts
to glycolysis as a major source (80%) of energy. As CMs mature and become terminally differentiated,
mitochondrial oxidative capacity increases, with fatty acid β-oxidation (80%) becoming a major source
of energy [146]. PSC-CMs recapitulate both mitochondrial structure and glycolytic dependence of
embryonic-state CMs [92,147]. Recent studies have shown that tweaking the culture media composition
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to mimic these metabolic changes, e.g., replacing high-carbohydrate, high-insulin, glucose-based,
with low-carb, low-insulin fatty-acid-based media-enhanced maturation [148]. Table 1 summarizes the
major differences between human-PSC-derived and adult CM.
Table 1. Major structural, electrophysiological and metabolic differences between human PSC-derived
CMs and maturated/adulte CMs.
PSC-Derived CM Mature/Adult CM
Smaller in size, roundish in shape Larger in size, elongated in shape
Disorganized sarcomeres Organized sarcomeres
Slow/skeletal troponin I (TnIs) Adult cardiac troponin I (TnIc)
Titin N2BA isoform Titin N2B isoform
Higher αMHC:βMHC Lower αMHC:βMHC
Poor expression of ion-transport components genes
(e.g., KCNJ2, RYR2) High expression of ion-transport components genes
Less efficient Calcium handling Improved Calcium handling
Less negative resting membrane potential More negative resting membrane potential
No or few T-tubules Abundant T-tubules
Few, underdeveloped mitochondria
Glucose as major energy source
Dense, well-distributed and developed
mitochondria
Fatty acids as major energy source
Over the years, efforts have been made to enhance the maturation of PSC-CMs, and these include
prolonged cultures, using stiff gel micro-patterned substrates, and application of electrical and/or
biochemical stimuli [132,149–152]. The overall goal was to simulate the in vivo environment of the
myocardium, where CMs are under constant physical, topographic, and humoral stimuli leading to
their structural and functional maturation.
4.3. Engineered Heart Tissue
Importantly, the accumulated knowledge of cardiac stem cell biology and maturation has
culminated in the so called “Engineered Heart Tissue” (EHT), a milestone achievement. The nascent
EHT is attributed to work done by Zimmermann and Eschenhagen in the early 2000s [153,154].
Ever since, EHT technology has rapidly progressed through refinements in mechanical loading,
electrical stimulation, medium supplementation, and miniaturization. The result was a 3D cardiac
tissue structure with mature CMs and near-physiological contractile forces [155]. The pioneering work
of these scientists has opened the doors for more revolutionary developments, such as 3D bioprinting,
organ-on-chip platforms, and laser-cut decellularized myocardium, all with ample opportunities for
both basic research and clinical applicability [156–158].
5. Applications of PSCs in Cardiovascular Research
5.1. Pluripotent Stem Cells in Cardiovascular Disease Modeling
The use of PSCs to model cardiac disease in vitro has become highly attractive, especially after
the introduction of iPSCs [107]. This is mainly because of inadequacies of other models in terms
of sampling, propagation, and maintenance, as for human primary cardiomyocytes, or their ability
to fully recapitulate physiological properties of human CMs, as in rodent models. Considering
the relative difficulty in cloning and genetically modifying human ESCs, most established models
of CVDs are iPSC-based [107]. The feasibility in sampling and propagation of iPSCs, as well as
advances in reprogramming protocols, which later adopted nonintegrating genomic approaches
to deliver the reprogramming factors, has greatly increased their popularity [159]. Patient-specific
iPSC-CMs have enabled the study of genetic variants underlying several CVDs and establish a
phenotype–genotype understanding of not only monogenic, but rather complex and difficult-to-model
genetic variants (e.g., chromosomal deletions or translocations), and, most important, model congenital
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heart disease (CHDs) in newborns [160,161]. As a result, several patient-derived iPSCs lines have
been developed to model CVDs. The first of such was reported by Carvajal-Vergara et al. in 2010 for
LEOPARD syndrome, an autosomal dominant developmental disorder characterized by hypertrophic
cardiomyopathy [162]. Ever since, several other cell lines have been reported, mainly modeling
cardiac channelopathies, (e.g., long QT syndromes), cardiomyopathies of wide etiology spectrum (e.g.,
dilated, hypertrophic, arrhythmogenic, Barth syndrome, and Pompe-disease-associated), and infectious
myocarditis [163–177].
Despite the previously discussed disparities in structural and electrophysiological characters of
iPSC-derived and adult CMs, these studies have shown that patient-specific iPSC-CMs recapitulate
their corresponding disease phenotypes. For example, whole-cell patch-clamp analyses of different
long QT syndrome (LQTS) patient-derived iPSC-CMs showed typically prolonged APs, decreased
rectifier potassium currents IK, increased late sodium currents INaL, and impaired voltage-dependent
inactivation of the L-type channels (LTC), due to malfunctions in corresponding proteins of potassium
(KCNQ1, KCNH2 in LQTS1 and 2), sodium (SCN5A in LQTS3), and calcium (CaV1.2 in LQTS8 or
Timothy syndrome) channels, respectively. Moreover, these patient-specific models demonstrated
great utility for pharmacological screening of several drugs with disease-modifying abilities, leading
to both novel and/or personalized therapeutic strategies (reviewed in [160]).
Finally, patient-specific iPSC-derived non-CMs were also generated, for example, of SMCs or
endothelial cells. A more recent example is an elegant publication by Gu et al., utilizing iPSC-derived
endothelial cells from patients with autosomal-dominant mutations in BMPR2 associated with familial
pulmonary arterial hypertension (FPAH) [178]. In their study, comparing symptomatic patients
with unaffected carriers highlighted important modifiers of the BMP-receptor pathway, as well as
differentially expressed genes, which imparted protection against FPAH. Their findings were of great
importance as to the identification of multiple genetic factors affecting disease penetrance, which could
be therapeutically targeted to modify disease progression and severity.
Importantly, the previous example behooves an important consideration when conducting studies
on patient-specific iPSCs for CVD modeling, which pertains to the identification and/or the availability
of proper control lines. This is because, even among patient-matched donor cohorts, genetic variability
can still confound the analysis of the disease phenotype, especially in the presence of disease modifiers,
or when the genotype–phenotype is less conspicuous [169,179]. In such cases, it is possible to rely on
more than one control cell line—albeit a laborious approach. Alternatively, the patient’s iPSC-CMs can
be compared to those from a healthy sibling, thus limiting genetic variability [171]. However, recently
developed computational in silico models of iPSC-CMs and their optimization by Paci and colleagues
have provided an unprecedented approach to this issue, enabling simulation and calibration of over a
thousand diseased or control iPSC-CM models [180–182]. Finally, in case of monogenetic diseases,
an isogenic cell line created by correction of the disease-causing mutation in the patient iPSCs by
means of gene-editing approaches can serve as the best control cell line (discussed below). An elegant
example was reported in a study by Bellin and colleagues, where they used iPSC-CMs from LQTS2
patients with a distinct mutation in potassium channel KCNH2, and compared it to an isogenic control
upon correction of the genetic mutation [183]. Furthermore, they reproduced the study model in
human ESC-CMs, where they introduced the same mutation, and recapitulated the disease phenotype,
thus generating two genetically distinct isogenic pairs of LQTS2 and control lines.
5.2. Pluripotent Stem Cells in Pharmaceutical Screenings
Since their first introduction, iPSC-CMs have become attractive for drug testing, antiquating the
hERG test, which utilizes cell lines that stably express the human ether-a-go-go-related gene (hERG)
KCNH2 encoding the IKr channel involved in cardiac repolarization. Whole-cell patch-clamp screening
for compounds that block the IKr current serves as a good marker of cardiotoxicity, as such blockade
leads to the prolongation of the QT interval, i.e., ventricular repolarization, resulting in potentially
fatal ventricular tachycardia called Torsade de Pointes [184]. Since the actual risk for cardiac toxicity
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is not confined to a certain channel and/or mechanism, iPSC-CMs are hence more representative in
typifying cardiac toxicity to drugs. Furthermore, recent introduction of automated patch-clamp (APC)
devices, all-optical cardiac electrophysiology with novel optogenetic actuation, and video microscopy
have all revolutionized drug screening in iPSC-CMs and tissue constructs, enabling high-throughput
testing platforms for hundreds of samples and/or drugs, thus creating a wealth of information in
short time [185–188]. Furthermore, comprehensive in vitro proarrhythmic Assay (CIPA) has recently
emerged as a powerful model to predict cardiac toxicity by integrating the knowledge from both
in vitro and recently developed in silico computational models (http://cipaproject.org/about-cipa/) [189].
However, as discussing this is beyond the scope of this review, we refer the reader to the cited work by
Paci et al.
5.3. Genetic Modification of Pluripotent Stem Cells
The advent of genome-editing methods has incited great progress in PSC research. Exploiting the
cell’s inherent DNA-repair mechanisms, such as nonhomologous end-joining (NHEG) or homologous
recombination (HR), has long been used to introduce small but disruptive mutations to target
genes, either by insertion or deletions of base pairs, also known as “Indels”. The discovery and
later advances of nucleases that can more specifically target desired sequences, such as zinc-finger
nucleases (ZFNs) or transcription activator-like effector nucleases (TALENs), have enabled the study
of several disease causing mutations [190–192]. Many PSC-lines have been generated by using this
technology for both disease modeling and even clinical applications [193–196]. Vector-mediated
delivery of sequence-specific nucleases along with a homologous DNA template to patient-derived
iPSCs leads to the excision of targeted locus and, by virtue of cellular homology directed repair
(HDR) system, can be corrected by the homologous template with the desired genetic modification.
A prominent example is the combination of ZFNs and piggyBac technology which could achieve
a biallelic correction of a disease-causing mutation in human iPSCs [197]. In a recent study by
Karakikis et al., they reported the use of TALENs to correct gene mutations in patients with hereditary
heart failure [198]. These patients harbor an amino acid deletion mutation (R14del) in the coding
region of the phospholamban (PLN) gene, which is an important regulator of cardiac calcium cycling
in the sarcoplasmic reticulum (SR). They display a phenotype of dilated cardiomyopathy, hypertrophy,
episodic ventricular arrhythmia, and overt HF by middle age [199,200]. Skin-derived iPSCs from these
patients were isolated, edited, and CM-differentiated, where further analyses showed reversal of the
disease’s phenotype. Nevertheless, engineering of sequence-specific ZFNs or TALENs, as well as
achieving their robust delivery for this purpose, can be laborious and technically challenging, let alone
high in cost [192,194,201].
In recent years, CRISPR/Cas9 has emerged as the new horsepower of genome-editing technology,
overshadowing ZFNs and TALENs [202]. The system, first described in prokaryotes as part of
their adaptive immune system, relies on an RNA-guided endonuclease (Cas9) that localizes to
complementary DNA sequences, where it creates double-strand break amenable for correction by the
cell’s endogenous HR. Provided that a homologous sequence is available, desired gene modifications
can be introduced [202]. Indeed, CRISPR/Cas9 has been zealously received by cell biologists as
an attractive tool for SC research [203]. In cardiovascular biology, CRISPR/Cas9 was successfully
applied to patient-derived iPSC to target disease-causing mutations of CVDs [204–206]. A recent study
demonstrated the utility of CRISPR/Cas9 in phenotypic characterization of iPSC-CMs from patients
with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) [207]. In this patient
cohort, mutations in the SCN5A encoding the Nav1.5 sodium channel protein led to the phenotype,
which could be reversed in this study upon editing with CRISPR/Cas9.
A study published earlier this year by Seeger and colleagues made use of genome-editing
techniques to create isogenic iPSC lines from patients with heterozygous mutations in the
myosin-binding protein C3 (MYBPC3), which is deemed as the underlying cause of hypertrophic
cardiomyopathy (HCM) [208]. Their results refuted previous hypotheses of either MZBPC3
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haploinsufficiency or truncated poison peptide as the underlying cause of HCM. However, they were
able to provide evidence for chronic activation of the nonsense-mediated decay (NMD) as the initial
pathogenic trigger that leads to dysregulated gene expression and aberrant calcium signaling upon
MYBPC3 mutations.
The aforementioned examples give a great promise to SC therapy of CVDs. One might also
envisage the possibility of autologous cell transplantation of iPSC-derived CMs with rectified mutations
to ameliorate or even cure disease conditions. However, great challenges remain as to the validation of
these technologies, let alone deciding on a safe and effective clinical setting for PSCs delivery to treat
CVDs. The next chapter outlines recent advances in preclinical research on SC-based therapy for CVDs.
6. Translational Potential of PSCs in Cardiovascular Regenerative Therapy
Harnessing the multifaceted potential of SCs for effective therapeutic purposes to treat CVDs is
the ultimate goal of the above-introduced laborious efforts of scientists over the past decades. Provided
that SC-derived CMs are sufficiently propagated, differentiated, and maturated, their application to the
diseased myocardium spans a wide spectrum of delivery methods, from intravenous administration
to direct myocardial injection. Nevertheless, several factors are to be considered with regard to
engraftment of transplanted cells and integration, as well as functional contribution to host myocardium,
electromechanical coupling between graft and host CMs, and long-term survival. The aforementioned
limitations have long been challenges to preclinical and translational applications of SC therapy in
general, and in cardiac regenerative therapy in particular. The following summarizes advances made
in the realm of preclinical and translational research with PSCs over the past decades, in light of
examples from small and large animal models and up until the first clinical initiatives.
6.1. Pluripotent Stem Cells in Rodent Models
Earlier studies attempted to engraft human ESC-derived cardiomyocytes in rodent models and
reported transient functional improvement in cardiac parameters [209,210]. However, poor engraftment
and survival of transplanted cells has been a challenge in these settings. Laflamme et al. utilized
pro-survival factor cocktail to limit CM death upon engraftment in infarcted rat heart and reported
positive outcomes [108]. To overcome poor engraftment and survival issues, Masumoto and colleagues
developed a layered-sheet assembly of three cardiovascular cell populations, namely CMs, endothelial
cells, and vascular mural cells, differentiated from mouse ESCs and transplanted into nude-rat model
of MI. The transplanted sheets were reported to ameliorate infarct size and improve cardiac function;
however, such benefits were shown to be attributed to paracrine-mediated neovascularization and not
to actual contribution of transplanted cells [211]. Despite these results, the same group of scientists
from Kyoto continued to optimize the stacked-sheet approach, and they recently reported successful
long-term survival of engrafted cells through insertion of gelatin hydrogel microspheres between
each cardiovascular cell sheet [212]. Analogously, human iPSC-CMs have recently demonstrated
favorable therapeutic outcomes when injected in infarcted myocardia of mice. Interestingly, however,
the engraftability and survival of those cells depended heavily on the maturation stage [142].
Importantly, electromechanical coupling between the graft and host myocytes is a rather crucial
consideration to avoid ventricular arrhythmia. In a Guinea pig model, Shiba et al. reported successful
engraftment of human ESC-derived CMs with a 1:1 electrophysiological coupling and improved
mechanical function of injured hearts [213].
6.2. Pluripotent Stem Cells in Large-Animal Models
6.2.1. Porcine Models
Swine models were featured in the earliest attempts of cell therapy for heart disease. A number of
features make the pig an attractive translational model. These include a heart weight-to-body ratio
that is equal to a human’s and a similar sinus rate (~90 bpm) [214]. ESC-derived cardiomyocytes have
12
Cells 2019, 8, 1530
been functionally tested in a swine model of complete atrioventricular block as biologic pacemaker
for the treatment of bradycardia [215]. Hereof, Kehat et al. reported survival and functional
integration of the transplanted cells, which were able to pace the porcine ventricle with complete
heart block [215]. In another porcine model of acute MI, Ye and colleagues used a mixture of
cardiovascular cell populations—this time from human iPSCs origin—loaded on a three-dimensional
fibrin patch containing IGF-1 (insulin-like growth factor 1) and reported functional integration and
significant improvements of several cardiovascular parameters [216]. More recently, Kawamura
et al. took a rather unprecedented approach to enhance survival and engraftment of transplanted
human iPSC-CMs by combining cell-sheets with pedicle omentum flap as a source of angiogenic
factors and reported enhanced engraftment, survival, and therapeutic outcome in a porcine model
of ischemic cardiomyopathy [217,218]. The aforementioned tissue sheet technology from Kyoto was
also recently applied to a porcine model of MI, where a heterogeneous mixture of cardiovascular cell
populations differentiated from human iPSCs and reported functional restoration of the infarcted
hearts and attenuated remodeling [219]. Another study from 2018 by Gao and colleagues reported
the application of human iPSC-derived fabricated cardiac muscle patches (hCMPs) composed of
CMs, smooth muscle and endothelial cells, reprogramed from cardiac fibroblasts and maturated
in dynamic culture conditions [220]. They transplanted these patches in infarcted pig hearts and
demonstrated significant improvements upon histological and functional analyses. Altogether, these
results highlight the importance of co-administration of nonmyocyte cardiac cells, which provide
paracrine and angiogenic support equally important to both host and graft tissue. Furthermore,
they highlight the superiority of modern tissue engineered scaffolds over direct application of cells.
Finally, these studies corroborate the utility of swine models for translational cardiovascular research.
6.2.2. Non-Human Primate Models
The utility of non-human primates (NHPs) in regenerative medicine has long been appreciated,
especially in transplantation medicine [221]. In this regard, certain macaque species (e.g., Macaca
fascicularis or Mauritian Cynomolgus macaque) are a valuable preclinical model to study allogenic
transplantation of iPSCs [222]. This is because they exhibit limited diversity in their major
histocompatibility complex (MHC) genes, which are distributed only among seven haplotypes
and are structurally identical to those in humans [223,224]. Indeed, allogenic transplantation of
iPSC-CM among MHC-matched Cynomolgus monkeys was shown in a study by Shiba et al. to
be immune-tolerable, and improved cardiac contractile function upon MI [224]. Matching MHC
antigens between donors and recipients was shown by others to reduce immunogenicity upon allogenic
transplantation of iPSC-CM in the Cynomolgus macaque [225].
NHPs continue to provide unmatched insights to PSC-therapy of CVDs in late-translational
studies. In a recently published elegant work by Chong et al., human ESC-CMs were utilized in the
pigtail macaque (Macaca nemestrina) as a model of ischemia-reperfusion injury [226]. They reported
significant re-muscularization of the infarcted areas, structural and functional integration of the grafted
cells via establishment of adherent junctions, and electromechanical coupling, typified by synchronous
calcium transients. Such promising results were slightly relegated by the presence of arrhythmia in the
grafted animals—albeit nonfatal.
7. Pluripotent Stem Cells in First Human Trials
The aforementioned successes in late-translational studies with large animal models, as well
as the advances made in tissue engineering and grafting techniques, paved the way to the first
clinical application of PSC therapy in cardiac settings, which was recently reported in a case study
by Menasche et al., using ESC-derived cardiac progenitors [227]. They used the ESC I6 line, which
was enriched in vitro by culturing on clinical-grade irradiated human foreskin fibroblasts as feeder
cells. Cardiac commitment was then achieved by bone morphogenic protein-2 (BMP-2) and a specific
tyrosine kinase inhibitor of the fibroblast growth factor receptor (FGFR), and then confirmed by the
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expression of the cardiac specific transcription factor Isl-1, as well as the stage-specific embryonic
antigen-1 (SSEA-1), which was used for cell purification by immunomagnetic sorting. The cells were
embedded in a fibrin scaffold patch and surgically implanted in the infarcted area of a 68-year-old
woman patient with severe heart failure. The three-month follow-up showed functional integration
of the patch, evident by electrocardiography, and overall symptomatic improvement marked by
enhanced left-ventricular ejection fraction (LVEF), with no complications of arrhythmia, tumors,
or immunosuppression-related adverse events. The results were encouraging, and the Parisian group
conducted a larger-scale study, wherein six patients received cellularized patches of ESC-derived
committed cardiac progenitors [228]. Their one-year follow-up demonstrated safety and tolerability of
the grafted cells, with no detected tumors. Moreover, they reported modest symptomatic improvements,
as well as in different cardiac parameters.
As for iPSCs, a group of scientists from Osaka have reported their granted permission to pursue
with their clinical application last year and the results are yet to be reported [229].
8. Conclusions and Remarks
Stem cells are a novel source of cells which might be used as a screening tool for pharmaceutical
developments. Here, single cells on iPSC status, as well as differentiated cardiomyocyte progenitors,
might be used. In addition, engineered heart tissue displays a second model situation for screening of
novel therapeutic options, before applying in animal experiments or clinical trials. Since these systems
are based on human sources of cells, testing in these model situations might enhance safety and side
effect prediction in novel approaches of cardiovascular therapies. Utilization of stem cells in patients
suffering from cardiovascular disease is a second interesting field with great potential. The allogenic
transplantation of stem cells requires only a modest immunosuppression and might improve cardiac
function and thereby survival, as well as quality of life, in patients suffering from cardiac conditions,
e.g., heart failure. However, the clinical potentials, as well as the potential side effects, need to be
investigated in clinical trials before establishing stem-cell-based therapy as a standard of care in
cardiovascular patients. In summary, stem cells, especially induced pluripotent stem cells, have wide
therapeutic potential, but need to be characterized and investigated in more detail in preclinical, as well
as clinical, trials to understand in more detail their potentials and risks.
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Abstract: Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (CM) have been
intensively used in drug development and disease modeling. Since iPSC-cardiomyocyte (CM) was
first generated, their characterization has become a major focus of research. Multi-/micro-electrode
array (MEA) systems provide a non-invasive user-friendly platform for detailed electrophysiological
analysis of iPSC cardiomyocytes including drug testing to identify potential targets and the assessment
of proarrhythmic risk. Here, we provide a systematical overview about the physiological and technical
background of micro-electrode array measurements of iPSC-CM. We introduce the similarities and
differences between action- and field potential and the advantages and drawbacks of MEA technology.
In addition, we present current studies focusing on proarrhythmic side effects of novel and established
compounds combining MEA systems and iPSC-CM. MEA technology will help to open a new gateway
for novel therapies in cardiovascular diseases while reducing animal experiments at the same time.
Keywords: cardiomyocytes; multi-electrode-array; micro-electrode-array; MEA; drug/toxicity
screening; field potential
1. Introduction
The first generation of induced pluripotent stem cells (iPSCs) by Yamanka and co-workers in
2006 was a milestone for stem cell research as it allows the in vitro production of human cells without
ethical concerns. Like embryonic stem cells, iPSCs have the capability to differentiate into any cell type,
including cardiomyocytes, therefore providing an easy accessible cellular source for the generation of
cardiac organoids and tissue structures [1–3].
One possible application for iPSC-derived cardiomyocytes (CMs) is their use in cell therapy
replacing damaged tissue by in vitro generated CMs. As cardiovascular diseases are the major cause
of death worldwide such regenerative approaches are needed for the development of novel treatment
options. The potential and feasibility of iPSC-CM transplantation has been investigated in small and
large animal models [4–7].
Thereby, an important future option of iPSC-CMs will be their generation from patient specific
tissue enabling the implementation of autologous cell transplantation strategies. In this respect,
iPSC-CMs can be used for the development of personalized drug screening approaches and clinically
relevant diseases models. Therefore, iPSCs enable cost-effective methods to identify potential drug
targets, even more accurately than animal models or other in vitro cell systems. Successful pre-clinical
application of iPSC-derived cardiomyocytes for drug screening assays has been lately demonstrated by
the CiPA initiative, which was initiated to assess the proarrhythmic risk of novel cardio therapeutics.
A myriad of studies investigated in vitro drug effects on different ion channels of iPSC-CMs [8–11],
reflecting the importance of electrophysiological measurements using stem cell derived cardiac cells.
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However, the maturation of iPSC derived CMs is still a critical point for their application in
cardiovascular research as well as for clinical applications. Besides metabolic and structural maturation,
proper ion channel composition is crucial for the development of a mature cardiac phenotype. During
the last decade, extensive analyses have been performed on the electrophysiological properties of
iPSC-CMs [12–15]. Several ion channels and ion currents have been found to be present in iPSC-CMs,
including sodium (INa), potassium (IK1 and IKr), L-type and T-type calcium channels, etc. Although
multiple differentiation protocols have been developed, researchers failed to generate fully mature
cardiomyocytes in vitro, possessing identical electrophysiological properties as their native adult
counterparts [16–18]. Moreover, it has largely been shown that iPSC-CMs represent a heterogeneous
population of electrophysiological phenotypes, i.e., atrial, ventricular and nodal-like cells [19], each
characterized by a specific electrical profile. Therefore, it is important to obtain electrophysiological
data for detailed characterization of iPSC-CMs, in particular when differentiation into a certain cardiac
subtype is desired [20,21].
Typical approaches to investigate the electrophysiological properties of stem cell derived CMs
will be discussed in the following paragraph.
2. Methods for Electrophysiological Characterization of iPSC-CMs
Several different techniques exist to study the electrophysiological properties of cardiac cells,
including patch clamp analysis, MEA measurement and fluorescence dye-based assessment of the
membrane potential. Each of these techniques has its own advantages and limitations, which are
described in detail in the following.
2.1. Patch Clamping
Patch clamping is the gold standard technique for the acquisition of ion current data and detailed
measurement of action potential (AP) properties in individual cells. The basic principle of patch clamp
relies on a blunt ended glass pipette that is sealed onto the cellular membrane to obtain a so-called
gigaseal [22].
In the “current patch clamp” mode the membrane potential is recorded while the current applied
by the patch pipette is controlled by the operator [23]. The current patch clamp technique allows
detection of APs that occur spontaneously or after stimulation with a current change induced by the
recording pipette. Considering the fact that iPSC-CMs also contain non-beating populations, current
patch clamp methodology allows the detection of AP patterns in these quiescent cells [23,24]. Moreover,
detailed AP features, such as AP duration, amplitude, beating rate and mean diastolic potential can
reliably be acquired with current patch clamping [25].
When precise characterization of ion channel subtypes is desired, “voltage patch clamp” is
performed to measure individual ion currents. Unlike in the current patch clamp mode, the operator
keeps the membrane potential at a certain value that enables detection of the net membrane current.
In hiPSC-CMs, voltage patch clamp has been successfully applied to obtain data about ion channel
density, voltage dependency and activation/deactivation characteristics [23].
However, these manual patch clamp methods are complex, technically challenging procedures
that require high operator skills as well as a biophysical background for data interpretation. Another
limitation is the low throughput since measurements are usually performed on the single cell level.
Therefore, automated patch clamp devices have been developed to overcome the aforementioned
drawbacks of manual patch clamp approaches [26]. Automatic platforms profoundly increase the
efficiency of electrophysiological data recording by assessment of 10–700 cells at the same time [27].
However, while automated systems are capable to analyze hundreds of cells under variable experimental
conditions, the accuracy of obtained data is reduced if compared to manual patch clamping [28,29].
High-throughput analysis is realized by analysis of single cell suspensions, in contrast to manual
patch clamping where cells are usually processed in an adherent state. Recently developed systems
are equipped with temperature control, optical stimulation and internal perfusion systems to ensure
30
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high data quality and reproducibility [27,30]. Data consistency and robustness is further determined
by the homogeneity and density of the applied single cell suspension—a point that is particularly
important for iPSC-CMs that are sensitive to dissociation as it can affect membrane proteins and
electrical physiology of the cell, including ion channel expression [31,32]. Automatic techniques also
do not provide the possibility of selective cell capturing. Hence, the system demands highly purified
cell populations, which could be challenging when working with CMs differentiated from iPSCs that
commonly represent a mixture of different cardiac subtypes [29].
2.2. Optical Recordings of the Membrane Potential
An indirect technique to assess electrophysiological data of iPSC-CMs is the application of
voltage-sensitive dyes that change fluorescence intensity or emission spectra upon alteration of the
membrane potential. Considering fluorescence microscopy as one of the most commonly used methods
in cell research, utilizing voltage-sensitive dyes is operationally simple and does not require special
instrumentation. Moreover, it is less invasive and it enables monitoring of voltage dynamics over
thousands of cells with very high temporal resolution [33]. Several studies have proven feasibility
of voltage sensor probes for drug screening experiments in iPSC-CMs [34–36]. Recently, Takaki and
colleagues [37] applied voltage sensitive dyes for the identification of distinct cardiac subtypes in
an iPSC-CM population. Further, the authors were able to detect differences in the AP pattern in
iPSC-CMs obtained from patients suffering from the long QT syndrome, compared to control cells.
Alternatively, voltage sensitive probes can be engineered as fluorescent proteins that are stably
expressed in target cells. Compared to voltage-sensitive dyes, these proteins possess lower phototoxicity,
thus, facilitating long-term measurements. These genetically encoded probes are designed by
conjugating a voltage-sensing domain to a single fluorescent protein, a fluorescence resonance
energy transfer (FRET) pair or rhodopsin proteins [38,39]. Changes of the membrane potential induce
conformational rearrangement of the voltage-sensor, which in turn modulates the emission spectra
of the attached fluorescent protein. The latest generation of genetically encoded voltage sensors,
such as ArcLight, Archer1 or QuasAr1, show large fluorescence alteration upon depolarizing events
(40%–80% for a 100 mV depolarization) associated with faster on/off kinetics (1–10 ms). Shaheen
et al. generated ArcLight expressing human iPSC-CMs to establish a 2D cardiac tissue platform for
optical mapping and pharmacological studies [40]. Former data confirmed the suitability of genetically
encoded voltage sensors for iPSC-CM drug screening applications and disease modeling attributed
to altered AP phenotypes [41–44]. However, there are certain limitations of this technology. Like
fluorescence dyes, genetically encoded voltage indicators provide only relative, not absolute values for
the membrane potential [45]. The lower on/off kinetics increase the probability of losing high frequency
AP elements [41,45]. Furthermore, introduction of voltage-sensitive proteins like ArcLight could affect
the electrophysiological properties of iPSC-CMs. This needs to be carefully addressed by the operator
as well as proper folding and membrane integration of the voltage sensitive probe.
2.3. MEA-Based Analysis of Cell Behavior
A common MEA system is composed of dot-like electrodes arranged in two-dimensional grids
that measure the fluctuations in the extracellular field potential (FP) of an attached cell layer in
respect to a reference electrode placed outside the grid (Figure 1). MEA is a non-invasive, label
free methodology that has been initially applied to investigate neuronal activity [46]. However, in
recent years an increasing number of studies have taken advantage of MEAs to particularly analyze
compound-induced cardiac toxicity in iPSC-CMs [47–49]. Like optical recordings of the membrane
potential, MEA systems allow non-invasive and cost-effective measurements at high throughput
scale, and long-term observations [46,50]. On the other hand, Rynnännen et al. published data of
a custom-made MEA platform for FP detection based on a single cell analysis [51]. In contrast to
conventional MEA systems, this optimized device demonstrated a modified layout of larger electrodes,
most suitable for observation of single iPSC-CMs. Similarly, agarose micro-chambers printed on MEA
31
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have been found to facilitate single cell detection of FPs in stem cell-derived CMs [52]. Moreover,
electrophysiological assessment using MEAs is not only restricted to cell culture but can also be
performed on the tissue level to better simulate in vivo conditions, as shown for murine and human
heart tissue slices [53–55].
Figure 1. (A) Glass multi-/micro-electrode array (MEA) chip used to detect field potential (FP) of cells.
(B) Cells seeded on an MEA surface, grown on top of the electrodes (black dots), Video S1.
An advantage of the MEA technology is its high flexibility as it can be combined with other
detection methodologies to multiply the number of parameters describing cellular functions. The
main parameter assessed is the FP of spontaneously beating CMs that can be correlated with certain
elements of the AP pattern. Additionally, newly developed platforms provide the possibility to detect
impedance of the attached cell layer [56,57]. Unlike the FP that reflects the electrical activity, impedance
corresponds to the mechanical movement of the cell on the electrode. It is influenced by cell density,
cell number and the extent of cell adhesion. Thus, measuring impedance helps to acquire valuable
information about beating behavior, proliferation, cell death and viability [22,58].
A relationship between contraction parameters and electrophysiological activity has also been
investigated by combination of MEA and high-speed video microscopy, followed by motion based
image analysis of beating cells [59]. Likewise, fluorescence microscopy was used to correlate FP
measurements with subcellular information [60]. However, the combined setup of MEA platforms
with optical techniques requires certain structural features to achieve optimal visualization of target
cells, such as transparent electrodes [51,60,61].
In another study, Siemenov et al. developed a combined scanning ion conductance
microscopy–MEA system for simultaneous detection of cell surface morphology and FP in
cardiomyocytes [62]. The platform reveals morpho-dynamic parameters, including maximum
displacement and cell volume changes in a time-dependent manner. Together with the FP data
obtained from MEA measurements, the authors were able to reconstruct 3-dimensional motion of the
cell surface over a complete contraction-relaxation cycle [62].
In order to obtain reproducible and reliable experimental data, a number of points need to be
considered when working with MEA systems that are particularly important for drug screening assays.
Since individual iPSC-CMs show variations in AP waveforms [63], confluent monolayer cell sheets are
preferred to reduce the variability of the acquired FP patterns. In this regard, cell density needs to be
carefully addressed by the operator as it was found to influence electrical remodeling of CMs derived
from human iPSCs [64].
3. Action Potential vs. Field Potential
Both, AP and FP are parameters describing the membrane potential of cardiomyocytes or any
other cell type that is electrically active. They are generated by ion currents between the extra- and
intracellular space, tightly regulated by several different membrane-located ion channels [65]. In drug
32
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development, pharmacological compounds are classified in respect to their cardiotoxic effects based on
the AP or/and FP pattern in iPSC-derived CMs [34]. In addition, electrophysiology is used to identify
and characterize the different cardiac subtypes in iPSC derived CM populations, which is crucial for
specific cell programming strategies [20,66,67].
3.1. Action Potential in Native Cardiac Cells and iPSC Derived CMs
The AP represents the time-dependent alterations of the membrane potential in CMs that occur
during the contraction of heart tissue. This requires a well-defined orchestration of numerous ion
channels. Since the human heart comprises different cardiomyocyte subtypes, the AP pattern varies
significantly, depending on the regions of heart (e.g., atrium, sinus node and ventricle) [68].
Despite this electrical heterogeneity, each subtype specific pattern consists of five different phases,
reflecting the activity of certain ion channels (Figure 2A). Based on an incoming depolarization stimulus,
opening of voltage-gated Na+ channels induces sodium influx into the cytoplasm, resulting in a rapid
depolarization of the membrane potential up to +20 to +40 mV (Phase 0). Subsequently, phase 1 is
determined by time and voltage-dependent opening and closing of various ion transporters permeable
to Na+, Ca2+ and K+, leading to a slight, transient hyperpolarization of the membrane potential (−10 to
−30 mV). The following phase 2 is characterized by a relatively high capacity of the cell membrane and
it is primarily driven by depolarization-dependent L-type Ca2+ channels. Due to a balanced interplay
between inward currents of calcium and efflux of potassium phase 2 demonstrates a plateau period,
which is particularly prominent in ventricular muscle cells [68,69]. During the plateau phase, Ca2+
channel conductance decreases while the outward current of K+ inclines. This in turn promotes further
repolarization (phase 3) leading to a resting potential of ~−85 mV (phase 4).
As stated above, AP patterns are unique for each cardiac subtype resulting from different ion
channel composition within the cellular membrane (Figure 2A). Nodal cells, found in sinoatrial and an
atrioventricular AV node or His-bundles, are capable to generate their own AP without an additional
depolarizing stimulus. Compared to atrial and ventricular cells, the resting potential in nodal cells
is unstable, begins at ~−60 mV (vs. ~−85 mV in atrial and ventricular cells) and gradually increases
towards a threshold. This “pacemaker potential” is generated by K+ channels that open slowly upon
depolarization and deactivates with time. Concurrently, depolarization of about −60 mV activates a
nodal specific Na+ channel, known as the “funny channel”, causing an increase of the intracellular Na+
level. Once a threshold is reached, opening of voltage-gated Ca2+ channels induce a strong upstroke.
This is in contrast to atrial and ventricular cells where a Na+ influx mainly contributes to the rapid
depolarization in phase 0.
Differences in the AP pattern are also distinct between atrial and ventricular regions of the heart.
Atrial CMs undergo a more rapid early repolarization and demonstrate a less profound plateau phase,
followed by slow phase 3 repolarization (Figure 2A). These differences emanate from specific K+
channels, expressed in atrial cells, but not found in ventricular tissue [68].
Analysis and classification of AP patterns of iPSC-CMs is challenging as they demonstrate a
large amount of variability, which supports the notion that CMs derived from iPSCs are a mixture of
different cardiac subtypes of distinct maturation level [16,19,70]. Although multiple differentiation
protocols have been established, researchers failed to generate fully mature cardiomyocytes in vitro
possessing identical electrophysiological properties as their native adult counterparts [16,18]. For
example, Ronaldson-Bouchard et al. have shown structural and metabolic maturity and adult-state like
gene-expression of three iPSC cell lines after cultivation as cardiac tissues for four weeks, it remains to
be seen whether this approach can be generally transferred to any iPSC cell line [71]. In addition, it is
difficult to compare APs among different studies because of various experimental conditions used.
Nevertheless, a common feature of iPSC-CMs compared to native CMs is their ability to generate APs
without the need of an external, depolarizing signal, indicating a relative similarity with nodal tissue
cells. Indeed, iPSC-CMs were found to express funny channels to drive spontaneous activity. Another
nodal-cell characteristic of iPSC-CMs is their relatively positive resting potential of −60 to −70 mV that
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mainly relies on a lower or absent expression of the K+ channel IK1 [16,72], allowing the depolarizing
funny current to trigger the AP. This low level of IK1 further evokes a slower upstroke velocity in
phase 0. Computational simulations revealed that an increasing expression of IK1 in iPSC-CMs would
induce a more negative and more stable resting potential [16,72–74]. These data also indicate an
immature state of iPSC derived-CMs and suggests possible limitations for cardiovascular research and
clinical applications.
Figure 2. (A) Subtype specific pattern of the cardiac action potential. Ventricular, atrial and nodal cells
are characterized by unique depolarization and repolarization processes leading to different action
potential (AP) waveforms. Numbers correspond to the different phases that reflect the activity of
involved ion channels. (B) Comparison of the different phases between recorded action potential
and field potential. As field potential measurements allow reconstruction of the corresponding
action potential it provides important physiological parameters of electrically active cells, including
spike amplitude, FP interval, etc. (C) Moreover, MEA analysis can be applied to obtain data about
prolongation velocity and direction of the field potential spreading throughout the cell layer.
3.2. Field Potential
Classically, the cardiac action potential of single cells is analyzed using patch clamp devices, which
allow detection of each individual ion current contributing to the AP pattern [69,75]. In contrast, MEA
does not directly measure the AP but rather record cardiac FP instead, shown in Figure 2B. The FP
encompasses the spatiotemporal electrical activity of cell clusters attached to the electrode, thus, it is the
superposition of all ionic processes, ranging from fast action potentials to slowest fluctuations [76,77].
The measured FP arises from spreading of the cardiac AP throughout the cell monolayer relative to the
recording electrodes. Therefore, it is comparable to the clinical electrocardiogram signal that represents
voltage change over time due to electrical activity of the heart [47].
Since the biophysical processes underlying the generation of FPs are well known, it is possible
to reconstruct the corresponding AP pattern and to extract important physiological parameters [76].
34
Cells 2019, 8, 1331
Figure 2B depicts the different phases of a typical ventricular AP pattern and the corresponding FP
measured by MEA. The FP waveform contains a strong transient spike attributed to the Na+ influx and
associated membrane depolarization, followed by a gentle incline based on the intracellular increase
of Ca2+ level and ending with repolarization associated with K+ efflux. In addition, a comparative
analysis of patch clamp data and MEA recordings revealed that duration of the FPs correlate well with
the length of the QT interval of APs [78]. Similar results were obtained by Asakura et al., showing that
MEA-based FP detection can be applied to determine the prolongation of the QT interval following
drug administration in iPSC-derived CMs [49]. In addition to the QT interval and K+/Ca+ flux,
the FP pattern provides valuable information about the beating frequency as well as AP duration
(Table 1, Figure 2B). Moreover, since MEA measurements are commonly performed on cell monolayers,
propagation and direction of the AP can be determined (Figure 2C, Video S2).
Table 1. Functional parameters acquired by FP measurements using MEA Systems.




origin of AP spread
FP Duration QT interval of AP
FPs Over Time Beating frequency
Spike Amplitude Na+ current
Spike Plateau Ca2+/K+ current
Beat-to-Beat Interval AP duration
For a more precise comparison of FPs and patch clamp measurements, MEA platforms have
been developed that allow the detection of APs. These local extracellular AP assays, utilize electrodes
capable to apply electrical stimulation in order to induce small pores in the cellular membrane for the
acquisition of stable AP patterns over longer timescales [79,80]. In addition, the use of 3-dimensional
electrodes can facilitate the coupling intensity and decrease the membrane resistance of individual
cells required for intracellular recordings [81,82].
4. Application of MEAs for Cardiotoxic Risk Assessment
In 2014 the US department of health and human services estimated that nearly 1 million patients
show adverse drug reactions each year—among these drug induced arrhythmias are the leading
cause [83].
The comprehensive in vitro proarrhythmia assay (CiPA) initiative was originated for drug
proarrhythmic potential assessment in order to analyze several known drugs and substances on their
potential to affect the cardiac system. Thus, a list of 28 relevant drugs with a potential effect was
published. The list reaches from vandatanib, clarithromycin, droperidol over metoprolol to tamoxifen
and verapamil to name only a few. The drugs were categorized into high risk, intermediate risk and no
or very low risk for torsade-de-pointes-tachycardia (TdP; Table 2). TdP is characterized by polymorphic
ventricular tachyarrhythmias, which can follow drug induced delayed ventricular repolarization (OT
interval prolongation) [84,85]. For the categorization the initiative recommends and describes assays
that are mechanistically based in vitro assays and are composed of four different steps that in total
should give a comprehensive overview of the possible proarrhythmic potential:
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Table 2. List of CiPA compounds defined by CiPA initiative * (May 2016) [86].










D,l Sotalol Risperidone Verapamil
Ondansetron
First, the effect of potential drugs and substances on several cardiac ion currents, which are defined
as a core set of ion channel types needs to be analyzed. Second, the electrophysiological properties are
simulated in in silico models. Since ventricular cardiomyocytes can be generated from human stem
cells they represent a promising platform for drug testing, consequently the drug effects are measured
in this in vitro setting as the third step. Finally, the expected and unexpected effects on the entire
human organism need to be clinically evaluated [84].
Since the inception of the CiPA initiative in 2013, the analysis of the listed drugs was set into focus
of research by the research community. Several cell lines (including self-generated and commercially
available cell lines like iCell Cardiomyocytes (Fuji), Pluricytes (Pluriomics), Cor4u (Ncardia), Axol
Bioscience, i-HCm (Cell applications), ASC (Applied Stem Cell, ix Cells Biotechnologies), CDI (Cellular
Dynamics International), Cellartis (Clontech, Takara), ReproCardio (ReproCELL) and ACCEGEN
(immortalized from patients or transdifferentiated from hSC) have been used to analyze the impact
of compound administration on cardiomyocyte electrophysiology. The methodology used for the
measurements range from (automated) patch clamp over MEA to optical measurement.
There is a tendency noticeable promoting the assessment of not only hERG inhibition or QT
prolongation but also analysis of Nav1.5 (voltage gated Na+ channel), Cav1.2 (voltage gated Ca2+
channel) or of index of cardiac electrophysiological balance (assesses balance between OT interval and
QRS duration).
The Consortium for Safety Assessment using Human iPS cells (CSAHI) was established in 2013 by
the Japan Pharmaceutical Manufacturers Association in order to “give recommendations for the usage
of human iPS-cell derived cardiomyocytes, hepatocytes and neurons in drug testing evaluation” [87].
The CSAHI study is also aiming at the analysis of potential unknown effects on the cardiac system
and tries to overcome/decrease proarrhythmic-risk market withdrawal. There have been several
substances being tested that are not listed on the CiPA list. CSAHI provides a generalizable platform
with the promising method for prediction of cardiotoxicity [88]. There are different parameters that are
analyzed for the named prediction, such as QT prolongation, arrhythmia, but not only using the hERG
assay. The latter is known to be an inaccurate predictor, because it only focuses on the inhibition of
this particular ion channel—yet for cardiac adverse effects, mostly a broader range of (different) ion
channels is affected [89].
Using animal hearts as a model, (which is also done for drug testing approaches) or the guinea pig
papillary muscle action potential assay (qpAPD), is also not sufficient due to interspecies differences in
electrophysiological properties and different responding behavior to drugs [87,90].
The tested substances are modulating a range of cardiac ion currents and consequently can
have multiple arrhythmogenic effects. Due to this fact, multiple parameters are required to be
evaluated, especially when using MEA technology. The electrophysiological response to drugs can
be analyzed using the heart rate, field potential duration (FPD) and the corrected FPD (cFPD), all
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indicating arrhythmia-like waveforms [85]. Moreover, further analytical parameters are available
using impedance measurement, deformation analysis or high content imaging [87].
The usage of human iPSC-CMs for drug testing is a promising tool due to their large-scale
production circumventing the lack of a source for human adult cells [85]. However, they are
displaying/carrying the disadvantage of not being identical to isolated primary adult cardiomyocytes
and showing indicators for immature state, iPSC-CM are comparable in expression of cardiomyocyte
marker. Especially the expression of relevant cardiac ion channels such as INa, ICaL, If, Ito, IK1, IKr and
IKs has been analyzed [91,92]. Compared to previously used single ionic current model approaches
they have shown a higher sensitivity and specificity [85]. Techniques such as qpAPD evaluated several
false negative results [87], leading to possibly high risk in drug administration on patients. Many
attempts have been carried out to analyze the response of human iPSC-CM to the administration of
not only cardiogenic drugs and to further compare it to human adult cardiomyocytes. Yet, limitations
must be kept in mind when transferring results from cell models to the human organism.
Since comparability within CiPA associated data generation is crucial Kanda et al. aimed to develop
a standardized protocol for the experimental data generation including experimental conditions and
calibration compounds providing it to a big community [63].
In order to validate the reliability and comparability of iPSC-CM based drug testing CiPA
associated studies have been examined using a batch of known (formerly analyzed) drugs, various
commercial cell lines, different electrophysiological platforms and multiple experimental sites [85,93].
Differences between the various analyzed combinations could be seen but also representative effects on
depolarization, confirming the utility of the CiPA paradigm. Promoting the concept of CiPA, the CSAHI
study from Japan HEART TEAM could not detect any inter-facility variability [90] and is providing
new insights from their large scale drug testing combining electrophysiological data (from the MEA
platform) with gene expression profiles [87,88]. A comprehensive overview of tested substances on
their proarrhythmic risk/cardiac side effects using the combination of MEA technology with iPSC-CM
is given in Tables 3 and 4. Table 3 summarizes drugs with a primarily non-cardiac medical indication
such as antibiotic or antipsychotic drugs. Anti-arrhythmic drugs and cardiac ion-channel blocker are
included in Table 4, containing cardiogenic substances.
To consider the influence of serum containing medium during administration and measurement
of potential cardiotoxic drugs Schocken et al. compared serum containing and serum free medium in
pro-arrhythmia risk assessment. The solubility of a drug connected with the precise drug concentration
as well as cardiomyocyte electrophysiology may be affected by the serum. Mostly the precise serum
composition is unknown. Using a high-throughput MEA 25 substances have been analyzed, showing
differences in drug availability and the tendency of serum to influence the FPD in an increasing or
decreasing manner for several drugs [94].
To further improve and expand the system of iPSC-CM drug testing, Zeng et al. addressed the
diversity of iPSC-CM models from different gender and ethnical origin with known pharmaceuticals,
detecting possible inter-sex differences [95]. Therefore, they prefer/vote for generalized pre-set
acceptance criteria for iPSC-CMs. Burnett et al. recently published a study using not only a
population-based CM model, generated from cells of 43 individuals (both gender and diverse ancestry)
to defeat the drawback of inter-individual variability but also tested a large scale of substances of
pharmaceuticals, environment and food. Both for control and substrate administration they found
inter-individual variability, increasing the requirement of population based-models (to reproduce a
whole population) [96].
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5. Disease Modeling Using hiPSC-CM
Cardiovascular diseases (CVD) are the number one cause of death globally according to the WHO.
This group of disease is not only present in developed countries but also in low income countries. CVD
affects both the blood vessels and the heart and range from coronary heart disease, thrombosis, over
structural abnormalities of the heart and arrhythmias to stroke and heart failure [83].
In order to understand the pathological mechanisms of the disease iPSC-derived cardiomyocytes
generated from patient cells like dermal fibroblasts or blood cells showed high potential as a tool to not
only generate immortalized cell lines from healthy donors but also from diseased patients [105]. The
generated cell lines can show disease-specific phenotypes [99]. Especially physiological characteristics
can be determined when carrying the mutations in the cardiac relevant genes. This suggests that
the disease phenotype can be recapitulated in vitro. To further analyze the pathogenic mechanisms
causing the disease and the disease specific phenotype patient originated iPSC-CM were analyzed
and afterwards genetically fixed. Here, RNA interference can be used for silencing or suppressing
mutant genes [106]. To determine and control the effects caused by mutations the initial genetic defect
was induced and replicated in hESC derived CM on the contrary. A correction of the defect led to a
normalization of the analyzed parameter whereas the induction led to the diseased phenotype [107].
Besides a better understanding of heart disease, the transgenic models should contribute to testing
of cardiogenic drugs on their positive therapeutic as well as detrimental side effects. Moreover, the
sensitivity of patients for side effects of drugs can be evaluated and, the clinical vulnerability of
high-risk groups (population) to drug induced-cardiotoxicity can be set into consideration. This testing
of therapies in vitro is another promising tool [99,108].
For the analysis and validation of the generated iPSC-CM based disease models patch clamp
analyses are still the gold standard, despite the number of MEA based measurements in increasing
(Figure 3). In this part we want to give a selective overview about already developed disease
models for cardiac disease generated from human iPSCs, where the usage of MEA platform is
additionally mentioned.
Figure 3. Increase of PubMed listed publications involving MEA based analysis of “heart” or “drugs”
over the last five decades. The terms (multielectrode array and drug) or (microelectrode array and drug)
and (multielectrode array and heart) or (microelectrode array and heart) were used for the PubMed
search (date: Sept 2019).
6. Overview of Developed Disease Models
Ping Liang et al. generated a library of iPSC-derived CM from patients suffering from
various hereditary cardiac disorders to show that cardiac drug toxicity differs between different
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pathophysiological conditions. The iPSC-CM was generated from patients with hereditary long-QT
syndrome, familial hypertrophic cardiomyopathy and familial dilated cardiomyopathy. They have
shown that patients that already suffer from a heart disease have a higher incidence to show adverse
effects arising from their medical treatment. They seem to have a higher sensitivity to cardiotropic
drugs and can have a higher risk for arrhythmias, which possibly are leading to death [99].
In 2014 Zhang et al. generated cardiomyocytes derived from iPSC from patients with recessive,
life-threatening cardiac arrhythmia of Jarvell and Lang–Nielsen syndrome. They gave new insights
into the pathological mechanisms and showed enhanced sensitivity to proarrhythmic drugs in the
generated cell-based disease model using MEA technology and patch clamp [109].
Considering the literature of the last years for ion channelopathies, these appear to be in focus of
disease modeling, revealing many well-established human iPSC generated disease models. Among
these the long QT syndrome is the most common. The first model has been developed by Moretti
et al. (2010). Ventricular and atrial cells in contrast to nodal type or healthy control cells, have shown
significantly increased APDs [110]. The response of sporadic Long QT1-iPSC-CM to small molecule
inhibitors has been analyzed measuring changes in the FPD with the MEA platform [97].
A mutation in the gene of the sodium voltage-gated channel (Nav1.5) alpha subunit 5 (SCN5A)
for example is leading to conduction defects, phenotypes of the LQT3 and Brugada syndrome due to a
gain and loss of function [24]. A review on modeling long QT syndrome with the aid of iPSC-CM can
be found by Sala et al. [111].
Another channelopathy that has been used for the generation of a disease model is the
catecholaminergic polymorphic ventricular tachycardia (CPVT). An incorrect and insufficient Ca2+
handling (inclusive spontaneous release or sequestration) is leading to this adrenergically mediated
polymorphic ventricular tachycardia [112]. Sasaki et al. generated CM from CPVT patient- derived
iPSCs and identified S107 as a potential therapeutic agent since a pre-incubation with S107 led to a
reduction of isoprenaline induced delayed afterdepolarizations [113]. Acimovic et al. (2018) developed
a CPVT model using a novel ryanodine receptor mutation and further analyzed the response to a
treatment with flecainide and metoprolol [103].
Furthermore, models of structural myopathies have been developed: among these, the
hypertrophic cardiomyopathy (HCM) and the familial dilated cardiomyopathy (DCM) are the most
common being analyzed. HCM associated death is mostly caused by ventricular fibrillation developed
from ventricular arrhythmias. Despite that not all pathophysiological mechanisms are known yet,
some detected mutations have been the basis of developed disease models. HCM iPSC derived
cardiomyocytes have shown enhanced sarcomere arrangement [114], deviating electromechanical
properties such as delayed after depolarizations and calcium handling [115]. DCM is leading to
systolic dysfunction such as decreased ejection fraction due to an expanded size of the left ventricle
combined with decreased chamber thickness. Several known mutations have been fundamental
for the generation of a DCM model, including MYH7 [116], TNNT [117], LMNA (laminin A/c) [118],
Desmin [119], Titin [120] and RBM20 RNA-binding motif protein 20 [121,122]. On the cellular level
an increase in cell size, abnormal sarcomere structure and organization e.g., sarcomeric α actinin and
defective calcium handling (altering calcium machinery) [121] could be seen within these models.
For further detailed and completely information we would recommend the review by Giacomelli
et al. [123].
Moreover, cardiomyocytes have been generated from patients with Duchenne muscular dystrophy
iPSCs showing phenotypical deficiency of dystrophin and increased Ca levels in resting cells. The
before mentioned disease caused by a high quantity of mutations is characterized by a knockout of the
dystrophin protein resulting in muscle degeneration [124]. For further detailed reading we recommend
the systematic review on cardiomyopathy phenotypes in iPSC-CM (HCM and DCM) by Eschenhagen
and Carrier [125].
Besides the generation of disease models from patient derived cells, new gene editing technologies
find application: de la Roche et al. generated a model for the Brugada syndrome carrying the A735V
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mutation in the SCN5A gene introduced by CRISPR/Cas9 in order to be independent of the patient’s
genetic background. The generated CM showed electrophysiological alteration such as decreased
upstroke velocity and sodium current density [126].
Among the current literature the number of developed models that are not primarily heart
diseases (structural caused heart disease) but show heart related symptoms is increasing. For example
a model for Chagas disease, a parasite caused infection by Trypanosoma cruzi that is associated with
cardiomyopathy symptoms since the parasites are replicating in the cardiomyocytes, was developed
by Bozzi et al. after infection of iPSC-CM with Trypanosoma cruzi [127]. Lee et al. developed a model
for autosomal dominant polycystic kidney disease (ADPKD) form patient derived iPSC-CM showing
mutations in the PKD1/PKD2 gene [128], to name only two of them.
Since the generation of disease models with patient derived iPSC-CM was developed and
practiced within the last years, the first scientific outcome has been produced in a more detailed
understanding of the pathophysiological mechanisms that underlie known symptoms. Several recent
studies were performed:
Using patient derived iPSC-CM from Fabry disease combined with gene editing technology
Birket et al. analyzed the functional consequences of underlying genetic defects. They have shown
the accumulation of GL-3 and alterations in excitability and calcium handling in cardiomyocytes.
Moreover LIMP-2, shown to accumulate in the cells, was detected as a new potential biomarker [129].
Caluori et al. developed a system combining MEA platform with cantilever of atomic force
microscopy (AFM) in order to analyze the topography, beating force and electric events simultaneously
of control and DCM-derived iPSC-CM. Meanwhile substances for the cell characterization and toxicity
testing have been administrated [130].
Moreover, microtissues have been generated from the disease model cardiomyocytes for
hypertrophic cardiomyopathy HCM [131] and for catecholaminergic polymorphic ventricular
tachycardia CPVT [132]. The HCM model was used to analyze contraction force development and
calcium transient under mechanical overload revealing that both genetic defects and environmental
stress reinforce dysfunctions in contractility [131]. The CPVT tissue construct examined molecular
and cellular abnormalities and is confirming the approach of generating tissue like structures for the
analysis of arrhythmia, which is mostly generated by the connection of many cells [132].
Another approach for the further use of these disease models and an improved reliability of the
results/predictions are large scale simulations in in silico models. In order to enable this approach for
the LQT syndrome with regards to the phenotypical variation (due to the large amount of different
mutations) this system was developed and showed comparable results to experimental data concerning
electrophysiological properties. Additionally, this simulation can facilitate the understanding of further
biophysical mechanisms [133].
7. Conclusions and Outlook
Cardiomyocytes generated from human iPSCs are used to study heart development, cardiac
function and heart diseases, and to develop novel pharmacological therapeutics [11,21,23,134]. This
involves a detailed electrophysiological characterization of these cardiomyocytes under physiological
and pathological conditions. Due to its non-invasive, label-free character MEA methodology has
become a widely used tool to assess the electrical properties of cells in vitro. Besides iPSC-derived
cardiomyocytes, acquisition of the FP by MEA assays can also be applied to any other cell type
that shows electrical activity, including adult cardiomyocytes or neuronal cells. However, MEA
measurements are not only restricted to cell monolayers, but can also be performed on slices of cardiac
and brain tissue to better simulate in vivo conditions. Similarly, the replication of human physiology
can be enhanced when MEA technology is combined with in vitro generated organoids. Therefore,
MEA platforms can become a valuable tool in organ-on-a-chip engineering, promoting the clinical
translation of acquired data [135,136].
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As a high-throughput technology, MEA devices are particular important for the identification of
novel therapeutics in drug research. The combination of MEA systems and iPSCs has been successfully
applied in pharmacological studies and disease modeling, suggesting iPSC-based MEA measurements
as a powerful approach for the development of personalized therapies that allow a more specific
therapeutic intervention compared to conventional treatment options [137–139]. In this concept,
patient-derived iPSCs are obtained by reprogramming of fibroblasts and induced to differentiate into
cardiomyocytes. Subsequent analyses, e.g., transcriptomics and proteomics, enable the identification
of molecular targets needed for pharmacological therapy. In a second step, the potency and efficiency
of tested drugs is evaluated by MEA measurements, which in turn can provide important information
to establish personalized drug treatments. Thus, MEA technology will help to open a new gateway for
novel therapies in cardiovascular diseases.
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ADPKD Autosomal dominant polycystic kidney disease
AFM Atomic force microscopy
AP Action potential
APD Action potential duration
ATM Atomic force microscopy
AV Node Atrioventricular node
HCM Hypertrophic cardiomyopathy
Ca2+ Calcium
CiPA Comprehensive in vitro proarrhythmia assay
CM Cardiomyocytes
CPVT Catecholaminergic polymorphic ventricular tachycardia
CSAHI Consortium for Safety Assessment using Human iPS cells
CVD Cardiovascular disease
DCM Familial dilated cardiomyopathy
FP Field potential
FPDc Field potential duration (corrected)
FRET Fluorescence resonance energy transfer
GL-3 Basic helix-loop-helix proteins, GLABRA3
gpAPD Guinea pig papillary muscle action potential assay
hERG Human ether-a-go-go Related gene-voltage sensitive potassium channel
hiPSC Human induced pluripotent stem cell
K+ Potassium
LIMP-2 Lysosomal integral membrane protein 2
LMNA Lamin A/C
MEA Multi-/micro-electrode array
MYH7 Myosin heavy chain 7
Na+ Sodium
48
Cells 2019, 8, 1331
PKD1/2 Polycystic kidney disease 1
RNA Ribonucleic acid
SCN5A Sodium voltage-gated channel alpha subunit 5
TBX5 T-box transcription factor
TdP Torsade-de-Pointes-Tachycardia
TnnT TroponinT
VSO Voltage-sensitive optical system
WT Wild type
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Abstract: Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) represent an
unlimited source of human CMs that could be a standard tool in drug research. However, there is
concern whether hiPSC-CMs express all cardiac ion channels at physiological level and whether they
might express non-cardiac ion channels. In a control hiPSC line, we found large, “noisy” outward
K+ currents, when we measured outward potassium currents in isolated hiPSC-CMs. Currents
were sensitive to iberiotoxin, the selective blocker of big conductance Ca2+-activated K+ current
(IBK,Ca). Seven of 16 individual differentiation batches showed a strong initial repolarization in
the action potentials (AP) recorded from engineered heart tissue (EHT) followed by very early
afterdepolarizations, sometimes even with consecutive oscillations. Iberiotoxin stopped oscillations
and normalized AP shape, but had no effect in other EHTs without oscillations or in human left
ventricular tissue (LV). Expression levels of the alpha-subunit (KCa1.1) of the BKCa correlated with
the presence of oscillations in hiPSC-CMs and was not detectable in LV. Taken together, individual
batches of hiPSC-CMs can express sarcolemmal ion channels that are otherwise not found in the
human heart, resulting in oscillating afterdepolarizations in the AP. HiPSC-CMs should be screened
for expression of non-cardiac ion channels before being applied to drug research.
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1. Introduction
Human induced pluripotent stem-cell derived cardiomyocytes (hiPSC-CMs) have gained interest as
a human model to study heart physiology and pathophysiology [1–4], cardiovascular pharmacology [5]
and cardiac repair [6]. In this context, it is important that hiPSC-CMs share properties of human
adult CMs. Many reports claimed that characteristics of hiPSC-CMs might differ from adult CMs, a
finding frequently interpreted as immaturity. On the one hand, immaturity could be caused by the lack
of cardiac ion channels or by differences in expression levels such as the inward rectifier potassium
current (IK1) [7–10]. On the other hand, hiPSC-CMs can show ion currents, which are absent in adult
human CMs such as the T-type calcium current [11,12]. Based on these findings, there is a need for a
detailed electrophysiological characterization of hiPSC-CMs before using them as a model for human
CMs. Here we report the coincidently found expression of a non-cardiac ion channel in hiPSC-CMs
as a peculiarity of a single control cell line: the big conductance calcium activated potassium current
(BKCa; alternatively used names: Maxi-K, slo1, KCa1.1).
BKCa is a voltage- and calcium-gated potassium channel (KCa1.1) generating huge conductivity
for potassium. BKCa is widely expressed in the human body, mainly in neural cells, blood vessels,
kidney, but not in in cardiomyocytes. Recently, artificial expression of BKCa was shown to be able to
shorten action potentials (APs) in murine CMs [13]. Consequently, expression of the non-cardiac BKCa
current in human CMs was proposed as a genetic therapy for the long QT syndrome. However, the
contribution of individual ion channels to repolarization and resulting AP shape differs from murine
to human CMs. Putative impact of BKCa to human cardiac electrophysiology remains unclear.
The goal of this study was to draw attention to the fact that hiPSC-CMs can express non-cardiac
ion channels. In addition, we had the chance to elucidate how the expression of BKCa may influence
the membrane potential of human CMs. Based on our findings, we propose a regular assessment for
expression of non-cardiac ion channels as a part of quality control when using hiPSC-CMs.
2. Methods
2.1. Generation of hiPSC and Engineered Heart Tissue (EHT)
The hiPSC line C25 (kind gift from Alessandra Moretti, Munich, Germany) was reprogrammed by
lentivirus [1] and was expanded in FTDA medium and differentiated in a three step protocol based on
growth factors and a small molecule Wnt inhibitor DS07 (kind gift from Dennis Schade, Dortmund,
Germany) as previously published [14–16]. The hiPSC line ERC018 were generated in-house from
skin fibroblasts of a healthy subject using the CytoTuneTM-iPS Sendai Reprogramming Kit (Thermo
Fisher Scientific, Waltham, MA, USA) and differentiated to cardiomyocytes as described for C25.
In brief, confluent undifferentiated cells were dissociated (0.5 mM EDTA; 10 min) and cultivated in
spinner flasks (30 × 106 cells/100 mL; 40 rpm) for embryoid body formation overnight. Mesodermal
differentiation was initiated in embryoid bodies over three days in suspension culture with growth
factors (BMP-4 (R&D Systems, 314-BP), activin-A (R&D Systems, 338-AC) and FGF2 (PeproTech,
100-18B)). Cardiac differentiation was performed either in adhesion or in suspension culture with
Wnt-inhibitor DS07. Cells were cultured in a humidified temperature and gas-controlled incubator
(37 ◦C, 5% CO2, 5% O2 and 21% O2 for final cardiac differentiation). At day 14 the spontaneously
beating hiPSC-CMs were dissociated with collagenase II (Worthington, LS004176; 200 U/mL, 3.5 h).
For quality control, dissociated cells were analyzed by flow cytometry as described before [14,17] with
anti-cardiac troponin T-FITC (Miltenyi, clone REA400, 130-112-756). All differentiation runs utilized for
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this study had 64–96% cardiac Troponin T positive cells (Supplementary Materials Figure S2). Further
characterization of the non-CMs within the EHT was evaluated previously by our group [6], showing
low expression of vimentin-positive fibroblast-like markers and the virtual absence of endothelial,
neuronal, and endodermal markers. ICell and iCell2 cardiomyocytes are commercially available
hiPSC-CM lines purchased from Fujifilm Cellular Dynamics (Madison, Wisconsin, USA) and were
included in expression analysis after culture in EHT. For three-dimensional culture EHTs were generated
with 1 × 106 hiPSC-CM/100 μL EHT mastermix as previously described [18]. EHTs were cultured in a 37
◦C, 7% CO2 and 40% O2 humidified cell culture incubator with a medium consisting of DMEM (F0415,
Biochrom; Berlin, Germany), 10% heat-inactivated horse serum (Gibco 26050, Thermo Fisher Scientific,
Waltham, MA, USA), 1% penicillin/streptomycin (Gibco 15140), insulin (10 μg/mL; Sigma-Aldrich
I9278, St. Louis, MO, USA) and aprotinin (33 μg/mL; Sigma-Aldrich A1153). EHTs were cultured for at
least 3 weeks to allow maturation. The work with hiPSC was approved by the Ethical Committee of
the University Medical Center Hamburg-Eppendorf (Az. PV4798, 28.10.2014). All donors gave written
informed consent.
2.2. Human Adult Heart Tissue
This investigation conforms to all principles outlined by the Declaration of Helsinki and the
Medical Association of Hamburg. All materials from patients were taken with informed consent of the
donors. Left ventricular free wall and left ventricular septum samples were obtained from patients
undergoing heart transplantation or from aortic valve surgery.
2.3. Current Recordings
HiPSC-CMs in EHT were isolated with collagenase II for 5 h (200 U/mL, Worthington, LS004176
dissolved in HBSS-Puffer without Mg2+ or Ca2+, Gibco 14175-053 and 1 mM HEPES; pH 7,4), and
re-plated on gelatin-coated coverslips for 24–48 h in order to maintain adherence under perfusion.
Outward K+ currents were measured at 37 ◦C, using the whole-cell configuration of the patch clamp
technique. Axopatch 200B amplifier (Axon Instruments, Foster City, CA, USA) and ISO2 software
were used for data acquisition and analysis (MFK, Niedernhausen, Germany). Heat-polished pipettes
were pulled from borosilicate filamented glass (Hilgenberg, Malsfeld, Germany). Tip resistances were
2.5–5 MΩ when filled with pipette solution. Seal resistances were 2–4 GΩ. The cells were investigated
in a small perfusion chamber placed on the stage of an inverse microscope. Application of drugs was
performed by a system for rapid solution changes (Cell Micro Controls, Virginia Beach, VA, USA;
ALA Scientific Instruments, Long Island, NY, USA) [19]. The experiments were performed with the
following bath solution (in mM): NaCl 120, KCl 5.4, HEPES 10, CaCl2 2, MgCl2 1 and glucose 10 (pH 7.4,
adjusted with NaOH). Outward currents were elicited by 1000 ms depolarizing test pulses from −80 to
+70 mV (0.2 Hz). The pipette solution included (in mM): DL-Aspartate potassium salt 80, KCl 40, NaCl
8, HEPES 10, Mg-ATP 5, Tris-GTP 0.1, EGTA 5 and CaCl2 4.4, pH 7.4, adjusted with KOH [20].
2.4. AP Recordings
To record APs in intact EHT and in left ventricular trabeculae we used sharp microelectrodes as
reported previously [5,9,21]. Microelectrode tip resistances were 20–50 MΩ when filled with 3 mM
KCl. APs were elicited by field stimulation at 1 Hz, 0.5 ms stimulus duration and 50% above threshold
intensity. The following bath solution was used (in mM): NaCl 125, KCl 5.4, MgCl2 0.6, CaCl2 1,
NaH2PO4 0.4, NaH2CO3 22 and glucose 5.5 and was equilibrated with O2–CO2 (95:5). The experiments
were performed at 37 ◦C.
2.5. Molecular Biology
Total RNA was extracted from snap frozen LV and EHT using an RNAeasy mini Kit (Qiagen,
Valencia, CA, USA). RNA concentration was determined per fluorometric quantitation with QubitTM
(Thermo Fisher Scientific; Waltham, MA, USA) according to the manufacturer’s instructions. Of total
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RNA 50 ng was used for expression analysis by nanoString nCounter® SPRINT Profiler according
to the manufacturer’s instructions. Raw data were analyzed with nSolverTM Data Analysis Software
including background subtraction using negative controls and normalization to two housekeeping
genes (GAPDH and PGK1).
2.6. Mathematical Modelling and Computer Simulations
To simulate the BKCa current in silico, we extended a previously published formulation [22]
to include (1) calcium dependence according to the Lin et al. [23] data, and (2) inactivation kinetics
according to Ding et al. [24] data. To demonstrate the contribution of BKCa current on AP repolarization,
we integrated the BKCa model to a well-established human left ventricular CM model [25].
2.7. Statistical Analysis
Results are presented as mean values ± SEM. Area under the curve was calculated by using the
GraphPad Prism Software 5.02 (GraphPad Software, San Diego, CA, USA). Statistical differences were
evaluated by using the Student’s t-test (paired or unpaired) or repeated measures ANOVA, followed by
a Bonferroni test, where appropriate. A value of p < 0.05 was considered to be statistically significant.
2.8. Drugs
All drugs and chemicals were obtained from Sigma-Aldrich (St. Louis, MI, USA) except for
iberiotoxin (IBTX, Tocris Bioscience, Bristol, UK).
3. Results
3.1. Outward Potassium Currents in hiPSC-CMs, Appearance of IBK,Ca
Large, transient outward currents were elicited in hiPSC-CMs (Figure 1A) by depolarizing test
pulses. We found in several C25-hiPSC-CMs a large, inactivating outward current followed by a late
sustained current with an irregular shape during the entire depolarizing test pulse. The irregular-shaped
“noisy” currents were similar to BKCa currents, which were reported previously in mesenchymal stem
cells [26]. Similar to that report we used rather high test pulse potentials (+70 mV) from physiological
resting membrane potential of −80 mV and increased the free Ca2+ concentration of the pipette solution
from 2 to 4.4 mM to facilitate the detection of BKCa [26]. The selective IBK,Ca blocker IBTX (100 nM) was
used to identify the IBK,Ca (Figure 1A). Of the hiPSC-CMs 76% (19 out of 25) showed IBTX-sensitive
outward currents suggesting the presence of BKCa; the area under the curve was reduced by IBTX from
30.6 ± 5.1 pAs/pF to 20.2 ± 4.1 pAs/pF (n = 19, p < 0.0001, paired t test, Figure 1B). IBTX inhibited both
the peak and late current density (peak from 82.9 ± 11.5 pA/pF to 44.8 ± 7.6 pA/pF, p < 0.0001, Figure 1C
and late: from 29.2 ± 5.4 pA/pF to 17.8 ± 3.4 pA/pF; n = 19, p = 0.004, Figure 1D). In IBTX-insensitive
hiPSC-CMs, baseline values of outward peak and late currents were smaller compared to IBTX-sensitive
hiPSC-CMs. Furthermore, in hiPSC-CMs without the irregular-shaped outward current IBTX did not
change peak or late currents (peak: 45.4 ± 6.4 pA/pF baseline vs. 43.4 ± 3.9 pA/pF IBTX, p = 0.594, n = 6
and late: 8.3 ± 2.6 pA/pF baseline vs. 7.5 ± 1.8 pA/pF IBTX, n = 6, p = 0.363; paired t test). HiPS-CMs
from the commercially available iCell cell line did not show irregular-shaped “noisy” currents or
IBTX-sensitivity (Supplementary Materials Figure S1).
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Figure 1. Outward currents in C25 human induced pluripotent stem cell-derived cardiomyocytes
(hiPSC-CMs) and the effect of iberiotoxin (IBTX). (A) Original outward traces before (black) and after
(green) exposure of 100 nM IBTX in insensitive (upper, black directly underlying green curve) and
sensitive (lower panel) hiPSC-CMs. (B–D). Summary of IBTX (100 nM) effects in insensitive (left panel)
and sensitive (right panel) hiPSC-CMs quantified by area under the curve (B), peak current (C) and
current at the end of the test pulse (late current, D). Mean values ± SEM. * p < 0.05, unpaired Student’s
t test for basal values in insensitive vs. sensitive hiPSC-CMs; ## p < 0.01, ### p < 0.001; paired Student’s
t test for basal vs. IBTX; n = number of isolated cells/number of individual differentiation batches.
3.2. Action Potentials with Strong Initial Repolarization and Oscillations Are Sensitive to Iberiotoxin
APs recorded in C25-EHTs, exhibiting the IBTX-sensitive irregular-shaped outward current,
showed a pronounced initial repolarization (“notch”) below the later plateau level of the AP and
the initial notch was followed by a (very) early afterdepolarization (Figure 2). In some APs the
notch was followed by a peculiar oscillation during plateau phase of the AP. This peculiarity of
notch/oscillation was only observed in some of independent differentiation batches of the C25 cell line,
but never in any other of three in-house cell lines or five commercial cell lines investigated with sharp
microelectrodes as previously described [5,9,27–30]. When the notch/oscillation was detected in one
EHT, all impalements showed this peculiarity including all EHTs from this differentiation batch. From
all C25 batches investigated with sharp microelectrode, we detected seven with notch/oscillations and
11 without. The passage number of individual differentiation batches was not significantly different
with or without notch/oscillations (77.1 ± 5.9, n = 7 vs. 67.9 ± 7.9, n = 9; p = 0.391) as well as the
hiPSC-CM differentiation efficiency (81% ± 5% vs. 85% ± 3% TnT + cells, p = 0.51). In addition,
spontaneous beating frequency was not different between EHTs with or without notch/oscillations
(1.09 ± 0.19 Hz, n = 9 vs. 0.92 ± 0.07 Hz; n = 14; p = 0.34). EHTs were treated with 300 nM ivabradine
to allow pacing at 1 Hz as previously described [5]. Under these conditions, APD90 was slightly longer
in EHTs with notch/oscillations than without (279 ± 12 ms, n = 18/9/6 vs. 226 ± 6 ms, n = 30/17/9;
p = 0.0044). Take-off potential, upstroke velocity and AP amplitude were not significantly different.
The number of oscillations within one AP varied between 1 and 6. In case of several oscillations, there
was a rather constant cycle length of oscillations in different EHTs (22.8 ± 0.9 ms, n = 11). In case of
multiple oscillations, the amplitude decreased with each subsequent oscillation (ranging from 50 to
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10 mV, Figure 2B). We used the specific inhibitor IBTX (100 nM) in order to evaluate whether oscillations
originate from IBK,Ca. To quantify effects of IBTX on early repolarization we analyzed the membrane
potential when the initial repolarization reached its lowest point (on average 9.2 ± 0.7 ms after AP
upstroke).
Figure 2. Pronounced notch with oscillation in the plateau phase of action potential (AP) recorded
from engineered heart tissue (EHT) derived by C25 human induced pluripotent stem cell-derived
cardiomyocytes (hiPSC-CMs). (A) Original AP recordings without (A) and with (B) notch followed
by oscillating afterdepolarizations in EHT from cell line C25. (C) Summary of the results for take-off
potential (TOP), AP amplitude (APA), maximum upstroke velocity (Vmax), AP duration at 90%
repolarization (APD90), ** p < 0.01, unpaired Student’s t test; n = number of impalements/number of
EHTs/number of individual differentiation batches.
In case of notch/oscillations, IBTX (100 nM) lifted the membrane potential at this time point from
−43.5 ± 5.6 to −13.2 ± 8.3 mV (n = 7, p = 0.001, paired t-test). APD10, APD20, APD50 and APD70
but not APD90 was significantly prolonged by IBTX (Figure 3). IBTX did not affect AP duration in
EHTs without notch/oscillations. In addition, IBTX did not show any effect on AP in human LV tissue
(Figure 3).
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Figure 3. Effects of iberiotoxin (IBTX) on action potentials (APs) in C25 engineered heart tissue (EHT)
and in human left ventricular tissue (LV). Original AP recordings before and after exposure to IBTX
(100 nM, green) in EHTs with (A) and without (B) notch/oscillations from cell line C25 and in LV (C).
Mean values of AP duration at different levels of repolarization (APD10-90) before and after exposure to
IBTX (100 nM) in EHTs with (D) and without (E) notch in cell line C25 and in LV (F). Mean values ± SEM,
* p < 0.05, ** p < 0.01, paired Student’s t test.
3.3. EHT with Notch/Oscillations in the AP Showed Large BKCa Expression
The BKCa channel is formed as a tetramer of the channel forming alpha-subunit KCa1.1 encoded
by the KCNMA1 gene. We performed retrospectively expression analysis in order to investigate
whether there was an association between appearance of oscillations and the expression level of
KCNMA1. The mRNA level for the channel forming alpha-subunit KCa1.1 showed very low expression
in human LV tissue. The same holds true for the in-house control cell line ERC018 and the commercially
available cell lines iCell and iCell2, where notch or oscillations in the AP have never been detected [5].
In contrast, all EHTs from C25 from which we could record notch/oscillations showed a substantial
increase in KCNMA1 mRNA, which is encoding for KCa1.1 (Figure 4). In addition, RNA sequencing
showed a 12-fold higher expression level for KCNMA1 in C25 than in the control cell line ERC001
(Supplementary Figure S4). Other genes related to KCNMA1 did not show major alterations in
expression. Immunofluorescence analysis of hiPSC-CMs revealed the expression of the alpha-1 subunit
of the BKCa channel in the C25 cell line with enhanced signal intensity at cell-cell contacts, whereas no
signal was detected in the control cell line [30] (Supplementary Figure S5).
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Figure 4. Expression analysis for the alpha subunit (KCNMA1) of big conductance calcium activated
potassium channel. Individual expression levels of KCNMA1 in left ventricular tissue (LV) and
engineered heart tissue (EHT) from cell line C25 (without and with notch/oscillations), ERC018, iCell
and iCell2. Mean values ± SEM, *** p < 0.001, 1-way ANOVA with multiple comparison, n = number of
patients for LV and n = number of EHT/number of individual differentiation batches.
3.4. Computer Simulations Corroborate the Effect of the Non-Cardiac BKCa to Human AP
To evaluate the impact of BKCa on repolarization quantitatively, we integrated a BKCa model into
a human ventricular CM model. Simulation results in Figure 5 demonstrated that a reasonably sized
BKCa current can cause a deep notch in the AP. The dynamics of the notch (Figure 5A) match the kinetics
of the simulated BKCa current (Figure 5B). Although inclusion of BKCa did not cause oscillations of the
membrane voltage similar to in vitro observations, the deep notch enhanced drastically L-type Ca2+
current (ICa,L, Figure 5C).
Figure 5. Impact of including BKCa in a mathematical model of human ventricular cardiomyocytes.
BKCa current (B) causes a deep notch in the action potential (A), and a substantial increase in the
amplitude of L-type Ca2+ current (C).
4. Discussion
The main findings of this study were:
(1) HiPSC-CMs could express ion channels otherwise not found in adult cardiomyocytes.
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(2) In human adult ventricular myocardium, BKCa did not contribute to AP shape.
(3) In hiPSC-CMs BKCa could induce irregular AP shapes with oscillations resembling very early
after depolarizations.
BKCa channels are widely expressed in various cell types, including electrically excitable and
non-excitable cells [31]. Due to the Ca2+-sensitivity, they provide relevant negative feedback mechanism
in the regulation of intracellular Ca2+ elevation and membrane potential [32]. Almost every cell type
expresses BKCa in the inner mitochondrial membrane (BKmito) [33]. In CMs, pharmacological opening
of BKmito reduces ischemia reperfusion injury [34]. Sarcolemmal expression of BKCa is typically
found in vascular smooth muscle cells, regulating myogenic tone and thereby blood flow. In CMs
from rodents and cardiac tissue from humans, sarcolemmal expression of BKCa is very low or almost
non-existent [35–37]. Here we confirm low expression levels of BKCa in human LV myocardium.
Among CMs from other species, IBTX sensitive currents were found only in cultured embryonal chicken
CMs [38]. Contribution to repolarization in this species is unclear. In rat ventricular myocardium, IBTX
does not affect AP shape [39]. Here, we demonstrated for the first time that human ventricular APs
were insensitive to IBTX. In consequence, the detection of IBK,Ca in C25-hiPSC-CMs during patch clamp
recordings was unexpected and surprising, since BKCa is not known to be expressed in the sarcolemma.
The effectivity of the selective blocker of IBK,Ca [26,40], IBTX, which only binds from the external
side of the channel [41], confirmed the hypothesis that a non-cardiac channel is present and active at
transmembrane level in the hiPSC-CMs. These findings were also confirmed by expression analysis
in which the existence of the notch/oscillation in the AP correlated with the high expression levels of
KCNMA1, encoding for the alpha-subunit (KCa1.1) of the BKCa. In contrast, KCNMA1 expression was
low in human LV tissue and correspondingly IBTX did not show any effect on APs from human LV,
which to our knowledge has not been described before.
Recently, overexpression of non-cardiac BKCa in CMs was proposed as a treatment for LQTS [13],
since BKCa is a hyperpolarizing channel, which might shorten human AP. Support for this idea came
from a study describing the electrophysiological function of BKCa in HL-1 cells by viral overexpression,
a cell line derived from a murine atrial tumor. BKCa overexpression reduced the very short AP of this
murine model by 50% (APD90 from 30 to 14 ms) and was proposed as a potential genetic therapy to
reduce AP duration (APD) of the LQT syndrome [13]. In contrast to the experiments in HL-1 cells, we
observed that in hiPSC-CMs, the presence of BKCa induces oscillations in the early plateau phase and
no speed-up in the final repolarization [13].
The pronounced initial repolarization could be confirmed by the in-silico integration of the IBK,Ca
in modeling ventricular myocyte AP (Figure 5). However, the inclusion of BKCa could not resemble
oscillations of the membrane voltage. Nevertheless, we would expect that oscillation might be induced
by an alternating feedback mechanism [32] of the IBK,Ca and the L-type Ca2+ current (ICa,L), since the
deep notch drastically enhanced L-type Ca2+ current (Figure 5C). The afterdepolarizations following
the initial repolarization might be also due to activation of ICa,T [11] or the sodium calcium exchanger,
however, the exact mechanism remains unclear. More accurate and detailed mathematical modeling
would require in vitro data on spatial distribution and localization of the BKCa and Ca2+ channels,
which is beyond the scope of this study.
Afterdepolarizations might complicate the evaluation of how the BKCa affects APD. In vitro, there
was a slightly longer APD90 when BKCa was present, which could be confirmed in silico. However,
the inhibition of IBK,Ca by iberiotoxin in AP with notch/oscillations did not significantly alter APD90,
averaged values tended even to longer APD90. The apparent differential contribution of BKCa to the
APD revealed at baseline level or by pharmacological intervention might be due to remodeling of other
ion channels downstream to BK expression or due to potential off-target effects of iberiotoxin. Taken
together, our results do not support the idea that BKCa overexpression can cure LQTS in humans, since
BKCa might lead to afterdepolarization and arrhythmia.
Previously, it was shown that the IBK,Ca current contribute to outward currents in the murine
sinoatrial node and the selective blocker paxilline decreased beating rate by more than 50% [42].
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However, the exact role of IBK,Ca in pacemaking is widely unclear, since substantial decrease in diastolic
depolarization by paxilline does not fit to very small contribution of BKCa to total potassium outward
currents activated at positive membrane potentials. Nevertheless, spontaneous beating is a peculiarity
of hiPSC-CMs and the autonomic activity of hiPSC-CMs is not fully understood. Therefore, it seems
reasonable to speculate that BKCa may be involved in pacemaking of hiPSC-CMs. However, we would
not expect a large impact of IBK,Ca to pacemaking in EHT, since beating rate in EHT with and without
expressing BKCa did not differ.
The reason for the unexpected expression of BKCa in individual differentiation batches of a single
hiPSC-CM cell line (C25) is very difficult to evaluate retrospectively. Cell line C25 did not show
chromosomal anomalies at passage number 40 and 92 (Supplementary Figure S3). Since 6 out of 7
individual differentiation batches were done from lower passage numbers than 92, it seems that BK
expression was not the consequence of karyotype abnormalities. As notch/oscillation were observed
also in preparations with very high differentiation efficiencies (90% and 93%) and hiPSC-CM fraction
in EHT was even enriched in comparison to 2D culture (Supplementary Materials Figure S2B), we
are confident that BK expression is not due to an extraordinary high fraction of non-cardiac cells
within the EHT. Strong batch effects, as either all or none of the EHTs from one preparation depicted
signs of BKCa expression, argue for an upregulation of BKCa due to events occurring during stem cell
culture and cardiac differentiation. There are two factors that might have raised the likelihood for
spontaneous mutations in the stem-cell culture. The C25 cell line was reprogrammed by lentivirus
and it was passaged to very high number (up to 107 passages). To avoid these factors, we changed
to Sendai virus and restricted passage number for future experiments. Since KCNMA1 related genes
did not show major alterations in contrast to KCNMA1 itself, we would account a genetic alteration
more likely than an upregulation due to regulatory pathways. In addition, various reports show
that iPS-cells frequently acquire genetic alterations in cell culture. Kilpinen et al. [43] showed that
chromosome 10, harboring BKCa/KCNMA1, was among the most susceptible loci to copy number
alterations. In addition, in a study searching for variants that provide mutated cells with a growth
advantage in culture, KCNMA1 candidate mosaic variants were identified in two independent hES cell
lines [44]. Thus, a genetic alteration leading to a reoccurring overgrowth of BK misexpressing hiPSC is
the most likely explanation for our finding. Regulatory expression profiling might reveal this change
of BKCa activity in advance.
5. Conclusions
Our results clearly demonstrated that hiPSC-CMs could possess even non-cardiac ion channels
affecting AP waveform causing afterdepolarizations and oscillations in the AP. This might serve as an
example that iPS cell culture could lead to genetic alterations with functional consequences. Therefore,
we felt that cell culture and differentiation protocols should be standardized as much as possible and
that expression of non-cardiac sarcolemmal ion channels should be considered before hiPSC-CMs are
used for pharmacological studies. Screening for the expression of the KCNMA1 gene might be one
potential quality parameter.
6. Limitations
We are aware that the description of the BKCa in a single control cell line of hiPSC-CMs is of limited
transferability, especially since we could not uncover conditions or mechanisms of the unexpected
BKCa expression. Nevertheless, presence of BKCa is a good example that hiPSC-CMs can express
non-cardiac proteins with a huge impact on physiological parameters. Although IBTX has been
described as selective for IBK,Ca [41], non-specific effects of IBTX cannot be completely excluded. LV
tissue was obtained from patients with heart disease; a potential difference to healthy LV tissue is
unclear. We implemented the BK in the previously developed hiPSC-CM model [5], but we failed to
induce notch/oscillations in that model. Obviously, our present model does not reflect the cellular
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ultrastructure at the level of detail that would be required for simulating the putative close proximity
of the BK and CaL channels.
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AP Action potential
APD Action potential duration
APD90 Action potential duration at 90% repolarization
BKCa Big conductance calcium activated potassium channel, (Maxi-K, slo1, KCa1.1)
CM Cardiomyocytes
EAD Early afterdepolarization
EHT Engineered heart tissue
hiPSC-CMs Human induced pluripotent stem cell-derived cardiomyocytes
IBTX Iberiotoxin
IBK,Ca Big-conductance calcium activated potassium current
ICa,L L-type calcium current
LV Left ventricle
RMP Resting membrane potential
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Abstract: Background: Ventricular arrhythmias (VA) are a common cause of sudden death after
myocardial infarction (MI). Therefore, developing new therapeutic methods for the prevention
and treatment of VA is of prime importance. Methods: Human bone marrow derived CD271+
mesenchymal stem cells (MSC) were tested for their antiarrhythmic effect. This was done through the
development of a novel mouse model using an immunocompromised Rag2−/− γc−/− mouse strain
subjected to myocardial “infarction-reinfarction”. The mice underwent a first ischemia-reperfusion
through the left anterior descending (LAD) artery closure for 45 min with a subsequent second
permanent LAD ligation after seven days from the first infarct. Results: This mouse model induced
various types of VA detected with continuous electrocardiogram (ECG) monitoring via implanted
telemetry device. The immediate intramyocardial delivery of CD271+ MSC after the first MI
significantly reduced VA induced after the second MI. Conclusions: In addition to the clinical
relevance, more closely reflecting patients who suffer from severe ischemic heart disease and related
arrhythmias, our new mouse model bearing reinfarction warrants the time required for stem cell
engraftment and for the first time enables us to analyze and verify significant antiarrhythmic effects
of human CD271+ stem cells in vivo.
Keywords: arrhythmia; electrocardiography; cardiac regeneration; stem cells
1. Introduction
Deaths arising from ventricular arrhythmias (VA) after acute cardiac events, in Germany, have
increased by 100% over the last twenty years [1]. Therefore, new therapeutic methods for the
prevention of VA following myocardial infarction (MI) need to be developed. There are reports that
have indicated that transplanting of various stem cell populations post MI can influence the heart
rhythm. Some have been defined as pro-arrhythmogenic cells, i.e., skeletal myoblasts, while others
have shown antiarrhythmic effects, such as embryonic cardiomyocytes and mesenchymal stem cells
(MSC) [2–5]. Our research group has focused on the role of human bone marrow (BM) derived
hematopoiesis such as MSC in regenerative medicine [6–9]. In previous studies we have shown that it
is safe to use CD117+ stem cells for myocardial regeneration, as their electrophysiological properties
make them very unlikely to produce hazardous action potentials or contribute to arrhythmias [10,11].
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However, the availability of a realistic small animal model reflecting the situation in patients is of utmost
importance. For testing the rhythmological behavior of human cells, Rag2−/− γc−/− has been selected.
These mice (strain C, 129S4-Rag2tm1.1FlvIl2rgtm1.1Flv/J) have been derived from a V17 embryonic stem
cell line (BALB/c × 129 heterozygote) targeted for the Rag2 and Il2rg genes and lack B, T, and natural
killer (NK) cells [12]. They have a deletion of the common cytokine receptor γ chain (γc) gene, and
thus reduced numbers of peripheral T and B lymphocytes, and absent natural killer cell (NK) activity.
A genetic cross with a recombinase activating gene 2 (RAG2) deficient strain produced mice doubly
homozygous for the γc and RAG2 null alleles (Rag2−/− γc−/−) with a stable phenotype characterized
by the absence of all T lymphocyte, B lymphocyte, and NK cell function [13]. This phenotype makes
the completely a lymphoid strain useful for studies on human tissue xenotransplantation [14].
As previously shown, stem cell antiarrhythmic effects appear after completion of an approximately
one-week engraftment period [4]. The major objective of the present study was to develop a mouse
model that enables us to reproduce VA several days after an initial MI. In vivo electrophysiological
mouse models are well established: Previously, Berul et al. established an open chest epicardial
study of conduction properties with the ability to induce second and third degree heart blocks, but
no induction of tachyarrhythmias after programmed stimulation [15]. Hagendorff et al. used a rapid
transesophageal atrial stimulation with the ability to induce some types of heart block and atrial
tachyarrhythmias with induction of VA [16]. Roell et al. used a method relying on burst and extra
stimulus pacing mediated induction of VA, leading to induction of ventricular tachycardia (VT) in
38.9% of the non-infarcted control group and 96.4% of the infarcted group [4].
This mouse model can also be considered representative for patients that suffer from severe
ischemic heart disease and related arrhythmias. In this respect the application of the second MI at
various points in time will be of interest.
2. Materials and Methods
2.1. Bone Marrow Aspiration
Informed donors gave written consent to the aspiration of their BM according to the Declaration of
Helsinki. The ethical committee of the University of Rostock approved the presented study (registered
as no. A201023) as of 29 April 2010. The BM samples were obtained by sternal aspiration from
patients undergoing coronary artery bypass graft surgery at Rostock University, Germany. The donors
had no BM or hematological diseases and were not receiving any immune suppressing medication.
The amount of the aspirated BM ranged from 60–100 mL. The BM samples were received from four
donors. Two donors got more than 200,000 isolated CD271+ MSC in their BM samples and each one
has been used for 2 mice (100,000 cells/animal). Anticoagulation was achieved by heparinization with
250 i.E./mL sodium heparine (B. Braun Melsungen AG, Melsungen, Germany).
2.2. Cell Isolation
The mononuclear cells (MNC) were isolated by density gradient centrifugation using Lymphocyte
Separation Medium (LSM; 1.077g/L, PAA Laboratories GmbH, Pasching, Austria). The MNC were
indirectly labeled with CD271 APC and anti-APC micro beads (Miltenyi Biotec, Bergisch Gladbach,
Germany) and CD271+ cells were enriched by positive magnetic selection using the magnet activated
cell sorting (MACS) system (Miltenyi Biotec).
2.3. Flow Cytometric Analysis
Purity and viability of all cell isolations were verified by flow cytometry. Antibodies were all mouse
anti-human and appropriate mouse isotype antibodies were applied for validation of our gating strategy.
Anti-CD271 allophycocyanine was obtained from Miltenyi Biotec. Anti-CD45 allophycocyanin-H7,
anti-CD45 Horizon V500, anti-CD29 allophycocyanin, anti-CD44 peridinin-chlorophyll-protein Cyanine
5.5 tandem dye, anti-CD73 phycoerythrin, as well as 7-aminoactinomycin were from BD Biosciences
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(Heidelberg, Germany) and anti-CD105 Alexa Fluor 488 was purchased from AbD Serotec GmbH
(Puchheim, Germany). Near-IR live dead stain and 4’,6-diamidino-2-phenylindole (DAPI) were
obtained from Thermo Fisher Scientific (Waltham, Massachusetts, USA).
Cells were suspended in MACS buffer containing PBS, 2mM EDTA, and 0.5% bovine serum
albumin. To reduce unspecific binding, FcR blocking reagent (Miltenyi Biotec) was added to all samples.
Cells were incubated with the antibodies for 10 min in the dark at 4 ◦C. RBC lysis buffer (red blood cell,
eBioscience GmbH, Frankfurt/Main, Germany) was added for 10 min on ice. Samples were analyzed
by BD LSRII flow cytometer and data were analyzed using FACSDiva software, version 6.1.2 (both
Becton Dickinson, Franklin Lakes, New Jersey, USA). For optimal multicolor setting and correction of
the spectral overlap, single stained controls were utilized, and gating strategy was performed with
matched isotype/fluorescence minus one control. The CD271+ cells with a low granularity (SSClow)
were included for further flow cytometric analysis and positivity for mesenchymal markers such as
CD29, CD44, CD73, CD105, and CD271 was evaluated based on viable CD45− cells in an established
6-fold staining, as previously described [17]. After performing antibody staining, as described above,
15 μM DAPI was added; cells were incubated for 2 min and then immediately acquired.
2.4. Animals
All animal procedures were performed according to the guidelines from Directive 2010/63/EU of
the European Parliament on the protection of animals used for scientific purposes. The federal
animal care committee of LALLF Mecklenburg-Vorpommern (Germany) approved the study
protocol (approval number LALLF M-V/TSD/7221.3-1-020/14). The Rag2−/−γc−/− mice (strain C,
129S4-Rag2tm1.1FlvIl2rgtm1.1Flv/J) were purchased from the Jackson Laboratory (USA).
2.5. Ambulatory ECG Monitoring and Ligation of the Left Anterior Descending Artery
For ambulatory electrocardiogram (ECG) monitoring, twelve-to-fourteen-week-old female
Rag2−/−γc−/− mice (n = 22) were implanted with a telemetric device (Data Sciences International, DSI,
New Brighton, Minnesota, USA) 7 days before performing the myocardial intervention. The mice were
anesthetized with pentobarbital (50 mg/kg, intraperitoneal). An incision was made on the left thorax
along the ribs to insert a telemetric transmitter (TA11ETA-F10 Implant; DSI) into a subcutaneous pocket
with paired wire electrodes placed over the thorax with leads tunneled to the right upper and left lower
thorax. The heart rate, PR interval and QRS complex as the entities of an ECG were recorded using
Ponemah Physiology Platform (DSI) until 48 h post infarction. Telemetric ECG signal was qualitatively
analyzed, and VA were detected and counted with ECG auto 1.5.11.26 software (EMKA Technologies,
Paris, France).
Mice were randomly assigned into three groups: (untreated reinfarction, URI; stem cell treated
reinfarction, SRI; and MI control, MIC). First, animals of all three groups underwent thoracotomy, as
well as the ligation of the left anterior descending (LAD) artery. After 45 min, each mouse received
an intramyocardial application of 20 μL BD MatrigelTM Matrix (BD Biosciences, San Jose, CA, USA)
and MACS Buffer in a ratio of 1/2. For stem cell treatment (SRI group) a total of 100,000 CD271+ MSC
were injected at 4 sites along the border of the blanched myocardium (25,000 cells per injection point).
Subsequently, the node was reopened (here, ischemia-reperfusion) leaving the ligature in the heart
looped around the LAD with their ends kept inserted in a soft flexible tube placed subcutaneously
(Figure 1A).
After an observation period of 7 days, every mouse underwent a second thoracotomy and,
subsequently, animals of URI, as well as the SRI group, underwent permanent LAD ligation at the
same site and using the suture from the first ligation (here, reinfarction). The rubber tube has facilitated
finding of the suture material which was easily exempted from the surrounding tissue. MIC operated
mice underwent an identical second surgical procedure without LAD ligation.
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Figure 1. Induction of ventricular arrhythmias (VA). Schematic drawing of the loose left anterior
descending (LAD) ligature positioning (A). Mouse ECG changes in relation to the time of the firs LAD
ligation during ischemia-reperfusion infarction (B). Mouse ECG changes in relation to the time of the
permanent second LAD-ligation (reinfarction and URI group C). Mouse ECG strips showing different
types of observed VA (D).
2.6. Basic ECG Parameters
To evaluate the antiarrhythmic mechanism of the CD271+ MSC the basic ECG parameters of the
mouse groups were measured at different time points. This was performed automatically with the
use of ecgAUTO v3.3.0.28 software after manual definition of the start of P wave, the start of Q wave,
R wave, end of S wave, and end of T wave. Then, the analysis was done for many subsequent beats at
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a specific time point. We measured the RR-interval, QRS duration, and QT-interval in milliseconds.
The corrected QT-intervals (QTc) were measured using the formula QTc =QT/(RR/100)1/2, as previously
described [18]. The basic ECG parameters were measured at the time points (1) 48 h after the first LAD
ligation, (2) immediately before, and (3) 48 h after the second intervention.
2.7. Definitions of Various Ventricular Arrhythmias
The first temporary occlusion of the LAD resulted in a rapid onset of hyper acute T waves along
with ST-segment elevation, as observed in the ECG record. Through reopening of the LAD 45 min post
ligation, and subsequent myocardial reperfusion, ST-segment returned back to the isoelectric line and a
development of Q waves could be observed. Figure 1B shows the recorded ECG before LAD occlusion,
at the time of LAD occlusion, immediately after reopening of the LAD and reperfusion, as well as 12 h
after the induction of the MI with clear Q waves and recognizable T waves.
Figure 1C shows the onset of the second infarction after permanently ligating the suture already
placed at the time of the first ischemia one week earlier. The ECG immediately prior to performing
reinfarction through the second LAD ligation shows deep S waves with deeply depressed ST-segment
7 days after the first operation (ischemia-reperfusion). The induction of the second MI with permanent
ligation of the LAD led into an immediate ST-segment elevation in the ECG with subsequent
development of deep Q waves. Two hours after reinfarction the ECG shows, a still elevated ST-segment
reflecting the permanent LAD ligation. At 12 h post the second MI, Q waves developed with still
elevated ST-segment with reappearance of T waves.
Both, the first and second infarctions resulted in the development of different types of VA, namely
ventricular premature beats (VPB), ventricular bigeminies and trigeminies (BG/TG), ventricular salvos,
as well as ventricular tachycardia (VT) (Figure 1D).
We have analyzed, named, and defined the observed VA in this mouse model in accordance with
a standard that fits the previously established guidelines for labeling and describing each type of
VA [19] as follows:
2.7.1. Ventricular premature beats
We have defined VPB, as a ventricular electrical complex which varies in voltage (i.e., height) or
duration (i.e., width) from the preceding non-VPB ventricular complex and occurs prematurely in
relation to it. This means that VPB are not preceded by a P wave if they appear during the early cardiac
cycle or they have shorter PR-intervals than those of non-VPB if they appear later in the cardiac cycle.
2.7.2. Bigeminies and trigeminies
A minimum sequence of VPB, normal sinus beat, and VPB repeated at least three times has been
defined as bigeminy. The number of repetitions has been defined as three in our model. Additionally,
we have defined a sequence of VPB, two normal sinus beats, and a consecutive VPB with a repetition
of three times as trigeminy.
2.7.3. Salvos
The observation of two or three consecutive VPB has been defined as salvo [19].
2.7.4. Ventricular tachycardia
VT is defined as a sequence of four or more consecutive VPB [19,20]. This varies between three
or more consecutive VPB to ten or more consecutive VPB [21,22]. A detailed description of the
morphological and durational subtypes and classifications of VT has not been performed in these
mouse models.
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2.8. Organ Harvesting
Every mouse underwent euthanization, 48 h after the second intervention by cervical dislocation.
Each heart was removed, embedded in O.C.T.TM Compound (Sakura Finetek, Alphen aan den Rijn,
Netherlands) and snap frozen in liquid nitrogen. For further histological examination of the infarction
area the heart tissue was divided into four horizontal levels from the apex to the base and cut into
5 μm thick slices.
2.9. Human Cells Detection
For detection of human cells on mouse heart cryosections, monoclonal anti-human nuclei primary
antibody (Chemicon, Temecula, CA, USA) was used in combination with M.O.M.TM Mouse Ig
Blocking Reagent and M.O.M.TM Protein Concentrate following the instructions of Vector® M.O.M.TM
Immunodetection Kit (Linaris, Dossenheim, Germany). Donkey anti-mouse Alexa Fluor® 594 served
as conjugated secondary antibody followed by counterstaining with DAPI (both from Thermo Fisher
Scientific).
2.10. Infarction Size and Leukocytes Infiltration Area Analysis
Randomly chosen histological heart sections of four horizontal infarct levels were stained with
Fast Green FCF (Sigma-Aldrich, Saint Louis, Missouri, USA) and Sirius Red (Chroma Waldeck GmbH
& Co. KG, Münster, Germany) assessing tissue localization and distribution of connective fibers.
Two contiguous levels of the heart (n = 6 for each group) which represent the major infarction ratio
were quantitatively estimated using computer aided image analysis (AxioVision LE Rel.4.5 software,
Carl Zeiss AG, Oberkochen, Germany). To evaluate leukocytes infiltration area 48 h after the second
ligation, the two contiguous levels of the heart which represent the major infarct ratio were stained
with Hematoxylin (Merck, Darmstadt, Germany) and Eosin (Thermo Shandon Ltd., Runcorn, UK) and
representative images were taken using computerized planimetry (AxioVision LE Rel.4.5 software).
2.11. Statistical Analysis
Statistical analysis was performed using SigmaStat (Version 3.5, Systat Software, San Jose, CA, USA)
and IBM SPSS Statistics for Windows (Version 22.0., IBM Corp., Armonk, NY, USA). The comparisons
of two experimental groups were performed using Mann–Whitney U test. p values ≤ 0.05 were
considered as statistically significant.
3. Results
3.1. Immunophenotypic Analysis of CD271+ Mesenchymal Stem Cells
We isolated CD271+ stem cells according to our established protocol which yields all mesenchymal
colony forming progenitors [17,23]. Again, flow cytometric analysis confirmed a mesenchymal
phenotype, reflected by significant overexpression of CD73 and CD105 markers in the isolated CD271+
cell fraction as compared with the entire BM-MNC fraction (9.2% ± 2.8% vs. 0.6% ± 0.2% for CD73
and 8.3% ± 2.8% vs. 0.5% ± 0.2% for CD105, respectively, Figure 2). Moreover, only a subfraction
of CD271+ cells coexpressed all of the mesenchymal markers while being CD45− (1.2% ± 0.3%
CD271+CD44+CD73+CD105+ of CD271+ cells).
3.2. Induced Ventricular Arrhythmias
Aiming to develop a murine in vivo model to study human stem cell transplantation, we found
that VA are only detectable in the first day after induction of MI. To study engraftment and any
alteration in the development of transplanted human cells in a murine model it is necessary to use an
immunodeficient mouse strain. The trial of testing the potential antiarrhythmic effects of CD271+ MSC
through catheter-based transjugular intracardial burst stimulation for induction of VA, a described
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method by Roell et al. [4], was not promising. We tested six immune compromised mice in which
three mice underwent MI and three were healthy animals. All mice of the infarction group and the
healthy group developed VA. This observation did not allow for the creation of a proper control group
for comparison. Therefore, burst stimulation does not appear to be a suitable approach when using
this mouse strain. Consequently, we developed a new mouse model in which we re-induce VA one
week after a first ischemia reperfusion by performing a second permanent ligation. This served to
simulate the situation in patients where the affected coronary vessel tends to reclose after successful
initial recanalization.
In total, one animal (URI group) out of 22 mice died one-hour post induction of the second
infarction, due to development of sinus, and, subsequently, third degree heart block. Consequently,
this specimen was excluded from the statistical analysis. No other complications were observed after
subcutaneous implantation of the telemeter and first LAD ligation, as well as the second LAD ligation.
Figure 2. Flow cytometric analysis of MACS-isolated human BM CD271+ stem cells. The freshly
isolated BM derived CD271+ stem cells showed a mesenchymal identity by a predominant expression
of CD73 and CD105 MSC markers as compared with the entire MNC fraction. Mean ± SD, * p ≤ 0.015
(Mann–Whitney U Test).
3.3. Induction of Ventricular Arrhythmias after the Reinfarction
To simplify the study of the mechanisms underlying the developed VA, the ECG analyses were
subdivided into an acute phase until 15 min and 15 to 45 min post intervention, as well as a delayed
phase after 12 h (Table 1), as previously classified by [24]. There were no significant differences in any
of the evolved arrhythmias between the groups after the first infarction. Likewise, quantitatively, there
was no observed difference in the frequency of the development of VPB, ventricular salvos, and BG/TG
12 h after the first myocardial insult (Figure 3A).
The quantitative assessment of VPB events within 12 h following the second LAD ligation
(URI) revealed a significant difference as compared with the control group MIC (1105.0 ± 1146.72 vs.
7.5 ± 8.98, respectively, Figure 3B). This significant difference is also evident in the time frame between
45 min and 12 h after the permanent infarction (URI 1082.2 ± 1127.77 vs. MIC 3.3 ± 2.42, Figure 3C).
There was no significant difference in the occurrence of VPB after the first LAD ligation of both groups
(URI 60.1 ± 42.19 vs. MIC 259.0 ± 457.69) for the first 12 h and at the time point between 45 min and
12 h (URI 54.5 ± 39.85 vs. MIC 246.8 ± 440.84).
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Table 1. Developed ventricular arrhythmias at various time points.
First LAD Ligation (Mean ± SD) Second LAD Ligation (Mean ± SD)
URI (n = 9) SRI (n = 6) MIC (n = 6) URI (n = 9) SRI (n = 6) MIC (n = 6)
VPB
0–12 h 60.1 ± 42.19 47.5 ± 25.8 259.0 ± 457.69 1105.0 ± 1146.72 178.16 ± 370.12 7.5 ± 8.98
0–15 min 1.8 ± 4.25 2.0 ± 3.63 7.5 ± 14.08 7.1 ± 7.97 4.0 ± 4.04 0.3 ± 0.81
15–45 min 3.6 ± 4.30 3.0 ± 4.69 4.6 ± 5.57 15.6 ± 22.75 0.33 ± 0.51 3.8 ± 7.22
45 min–12 h 54.5 ± 39.85 42.5 ± 27.38 246.8 ± 440.84 1082.2 ± 1127.77 173.8 ± 371.56 3.3 ± 2.42
BG/TG
0–12 h 1.1 ± 1.45 3.66 ± 4.17 23.6 ± 49.35 113.8 ± 146.02 9.5 ± 18.41 0 ± 0
0–15 min 0 ± 0 0.16 ± 0.40 1.3 ± 3.26 0.5 ± 0.72 0 ± 0 0 ± 0
15–45 min 0.1 ± 0.33 0.16 ± 0.40 0.6 ± 1.21 0.6 ± 1.65 0 ± 0 0 ± 0
45 min–12 h 1.0 ± 1.50 3.33 ± 4.32 21.6 ± 45.89 112.6 ± 144.78 9.5 ± 18.41 0 ± 0
Salvos
0–12 h 9.0 ± 9.89 3.5 ± 3.27 25.3 ± 29.96 201.7 ± 296.77 1.0 ± 1.67 0.5 ± 0.83
0–15 min 0 ± 0 1.16 ± 1.83 1.0 ± 1.54 0.3 ± 0.50 1.0 ± 1.67 0 ± 0
15–45 min 0.5 ± 0.88 0.5 ± 0.54 12.1 ± 0.64 0 ± 0 0 ± 0 0.5 ± 0.83
45 min–12 h 8.4 ± 10.17 1.83 ± 2.56 12.1 ± 18.17 201.4 ± 296.89 0 ± 0 0 ± 0
VT
0–12 h 1.3 ± 2.69 0.66 ± 0.51 4.1 ±3.97 32.6 ± 52.51 1.0 ± 1.26 0 ± 0
0–15 min 0.5 ± 0.83 0.16 ± 0.40 0 ± 0 0 ± 0 0.83 ± 1.16 0 ± 0
15–45 min 0.3 ± 1.00 0.16 ± 0.40 2.0 ± 4.42 0 ± 0 0.16 ± 0.40 0 ± 0
45 min–12 h 1.0 ± 2.64 0.33 ± 0.51 1.6 ±1.86 32.6 ± 52.51 0 ± 0 0 ± 0
Interestingly, while a significant occurrence of VT after performing the second LAD ligation was
identified for URI (32.6 ± 52.5), one week after the onset of the first ligation, none of that was observed
in the MIC. This occurred during the first 12 h after the second infarction (Figure 3B) and also in the
time frame between 45 min and 12 h after the second infarction (Figure 3C). There was no significant
difference in terms of the development of VT after the first infarction (URI 1 ± 2.6 vs. MIC 1.6 ± 1.8).
3.4. Antiarrhythmic Effects of CD271+ MSC Engraftment
The intramyocardial implantation of human CD271+MSC did not lead to a significant difference in
the number of VA early after the first MI (Figure 3A), but showed antiarrhythmic effects by significantly
reducing the quantitatively measured VPB which occurred after a reinfarction during the time frame
between LAD ligation until 12 h, thereafter (URI 1105.0 ± 1146.72 vs. SRI 178.16 ± 370.12, Figure 3B).
Such significant antiarrhythmic behavior was also reflected in a reduction of the number of VT 45 min
after the second LAD ligation until 12 h post reinfarction (URI 32.6 ± 52.51 vs. SRI 0 ± 0, Figure 3C).
Moreover, there was no significant difference in BG/TG and salvos occurrence between the two groups.
In order to further assess the mechanism of antiarrhythmic effect, ECG monitoring was used.
Accordingly, we measured the mean QRS duration and the corrected QT-interval (Figure 3D).
Immediately prior to the second LAD ligation (seven days after the first intervention), the stem
cell treated animals had a significantly shorter QRS duration (URI 20.77 ± 1.98 vs. SRI 14.66 ± 0.61 and
MIC 19.83 ± 0.54 milliseconds, Figure 3E). The significant shorter QTc-interval in SRI (URI 64.25 ± 3 vs.
SRI 53.54 ± 3.52 and MIC 67.25 ± 4.14 milliseconds, Figure 3F) could be secondary to the shorter QRS
duration as the QRS duration is an integral part of QT duration. There was no statistically significant
difference in the mean QRS durations and QTc between URI and MIC immediately prior to the second
intervention, as well as between any of the groups 48 h after the first LAD ligation.
After nine days, the engrafted human cells were successfully detected on SRI mouse heart
cryosections predominantly in the peri-infarct area by immunofluorescent staining (Figure 3G).
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Figure 3. Comparison of developed VA. Until 12 h post LAD ligation (A,B). At the time period 45 min
to 12 h post the second LAD ligation (C). ECG monitoring immediately prior to the second LAD ligation
(D). QRS duration and QTc-interval 48 h post the first infarction and immediately prior to the second
intervention (E,F). Mean ± SD, * p ≤ 0.05 as compared with MIC, # p ≤ 0.05 as compared with SRI
(Mann–Whitney U Test). Representative images illustrate the engrafted human stem cells 9 days post
transplantation performed for the SRI experimental group which the remaining human MSC were
found predominantly in the peri-infarct area as with the Fast Green and Sirius Red staining method
(the left picture) confirmed (G).
3.5. Alterations of the Infarct Scar
The first ligation of the LAD and opening of the node after 45 min (ischemia-reperfusion)
consistently resulted in a transmural MI with its typical histologic changes including the thinning of
the left ventricular free wall (Fast Green) and extensive collagen deposition (Sirius Red) nine days post
intervention (Figure 4A). After stem cell injection we observed no significant reduction in infarct scar
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formation (SRI, 14.78% ± 5.85%) in contrast to untreated infarction (URI 17.28% ± 5.10% URI), as well
as to control group (MIC, 19.42% ± 3.66%, Figure 4C).
The first ligation of the LAD followed by a permanent second LAD ligation resulted in leukocyte
infiltration within the infarction area as depicted in the images of Hematoxylin and Eosin stained slices
from hearts 48 h post infarction (Figure 4B). This cellular intervention consequently led to a significant
enlargement of the myocardial scar area in URI (38.54% ± 14.28%), as well as SRI (29.36% ± 8.63%) in
comparison to MIC (20.1% ± 4.04%, Figure 4C).
Figure 4. Alterations in MI size. Representative images show the infarction area (enclosed within
the yellow border) for URI, SRI, and MIC 9 days after the first LAD ligation (Fast Green and Sirius
Red staining) (A), as well as 48 h after the second LAD ligation (Hematoxylin and Eosin staining) (B).
Significant increase of the infarction size after the second LAD ligation, mean ± SD, * p ≤ 0.009 as
compared with the first LAD ligation, # p ≤ 0.041 in contrast to MIC (Mann–Whitney U test) (C).
4. Discussion
The purpose of this study was to develop a mouse model to reproduce VA that typically occurs
in patients several days after an initial MI. To study engraftment and development of human cells
in a murine model it was necessary to use an immunodeficient mouse strain. During development
of an in vivo model of immunodeficient mice for the study of human stem cell transplantation, we
found that VA are mostly seen only on the first day after induced MI. Our results supported the
hypothesis, that a therapeutic stem cell treatment could have no such antiarrhythmic effect early after
their transplantation, as previously shown for other cells [4]. For testing potential antiarrhythmic
effects of intramyocardially transplanted cells, Roell et al. induced VA in vivo through transjugular
venous catheter mediated burst stimulation of the myocardium after inducing MI [4]. However, this
conventional approach could not be utilized in immunodeficient mice, because of the sensitivity of
these animals as we observed. For this reason, there was an urgent need for the development of a new
mouse model that used immunodeficient mice for in vivo study of antiarrhythmic effects exerted by
various human-derived stem cells. On the basis of this, we aimed to develop a new mouse model with
re-induced VA by performing a permanent second LAD ligation seven days after re-perfused of the
first MI. Indeed, performing the second ligation, one week after the first infarction in Rag2−/−γc−/−
mice, reproduced cardiac arrhythmias. Other previously described small animal models in this field
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have utilized immune competent mice or rats subjected to higher stress after performing recurrent
transient ischemia following an operatively instrumented mice with the capability of subsequent
recurrent transient closure of the LAD [25,26].
The previously described development of VPB in the control group after anesthesia and surgery
without performing LAD ligation [27] has also been seen in our mouse model in the time period
between 15 and 45 min after re-thoracotomy (without the second LAD ligation) in MIC group. These
developed VPB were statistically not significant as compared with the SRI and URI groups.
Our stem cell therapy resulted in shorter QRS duration, shorter QTc-intervals, and decreased
occurrence of VT in the early period after the second MI. The observed shortening of QRS indicates
the ability of MSC to improve cardiac electric conduction, which is in line with findings from Boink
et al. who showed shortened QRS duration in a canine model of MI after MSC transplantation. [28].
However, antiarrhythmic behaviors of human MSC have also been shown in a clinical trial after their
intravenous injection following a re-perfused MI [29]. The positive effect may be due to the possible
coupling of the MSC with cardiomyocytes through connexin 43 (Cx43) bridges, as it has been found in
an in vitro study by our research group [17]. This may be especially relevant as Cx43 plays a major
role in post ischemia and post infarction cardiac arrhythmias in the time period between 45 min and
12 h after MI in different animal models [24].
As there is a close relationship between the infarct size and the incidence of VA [30], the significant
reduction of the developed VA in the SRI group could not be attributed to the infarct size because there
was no significant difference in the infarction area between the SRI and the URI group, early after the
second infarction. The Hematoxylin and Eosin staining of the heart sections 48 h after the second
intervention (second LAD ligation in SRI and URI groups, re-thoracotomy in MIC group) shows no
infarct area expansion and new inflammatory cell infiltration in the MIC group. This indicates that
the stained inflammatory cells in SRI and URI groups cannot be remaining cells of the initial MI and
their infiltration is the early consequence of the second infarction. Additionally, the lack of intensive
leukocyte infiltration in the MIC group after re-thoracotomy (no second LAD ligation) seen with
Hematoxylin and Eosin staining of the heart sections nine days after the first operation (LAD ligation)
in our mouse strain supports the finding of Yang et al. [31]. The described initial neutrophil infiltration
in the infarct border one to two days after LAD ligation in immunocompetent C57BL/6J mice used by
Yang and associates has been clearly seen in our SRI and URI groups 48 h after the second infarction.
However, the described later lymphocytic infiltration, seven to 14 days after myocardial injury could
not be noticeable in our complete alymphoid mouse strain, Rag2−/−γc−/− nine days after induced MI.
In this study, we introduce our novel mouse model for testing arrhythmias in the Rag2−/−γc−/−
mouse. Importantly, CD271+ MSC transplanted into the infarcted area were retained and did not bear
any proarrhythmic properties but rather antiarrhythmic effects. We have successfully utilized the model
to test potential antiarrhythmic effects of human BM derived CD271+ stem cells in vivo and showed
their safety and efficacy. Therefore, we conclude, that human BM derived MSC, i.e., CD271+ are suitable
cell types to prevent arrhythmias after MI. This finding supports the previous observations on the safety
of intramyocardial transplantation of BM derived stem cells and can be further evaluated for future
clinical implication of cell transplantation in the field of electrophysiology [32]. Overall, our novel
mouse model offers a new option for testing potential antiarrhythmic effects of cell transplantation
therapies with high clinical relevance.
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Abstract: Appropriate mechanical properties and fast endothelialization of synthetic grafts are key
to ensure long-term functionality of implants. We used a newly developed biostable polyurethane
elastomer (TPCU) to engineer electrospun vascular scaffolds with promising mechanical properties
(E-modulus: 4.8 ± 0.6 MPa, burst pressure: 3326 ± 78 mmHg), which were biofunctionalized with
fibronectin (FN) and decorin (DCN). Neither uncoated nor biofunctionalized TPCU scaffolds induced
major adverse immune responses except for minor signs of polymorph nuclear cell activation.
The in vivo endothelial progenitor cell homing potential of the biofunctionalized scaffolds was
simulated in vitro by attracting endothelial colony-forming cells (ECFCs). Although DCN coating
did attract ECFCs in combination with FN (FN + DCN), DCN-coated TPCU scaffolds showed a
cell-repellent effect in the absence of FN. In a tissue-engineering approach, the electrospun and
biofunctionalized tubular grafts were cultured with primary-isolated vascular endothelial cells in a
custom-made bioreactor under dynamic conditions with the aim to engineer an advanced therapy
medicinal product. Both FN and FN + DCN functionalization supported the formation of a confluent
and functional endothelial layer.
Keywords: vascular graft; endothelialization; tissue engineering; decorin; fibronectin; electrospinning;
endothelial progenitor cells; bioreactor; biostable polyurethane
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1. Introduction
Atherosclerotic cardiovascular disease is one of the leading causes of death worldwide [1,2].
It includes all medical conditions, where blood flow to organs and limbs is reduced due to plaque
deposition. Surgical intervention is required to reopen or replace the defective vessel. The use of
autografts, like the saphenous vein or mammary artery, are still the standard clinical approach for the
replacement of small diameter blood vessels [3]. However, mechanical or size mismatches, and mainly
the scarce availability make alternative grafts necessary [4,5]. In this context, two strategies have
emerged in recent years: synthetic substitutes and biological grafts [4]. Although large-diameter
synthetic substitutes (>6 mm) are successfully used, small diameter grafts (<6 mm) show low patency
rates due to their tendency to elicit thrombosis and the formation of intimal hyperplasia [6–8].
Appropriate mechanical properties and biocompatibility of the synthetic graft as well as a fast
endothelialization after implantation are key properties to ensure a long-term functional implant.
In addition, the graft should evoke a balanced immune reaction. On the one hand, a moderate immune
response is beneficial in order to promote tissue regeneration. On the other hand, chronic immune
responses can lead to inflammation, fibrosis, or calcification and should be avoided to ensure long-term
function of the vascular graft [9].
Electrospinning has proven to be a suitable method for the fabrication of fibrous scaffolds
and vascular constructs as it mimics the highly porous structure and physical properties of the
extracellular matrix (ECM) of the native tissue. Due to their high porosity, pore interconnectivity,
and large surface area, the fibrous scaffolds are able to promote cell adhesion, cell alignment, and cell
proliferation [10–13]. In addition, in order to elicit in situ endothelialization in the body, the material
surface can be functionalized with bioactive molecules. A central challenge in this context is the
attraction, adhesion, and proliferation of endothelial progenitor cells (EPCs) or endothelial cells
(ECs) to form a complete endothelium. Several strategies to address this issue have been described:
immobilization of antibodies targeting markers for EPCs such as vascular endothelial growth factor
receptor 2 (VEGFR2) and platelet endothelial cell adhesion molecule (PECAM-1) [14,15]; modification
of the surface with peptides such as the Arg-Gly-Asp (RGD) or Cys-Ala-Gly (CAG) sequence [16,17];
immobilization of growth factors such as the vascular endothelial growth factor (VEGF) or stromal
cell-derived factor-1 (SDF-1) [18,19]; immobilization of oligonucleotides and aptamers [20,21]; and
surface modification with oligosaccharides and phospholipids [22,23]. However, it is necessary to
develop surfaces with improved biocompatible, bioactive, targeted, and stable biofunctionalization [24].
A recent study described the attraction of EPCs by immobilized recombinant human decorin
(DCN) [25]. The small leucine-rich proteoglycan plays a pivotal role in the ECM [26]. It is named after
its first known function as a modulator of collagen fibrillogenesis [27]. In recent years, it has been shown
that DCN influences a variety of biological processes in addition to its structural function. It is involved
in cell attachment [28–30], proliferation [31,32], and migration [28,29,31,33]. Furthermore, it has been
described that DCN inhibits the proliferation and migration of vascular smooth muscle cells but does not
affect ECs [28,31]. With a proportion of 22% of all proteoglycans in the vessel wall, it also influences many
biological processes in vascular homeostasis and angiogenesis [34–36]. Depending on the molecular
environment, it can act pro-angiogenic or antiangiogenic [26,34]. For instance, DCN was shown to
interact antagonistically with the mesenchymal epithelial transition factor (c-MET) and the VEGFR2,
which significantly influences angiogenesis [26,34,37,38]. In addition, DCN binds to the transforming
growth factor β (TGF-β), which in turn has an inhibiting effect on the endothelial-mesenchymal
transition and fibrosis [26,39,40]. These properties make the protein a promising candidate for improving
the endothelialization of a vascular graft. Another highly relevant ECM protein is fibronectin (FN).
Since FN interacts with cells via the integrins α5β1 or αvβ3, it is a suitable protein for bioactivating a
material surface [41–44]. It is of interest with regard to endothelialization, as it plays a pivotal role in
wound healing [45,46]. Several studies described the coating of FN in combination with collagens type
I [47] and type IV [48], with fibrinogen and tropoelastin [49], hepatocyte growth factor [50], heparin,
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and VEGF [51] and with SDF-1α [19] to improve reendothelialization. However, it has never been
used in combination with DCN before.
Tissue engineering can be used as an alternative strategy to obtain a functional endothelium in a
synthetic graft utilizing a patient’s own cells [52]. After implantation, the tissue-engineered vascular
graft (TEVG) is replaced by the host’s cells and ECM and is thereby degraded [4]. However, the loss
of mechanical properties due to a too rapid degradation and unfavorable biological reactions to the
degradation products remain a major challenge [1,53]. A recent study addressed this problem by
producing a TEGV that consists of a combination of a biodegradable and biostable polymer [54].
In our study, a newly developed biostable polyurethane elastomer was used to develop an
electrospun scaffold with mechanical properties that are comparable to native vascular tissues, and a
bioactive surface that attracts endothelial progenitor cells or promotes endothelialization [55]. For this
purpose, planar and tubular electrospun scaffolds (Figure 1a) were biofunctionalized with FN, DCN,
or FN and DCN in combination (FN + DCN; Figure 1b,c). The influence of the FN- and DCN-coated
scaffolds on human immune cell features was examined (Figure 1d). Subsequently, the functionality
of the electrospun scaffolds was further investigated. First, endothelial progenitor cell homing was
simulated in vitro by attracting endothelial colony forming cells (ECFCs) with a potent angiogenic
capacity and the capability to support vascular repair (Figure 1e,f). Secondly, in a classical TEVG
approach primary-isolated vascular endothelial cells (vECs) were cultured in a custom-made bioreactor
to create an advanced therapy medicinal product (ATMP) (Figure 1g).
Figure 1. A newly developed polyurethane is used to produce planar and tubular electrospun scaffolds
(a), which are biofunctionalized with either fibronectin (FN) or decorin (DCN) or with both extracellular
matrix (ECM) proteins in combination (b,c). Besides investigating the immunology (d) and endothelial
colony forming cell (ECFC) behavior on either planar (e) or in tubular scaffolds (f), the tubular scaffolds
were also cultured with primary-isolated vascular endothelial cells (vECs) in an tissue-engineered
vascular graft (TEVG) approach (g) in order to assess an ECM protein-improved endothelialization.
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2. Materials and Methods
2.1. Electrospun Scaffold Fabrication
Planar and tubular scaffolds were produced by electrospinning of soft thermoplastic
polycarbonate-urethane (TPCU). This elastomeric material was synthesized in our laboratory for
special medical applications using the multistep one-pot approach [56], which gives good control of
the polymer architecture in catalyst-free systems. In more detail, a long-chain aliphatic polycarbonate
with more than 72% (w/w) in the TPCU formulation provides an additional crystallization of the soft
segment, which enhances biostability of the implantable material as well as improves its mechanical
properties. In vitro biostability of the TPCU was studied previously from a mechanical point of
view under long-term oxidative treatment [55]. Cytocompatibility of the TPCU material was also
demonstrated [57]. By adjusting the respective parameters to achieve a stable process and appropriate
mechanical properties of the scaffold (Figure S1a), 0.1 g/mL of the polymer was dissolved in 1,1,1,3,3,3
hexafluoro-2-propanol (804515, Merck, Darmstadt, Germany) and electrospun with the process
conditions summarized in Table 1. The electrospinning process was carried out in a temperature- and
humidity-controlled electrospinning apparatus (EC-CLI, IME Technologies, Eindhoven, Netherlands).
Table 1. Process conditions for electrospinning planar and tubular scaffolds.
Description Value
Distance 25 cm
Needle i.d. 0.4 mm
Voltage 18 kV/−0.2 kV (needle/collector)
Temperature 23 ◦C
Humidity 40%
Mandrel diameter 1 6 mm
Mandrel rotation speed 1 2000 rpm
Needle translation distance 1 80 mm
Volume 6 mL
Flow rate 4 mL/h
i.d.= inner diameter; 1 tubular scaffolds.
2.2. Biofunctionalization of the Scaffolds
Before biofunctionalization, the appropriate disinfection method was investigated. Since ethanol
did not affect the scaffold in terms of its mechanical properties (Figure S1b), the constructs were
disinfected with 70% ethanol for 20 min and afterwards washed three times for 10 min with
phosphate-buffered saline (PBS). Microbiological studies were carried out on the scaffolds to investigate
the effectiveness of the disinfection method (Figure S3). The scaffolds were functionalized by protein
adsorption. They were incubated for 2 h at 37 ◦C with 20 μg/mL human plasma FN (F1056,
Sigma-Aldrich, St. Louis, USA) or 20 μg/mL recombinant full-length human DCN [25], individually or
in combination. Excess protein was removed by washing the scaffolds with PBS.
2.3. Morphological and Mechanical Characterization of the Electrospun Scaffolds
For the morphological characterization, punches from the electrospun scaffolds were examined by
scanning electron microscopy (SU8030, Hitachi, Tokyo, Japan) followed by the analysis using ImageJ
and the DiameterJ package [58] to assess the pore and fiber sizes. For the investigation of the mechanical
properties, a ring tensile test was performed based on the methods described by Laterreur et al. [59] in
order to determine the circumferential tensile strength and burst pressure. Briefly, the tubular scaffolds
were cut into pieces with the length L0 = 7 mm, clamped into a uniaxial tensile testing device (Zwick
Roell, Ulm, Germany), and stretched over a distance s with a velocity of 50 mm/min until rupture.
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On the basis of the stress–strain curves (Figure S1c), the burst pressure Pb was then calculated by
relating the registered force at rupture Fb to the elongation sb as follows:
Pb =
Fbπ
L0dpin(π+ 2) + 2L0sb
(1)
where dpin represents the diameter of the pins that were used in the ring tensile test. A derivation of
Equation (1) is provided by Lattereur et al. [59]. Using an OCA40 (DataPhysics Instruments GmbH,
Filderstadt, Germany), the wettability of the scaffolds was analyzed as previously described [60].
A waterdrop with a volume of 2μL was placed onto the scaffold and measured using the SCA20 software
(DataPhysics Instruments, Filderstadt, Germany). The water absorption ability was determined by
weighing the specimens in their dry and wet states after submerging the specimens in water for 1 h.
The relative weight increase is referred to as the swelling ratio.
2.4. Immune Cell/Scaffold Co-Culture Assays
Polymorph nuclear cells (PMNs) were isolated from freshly donated human blood and peripheral
blood mononuclear cells (PBMCs) from buffy coats according to the ethical approval by the local
ethics committee at the Charité Berlin (EA2/139/10 approved on 10th December 2010; EA1/226/14
approved on 24th July 2014) and as recently described [61]. Monocytes were magnetically sorted
via CD14 beads (130-050-201, Miltenyi Biotec, Bergisch Gladbach, Germany) from PBMCs as
previously described [62]. Monocytes were differentiated into M0 macrophages by adding 50 ng/mL of
macrophage colony-stimulating factor (M-CSF) (130-096-491, Miltenyi Biotec) to the culture medium
for 7 days. All immune cell co-cultures were performed in Roswell Park Memorial Institute (RPMI)
1640 medium (F1415, Biochrom GmbH, Berlin, Germany) with 10% human serum type AB (H4522,
Sigma-Aldrich), 1% L-glutamine (25030-024, Thermo Fisher Scientific, Waltham, MA, USA), and 1%
penicillin/streptomycin (15140-122, Thermo Fisher Scientific).
First, the scaffold punches were incubated with 100 μg/mL of recombinant full-length human
DCN [25] or 20 μg/mL of FN (F1056, Sigma-Aldrich) at 37 ◦C for 4 h. Next, punches were washed with
PBS (L1825, Biochrom GmbH), placed into a well of a 48-well plate, and kept in place with a silicon ring
(Ismatec, Wertheim, Germany). Thereafter, the different immune cell types were applied as follows:
Human PMNs were cultured on the uncoated, DCN- or FN-coated scaffolds; 0.2 × 106 PMNs
in 200 μL of complete RPMI were seeded directly on the scaffold punches. Unstimulated cells were
used as a negative control, and PMNs that were stimulated with 500 ng/mL of lipopolysaccharide
(LPS; 297-473-0, Sigma-Aldrich) served as a positive control. LPS is a component of the bacterial cell
membrane that triggers the activation of immune cells. After 4 h of culture, cells were harvested
only by careful resuspension, stained with human-specific antibodies for CD11b (1:100; 557701, BD
Bioscience, San Jose, CA, USA) and CD66b (1:200; 305107, BioLegend, Fell, Germany), and measured
by flow cytometry (CytoFLEX LX, Beckman Coulter, Inc., Brea, CA, USA) as described recently [61].
The determined mean fluorescence intensities (MFIs) of marker expression were normalized to the
MFI of unstimulated PMNs directly after isolation.
Human monocytes or M0 macrophages were cultured on the uncoated, DCN- or FN-coated
scaffolds; 0.2 × 106 cells in 350 μL of complete RPMI were seeded directly on the scaffold punches.
Monocytes that were stimulated with 100 ng/mL of LPS served as a positive control, and unstimulated
monocytes served as a negative control. Macrophages cultured without any stimulus were used as
negative control. To induce the polarization into the M1 phenotype, 20 ng/mL of IFNγ (130-096-486,
Miltenyi Biotec) and 100 ng/mL of LPS were added to the medium of M0 macrophages. After two
days of culture, monocytes/macrophages were harvested, stained with human-specific antibodies for
CD80 (1:20; 305208, BioLegend) and human leukocyte antigen DR isotype (HLA-DR) (1:200; 307616,
BioLegend), and measured by flow cytometry. Cells were detached by adding 100 μL of Accutase
(A11105-01, Thermo Fisher Scientific) and incubating the cells at 37 ◦C for 30 min. The determined
MFIs of the marker expression were normalized to the MFI of the unstimulated cells.
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PBMCs were cultured on the uncoated, DCN- or FN-coated scaffolds; 0.3 × 106 cells were seeded
in 400 μL of complete RPMI directly on the scaffold punches. Unstimulated PBMCs served as a
negative control. For the positive controls, PBMCs were stimulated with anti-CD28 (556620, BD
Bioscience)/anti-CD3 (OKT3, Janssen-Cilag, Neuss, Germany) antibodies. After three days of culture,
PBMCs were harvested, stained with human-specific antibodies for CD69 (1:50; 310926 BioLegend),
CD25 (1:50; 302605, BioLegend) and HLA-DR (1:100; 307640, BioLegend), and measured by flow
cytometry. PBMCs were detached by adding 100 μL of Accutase and by incubating the cells at
37 ◦C for 30 min. After gating for single and living cells the CD14− and CD14+ populations were
defined. For CD3+ cells, the MFI of the activation markers CD25, CD69, and HLA-DR was determined.
The determined MFIs of the marker expression were normalized to the MFI of unstimulated PBMCs.
Co-culture supernatants of monocytes and macrophages were collected and the tumor necrosis
factor alpha (TNFα) concentration was analyzed by ELISA (430205, BioLegend) according to the
manufacturer´s instructions.
2.5. Cell Culture of Primary Endothelial Cells and Endothelial Colony Forming Cells
Human primary-isolated vECs were isolated from foreskin biopsies under the ethics approval no
495/2018BO2 by enzymatic digestion with dispase and trypsin as previously described [63]. The vECs
were cultured in endothelial cell growth medium and SupplementMix (C-22020, PromoCell, Heidelberg,
Germany), supplemented with 1% penicillin-streptomycin (15140122, Thermo Fisher Scientific).
Human ECFCs (00189423, Lonza, Basel, Switzerland) were cultured in endothelial cell growth
medium-2 with supplements (CC-3162, Lonza). Instead of the supplied fetal bovine serum, 5% of
human serum (H4522, Sigma-Aldrich) was used. In addition, 1% L-Glutamine (21051024, Thermo
Fisher Scientific) and 1% penicillin-streptomycin (15140122, Thermo Fisher Scientific) were added to
the cell culture medium.
Both cell types were cultured at 37 ◦C and 5% CO2 and passaged at approximately 80% confluence.
The vECs were used for the experiment after 2–4 passages.
2.6. Cell Seeding and Culture on Planar Scaffolds
Prior to cell culture experiments, general biocompatibility of the electrospun scaffolds was
examined with a cytotoxicity test based on EN ISO 10993-5 [64]. Briefly, the scaffolds were incubated
for 72 h at 37 ◦C and 5% CO2 in 1 mL endothelial cell growth medium supplemented with 1%
penicillin-streptomycin at an extraction ratio of 0.1 mg/mL; 2 × 104 vECs seeded in a 96-well plate
were then exposed for 24 h to the extracts supplied with the cell culture medium supplements.
Endothelial cell growth medium without the scaffolds served as a negative control. Cells exposed to
1% SDS served as positive control. The extraction and control medium were removed, and an MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay
(CellTiter 96Aqueous One Solution Cell Proliferation Assay, Promega, Madison, WI, USA) was
performed according to the manufacturer’s protocol; 20 μL MTS solution and 100 μL cell culture
medium were added to each well. After 30 min of incubation at 37 ◦C, the absorbance of each well
was measured at 450 nm using a microplate reader (PHERAstar, BMG Labtech, Ortenberg, Germany).
Cell viability was determined by the absorbance of the samples relative to the negative control. No toxic
effect of the material was observed (Figure S2a). Biofunctionalization of the scaffolds was then carried
out as described above. Cells were seeded afterwards onto the biofunctionalized scaffolds with a
diameter of 6 mm, which were placed in a 96-well plate. For the vECs, 5 × 103 cells/well and, for the
ECFCs, 1 × 104 cells/well were seeded in 150 μL of the appropriate medium. If required, media change
was carried out every 3 days.
2.7. Endothelial Colony Forming Cells (ECFC) Seeding Under Dynamic Conditions
The tubular electrospun scaffolds were cut to 6 cm length and biofunctionalized with FN and
DCN alone or in combination as described above. A cell suspension of 4 × 105 ECFCs/mL was pipetted
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into the tubular constructs. Afterwards, the constructs were closed at both ends and put in 15-mL
centrifuge tubes filled with the corresponding cell culture medium. Placed on a roller mixer (RM5,
CAT, Ballrechten-Dottingen, Germany), the tubes were rotated with 60 rpm for 24 h at 37 ◦C and
5% CO2. For cell number analysis, the attached cells were stained with 4′,6-diamidino-2-phenylindole
(DAPI) (1:50, 10236276001, Roche Diagnostics, Mannheim, Germany) and counted.
2.8. Development of a Bioreactor System for Tissue-Engineered Vascular Graft (TEVG) Culture
The TEVG approach was performed with a custom-made bioreactor setup. The culture chamber
consists of a 250-mL glass bottle (Schott Duran, Wertheim, Germany) and encloses a removable
custom-designed graft frame that holds the vascular graft. A computer-aided design (CAD) model for
the graft frame was created in Solidworks (Dassault Systèmes, Vélizy-Villacoublay, France) and milled
out of polyether ether ketone (PEEK; ADS Kunststofftechnik, Ahaus, Germany) using a 2.5-axis flatbed
milling setup (Isel, Eichenzell, Germany) with computer numerical control (CNC). The constructed
parts were subjected to the aforementioned cytotoxicity test to ensure no toxic leachables are released
into the medium under culture (Figure S2b). The modular design of the culture chamber allows for a
toolless assembly of the bioreactor system under a sterile bench.
The graft frame—once inserted into the culture chamber—is connected to medium reservoirs and
a bubble trap with flexible silicone tubing. Sterile gas exchange is facilitated by sterile filters connected
to the medium reservoirs. The entire setup is driven by a multichannel roller pump (Ismatec) (Figure 2).
The flow rates Q for dynamic culture were determined with a derived formulation of the





where μ denotes the dynamic viscosity. This gave an analytical approximation of the achieved wall
shear stress (τ) within the cultured vascular graft. To validate this approximation and the assumption
of a laminar regime within the vascular graft, in silico simulations were used to assess the local fluid
dynamics within the vascular graft and graft frame interior. Briefly, the CAD model of the graft
frame was meshed and exported to a computational fluid dynamics (CFD) solver (ANSYS Fluent).
Dynamic culture with a wide range of flow rates was simulated under steady-state flow and Newtonian
rheological conditions, after which the calculated wall shear stress on the interior graft wall was
analyzed and compared to the aforementioned analytical solution (Figures S4 and S5).
2.9. Tissue Culture of Vascular Endothelial Cells Under Dynamic Conditions
Tubular electrospun scaffolds were cut to 7.5 cm length and biofunctionalized with 20 μg/mL FN
as described previously. After inserting the graft frame into the culture chamber, 2 × 106 vECs/mL
were seeded into the tubular scaffold. In order to achieve homogeneous cell adhesion across the entire
tube, the culture chamber was placed horizontally and rotated every 15 minutes over 45 ◦ for 3 h at
37 ◦C and 5% CO2. The culture chamber was consecutively connected to the rest of the bioreactor
setup and filled with 70 mL culture medium, supplemented with 1% penicillin-streptomycin and 1%
PrimocinTM (ant-pm-1, InvivoGen, San Diego, CA, USA). The seeded cells were allowed to proliferate
under static conditions during the first three days, after which the flow rate was slowly increased over
the course of two days, as shown in Figure 2e. Subsequently, the tubular construct was cultured under
constant flow for seven days.
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Figure 2. (a) A cross-sectional schematic representation of the culturing chamber and its parts.
The wireframe model on the right is overlaid by the results of an in silico simulation and shows the
flow velocity when the system is perfused with a flow rate of Q = 20 mL/min. (b) This photograph
shows the graft frame (without scaffold), once it is taken out of the culturing chamber. (c) A schematic
representation of the entire bioreactor setup, showing the circulation and connections to the medium
reservoirs and pressure buffer/bubble trap. (d) A photograph showing the assembled bioreactor setup
with all the components for the intraluminal circulation. (e) Applied perfusion flow speed as function
of time with the corresponding wall shear stress.
2.10. Immunofluorescence Staining
In order to examine the protein coating, the biofunctionalized scaffolds were stained using
DCN mouse monoclonal IgG1 (1:200; sc-73896, Santa Cruz Biotechnology, Dallas, TX, USA) and FN
polyclonal rabbit IgG (1:500; F3648, Sigma-Aldrich) antibodies. For fluorescence labeling, AlexaFluor
488 anti-mouse IgG (1:250; A-11001, Thermo Fisher Scientific) and AlexaFluor 546 anti-rabbit IgG
(1:250; A-11035, Thermo Fisher Scientific) were used as secondary antibodies.
Cells cultured on the scaffolds were stained as follows: after washing once with PBS, the cell-seeded
scaffolds were fixed with 4% paraformaldehyde (P6148, Sigma-Aldrich). In order to reduce nonspecific
binding, the samples were incubated with 2% goat serum-containing block solution for 30 min.
Afterwards, the cells were incubated over night at 4 ◦C with the following antibodies: Vascular
endothelial cadherin (VE-cadherin) monoclonal mouse IgG2B (1:500, MAB9381, R&D systems,
Minneapolis, MN, USA), VEGFR2 polyclonal rabbit IgG (1:75, ab2349, Abcam, Cambridge, UK),
PECAM-1 monoclonal mouse IgG1 (1:100, sc-71872, Santa Cruz), von Willebrand factor (vWF)
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polyclonal rabbit IgG (1:200, A0082, Dako, Glostrup, Denmark), and vinculin monoclonal mouse IgG1
(1:500, MAP3574, Millipore, Burlington, MA, USA). F-actin was stained for 45 min in the dark with
Alexa Fluor 647 Phalloidin (1:500, A22287, Thermo Fisher Scientific). Subsequently, samples were
incubated with the appropriate secondary antibodies (AlexaFluor 488 anti-mouse IgG, AlexaFluor 546
anti-rabbit IgG, and AlexaFluor 488 anti-mouse IgG2b (all 1:250; Thermo Fisher Scientific)).
Finally, nuclei were stained with DAPI (1:50) for 15 min in the dark. Images were obtained by
using a fluorescence microscope (Cell Observer, Carl Zeiss AG, Oberkochen, Germany).
2.11. Examination of the Cell Coverage on the Tubular Scaffolds
The cell coverage of the inner wall of the tubular constructs was investigated using
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (M2128-1G, Sigma-Aldrich).
After culturing with vECs, the constructs were incubated for 20 min with 1 mg/mL MTT at 37 ◦C
and 5% CO2. The insoluble purple formazan produced by the cellular reduction of MTT was then
examined macroscopically.
2.12. Image Analysis
FN and DCN coating were quantified by measuring the relative pixel intensity (RPI) of the
immunofluorescence images. To assess protein expression in the experiments, the area within a defined
fluorescence intensity threshold was measured and normalized to the cell number. The cell count in the
static experiments was quantified by counting the DAPI-stained cell nuclei per area. The quantification
of the adherent ECFCs in the dynamic experiment was performed by measuring the DAPI-stained area
normalized to the total area. All images were analyzed using ImageJ [58].
2.13. Scanning Electron Microscopy of Cells
Prior to SEM imaging of the scaffolds with cells, a critical point drying step was performed. First,
cells were fixed for 60 min with 4% paraformaldehyde (PFA)/ 25% glutaraldehyde in PBS. Subsequently,
a series of ethanol solutions in ascending concentration up to 100% was carried out to remove water.
Critical point drying was done with a CPD 030 (Bal-Tec AG, Balzers, Liechtenstein) according to the
manufacturer’s protocol. Prior to imaging, the specimens were platina-coated (SCD050, Bal-Tec AG)
for one minute at 0.05 mbar and rinsed with Argon after the coating process. SEM imaging was
performed with a SU8030 (Hitachi, Tokyo, Japan) and an Auriga® 40 (Zeiss, Oberkochen, Germany).
For SEM imaging of the monocytes and macrophages, the cells were cultured for two days on
uncoated (w/o), DCN- or FN-coated scaffolds, followed by preparation (as described in Reference [62])
and imaging with a JCM 6000 Benchtop (JEOL, Freising, Germany).
2.14. Statistical Analysis
Except stated otherwise, data are presented as mean ± standard deviation. For the immune
data, GraphPad Prism (GraphPad Software, San Diego, CA, USA) was used to determine statistical
significance between two groups using a one-way ANOVA/Kruskal–Wallis test. For the other data,
a one-way ANOVA/Fisher’s Least Significant Difference test was performed. A Welch’s t-test was
performed to compare between two data groups using OriginPro (OriginLab, Northampton, MA,
USA). Probability values of 95%, 99%, 99.9%, and 99.99% were used to determine significance.
3. Results
3.1. Biofunctionalization Does Not Impact the Mechanical Properties of Electrospun Tubular Constructs
Electrospinning was used to fabricate 110-mm long tubular scaffolds with an inner diameter of
5 mm and a thickness of 0.40 ± 0.06 mm (Figure 3a). In order to modulate the cell–material interaction,
the surface was biofunctionalized with FN, DCN, or FN + DCN. The impact of the biofunctionalization
on the morphological and mechanical properties of the material was investigated (Figure 3). Fiber and
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pore size analysis of the SEM images revealed no significant alteration due to protein adsorption
(Figure 3e). Higher magnifications of the SEM images showed distribution of the proteins on the fibers.
While DCN formed randomly distributed aggregates on the TPCU scaffolds, FN coating showed
a network-like deposition in the nanometer range, which was also seen in the FN + DCN-coated
samples, in which clearly recognizable aggregates were deposited on the protein network (Figure 3b,
white arrows). Biofunctionalization utilizing both proteins individually and in combination was
confirmed by IF staining. DCN IF staining revealed a more heterogeneous distribution of DCN in
combination with FN than alone (Figure 3c, white arrows). The contact angle of the scaffolds was
not significantly changed by the adsorption of either FN or DCN in comparison with the uncoated
scaffolds. A significantly higher swelling ratio was observed of scaffolds that had been coated with
FN + DCN (Figure 3e; control: 93.7% ± 7.7% versus FN + DCN: 117.1% ± 8.7%, p < 0.05). Overall,
biofunctionalization had no significant influence on the mechanical properties (Figure 3e). The ultimate
tensile strength ranged from 21.1 ± 3.5 MPa (DCN) to 22.1 ± 3.7 MPa (FN). Burst pressures were in the
range between 3124 ± 466 mmHg (FN + DCN) to 3326 ± 78 mmHg (controls). Interestingly, the elastic
modulus of the samples coated with FN + DCN showed a lower value compared to the controls,
although this was not statistically significant (3.7 ± 0.5 MPa FN + DCN versus 4.8 ± 0.6 MPa controls,
p = 0.125).
We compared the mechanical properties (elastic modulus and burst pressure) of our electrospun
scaffolds with autologous grafts, which are today’s gold standard for vascular bypass surgeries, using
data obtained from literature (Table 2) [65]. The elastic modulus of our constructs (4.8 ± 0.6 MPa) was
slightly higher than that of saphenous veins (2.25–4.2 MPa) [66,67] and of iliofemoral arteries (1.54 MPa)
and veins (3.11 MPa) [68]. However, compared with an internal mammary artery (8 MPa) and a
femoral artery (FA, 10.5 MPa)—used for popliteal bypass surgery—our engineered scaffolds showed a
lower elastic modulus [66,69,70]. Regarding the burst pressure, engineered scaffolds (3326 ± 78 mmHg)
lied within the range of a saphenous vein (1250–3900 mmHg) [66,67,71,72] and an internal mammary
artery (2000–3196 mmHg) [66,71]. Konig et al. recommends for a TEGV a minimum burst pressure of
1700 mmHg [71]. We can therefore argue that our constructs have suitable mechanical properties to
serve as a vascular graft or TEGV.
Table 2. Mechanical properties of the electrospun constructs and native blood vessels.
Graft Type Elastic Modulus (MPa) Burst Pressure (mmHg) Ref.
Electrospun vascular graft 4.8 ± 0.6 3326 ± 78 -
Saphenous vein 4.2 1680–3900 [66]
Saphenous vein 2.25 1250 [67]
Saphenous vein NA 1680 [73]
Saphenous vein NA 2200 [72]
Saphenous vein NA 1599 [71]
Internal mammary artery NA 3196 [71]
Internal mammary artery 8 2000 [66]
Femoral artery 9–12 NA [69]
Iliofemoral artery 1.54 NA [68]
Iliofemoral vein 3.11 NA [68]
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Figure 3. Morphological and mechanical characterization of the tubular biofunctionalized scaffolds:
(a) Electrospun tubular scaffolds were fabricated with a length of 110 mm, an inner diameter of
5 mm, and a thickness of 0.40 ± 0.06 mm. (b) SEM images of control and biofunctionalized scaffolds:
Scaffolds coated with FN show a network-like structure on the fibers. Aggregates deposited on
the FN + DCN-coated samples are indicated by white arrows. (c,d) The coating of FN, DCN, or
FN + DCN in combination was confirmed with IF staining: FN (red) and DCN (green). The white
arrows indicate aggregates deposited on the FN + DCN-coated samples. Two-tailed t-test vs. control,
n = 3, RPI = relative pixel intensity. (e) Fiber and pore size analysis shows no significant difference
between the biofunctionalized scaffolds and the controls. Mechanical properties are not influenced by
the protein coating. One-way ANOVA, n = 4, p < 0.05 vs. control.
3.2. Decorin and Fibronectin Coating of the Scaffolds Does Not Induce a Disadvantageous Immune Response
The effect of DCN- or FN-coated TPCU scaffolds on immune cells was investigated in order to
estimate their suitability as vascular graft material. The immune response of a combination coating
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was not required as the immune system would not react differently to the presence of both proteins
in one coating. The performed immunological evaluation followed the normal sequence of immune
activation [9], starting with PMNs that are followed by monocytes, which differentiate into macrophages
at the site of injury, and finally T cells that become activated (Figure 4a).
Figure 4. Immune response profile of FN- and DCN-coated planar scaffolds: (a) Schematic overview
of the analysis steps and used immune cell assays. Polymorph nuclear cells (PMNs) and peripheral
blood mononuclear cells (PBMCs) were isolated from human blood. Monocytes were acquired from
PBMCs by magnetic separation via CD14 beads. Monocytes were differentiated into M0 macrophages
(MØ) by stimulation with 50 ng/mL of macrophage colony-stimulating factor (M-CSF) for 7 days.
(b) Surface expression of activation markers CD11b and CD66b by PMNs after 4 h: Displayed are the
mean fluorescence intensities (MFI) normalized to unstimulated PMNs after isolation as mean ± SEM
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(standard error of the mean) for unstimulated (unstim) and lipopolysaccharide (LPS)-stimulated
cells, as well as PMNs cultured on the uncoated (w/o), DCN-coated (DCN), and FN-coated (FN)
scaffolds determined with flow cytometry. Kruskal–Wallis test, n = 6. (c) Surface expression of
activation markers CD80 and human leukocyte antigen DR isotype (HLA-DR), and tumor necrosis
factor alpha (TNFα) release by monocytes. Shown are the MFI normalized to unstimulated monocytes
as mean ± SEM for LPS-stimulated cells as well as monocytes cultured on uncoated (w/o), DCN-coated
(DCN), and FN-coated (FN) scaffolds. Kruskal–Wallis test, n = 6–8. The TNF release is depicted in
ng/105 cells as mean ± SEM for unstimulated (unstim) and LPS-stimulated cells as well as monocytes
cultured on the uncoated (w/o), DCN-coated (DCN), and FN-coated (FN) scaffolds. Kruskal–Wallis
test, n = 5. (d) Surface expression of activation markers CD80 and HLA-DR, and TNFα release by
macrophage: Displayed is the MFI normalized to unstimulated M0 macrophages as mean ± SEM for
macrophages differentiated to M1 and as well as cells cultured on uncoated (w/o), DCN-coated (DCN),
and FN-coated (FN) scaffolds. Kruskal–Wallis test, n = 6–8. The TNFα release is shown in ng/105 cells
as mean ± SEM for unstimulated M0 macrophages; macrophages differentiated to M1; and as well as
cells cultured on the uncoated (w/o), DCN-coated (DCN), and FN-coated (FN) scaffolds. Kruskal–Wallis
test, n = 6–9. (e) Representative SEM images of monocytes (left) and macrophages (right) on uncoated
(w/o) and with biofunctionalized scaffolds (DCN and FN). Scale bars represent 50 μm. (f) Expression of
activation markers CD69, CD25, and HLA-DR on CD3+ T cells in whole PBMC co-cultures: Shown are
representative histograms (left) and the surface expression levels as MFI normalized to unstimulated T
cells as mean ± SEM (right) for αCD3/αCD28-stimulated T cells (stim) as well as T cells cultured on
uncoated (w/o), DCN-coated, and FN-coated scaffold. Kruskal–Wallis test, n = 6.
Initially, the expression of known PMN activation markers, the integrin CD11b, and the adhesion
molecule CD66b was analyzed (Figure 4b). The normalized mean fluorescence intensity (MFI) for
CD11b (stim 2.461 ± 0.3323, p = 0.0179; w/o 2.406 ± 0.3393, p = 0.0378; DCN 2.442 ± 0.3361, p = 0.0217;
FN 2.549± 0.3644, p < 0.0090; all versus unstim 0 hours 1± 0) and CD66b (stim 2.372± 0.3875, p = 0.0453;
w/o 2.448 ± 0.2728, p = 0.0414; DCN 2.431 ± 0.3041, p = 0.0453; FN: 2.893 ± 0.4239, p = 0.0073; all versus
unstim 0 h 1 ± 0) was significantly increased on PMNs after LPS stimulation (positive control) and,
after culture on the uncoated/coated scaffolds, compared to the level of PMNs directly after isolation
(dotted line, set to 1). Additionally, PMNs on FN-coated TPCU scaffolds displayed a significantly
higher CD66b expression compared with the unstimulated controls (FN 2.893 ± 0.4239 versus unstim
4 h 0.9438 ± 0.1723, p < 0.0345).
In a next step, monocyte responses were studied by flow cytometry analysis of the activation
markers CD80 and HLA-DR (Figure 4c). The expression level for the co-stimulatory molecule CD80
was significantly upregulated only on LPS-stimulated monocytes compared with all other experimental
groups (LPS 3.254 ± 0.5533 versus w/o 0.9592 ± 0.1342, p = 0.0143; versus DCN 0.8888 ± 0.1209,
p = 0.0046; versus FN 0.8325 ± 0.08414, p = 0.0018). No significant differences in HLA-DR expression
were detectable between the tested conditions. Additionally, no enhanced TNFα release of monocytes
cultured on the uncoated/coated scaffolds was measured in contrast to a significantly elevated secretion
in the LPS-stimulated controls compared to the unstimulated controls (LPS 0.08859 ± 0.03039 versus
unstim 0.0005580 ± 0.0002111, p = 0.0228).
Then, macrophages (M0 type) generated in vitro by M-CSF were screened for signs of activation
or polarization (Figure 4d). M0 (unstimulated) and M1 macrophages (IFNγ/LPS-stimulated) were
used as control groups. Enhanced CD80 and HLA-DR expression and increase of TNFα secretion are
hallmarks of pro-inflammatory M1 macrophages. There was no difference in the CD80 expression level
between M0 macrophages (dotted line, set to 1) and all other experimental groups. The expression of
HLA-DR by macrophages on uncoated scaffolds was significantly decreased compared with the M0
and M1 control settings (w/o 0.5220 ± 0.05753 versus M0 1 ± 0, p = 0.0106; versus M1 2.453 ± 1.040,
p = 0.0049). Whereas M1 macrophages significantly elevated their TNFα release compared with M0
macrophages (M1 0.01229 ± 0.003333 versus M0 0.0002707 ± 0.00004142, p < 0.0001), no enhancement in
pro-inflammatory cytokine release was measurable in all other experimental groups. Macrophages on
the FN-coated scaffolds actually decreased their TNFα release compared with the M1 controls
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(FN 0.0009826 ± 0.0004063 versus M1 0.01229 ± 0.003333, p = 0.0432). Complementary to the analysis
of changes in surface marker and pro-inflammatory cytokine release by monocytes and macrophages,
scanning electron microscopy was applied to assess the effects of co-culture on their morphology
(Figure 4e). Scanning electron microscopy images were taken after the cells were cultured for two days
on the different scaffold groups. Monocytes and macrophages on the DCN-coated scaffolds formed
clusters of preferentially rounded cells. Macrophages cultured on uncoated or FN-coated scaffolds
displayed more diverse shapes in contrast with cells grown on the DCN-coated TPCU scaffolds.
The potential activation of T cells was determined by flow cytometry analysis of known activation
markers CD69, CD25, and HLA-DR [74] after culturing complete human PBMCs on either uncoated
or coated scaffolds (Figure 4f). However, only anti-CD3/anti-CD28 stimulated T cells (stim; positive
control) significantly elevated the expression level for CD69 (stim 7.956 ± 1.319 versus unstim 1 ± 0,
p < 0.0001), CD25 (stim 265.6 ± 101.5 versus unstim 1 ± 0, p = 0.0008), and HLA-DR (stim 2.824 ± 0.3099
versus unstim 1 ± 0, p = 0.0001) compared with the level of the unstimulated controls (dotted line,
set to 1). No significant increase in T cell activation marker expression was observed in any other
experimental group.
3.3. Simulation of Endothelial Progenitor Cell Homing Using Endothelial Colony Forming Cells
3.3.1. ECFCs Show Altered VEGFR2 and PECAM-1 Expression Patterns on FN + DCN-Coated TPCU
Scaffolds Under Static Culture Conditions
ECFCs were seeded on the biofunctionalized planar scaffolds and cultured under static conditions
for 24 and 48 h. The amount of adherent ECFCs was significantly higher on samples coated with FN
(24 h: 257 ± 57 cells/mm2 versus control with 137 ± 46 cells/mm2, p < 0.01; 48 h: 301 v 64 cells/mm2
versus control with 52 ± 32 cells/mm2, p < 0.001) and FN + DCN (24 h: 243 ± 63 cells/mm2 versus
control with 137± 46 cells/mm2, p < 0.01; 48 h: 292± 54 cells/mm2 versus control with 52± 32 cells/mm2,
p < 0.001) when compared with the uncoated samples (controls) throughout the entire culture period
(Figure 5a). No significant difference of adherent cells was observed between FN coating and FN+DCN
coating (24 h: p = 0.656; 48 h: p = 756). DCN coating did not show any significant difference in
cell density in comparison with the uncoated controls (24 h: 105 ± 40 cells/mm2 versus control with
137 ± 46 cells/mm2, p = 0.340; 48 h: 30 ± 11 cells/mm2 versus control with 52 ± 32 cells/mm2, p = 0.460).
SEM analyses revealed that the ECFCs on the control and DCN-coated TPCU scaffolds had
attained a spherical shape after 24 h whereas those on TPCU scaffolds that were coated with FN and
FN + DCN showed a stretched morphology (Figure 5b). Immunofluorescence staining of samples
24 h after seeding (Figure 5c,d) identified a significantly lower PECAM-1 expression in ECFCs on
FN + DCN-coated samples in comparison with FN coating (0.64 ± 0.30 versus 0.90 ± 0.25, p < 0.05).
After 48 h, this effect tended to reverse, although the difference was not significant (0.70 ± 0.15
versus 0.54 ± 0.23, p = 0.073). A similar and statistically not significant tendency was detected for
the fluorescence intensity of vWF. No significant changes were observed in VE-cadherin or vinculin
expression. VEGFR2 expression was significantly decreased in cells cultured on FN-coated scaffolds
when compared with cells grown on FN+DCN-coated scaffolds after 24 h (0.64± 0.11 versus 0.29± 0.16,
p < 0.01). After 48 h, this effect vanished (0.28 ± 0.17 versus 0.28 ± 0.15, p = 0.942).
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Figure 5. Static experiments of human ECFCs on FN-, DCN-, or FN + DCN-coated scaffolds:
(a) Attachment and proliferation of the human ECFCs after 24 h and 48 h. Cells on FN and FN + DCN
coating show a significantly higher proliferation when compared with cells gown on DCN and
controls. Two-tailed t-test, compared to controls, n = 5, n.s. = not significant. (b) SEM images
and (c) Immunofluorescence staining of ECFCs 24 h after seeding on ECM protein-coated scaffolds:
Cells on FN and FN + DCN show a spread morphology in contrast to DCN coating and controls.
(d) Semiquantitative fluorescence intensity analysis (relative pixel intensity (arbitrary units)) of
cells on FN and FN + DCN shows no significant difference for the endothelial cell type marker
von Willebrand factor (vWF) as well as vinculin and vascular endothelial cadherin (VE-cadherin).
Platelet endothelial cell adhesion molecule (PECAM-1) expression is significantly decreased and
VEGFR2 expression is significantly increased on FN + DCN-coated scaffolds after 24 h. Two-tailed
t-test, n = 6, n.s. = not significant.
3.3.2. FN + DCN-Coating Attracts ECFCs Under Dynamic Culture Conditions
After ECFC seeding under static conditions, the cell-seeded scaffolds were dynamically cultured
on a roller mixer for 24 h (Figure 6a). This approach was performed to reflect more closely the in vivo
conditions. The analysis of the adherent cells showed a significantly increased cell number on the
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FN + DCN-coated samples when compared with the controls and DCN-coated samples (5.7% ± 4.4%
versus DCN coating with 1.0% ± 0.8%, p < 0.05 and versus control with 0.6% ± 0.7%, p < 0.05). The FN
coating led to a nonsignificant decrease of adherent cells compared to FN + DCN coating (Figure 6b;
3.4% ± 1.5% versus 5.7% ± 4.4%, p = 0.226). Cells on all samples showed comparable PECAM-1
and vWF expression levels (Figure 6c). Distinct differences were observed in the cell morphology.
F-actin staining helped visualizing the spread cells on the FN- and FN + DCN-coated scaffolds and
cells with a more rounded morphology on the control samples and DCN-coated scaffolds (Figure 6c).
 
Figure 6. In vitro simulation of in vivo processes: ECFC attraction under dynamic conditions. (a) ECFCs
were seeded into tubular constructs and cultured for 24 h on a roller mixer. (b) Adherent cells after 24 h
on control scaffolds and on DCN-, FN-, and FN + DCN-coated scaffolds. FN + DCN coating shows a
significantly higher cell number when compared with DCN coating and controls. One-way ANOVA,
n = 4. (c) PECAM-1 (green), vWF (red), and F-actin (yellow) expression in ECFCs. Cells on FN and
FN + DCN show a more spread morphology in contrast to the DCN and control samples.
3.4. In Vitro Tissue Engineering Approach Using Vascular Endothelial Cells
3.4.1. vECs Form an Endothelial Layer on FN- and FN + DCN-Coated Scaffolds Under Static
Culture Conditions
vECs were seeded on the biofunctionalized planar constructs and cultured for 1, 4, and 7 days
in order to investigate endothelialization (Figure 7a). One day after seeding, the cell number for
all conditions was not significantly different. On day 4, vECs significantly increased proliferation
on FN coating (78 ± 26 cells/mm2 versus control with 8 ± 7 cells/mm2, p < 0.01) and FN + DCN
coating (55 ± 27 cells/mm2 versus control with 8 ± 7 cells/mm2, p < 0.05), while the VEC count on the
DCN-coated samples had slightly decreased (7 ± 5 cells/mm2 versus control with 8 ± 7 cells/mm2,
p < 0.931). This trend continued until day 7, on which a significantly increased cell count was detected
for FN coating (186 ± 47 cells/mm2 versus control with 16 ± 16 cells/mm2, p < 0.001) and FN + DCN
coating (135 ± 50 cells/mm2 versus control with 16 ± 16 cells/mm2, p < 0.01) in comparison with the
uncoated controls. DCN coating of the TPCU scaffolds showed no improvement when compared with
the control samples. Over the entire period of the experiment, the cell count was not significantly
different between FN and FN + DCN coating.
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Figure 7. Static cell culture experiments of vECs on FN- and DCN-coated scaffolds: (a) Attachment and
proliferation of vECs after 1, 4, and 7 days. vECs on FN and FN + DCN coating show a significantly
higher proliferation rate compared with cells gown on DCN coating or control scaffolds. Two-tailed
t-test, compared with control samples, n = 3, n.s. = not significant. (b) SEM images and (c) IF staining
of vECs 7 days after seeding on ECM-coated scaffolds. Cells on FN and FN + DCN coating show a
spread morphology in contrast with cells on DCN coating and control samples. (d) Semiquantitative
fluorescence intensity analysis (relative pixel intensity (a.u.)) of cells on FN and FN + DCN coating
shows no significant difference for PECAM-1, vWF, vinculin, or VE-cadherin expression. Two-tailed
t-test, n = 5, n.s. = not significant.
While vECs on the control and DCN-coated scaffolds showed a spherical shape after 7 days as
assessed using SEM, on FN and FN + DCN-coated scaffolds, vECs were stretched out and formed
an almost confluent endothelial cell layer (Figure 7b). IF staining confirmed the expression of the
endothelial cell type-specific markers PECAM-1, vWF, and VE-cadherin in the vECs on both FN and FN
+ DCN coating (Figure 7c). Semiquantitative analysis of fluorescence intensities revealed no significant
differences of marker expression between FN and FN + DCN coating (Figure 7d). Vinculin expression
was comparable in vECs on both coatings. With regard to VEGFR2, an increased fluorescence intensity
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in cells grown on the FN + DCN-coated samples was observed. However, due to a high variation in
expression levels of individual experiments, no statistical significance between cells grown on FN or
FN + DCN coating could be determined.
In summary, our data showed that DCN coating of the TPCU scaffolds did not have a substantial
advantage when aiming for an increased VEC proliferation or an improved cell–cell or cell–material
interaction. For this reason, only FN biofunctionalized TPCU scaffolds were used for the following
in vitro tissue engineering experiments.
3.4.2. vECs Cultured in a Custom-Made Bioreactor Under Flow Form a Confluent and Aligned Cell
Layer on FN-Biofunctionalized TPCU
After successful implementation of the developed bioreactor system, we aimed to test whether the
FN-biofunctionalized TPCU scaffolds can be endothelialized under dynamic conditions. vECs were
seeded into the tubular TPCU scaffolds, and after an initial culture for three days under static conditions
to allow cell attachment, a flow was employed that was stepwise increased to 25 mL/min within
1.5 days (Figure 2e). Under this flow, which causes a shear stress of about 0.03 Pa, the vEC-seeded
FN-biofunctionalized scaffolds were cultured for seven days. Metabolic activity assessment using an
MTT assay showed that a large part of the inner wall of our construct was covered with living cells, as
indicated by the purple formazan stain (Figure 8a). IF staining and SEM further revealed a layer of
confluent vECs that were aligned in the direction of flow (Figure 8b,c).
 
Figure 8. Tissue-engineering approach with vascular endothelial cells cultured for 7 days on
FN-biofunctionalized electrospun tubular TPCU scaffolds under dynamic conditions: (a) Inner wall
of the tubular construct shows living vECs indicated by the purple formazan stain. (b) PECAM-1,
vWF, VE-cadherin, vinculin, VEGFR2, and F-actin expression were detected. vECs show an aligned
morphology. (c) SEM confirms vECs that had aligned with the flow to which they were exposed to
during the dynamic culture in the bioreactor.
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We confirmed the expression of the endothelial cell markers PECAM-1, vWF, and VE-cadherin.
However, PECAM-1 and VE-cadherin did not appear to be located on the cell membrane as usual.
Vinculin and VEGFR2 were also detected in the cells. Nevertheless, the staining of VEGFR2 showed
only a weak signal.
4. Discussion
Due to a proven biocompatibility and biostability at body temperature [55,57], we selected for this
study a novel thermoplastic polycarbonate urethane for the fabrication of a TEVG. At first, scaffolds
were produced by electrospinning of the TPCU and were disinfected with 70% ethanol. Microbiological
studies showed that ethanol treatment did not achieved 100% sterility (Figure S3; 2 out of 9 plates
showed germ growth). We are aware that disinfection with ethanol does not necessarily inactivate
all forms of microorganisms [75]; therefore, for the clinical translation, a more efficient sterilization
method should be considered.
After disinfection, scaffolds were then biofunctionalized by adsorption of FN and DCN, either
alone or in combination. The adsorbed proteins did not impact elastic modulus or burst pressure of
the tubular constructs (Figure 3). We demonstrated that the biomechanical properties of our constructs
were comparable to native vascular tissue (Table 2).
The ability to mimic the nanofibrous topography of the ECM makes electrospinning a powerful
method for cardiovascular tissue-engineering applications. Several studies have already described the
influence of fiber and pore size on cell adhesion, cell migration, proliferation, and differentiation, as
well as cell–cell interaction [76–78]. In native blood vessels, the ECs are located on the basal lamina,
a mixture of defined ECM proteins that form a network and bind cells [79]. The literature describes a
wide range of pore and fiber diameters (1–1000 nm) from different vessels, depending on the position
and physical properties of the vessel [80]. The main collagen component of the basal lamina is collagen
type IV. It forms fibers that range from 20 to 52 nm [80–82]. In our study, the fiber diameters were
between 699 ± 61 nm and 776 ± 163 nm, which is much higher compared to the collagen type IV
fibers in native vessels. However, other studies developing electrospun vascular grafts reported
comparable [83] or even larger fiber sizes [84,85] on which a functional endothelium was formed [84].
The pore size strongly depends on the vessel type and ranges between 5 nm and 8 μm [80,82,86–89].
Our constructs showed pore sizes between 0.08 ± 0.01 μm2 and 0.12 ± 0.05 μm2, which lies in the range
of a native vessel.
Several studies have already described that FN improves the endothelialization of vascular
grafts [19,48,49,51]. In our study, we observed a fibrous-like structure of the coated FN
(Figure 3b). This phenomenon can be interpreted as material-driven fibrillogenesis, first described by
Salmeron-Sanchez et al. [3]. In the human body, FN matrix assembly is a cell-mediated process [90]
that influences cell growth, cell differentiation, and cell–cell interaction [76–78,90,91]. It has been
shown that the adhesion of FN on poly (ethyl acrylate) (PEA) can lead to a spontaneous organization
of FN into protein networks. It has also been shown that cell-free material-induced FN fibrillogenesis
influences the maintenance and differentiation of stem cells [3,92]. Furthermore, it was described that
the FN network has an increased ability to store growth factors [93]. To the best of our knowledge, our
study is the first to show that material-driven fibrillogenesis can be observed on electrospun TPCU
fibers. We presume that the surface properties, such as hydrophobicity and polarity, are comparable to
those of PEA. Whether the FN network has a significant advantage in terms of cell behavior or growth
factor binding compared to dispersed, coated FN molecules would need further investigation.
In addition to FN coating, in this study, we also used DCN coating. We observed that, after coating
on the TPCU, DCN was randomly distributed in aggregates on the fibers (Figure 3b). Since DCN
does not form fibrils, this coating behavior was expected. Even larger, globular DCN aggregates were
observed on the FN + DCN samples (Figure 3b,d). Interestingly, these aggregates were predominantly
seen on the FN fibrils and not on the TPCU itself. It is known that DCN interacts with FN [94,95].
Furthermore, the interaction of proteins with materials is determined by the geometrical, chemical,
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and electrical properties of the substrate [96]. In this respect, it can be hypothesized that the DCN
prefers the FN surface more than the hydrophobic polyurethane surface. Interestingly, we observed a
significantly increased swelling ratio for FN +DCN (Figure 3e). This was not the case with individually
FN- or DCN-coated TPCU. Depending on the surface properties of the material and the interaction with
other proteins, the conformation, orientation, and bioactivity of a protein can also be influenced [96–98].
With this in mind, one can assume that both DCN and FN in combination can have a different
bioactivity [99].
In contrast to our previous findings using poly (ethylene glycol) dimethacrylate-poly (L-lactide)
(PEGdma-PLA) or a blend of poly-ε-caprolacton and gelatin [25,100], we identified a cell-repellent
effect of the DCN-coated TCPU electrospun scaffolds for both human ECFCs and human vECs.
As already discussed, cells prefer to adhere to hydrophilic surfaces [101]. Since the TCPU itself is
highly hydrophobic (control: 98.4 ± 3.7 ◦), it can cause a cell-repellent effect. DCN alone was not able
to diminish this effect (Figure 5a,b). Cell adhesion is influenced by cell-adhesive peptides such as the
RGD sequence. Since DCN does not contain these sequences, as it is the case with FN, we assume
that at least this integrin-based cell–material interaction cannot be mediated by DCN. It has been
described that DCN can even partially inhibit cell adhesion; however, this has only been observed with
fibroblasts and not with endothelial cells [28,102]. Hinderer et al. observed an attraction of ECFCs to
DCN-coated PEGdma-PLA [25]. A direct comparison with this study is therefore difficult, since this
polymer has different surface properties, which influence the amount and orientation of the adsorbed
DCN and thus may have an altered impact on cell behavior [96]. FN coating reversed the cell-repellent
effect of the TCPU, both with and without DCN (Figure 5). We can therefore conclude that the cell
attraction and proliferation is supported by FN but not affected by DCN [99,103].
Scaffolds should in general exhibit a low immunogenicity and at the same time support tissue
regenerative processes. The evaluation of the immune response profiles of the analyzed control
and ECM-coated scaffolds excluded any major adverse effects, with only minor innate activation
characteristics. Co-culturing PMNs, as the first cells of an innate immune response, induced an
activated cell phenotype regarding the expression of CD11b and CD66b. Monocytes were incompletely
activated after co-culturing with the scaffold as indicated by only a weak tendency to upregulate the
HLA-DR expression and to increase their TNFα release. From the literature, it is well known that
the upregulation of CD80 and HLA-DR would be a hallmark of M1 macrophages [62,104] and that
the fiber and pore size of electrospun scaffolds could impact the macrophage polarization state [105].
When analyzing the potential impact of the TPCU scaffolds on macrophage polarization, no clear trend
to drive the process into a specific macrophage subtype could be determined. Also, the coating by either
DCN or FN did not trigger a specific type of macrophage polarization. In contrast, co-culture studies
with soluble recombinant DCN demonstrated that macrophages responded with an upregulated
CD80 expression as well an increased secretion of TNFα and IL-10 [25]. The absent responses in
the present study may result from the far lower amount of protein present on the coated scaffolds
in comparison with the high protein amounts available within solutions or even by conformational
changes. Not surprisingly, adaptive T cell responses were also not detected. T cells on scaffolds simply
showed a trend to upregulate CD69 and HLA-DR without significant changes.
A functional endothelium is mainly characterized by cell–cell junctions [106]. As PECAM-1 is
the most abundant component of the EC junction, which contributes to the maintenance of the EC
permeability barrier, its expression is essential for a functional EC layer [107]. In our study, the ECFCs
on FN coating revealed a significantly increased PECAM-1 expression after 24 h compared with
ECFCs cultured on FN + DCN-coated scaffolds. In contrast, the VEGFR2 expression was significantly
decreased in the ECFCs on FN coating after 24 h compared with FN + DCN coating. It has been
reported that VEGFR2 is highly expressed in early endothelial precursor cells but not in all mature
ECs [108,109]. For example, PECAM-1 is less expressed in endothelial progenitor cells, as it is
typically associated with a more mature EC phenotype [110]. Interestingly, DCN has been reported
to stimulate the maintenance of undifferentiated progenitor cells [111], and FN promotes endothelial
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cell differentiation [112]. Therefore, we hypothesize that the FN + DCN coating in our experiments
kept the ECFCs in a precursor cell state compared with the culture on only FN. It may also be possible
that a direct interaction of DCN with VEGFR2 leads to its upregulation. A positive feedback loop
between VEGF and VEGFR2 has been described [113]. Whether DCN has the same effect remains to
be confirmed.
Since DCN exerts many other functions, an indirect regulation of VEGFR2 is also
conceivable [34,114]. Mazor et al. showed that the matrix metalloproteinase-1 (MMP-1) promotes
the expression of VEGFR2 [115]. The core protein of DCN in turn is able to stimulate the expression
of MMP-1 [116,117]. Furthermore, Murakami et al. reported that increased concentrations of the
fibroblast growth factor (FGF) led to an increase in VEGFR2 levels [118]. DCN, in turn, can bind to
FGF and can increase its activity [119]. It was also described that VEGFR2 expression is regulated
by the disruption of the c-MET receptor tyrosine kinase [120]. As an antagonistic ligand of c-MET,
DCN is able to inhibit its activity and thus might indirectly promote VEGFR2 expression [38]. We have
already discussed the hypothesis that DCN in interaction with FN may exhibit an altered bioactivity.
This would explain why DCN, which was adsorbed on the TPCU scaffold surface, impacted ECs in
combination with FN but did not without [96–98]. The reason for VEGFR2 upregulation can also
be due to FN. It might be possible that, in combination with DCN, its conformation and function is
also changed [96–98]. It has been shown that conformational remodeling of the FN matrix selectively
regulates VEGF signaling [121]. VEGF in turn regulates VEGFR2 expression [113]. By binding to
VEGF, FN can promote full phosphorylation and activation of VEGFR2 [122]. Interestingly, after 48 h,
the difference between FN and FN + DCN coating for both the PECAM-1 and VEGFR2 expression
had vanished (Figure 5d). With regard to VEGFR2, a short half-life of the receptor is described,
which enables ECs to adapt quickly to changes in the extracellular environment [118,123]. This leads to
the question of how long the biofunctionalized DCN coating was fully biologically active in our study.
Due to its natural presence in the body, it can be easily degraded [124]. We showed that DCN acts on
ECFCs for at least 24 h under static conditions. The culture of vECs over 7 days under static conditions
revealed the same expression of PECAM-1 and VEGFR2 on FN and FN + DCN coating (Figure 7).
This observation supports the assumption that the DCN was only active for a short period of time and
that its effect had disappeared after 7 days. In addition, it is possible that the vECs are not as sensitive
to DCN, as we have observed with the ECFCs. Several studies have described an increase in VEGFR2
expression during differentiation and expansion of endothelial progenitor cells [109,125]. At the same
time, VEGFR2 expression was relatively low during the proliferation phase [126]. Since the vECs
are mature cells, it can be assumed that the externally changed conditions do not affect the VEFGR2
expression significantly. Nevertheless, in this study, we successfully showed that vECs formed an
endothelium on biofunctionalized FN-coated constructs after 7 days of culture whereas DCN-coated
TPCU scaffolds did not show a significant effect on cell proliferation.
In our TEVG experiments using a custom-made bioreactor, we observed a unidirectional cell
orientation in the direction of the flow. The response of ECs to shear stress is well studied [127–129]. It has
been shown that, under flow, the morphology of vECs changes from a cobblestone (static) to an elongated
form and that vECs align in the direction of the flow in only 24 h [127]. The hemodynamic forces can
modulate not only the phenotype but also the gene expression of the cells. In this context, the correct flow
is of great importance for a properly functioning endothelium [130]. In our study, IF staining revealed
the expression of vWF, PECAM-1, and VE-cadherin. However, PECAM-1 and VE-cadherin were not
located on the cell membrane as usually seen. VEGFR2 expression was quite weak, and the F-actin
staining revealed a rather fibroblast-like cell morphology. We hypothesize that the vECs underwent
endothelial-mesenchymal transition (EndMT). ECs, which undergo EndMT, lose the expression of
the characteristic surface endothelial markers PECAM-1, VE-cadherin, and VEGFR2 [39,131,132].
Mahmoud et al. showed that the EndMT can be induced under low shear stress (0.4 Pa) [133]. In our
approach, the cells experienced a wall shear stress of about 0.03 Pa, which is slightly lower than
a venous wall shear stress (0.06 Pa) [134]. In silico simulations of our dynamic bioreactor culture
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confirmed laminar flow conditions along a large part of the vascular wall using the applied parameters.
Another reason for the fibroblast-like phenotype could be that ECs are highly plastic [135,136].
Therefore, culturing ECs in vitro in an artificial environment can lead to cell dedifferentiation [136,137].
This highlights the importance of fine-tuning the culture conditions to create a functional TEGV.
5. Conclusions
In the present study, we successfully engineered a TPCU electrospun vascular graft which
combines appropriate mechanical properties with a highly bioactive surface for the attraction of ECs.
The FN biofunctionalization was characterized by a material-driven fibrillogenesis, which might
have a positive impact on FN functionality [3]. To imitate the physiological conditions of a blood
vessel, a bioreactor for in vitro tissue culture was designed and manufactured. vECs seeded on the
FN-functionalized constructs formed a confluent and functional endothelium under static and dynamic
conditions. In contrast, DCN-biofunctionalized TPCU scaffolds had a cell-repellent effect on vECs and
ECFCs, most likely due to the high hydrophobic properties of the TPCU. However, since DCN has been
shown to inhibit the adhesion of fibroblasts, it remains a promising protein for the functionalization of
vascular grafts [29].
The challenge for the future will be to combine the advantages of different proteins and to thus
increase the selectivity, functionality, and stability of a biofunctionalized vascular graft while keeping
the complexity of the coating as low as possible.
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Abstract: Cardiac Progenitor Cells (CPCs) show great potential as a cell resource for restoring cardiac
function in patients affected by heart disease or heart failure. CPCs are proliferative and committed to
cardiac fate, capable of generating cells of all the cardiac lineages. These cells offer a significant shift
in paradigm over the use of human induced pluripotent stem cell (iPSC)-derived cardiomyocytes
owing to the latter’s inability to recapitulate mature features of a native myocardium, limiting
their translational applications. The iPSCs and direct reprogramming of somatic cells have been
attempted to produce CPCs and, in this process, a variety of chemical and/or genetic factors have
been evaluated for their ability to generate, expand, and maintain CPCs in vitro. However, the
precise stoichiometry and spatiotemporal activity of these factors and the genetic interplay during
embryonic CPC development remain challenging to reproduce in culture, in terms of efficiency,
numbers, and translational potential. Recent advances in biomaterials to mimic the native cardiac
microenvironment have shown promise to influence CPC regenerative functions, while being capable
of integrating with host tissue. This review highlights recent developments and limitations in the
generation and use of CPCs from stem cells, and the trends that influence the direction of research to
promote better application of CPCs.
Keywords: cardiac progenitor cells; induced pluripotent stem cells; transdifferentiation; direct
reprogramming; genetic engineering; cardiac tissue engineering; biomaterials
1. Cardiac Regeneration—A Problem to Solve or A Solution with Promise?
With morbidity rates associated with cardiovascular diseases in the decline in the developed
world from improved treatments and pharmacological intervention, scientists and clinicians have
been approaching therapies recently for these diseases with vigor. However, there is still no reliable
therapy for acute cardiac conditions like myocardial infarction (MI), which account for nearly half of
all cardiovascular deaths in the industrialized world [1,2]. Regenerative medicine-based strategies
for infarcted myocardium have shown promise in preclinical animal models as well as early clinical
trials [3]. Whilst these have demonstrated some physiological improvements in ventricular function,
they were associated with very low cell retention after some weeks, suggesting a paracrine effect of
transplanted cells rather than functional integration within the damaged tissue [4].
The heart was long viewed as a post-mitotic or terminally differentiated organ with no
ability to regenerate or repair, a dogma that has been challenged abundantly in recent years [5,6].
Cardiac regeneration, following injury, is still an unresolved debate over whether it is attributed
to dedifferentiation and proliferation of resident cardiomyocytes or from an inherent trigger in
differentiation of cardiac stem or progenitor cells in putative cell niches within the heart [7–11].
The turnover of cardiomyocytes in the adult heart is around 1% per year which is insufficient to counter
the loss caused by MI that can lead to loss of around 1 billion cardiomyocytes [12]. Therefore, the only
Cells 2019, 8, 1536; doi:10.3390/cells8121536 www.mdpi.com/journal/cells117
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long-term solution relies on heart transplantation, but this does not come without its own issues such as
insufficient number of donors coupled with the requirement for a life-long immunosuppressive therapy.
This catapulted research towards cell-based therapies for cardiac regeneration [13]. Cardiomyocytes are
the main cardiac cell type that is lost in cardiovascular disorders, like heart failure, myocardial infarction,
and ischemia, and therefore, replacing these cells could potentially restore heart function. However,
transplanting cardiomyocytes to repair diseased hearts has shown to yield only transient responses
as most cells are eventually lost in the host environment [14,15]. This is because cardiomyocytes
have very limited proliferative ability and as a result, they are unable to repopulate and replenish
the damaged tissue efficiently [16,17]. Furthermore, other cell types like smooth muscle cells, and
endothelial cells can suffer from collateral damage and their functional renewal is vital for effective
heart regeneration [18]. This puts emphasis on the role of a precursor cell type capable of extensive
expansion and differentiation into the key cell players of cardiac regeneration.
Even though some level of cell turnover has been observed in the adult heart, cells with self-renewal
or potency capabilities are generally considered lacking in this tissue [19]. Nevertheless, several studies
report the evidence of a progenitor population from resident cardiac stem cells (CSCs) in the heart,
called Cardiac Progenitor Cells (CPCs) [20–23]. In contrast to terminally differentiated cardiomyocytes,
CPCs are highly proliferative and can theoretically differentiate into all the necessary cardiac cell types
for effective reconstitution of damaged cardiac tissue and promoting its neovascularization [14,18,20,
21,24–31]. Therefore, CPCs present a more effective cell source than cardiomyocytes for cell-based
regenerative strategies. However, the application of CPCs has not been straight-forward particularly
in chronic infarcts, where CPCs are associated with senescence, decreased telomerase activity and
increased apoptosis [7]. Cell therapy using CPCs generally involve transplantation of in vitro-expanded
CPC populations which in turn yield mild improvements in cardiac function [32]. However, long term
prognosis with such therapies are poor owing to reduced cell viability and inefficient engraftment into
the host tissue. This is compounded by the somewhat hostile microenvironment created by MI, from
scar formation and associated inflammatory or tissue alterations, which compromises the effectiveness
of such therapies [33–35]. There are also reports that the administration of CPCs predisposed the risk
of cardiac arrhythmias and teratoma formation [36]. Therefore, better understanding of the CPC cell
behavior in dynamic pathophysiological microenvironments could aid in developing strategies to
optimize their contribution to cardiac repair.
Various approaches have been developed to generate CPCs ex vivo, in the hope of obtaining
reliable source of cells that can trigger mechanisms of cardiac regeneration. For example, CPCs from the
heart tissue (also known as putative CPCs) can be isolated and expanded in vitro [27,37–40]. However,
such cells are hard to access and are present in low numbers in the tissue, making them extremely
challenging to harvest and realize their potential [41]. Pluripotent stem cells, such as embryonic stem
cells (ESCs) and induced pluripotent stem cells (iPSCs), are thought to be a superior alternative cell
source since they could potentially provide an unlimited supply of cardiac progenitor cells. However,
ESC-based therapy faces several challenges like immunogenicity, high risk of tumor formation and
the characteristic ethical concerns, which have prevented their clinical application [42,43]. On the
other hand, iPSCs avoid the ethical issues associated with ESCs and allows for the development of
patient-specific derived CPCs, which represents an advantage over other cell sources in the creation
of immune-compatible cardiac therapies [44,45]. However, with issues surrounding the safety of
iPSC-based therapies, in terms of the potential risk of tumor formation associated with such therapies
or immune rejection of iPS-derived cells from a common donor, scientists are looking at reprogramming
from a different perspective [46–48]. Reprogramming patient somatic cells into other cell types,
bypassing the step of stem cell generation, can potentially overcome issues with translating iPSC
technology. This process is known as direct cellular reprogramming or transdifferentiation, and might
represent a more robust approach to rapidly generate sufficient numbers of CPCs from somatic cells
for therapy [49].
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This review focuses on the ongoing progress and limitations in generating CPCs from iPSCs and
through direct reprogramming. It will start by providing a concise introduction about the various
cardiac progenitor cells identified in embryonic and adult heart tissues. The review will then move
towards discussing reprogramming approaches that were successful in generating CPCs and the
functionality of these CPC-derived cells. Strategies to improve efficiencies of current protocols and
tissue engineering advances to mimic CPC microenvironment and in vivo applications of CPCs will
also be evaluated. Finally, the review will finish with a summary of existing challenges and limitations
and future directions for CPC research, hopefully convincing readers it is a promising strategy for
cardiac regeneration (Figure 1).
 
Figure 1. The interplay between genetics and biomaterials for understanding Cardiac Progenitor
Cells (CPCs) biology, function, and its regenerative applications. eCPCs (endogenous CPCs), rCPCs
(reprogrammed CPCs), iPSCs (induced Pluripotent Stem Cells), SPs (Side Population-derived CPCs),
CSs/CDCs (Cardiospheres/Cardiosphere-Derived Cells), EDPCs (Epicardium-derived CPCs), FHF/SHF
(First Heart Field-/Second Heart Field-derived CPCs) CMs (Cardiomyocytes), SMCs (Smooth Muscle
Cells), ECs (Endothelial Cells).
2. Cardiac Progenitor Cells (CPCs) In Vivo
Progenitor cells are distinct from embryonic stem cells as they have a predetermined differentiation
fate and therefore, their ability to self-renew and differentiate into other cell types is restricted [19].
CPCs generate cells of the three cardiac lineages: cardiomyocytes, smooth muscle cells and endothelial
119
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cells. These cells are also responsible for the maintenance of cardiac homeostasis under physiological
and pathological conditions [50]. Several studies have identified and isolated multiple CPC populations
from distinct stages of cardiac development and heart locations. These cells are collectively characterized
according to their cell surface and genetic marker expression profiles. The various CPCs reported to
date are described below and their specific features are summarized in Table 1.
2.1. c-KIT-Expressing CPCs
The first-ever detected CPCs were isolated from female rats and were characterized by the
expression of the stem cell surface marker c-KIT [28]. These CPCs are present throughout the ventricular
and atrial myocardium, particularly in the atria and the ventricular apex [28]. These progenitor cells
also express the cardiac transcription factors NKX2.5, GATA4, and MEF2C, and are negative for
hematopoietic lineage markers, such as CD45, CD34, CD3, CD14, CD16, CD19, CD20 and CD56 [50–52].
They are self-renewing, clonogenic and are able to differentiate into the three cardiac cell types
in vitro and in vivo [28,53]. The c-KIT receptor binds to the Stem Cell Factor (SCF) which leads to the
activation of the signaling pathways Phosphoinositide 3-kinase/Protein Kinase B (PI3K/AKT) and p38
Mitogen-Activated Protein Kinase (MAPK) [54,55]. These pathways regulate a variety of CPC functions
like self-renewal, proliferation, survival, and migration [54–57]. Even though c-KIT CPCs contribute to
the generation of cardiomyocytes at earlier stages of embryonic development and right after birth,
this ability is mostly lost in the adult heart and very low percentages of new cardiomyocytes seem to
originate from these CPCs [58–60]. Therefore, the improvement of cardiac function by c-KIT CPCs
might be a result of paracrine factors rather than the production of de novo cardiomyocytes [58,61].
Furthermore, c-KIT expression is considered necessary but not sufficient to define CPCs [62].
2.2. SCA1-Expressing CPCs
Another CPC population present in adult hearts expresses the Stem Cell Antigen 1 (SCA1).
The cells were first identified in adult mouse hearts [11] and are predominantly located in the atrium,
the intra-atrial septum, the atrium-ventricular boundary and scattered within the epicardial layer [37].
SCA1 is a cell surface protein of the Ly6 gene family and it was initially used to isolate hematopoietic
stem cells [63]. Additionally, SCA1 is widely expressed by stem and progenitor cells from a variety
of tissues, including the heart, and it has roles in cell survival, proliferation and differentiation [63].
Several studies have shown that SCA1 CPCs are negative for hematopoietic lineage markers and
are able to differentiate into the three cardiac lineages [11,64]. These CPCs also have the ability of
homing in response to injury and contribute to neovascularization in vivo [11,65,66]. Although this
CPC population seems promising for cardiac regeneration, their translational relevance is not without
caveats. First, all the SCA1 CPC populations identified to date display different gene expression
profiles and distinct differentiation potential [37,66–71]. In addition, several studies have shown that
the benefits resulted from the transplantation of these CPCs might be predominantly due to paracrine
mechanisms as these cells differentiate into cardiomyocytes with very low efficiency [66,68,70,71].
Finally, SCA1 is only present in murine cells and a human ortholog of SCA1 has yet to be identified [63].
Therefore, the nature of the epitope target of SCA1 in humans and the nature of regeneration of the
associated CPC population have yet to be determined.
2.3. MESP1/2-Expressing CPCs
During the development of mesoderm, embryonic cells express the transcription factor Mesoderm
Posterior Protein 1/2 (MESP1/2), which is essential for proper cell migration [15,72–74]. MESP1/2
expression marks the first step in the commitment of the nascent mesoderm into the myocardial
lineages, and it describes the first population of multipotent cardiac progenitor cells that produce
the various cardiac cell types of the heart [72,75]. Although MESP1/2 CPCs show increased cardiac
potential, in comparison to other CPC types, they are not irreversibly committed to the cardiac fate [76].
Consequently, there is a possibility that these cells will differentiate into derivates of the paraxial
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mesoderm and skeletal muscle [77,78]. Furthermore, MESP1/2 is only transiently expressed during
embryonic development, which increases the difficulty of tracking the expansion and differentiation of
the CPCs [79,80].
2.4. KDR/FLK1-Expressing CPCs
During cell movement from the primitive streak to the anterior regions of the embryo, the
precardiac mesodermal cells start to express a receptor for Vascular Endothelial Growth Factor (VEGF)
called KDR/FLK1 [20,81]. These FLK1-expressing progenitor cells have the ability to generate cells from
both hematopoietic and cardiac lineages [20,81–83]. Selection between these two lineages is determined
by the levels of FLK1 activity [81]. For example, high expression of FLK1 promotes differentiation
towards hematopoietic lineages, whereas low or absent FLK1 expression stimulates cells to follow
the cardiac fate [81,82]. These negative FLK1-expressing cells further generate a second FLK1+ cell
population that represents the first multipotent cardiac progenitor cells that are permanently committed
to the cardiogenic fate [20,29]. Because KDR/FLK1 displays a broad expression, it is frequently used in
combination with other cardiac markers, such as Platelet-Derived Growth Factor-alpha (PDGFRα),
C-X-C chemokine Receptor type 4 (CXCR4) and sometimes MESP1/2, to enrich for CPCs [79,80].
2.5. CPCs from the First and Second Heart Fields
The cardiac mesoderm contains two unique progenitor cell pools that give rise to the primary and
secondary heart fields [20,22]. The two fields develop sequentially and display distinctive molecular
profiles that lead to the formation of different heart components. CPCs of the first heart field (FHF)
express the transcription factor NKX2.5, whereas CPCs from the second heart field (SHF) express the
transcription factor ISL1 [15,22,40,75,84]. FHF-derived CPCs are more difficult to isolate owing to a
lack of unique markers except for NKX2.5 [84]. The hyperpolarisation-activated nucleotide-gated
cation channel HCN4 has been suggested as an additional marker for FHF, however, this marker
might isolate a more restricted CPC that preferentially generates cells of the conduction system [85–87].
Regardless of the markers, FHF-CPCs predominantly differentiate into cardiomyocytes and have some
tendency towards smooth muscle lineages [21]. On the other hand, ISL1 CPCs can generate cells of all
the three cardiac lineages and they are responsible for producing most of the cardiomyocytes (around
40%) during heart development [22,30,40]. In addition, these CPCs have also been identified in the
adult heart, specifically in the outflow tract, atria and right ventricle [30,40].
2.6. Epicardium-Derived CPCs
Several studies have demonstrated that a specific CPC population present in the postnatal and
adult heart is derived from the epicardium. They express the transcription factor Wilms tumor 1
(WT1) and are originally derived from CPCs of the second heart field [88]. Additionally, these CPCs
emerge from epicardial cells that migrate into the myocardium and undergo epithelial-to-mesenchymal
transition (EMT) [88,89]. The epicardial-derived CPCs can differentiate into several different cell
types such as coronary smooth muscle cells, cardiomyocytes, endothelial cells, perivascular and
cardiac interstitial fibroblasts, albeit with varying efficiencies [51,88–93]. Even though WT1 CPCs
could potentially be an additional cell source for cardiac regeneration, these cells seem to share
some characteristics with c-KIT CPCs: they participate in cardiomyocyte formation during cardiac
development but are present at extremely low levels in the adult heart [9,88,90,92]. Stimulatory factors
like peptide thymosin beta 4 (Tβ4) can potentially reactivate the developmental program of adult
epicardial cells, however, the reactivated cells still exhibit distinct phenotype from their embryonic
counterparts, raising doubts about their cardiogenic potential [92].
2.7. Side Population-Derived CPCs
Side populations (SPs) have been detected in various tissues, including the heart, and are enriched
for stem and progenitor cell activity [38,94–98]. These cells are generally identified in vitro by their
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ability to export the DNA Hoechst dye from their nuclei when stained [94,95]. This dye efflux is
performed by an ATP (Adenosine Triphosphate)-binding cassette transporter (also known as ABC
transporter protein) that is present in their cellular membranes [94,95]. The phenomenon causes the
side population cells to contain much lower concentrations of the dye in their nuclei compared to other
cell types, allowing for their isolation using cell sorting techniques [95]. The main ABC transporter
protein used to identify cardiac SPs is the ABCG2, which was demonstrated to have a role in stem
cell proliferation and differentiation and is expressed in SP cells during early development and in
the postnatal heart [38,94,95,99]. These cardiac SPs can be found in the perivascular and interstitial
areas of the heart, and display self-renewal, homing and multipotency [94,97,100–102]. Noseda et al.
(2015) demonstrated that cardiac SPs, co-expressing SCA1 and PDGFRα, displayed high clonogenicity
and multilineage potential [103]. They particurlaly demonstrated that clones derived from cardiac
SPs subjected to long-term propagation (more than 10 months and 300 doublings) still resembled
freshly isolated SP cells, showing maintainance of phenotype, self-renewal and tri-lineage capacity
and absence of replicative senescence. However, cardiac SPs exhibit a few disadvantages that could
potentially prevent their clinical application. For instance, the differentiation potential of human SPs
has not been thoroughly investigated [38]. In addition, the multipotency of SPs might be attributed to
their heterogeneous nature as they are composed of several subpopulations with distinct differentiation
potential (cardiac, hematopoietic and mesenchymal) [38,104]. Therefore, it is still inconclusive on
which markers can predict the SP subpopulation with the best cardiac potential.
2.8. Cardiosphere-Derived CPCs
Cardiospheres contain a mixture of stromal, mesenchymal and progenitor cells that are isolated
from human heart biopsy cultures [39,52]. They represent a niche-like environment containing a
mixture of cells, with cardiac-committed cells in the center and supporting cells, such as mesenchymal
and endothelial progenitor cells, in the periphery of the spherical cluster [105,106]. Many cells can
be harvested from these cell clusters and they are called cardiosphere-derived cells (CDCs) [52,105].
However, like in the case of c-KIT and epicardial CPCs, the regenerative potential of CDCs is
questionable as it has been shown that cardiac repair by these cells mainly results from paracrine
mechanisms rather than cell generation [105].
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3. Generation of CPCs from Human iPSCs
Native CPCs are present in very low numbers in the heart tissue, and therefore, a larger source of
cells is required for efficient cardiac regeneration [41]. The reprogramming of human adult somatic
cells into embryonic stem cell-like cells (known as iPSCs) using defined factors opened new possibilities
for the generation of patient-specific pluripotent cells. In turn, human iPSCs could potentially offer an
unlimited source of differentiated cells and in the process, offer the chance to recreate the development
process of CPCs in vitro [121]. This section will provide a detailed description and assessment of
current methods used to induce, expand and maintain CPCs derived from iPSCs.
Several techniques have been developed to modulate cardiac differentiation in iPSCs (Table 2).
However, the efficiencies for cardiac differentiation can vary considerably between iPSC lines [121–124].
Regardless of the type of culture employed, the first step in all protocols involves the dedifferentiation
of a chosen cell type into a pluripotent state using conventional reprogramming factors, such
as OCT4, SOX2, KFL4 and c-MYC [44,45]. Once pluripotency has been achieved, the following
step is to induce cardiac differentiation of the iPSCs. Different methods have been employed to
accomplish differentiation of iPSCs into cardiomyocytes: embryoid body (EB); monolayer-based
cultures supplemented with growth factors, serum or small molecules, matrices, and co-culture with
visceral endodermal stromal (END2) layers [15,122,125]. Recent protocols utilise a monolayer culture
with a serum-free medium, such as mTeSR1 or E8 medium, which maintains iPSC pluripotency and
self-renewal in a feeder-free culture [126,127]. Unfortunately, these studies predominantly focused
on the generation of iPSC-cardiomyocytes and not necessarily the homogeneity of CPC population
entering the cardiac lineages.
In addition to the nature of the pluripotent culture employed, the type and timing of growth
factors and/or small molecules added throughout the protocol affects cardiomyocyte differentiation
efficiency. Early differentiation protocols only employed growth factors that modulate key signaling
pathways involved in cardiomyogenesis, like Bone Morphogenic Protein (BMP), Activin/Nodal and
Fibroblast Growth Factor (FGF) signaling pathways [15,128]. Such factors included Activin A, BMP2/4
and FGF2 which induce cardiac mesoderm formation in iPSCs [15,29,122,128,129]. Lian et al. (2012)
demonstrated that iPSC differentiation towards cardiac lineages could be accomplished by exclusively
using small molecule modulators of the Wingless (WNT) signaling pathway [130]. Minami et al. (2012)
also showed that combining analogous WNT modulators during the early and middle stages of the
cardiac differentiation process can further enhance the protocol’s efficiency [131]. Many protocols rely
on adding a Glycogen Synthase Kinase (GSK3) inhibitor, such as CHIR99021 (CHIR), to the medium for
24 h to activate the canonical WNT signaling [126,130,132]. Induction of the canonical WNT signaling
stimulates the expression of the mesoderm marker Brachyury (T) in undifferenced iPSCs, initiating
mesoderm induction [126,132]. Once T+ cells have been established, the WNT signaling is then
suppressed to direct the mesodermal cells towards the cardiac fate [126]. Several inhibitory molecules
can be used, like XAV939, inhibitor of WNT production (IWP), inhibitor of WNT response (IWR) or
an exogenous β-catenin small hairpin RNA (shRNA). After 3/4 days of WNT signaling suppression,
iPSC-derived T+ mesodermal cells begin to express cardiac transcription factors, like NKX2.5, ISL1,
FLK1, and PDGFRα, which transitions into the CPC population.
More recent studies have been successful in generating CPCs from iPSCs using a single
small molecule, potentially reducing costs, time and labor. For instance, the immunosuppressant
cyclosporin-A (CSA) was shown to stimulate differentiation of FLK1-positive mesodermal cells into
FLK1+/CXCR4+/VE-cadherin− CPCs and cardiomyocytes [133,134]. When CSA was added to the
medium, the CPC and cardiomyocyte yield was 10 to 20 times higher compared to untreated cells.
Additionally, the generated cardiomyocytes exhibited molecular, structural and functional properties of
adult cardiomyocytes. However, additional factors and/or other protocols may be required to produce
cells from the other cardiac lineages as FLK1+/CXCR4+/VE-cadherin− CPCs have an exceptionally
low endothelial potential and cannot differentiate into smooth muscle cells [110,133]. Furthermore,
the study used co-culture with END2 cells to induce cardiac differentiation in iPSCs, which prevents
126
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reproducibility of the protocol due to the presence of END2-derived growth factors at unknown
concentrations [135]. Another study also demonstrated that treating human iPSCs with the cardiogenic
small molecule isoxazole (ISX-9) for 7 days stimulated the expression of CPC markers [136]. These CPCs
expressed NKX2.5, GATA4, ISL1, and MEF2C and were able to generate cardiomyocytes, smooth
muscle cells and endothelial cells under basal differentiation conditions. Furthermore, ISX-9 seems to
modulate key signaling pathways involved in cardiomyogenesis, like VEGF, Activin A and canonical
and non-canonical WNT signaling. The study also demonstrated that the small molecule might
participate in CPC generation by upregulating activators involved in both canonical and non-canonical
WNT pathways in a temporal and sequential manner (WNT3A at day 3 and WNT5A and WNT11 at
day 7, respectively).
Therefore, the application of iPSC technology in CPC research has great prospects for improving
current cardiac regeneration approaches through the development of novel cell therapies, disease
models and drug screens. However, most studies using iPSCs in cardiac regeneration predominantly
focus on producing cardiomyocytes and improving their maturation [15,126,130,137–142]. Current
knowledge about associating this with the generation of iPSC-CPCs, however, remain limited.
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4. Direct Reprogramming into CPCs
The discovery of iPSC reprogramming prompted studies to evaluate if it would be possible to
reprogram somatic cells directly into other cell types without an iPSC intermediate stage, a process
known as transdifferentiation or direct reprogramming. Transdifferentiation has shown to be a
much quicker process than dedifferentiation into iPSCs, with the former taking only a few days to
achieve, whereas the latter can last up to 3 weeks plus differentiation time to produce the desired cell
lineages. With the added advantage of avoiding potential cumulative mutation or epigenetic changes,
generally associated during complex iPSC reprogramming processes, direct reprogramming of somatic
cells can potentially offer a simpler, faster and safer alternative to generate cells compared to iPSC
dedifferentiation [41]. Most transdifferentiation studies in the cardiac field involve the generation of fully
differentiated cardiac cells, particularly cardiomyocytes, rather than cardiac progenitor cells [159–172].
Potentially, using transdifferentiation protocols to generate CPCs might be a superior approach for
regenerative medicine applications. This section focuses on the current approaches that are associated
with producing CPCs from direct reprogramming.
4.1. Partial Somatic Cell Reprogramming into CPCs
Some studies have developed transdifferentiation protocols that involve a transient stage of
pluripotency of somatic cells before they continue into CPC fates. The use of reprogramming factors
(OCT4, SOX2, KLF4 and C-MYC) seems to be enough to initiate resetting of epigenetic memory of
somatic cells towards a stem cell path (partial reprogramming), but the factors alone are insufficient to
directly activate cardiac lineage-specific genes for directed differentiation [159]. In order to achieve
lineage commitment, signaling molecules involved in cardiogenesis, like BMPs, WNT modulators and
FGFs, need to be activated in the cultures [14,159], similar to differentiation protocols for cardiomyocytes
from iPSCs. One study demonstrated that secondary mouse embryonic fibroblasts can be converted into
CPCs using a technique developed by Wang et al. (2014) called Cell Activation and Signaling-Directed
(CASD) lineage conversion [165], which combines reprogramming and cardiac-specific factors to
induce cell activation and direct cell fate towards cardiogenesis, respectively [14]. Zhang et al. (2016)
transiently exposed the mouse fibroblasts to reprogramming medium containing doxycycline and JAK
inhibitor 1 (JI1) for 6 days, and then to transdifferentiation medium with CHIR99021 and JI1 for 2 days
to induce cardiac differentiation. Following this, the cells are treated with a mixture of CHIR99021,
BMP4, Activin A, and SU5402 (inhibitor of FGF, VEGF, and PDGF signaling) for 3 days. The obtained
CPCs from this protocol expressed the proliferative marker Ki-67, the typical cardiac transcription
factors GATA4, MEF2C, TBX5 and NKX2.5, and the cell surface molecules FLK1 and PDGFRα and
were capable of producing cells from the three cardiac lineages. Efe et al. (2011) also demonstrated that
transient expression of pluripotent markers (OCT4, SOX2, KLF4 and C-MYC) followed by exposure to
chemically defined media containing BMP4 and the JAK inhibitor JI1 induced cardiac conversion of
mouse embryonic and tail-tip fibroblasts [159]. JI1 was added to the reprogramming media for 9 days
and from day 9, BMP4 was added and the media was subsequently changed to RPMI supplemented
with N2 and B27 lacking vitamin A for 5 additional days. This protocol upregulated the expression of
several CPC markers such as NKX2.5, GATA4, and FLK1 by day 9/10.
Wang et al. (2014) were able to significantly reduce the number of reprogramming factors to
successfully stimulate cardiac transformation in mouse fibroblasts [165]. This protocol involved a single
transcription factor (OCT4) and a cocktail of small molecules: an activin A/TGF-β receptor (ALK4/5/7)
inhibitor (SB431542), GSK inhibitor (CHIR), Lysine (K)-Specific Demethylase 1 (LSD1/KDM1) inhibitor
(parnate/tranylcypromine) and an adenylyl cyclase activator (forskolin). Mouse fibroblasts were first
exposed to the reprogramming media, containing the small molecules, for 15 days. This was followed by
media change to RPMI supplemented with N2 and B27 lacking vitamin A and addition of BMP4 during
the first 5 days. CPC markers, like FLK1, MESP1, ISL1, GATA4, and Ki-67, can be detected around
days 15–20. These cells went on to differentiate into cardiomyocytes, endothelial cells and smooth
muscle cells under specific conditions. Another study developed an entirely chemical reprogramming
133
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protocol that utilised a larger combination of small molecules compared to Wang et al. (2014): CHIR,
the ALK5 inhibitor RepSox, forskolin, the histone deacetylase (HDAC) 1 inhibitor valproic acid (VPA),
parnate and the retinoid pathway activator TTNPB [173]. Mouse fibroblasts were exposed to the
reprogramming cocktail for 16 days and CPC markers could be detected around day 8-20. The markers
identified included SCA1, ABCG2, WT1, FLK1, and MESP1, demonstrating that the protocol can
generate CPC populations. Most of the studies described protocols predominantly focused on their
ability to generate cardiomyocytes from somatic cells using some iPS factors, and whilst CPCs were
observed in some of these studies, their characteristics were not necessarily a focus of their attention
and would warrant some investigation in their potency independently.
4.2. Direct Somatic Reprogramming into CPCs
Direct reprogramming of somatic cells involves the transdifferentiation into other cell types
without an iPSC intermediate stage. One study showed that CPCs can be directly generated from adult
mouse fibroblasts from different tissues (cardiac, lung and tail tip) using a 11- (MESP1, MESP2, GATA4,
GATA6, BAF60C, SRF, ISL1, NKX2.5, IRX4, TBX5 and TBX20) or a 5- Factor (MEF2C, TBX5, GATA4
NKX2.5, BAF60C) reprogramming protocol [24]. Both protocols led to the formation of CPCs expressing
the genes NKX2.5, MEF2C, MESP1, TBX20, IRX4, and the cell surface protein CXCR4, independently
of factor combination and tissue origin of the fibroblasts. The CPCs also showed downregulation
of fibroblasts-specific genes, such as FSP1, and could differentiate into the three cardiac lineages.
Furthermore, adding a canonical WNT activator, and a JAK/STAT activator during the reprogramming
process can increase the protocol efficiency, leading to the production of more CPCs. Even though the
11-factor and 5-factor protocols generated CPCs with comparable characteristics, they differ in the
amount of CPC colonies generated, with the former producing more, and in the expression of smooth
muscle cell and endothelial cell markers in CPC-differentiated cells, with the 5-factor protocol-based
CPCs generating more of these markers than the 11-factor system. Another study showed that human
dermal fibroblasts can be directly reprogrammed into CPCs by overexpressing the genes MESP1 and
ETS2 [174]. In this specific reprogramming protocol, human dermal fibroblasts are converted into CPCs
through a 4-day co-expression of ETS2 and MESP1 using lentiviral vectors, which is then followed by
Activin A and BMP2 treatment for another 2 days. Human ETS2 is a transcription factor involved in
development, apoptosis and oncogenic transformation and when co-expressed with MESP1, induces
the expression of BMP2, initiates the Activin A/Nodal signaling and stimulates the emergence of
CD31/PECAM-1 (endothelial cells) and KDR cells (CPCs). ETS2 could potentially be substituted by
other ETS transcripts, such as ETS1, FLI1, ETV1, ETV5, ERG and ETV that are also highly abundant in
the developing heart, and might function similarly to ETS2 in reprogramming human somatic cells
into CPCs.
All these protocols described required the use of viral vectors, usually lentiviruses, to deliver the
reprogramming factors into cells. This implied host cell genome changes which could potentially affect
its suitability for translational applications. One method that addresses this concern is through the
delivery of reprogramming proteins, related to transcription factors, directly into cells. These proteins
can modulate the gene expression of cells to convert them into other cell types. For example, using
a nonviral-based protein delivery system with the cardiac transcription factors GATA4, HAND2,
MEF2C, and TBX5 induces reprogramming of human dermal fibroblasts into CPCs [41]. Additionally,
adding growth factors such as BMP4, Activin A and basic Fibroblast Growth Factor (bFGF) can further
stimulate and sustain potency towards a CPC state. This combination increased the cellular expression
of CPC markers (FLK1 and ISL1) and decreased the expression of fibroblast-specific markers (COL1A2
and FSP1). Furthermore, the protocol demonstrated high efficiency in direct transdifferentiation,
converting more than 80% of the human dermal fibroblasts into CPCs.
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4.3. Somatic Reprogramming into Cardiospheres
Recent studies have shown that adult skin fibroblasts from mouse and human can be converted
into cardiospheres that, in turn, have the potential to generate CPCs [175,176]. For this, the skin cells
were first reprogrammed with the Yamanaka factors SOX2, KLF4 and OCT4 overnight, followed by
media change to Knockout Serum Replacement-based media for 18 days and finally treatment with
the GSK3 inhibitor BIO and Oncostatin for 2 days [175,176]. The resulted cardiospheres resembled
endogenous cardiospheres formed from the cellular outgrowth of cardiac explants in vitro [39], but
produced a higher number of MESP1, ISL1-, and NKX2.5- expressing cells [175,176]. On passaging,
the cardiospheres became enriched with CPCs expressing c-KIT, FLK1 and CXCR4, which were
able to differentiate into cardiomyocytes [175]. However, human cardiospheres do not display
spontaneous beating and fail to propagate in vitro compared to mouse cardiopsheres, suggesting
different signaling pathways being utilized for somatic reprogramming into cardiospheres in both
mice and humans [175,176].
4.4. In Vivo Direct Reprogramming
One exciting potential of direct reprogramming is its application in vivo, in which endogenous
cardiac cells would be directly converted into CPCs to repair the damaged myocardium. This approach
could represent an improvement in promoting cardiac regeneration as it bypasses the several issues
associated with cellular transplantation [166,177]. In addition, it avoids the need for cell harvesting,
expansion, maintenance, and/or effective delivery systems, which are current challenges faced by cellular
in vitro methods. In vivo direct reprogramming takes advantage of the heart native environment that
might contain extracellular matrix proteins and growth factors that could make cells more permissive
for functional reprogramming and lead to the formation of more mature cardiac cells [160,177–180].
In a study using an in vivo zebrafish model [181], cardiac ventricular injury induced the expression
of Notch and RALDH2 in atrial cardiomyocytes, which caused the cells to lose their sarcomeric
organization and re-express CPC transcription factors, such as GATA4, HAND2, NKX2.5, TBX5,
TBX20 and MEF2. Once these dedifferentiated atrial cardiomyocytes reached the ventricle, they
further expressed ventricle-specific markers, like Iroquois Homeobox Protein Ziro 1 (IRX1A) and
ventricular Myosin Heavy Chain (vMHC), and differentiated into ventricular cardiomyocytes. Another
study demonstrated that adult murine atrial and ventricular cardiomyocytes can acquire properties
of CPCs through spontaneous dedifferentiation in vitro [182]. The dedifferentiated cardiomyocytes
gave rise to CPCs that expressed the cardiac markers c-KIT, GATA4, and NKX2.5, self-organised into
cardiospheres and were able to differentiate into functional cardiomyocytes and endothelial cells [182].
These results were further investigated by Zhang et al. (2015) in vivo using a MI mouse model [183].
They specifically analysed DNA methylome changes during cardiomyocyte dedifferentiation and
observed that cardiomyocyte-specific genes, like Myosin Light Chain Kinase 3 (MYLK3) and Myosin
Heavy Chain 6 and 7 (MYH6 and MYH7), became hypermethylated (repressed), whereas cell cycle
and proliferation genes, such as Epiregulin (EREG) and SRY-box 4 (SOX4), were hypomethylated
(upregulated) in the generated CPCs. This concept could potentially be applied in in vivo CPC
reprogramming. However, the molecular mechanisms involved in somatic cell dedifferentiation are
not fully elucidated and more information is needed to identify the factors responsible.
Although in vivo reprogramming shows great potential, it has only been employed to derive fully
differentiated cardiac cells, specifically cardiomyocytes, and not CPCs as such [160,177–180,184,185].
Therefore, even though direct reprogramming seems to be a suitable approach to generate CPCs,
there are still some issues that influence its application in regenerative therapeutics. These include
sub-optimal efficiencies in transdifferentiation protocols for CPC generation and lack of in-depth
characteristics of CPC potency, differentiation potential and functionality of their derivatives.
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5. In Vitro Culture of CPCs Derived Through Reprogramming Protocols
Establishing reprogramming protocols to generate CPCs from iPSCs and somatic cells is essential
to advance CPC research for cardiac regeneration. However, the field also faces issues regarding the
isolation, propagation, and expansion of CPCs in vitro. This section focuses on the current methods
that have been successful in isolating, expanding and maintaining CPCs in vitro.
5.1. Isolation of CPCs
Isolation of CPCs is usually performed based on their characteristic gene expression patterns and
surface markers (see Table 1). For example, ISL1 and NKX2.5 genes are frequently used to identify
CPCs [186]. However, these genes are transiently expressed in cells which can lead to the isolation of a
heterogeneous cell population containing various CPCs with distinct self-renewal and differentiation
potential [186]. When using only cell surface markers, a combination of at least two markers is frequently
used as a single surface marker seems insufficient to discriminate a CPC signature. For instance, Nsair
et al. (2012) demonstrated that the co-expression of two cell surface markers, FLT1 (VEGFR1) and FLT4
(VEGFR3) specifically identifies ISL1/NKX2.5-expressing CPCs [187]. This combination was also shown
to be more effective in identifying homogenous CPC populations (approximately 89% pure) compared
to other combinations, such as FLK1 alone or FLK1 with PDGFRα. Furthermore, the isolated CPCs
were able to differentiate into the three cardiac lineages and engraft into the host tissue. One study by
Nelson et al. (2008) used the cell surface markers CXCR4 and FLK1 to isolate a more restricted CPC
from a heterogeneous FLK1 positive population [188]. Zhou et al. (2017) also demonstrated that the
marker SIX2 is able to target temporally distinct cell subpopulations from second heart field-associated
CPCs [189]. One very recent study (Torán et al., 2019) used proteomic and genomic approaches to
comprehensively characterize the proteome of human adult c-KIT CPCs [190]. It was demonstrated
that these CPCs highly express 4 surface markers: GPR4 (G protein-coupled receptor 4), CACNG7
(calcium voltage-gated channel auxiliary subunit gamma 7), CDH5 (VE-cadherin) and F11R (F11
receptor) in comparison to mesenchymal stem cells, human dermal fibroblasts and cardiac fibroblasts.
More research, however, will be required to further clarify the role of these proteins in CPC functions.
Thus, new markers are continuously being discovered to isolate specific CPC populations.
However, they are frequently identified in CPCs derived from neonatal/adult tissue but fewer in
ESC-CPCs and iPSC-CPCs [107,133,134,190–192]. Further validation of such markers is vital to assign
a common signature that accurately identifies these cells.
5.2. Expansion and Maintenance of iPSC-CPCs
The maintenance of β-catenin concentration seems to be an efficient method for CPC expansion
in vitro [187,193]. Applying GSK3 inhibitors, like WNT3A, CHIR, or 6-bromoindirubin-3′-oxime/BIO,
can promote CPC expansion and suppress myocytic differentiation, leading to the formation of a
relatively homogenous CPC colony [193]. Furthermore, the combination of a WNT/β-catenin inhibitor
(IQ-1) and a ROCK inhibitor (Thiazovivn) is also able to expand CPCs in a feeder-free medium
for a minimum of 4 weeks, while maintaining their multipotent state (more than 90% remained
multipotent) [187]. IQ-1 is a selective β-catenin inhibitor that targets the signaling mediated by the
protein’s interaction with p300. This suppresses p300 pro-differentiation function and stimulates a
pluripotency state. Furthermore, WNT signaling seems to interact with other signaling pathways, such
as Notch and FGF signaling, to stimulate the expansion of CPCs [194,195]. For example, activation of
the Notch signaling by Notch1 represses expansion, self-renewal and β-catenin activity in CPCs [195].
Activation of both WNT and FGF signaling pathways enhances ISL1 CPCs in a cooperative manner [194].
Therefore, using biomolecules that inhibit and activate the Notch and FGF signaling, respectively,
together with WNT activators might facilitate CPC expansion. Notably, inhibition of FGF signaling
has also been demonstrated to enhance CPC expansion, but this inhibition is suggested to affect only a
subset of CPCs (expressing SCA1) [196] and therefore, warrants further investigation.
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Several studies have shown that persistent inhibition of the BMP signaling enhances expansion
of CPCs and prevents their differentiation [186,197,198]. For example, the BMP inhibitor Gremlin
2 (GREM2), whose expression initiates in NKX2.5+ CPCs after cardiac mesoderm specification and
follows cardiac lineage differentiation, promotes proliferation of CPCs from iPSCs by suppressing
the BMP4 receptor activity [197]. This effect was demonstrated to be consistent across distinct iPSCs
lines and independent of the differentiation method used. However, GREM2 is also able to induce
differentiation of CPCs into the cardiac cell subtypes. Therefore, timing and potency of this BMP
antagonist may need careful evaluation to CPCs and avoid spontaneous differentiation. Notably,
GREM2 appears to only increase the number of KDRlow and NKX2.5+ CPCs in vitro, and its function
seems to be lost in the adult heart. Ao et al. (2012) used a second-generation BMP inhibitor called
Dorsomorphin homologue 1 (DMH1) that was able to enrich CPCs, expressing Branchyury, MESP1
and ISL1 markers, from pluripotent cells [198]. Additionally, DMH1 was shown to be a more selective
inhibitor of BMP type 1 receptors compared with other BMP inhibitors. This selective inhibition
is, therefore, best applied during early stages of cardiac differentiation (pre-mesoderm and cardiac
mesoderm stages) in order to increase the number of CPCs.
Another molecule that enhances CPC expansion in vitro is Ascorbic acid (AA) [143]. AA was shown
to enhance the expansion of isolated iPSC-derived FLK1+/CXCR4+ CPCs through the MEK-ERK1/2
pathway by promoting collagen synthesis. However, the effects of AA on other CPC types need to be
evaluated before AA can be used as a universal factor for efficient CPC expansion. Birket et al. (2015)
used a cocktail of molecules modulators of the FGF, VEGF, PDGF, BMP, Nodal, AKT and hedgehog
signaling pathways (SU5402, DMH1, SB431542, Insulin-Like Growth Factor 1 (IGF1) and Smoothened
Agonist (SAG)) that was capable of expanding CPCs for more than 40 population doublings [186].
However, this study used MYC-transduced iPSC lines and consequently, the method needs further
assessment using CPCs derived from non-transgenic iPSCs. Bao and colleagues (2017) developed
two protocols, with and without serum, to maintain self-renewal and stimulate expansion of human
iPSC-derived epicardial CPCs for long periods of time [152,153]. Both methods involve the addition
of a TGF-β inhibitor, such as SB431542 or A83-01, to the medium. The epicardial CPCs can either be
cultured in LaSR basal medium, which contains albumin, or in RPMI with ascorbic acid and insulin
(RPMI/Vc/Ins), a xeno-free/chemically defined medium. Cells kept in LaSR basal medium can be
maintained for up to 2 months, whereas CPCs in RPMI/Vc/Ins can be cultured for approximately 24 days
before they start undergoing epithelial-to-mesenchymal transition (EMT) and lose their morphology.
The use of a gentler dissociating buffer (Versene) also seemed to improve expansion efficiency of
the CPCs from human pluripotent stem cells (iPSCs and ESCs) after 8 passages [152]. One study
developed a Good Manufacturing Practice (GMP)-compatible system for the expansion of CPCs, using
stirred tank bioreactors and microcarrier technology [199]. Human CPCs from three different donors
were inoculated with microcarriers (Cytodex 1 coated with CELLstartTMCTSTM) for up to 7 days.
The microcarrier-based stirred cultures lead to a cell suspension increase of 3-fold and greater cell
viabilities compared with standard static T-flask monolayers. Furthermore, the CPCs in the culture
system expressed the markers CD44, CD105, CD166, KDR, GATA4, and TBX5. This method provides
tight control of environmental cues to mimic physiological conditions, which could potentially improve
the production of high-quality CPCs for therapeutic applications.
5.3. Expansion and Maintenance of Transdifferentiated CPCs
CPCs derived from direct reprogramming of somatic cells seem to have similar requirements as
iPSCs-CPCs for expansion and maintenance. For instance, adding a canonical WNT activator and
a JAK/STAT activator to the cultures was shown to maintain the proliferative and multipotent state
of the CPCs for several passages (over 20 and 30 passages for a 5- and 11- Factor reprogramming
protocol, respectively) without continuous expression of the reprogramming factors [24]. However,
CPC maintenance and expansion potential can be negatively affected when utilising somatic cells from
tissues other than cardiac tissue, like lung and skin tissues. Furthermore, fibroblast-derived CPCs
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can be alternatively expanded and maintained using a combination of signaling molecules (BMP4,
Activin A, CHIR, and SU5402) that synergistically repress cardiac differentiation and sustain CPC
self-renewal [14]. In this case, the CPCs’ undifferentiated morphology, gene expression pattern and
cell surface molecule expression remain the same for more than 18 passages regardless of the tissue
origin of the donor cells.
Overall, the requirements for in vitro culture of CPCs involved the precise temporal activation and
suppression of several signaling pathways. It remains challenging to expand CPCs while maintaining
their self-renewal and multipotent differentiation potential as the process is extremely complex,
preventing the development of standard conditions yet. This can be more complicated when considering
CPCs derived from iPSCs and direct reprogramming and their associated characteristics [186,200–202].
Therefore, more comparative studies of current protocols will be imperative to establish standard in vitro
culture conditions that are optimal for the isolation, expansion and maintenance of specific CPCs.
6. Strategies to Improve CPC Reprogramming
Strategies for producing CPCs are still developing with time. Whilst the concept of CPC
generation through reprogramming or transdifferentiation has taken precedence to produce desired
cardiac lineages, the protocols suffer from poor efficiency or lack of mechanistic insight to achieve the
target population and desired functional improvement. Strategies to accelerate proliferation and extend
replicative lifespan of CPCs are being essentially employed to understand and potentially overcome
the inherent limitations of patient CPC populations derived from compromised, aged, or damaged
myocardium. With developments in genetic engineering approaches and factors, such as CRISPR
gene editing, epigenetic modulators and/or microRNAs, and its significance in cardiac development,
there seems scope for applying this in the field of CPC regeneration and address some of the current
limitations. This section will describe examples of such strategies in the context of CPCs.
6.1. Genetic Engineering with PIM1
Genetic engineering with PIM1, has been applied in CPCs to enhance their properties, like
proliferation, survival and differentiation [203]. Pro-viral insertion site for the moloney murine
leukemia virus (PIM1), a proto-oncogene serine/threonine-protein kinase, is highly expressed in bone
marrow, tumor cells and fetal heart and is associated with many signaling pathways, mostly related to
anti-cell apoptosis and cell cycle regulation [204]. Mohsin and colleagues (2013) genetically modified
patient-derived human CPCs (hCPCs) with PIM1 kinase (termed hCPCeP) to increase proliferation,
telomere length, survival and decrease expression of cellular senescence markers, rejuvenating the
phenotypic and functional properties of hCPCs, in an effort to ameliorate the cumulative effects
of age and disease [205]. The PIM1-engineered cells also showed increased commitment to the
three cardiac lineages [203]. Interestingly, the effect of PIM1 in hCPCeP normalizes after several
rounds of passaging, consistent with the notion that PIM-1 can transiently increase mitosis coupled
with telomere stability (increased TERT activity) and without resultant oncogenic transformation
through a c-MYC synergy. These properties of hCPCeP can be modulated by targeted localization of
PIM1 in mitochondrial or nuclear components, conferring an optimal stem cell trait irrespective of
patient-associated cell heterogeneity [206]. Furthermore, intramyocardial injection of hCPCeP into
cardiomyopathic challenged-SCID mice demonstrate increased cellular engraftment and differentiation
with improved vasculature and reduced infarct size [203]. Similar results were also observed when
using murine CPCs [207] but these earlier studies relied largely on viral delivery methods to induce
PIM1 overexpression. In an alternative strategy, a non-viral modified plasmid-minicircle (MC) was
used as a vehicle to deliver PIM1 into mouse CPCs (mCPCs) in vitro and the myocardium in vivo [208].
Mice with PIM1-MC injection showed increased protection compared to control groups measured by
ejection fraction at 3- and 7-days post injury, supporting the potential of a non-cell based therapeutic
approach for treatment of ischemic heart disease and MI.
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6.2. CRISPR in Context with CPCs
In an effort to identify previously unknown regulators of cardiomyocyte differentiation from
human ESCs (hESCs) through quantitative proteomics, Murry lab [209] demonstrated that DAB2
(Disabled 2) plays a functional role in cardiac lineage specification towards cardiomyocytes by
being preferentially upregulated in CPCs. CRISPR/Cas9 deletion of Dab2 in zebrafish embryos
was used to show increase in WNT/β-catenin signaling and consequent decrease in cardiomyocyte
number, suggesting that inhibiting WNT/β-catenin signaling by DAB2 (or analogous inhibitors like the
Dickkopf WNT signaling Pathway Inhibitor 1 (DKK1)) can be crucial in maintaining cardiomyocyte
numbers from CPCs in the developing heart. Supporting this mechanism, the same lab, using
antisense knockdown and CRISPR/Cas9 mutagenesis in hESCs and zebrafish, went on to demonstrate
that Alpha Protein Kinase 2 (ALPK2) is temporally expressed during specification of CPCs (but
not in endocardial-like endothelial cells), and cardiac commitment through negative regulation of
WNT/β-catenin signaling [210]. In a more recent study [211], CRISPR-mediated ablation of Furin gene
in mouse CPCs, whose product is a natural target of Nkx2.5 repression during heart development,
produces abnormalities in embryo characterized by reduced proliferation of CPCs and their premature
differentiation, suggesting Furin mediates some aspects of Nkx2.5 function in heart and is necessary
for CPC differentiation. This role of Furin in the maturation of CPCs is, in part, mediated by the
modulation of the BMP pathway by Nkx2.5. Therefore, genetic engineering using CRISPR has been
pivotal in recent years to identify mechanisms associated with CPCs and continue to show promise
with a perpetual trend in CRISPR advances.
6.3. Epigenetic Modulators
Distinct cell types display different epigenetic profiles that leads to differential gene expression.
Cellular reprogramming is associated with changes in the epigenetic signature of cells. During these
epigenetic transitions, proteins called epigenetic modulators bind to specific regions of the chromatin
and regulate the transcription of genes. Therefore, inhibition and/or overexpression of these modulators
might affect cardiac reprogramming efficiency [41,212]. For example, knockdown of the polycomb
ring finger pro-oncogene Bmi1 in several fibroblast types (murine embryonic, neonatal and adult tip
tail and adult cardiac fibroblasts) results in the activation of core cardiac transcription factors, such as
GATA4, ISL1 and TBX20, which converts the cells into cardiomyocytes [212]. Additionally, Zhou et al.
(2016) demonstrated that silencing of Bmi1 allowed for efficient cardiomyocyte reprogramming using
just two factors (MEF2C and TBX5). The induced cardiomyocytes displayed features of advanced
maturity, such as contractile activity, sarcomere structures and periodic calcium oscillation. Therefore,
it would be useful to investigate the role of Bmi1 in the context of CPC reprogramming, considering
the significance of ISL1 upregulation under Bmi1 depletion. Another epigenetic modulator that could
potentially be employed in CPC reprogramming is the BAF chromatin remodeling protein BAF60A.
BAF60A is thought to have a role in the maintenance of CPC self-renewal thought interaction with
TBX1 [213,214]. TBX1 seems to recruit BAF60A onto the promoter region of WNT5A gene, upregulating
its expression in CPCs [214]. WNT5A is a non-canonical WNT pathway ligand that is highly expressed
in CPCs derived from the SHF, and it cooperates with another non-canonical WNT ligand, called
WNT11, to induce development of CPCs from the two heart fields [215]. Accurate identification of the
cellular epigenetic barriers could potentially reduce the number of reprogramming factors employed
to generate CPCs and ultimately, lead to faster and safer protocols.
6.4. MicroRNAs
MicroRNAs are short non-coding RNA molecules that bind to messenger RNA and repress gene
expression. MicroRNAs show a promising alternative to traditional reprogramming protocols as they
are easily delivered and display low toxicity in animal models [184]. In addition, several microRNA
transcripts can be packed into a single delivery vector, which could potentially increase reprogramming
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efficiency. However, most studies have mainly examined the use of microRNAs in converting somatic
cells directly into cardiomyocytes, not CPCs as such [180,184,216]. Nevertheless, microRNAs have
been shown to modulate CPC functions [217–219] (see Table 3). Sirish et al. (2012) investigated the
miRNA expression changes in CPC development [219]. They identified 8 differentially expressed
microRNAs (miR-103, -130a, -17, -130b, -208b, -185, -200b and -486) in mouse neonatal and adult
LIN−/c-KIT+ CPCs. The target proteins of microRNAs were predicted to be predominantly involved in
cell proliferation, with a few proteins having roles in cell organisation, development, metabolic process,
adhesion, homeostasis, activation, communication, and motility. The group also demonstrated that
overexpression of the miR-17-92 cluster, which targets cell cycle proteins, in adult CPCs increased their
proliferative capacity by 2-fold in vivo. Two studies showed that the microRNAs miR-1, -499 and -204
repress proliferation and stimulate differentiation in committed SCA1+ CPCs [217,218]. Additionally,
Xiao et al. (2012) revealed that inhibition of miR-204 suppressed CPC differentiation and promoted
proliferation without affecting cell viability [218]. A study in 2016 identified several microRNAs that
regulate cardiac fate, like let-7, miR-18, miR-302 and the miR-17-92 cluster, in MESP1+ CPCs [220].
It was also shown that the CPCs were particularly enriched for the miR-322/-503 cluster which targets
the CUG-binding protein Elav-like family member 1 (CELF1). Ectopic CELF1 expression promoted
neural lineage-specification at the expense of cardiomyocyte differentiation in the CPCs. Therefore,
miR-322/-503 may be a key regulator in promoting the cardiac program in early mesodermal cells
by cross-suppressing other lineages. Garate et al. (2018) investigated the expression of microRNAs
during the differentiation of human pluripotent stem cells (hPSCs) towards mesoderm and cardiac
cells [221]. They found several microRNA families (miR-302, C19MC, miR-17/92 and miR-26) that were
highly expressed in EpCAM/CD326-negative and NCAM/CD56-positive mesoendodermal progenitor
cells (MPCs) [222]. The microRNA families identified were speculated to be associated with the
epithelial to mesenchymal transition occurring during the development of mesoderm. However, the
specific roles of the microRNAs in CPCs will need to be determined as MPCs are able to generate
all the mesoendodermal lineages, including cardiovascular, hematoendothelial and mesenchymal.
One very recent study by Cheng et al. (2019) showed that the ischemic heart secretes microRNAs
(miR-1a, miR-133a, miR-208a and miR-499) that mobilised LIN−/c-KIT+ bone marrow progenitor
cells (BM PCs) into the site of injury, where they proliferated and promoted vascularisation [223].
These results demonstrated the principle of employing microRNAs to target endogenous progenitor
cells to enhance ischemic cardiovascular repair. Therefore, as molecular mechanisms regulated by
microRNAs during CPC development get explored more, they offer a suitable choice of target for
improving CPC generation from iPSCs or for transdifferentiation.
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7. Tissue Engineering with CPCs and CPC-Derived Cardiomyocytes
Several studies have demonstrated that the cells generated from CPCs, particularly cardiomyocytes,
display an immature phenotype similar to that of embryonic cardiac cells [3]. However, when the
CPCs are transplanted into a host environment, the differentiated cells reach a more advanced
maturity, such as greater organisation of sarcomeres and formation of gap junctions (in the case of
cardiomyocytes) and development of tubular-like structures (for smooth muscle and endothelial
cells) [11,24,27,28]. Furthermore, CPCs seem to have distinct differentiation potential in vitro and
in vivo [96,111]. This could mean that the microenvironment of the heart might have a key role in CPC
functions. Stem and progenitor cells reside in specific tissue microenvironments, called niches, which
provide protection and support to the cells [241]. A way to potentially enhance CPC regenerative
potential could be to mimic their microenvironment. Cardiac tissue engineering aims to achieve this
goal by combining multiple microenvironment components, such as cells, extracellular matrix (ECM)
and biochemical factors like BMP2, VEGF, bFGF, DKK1, and IGF1, to create cardiac tissue constructs.
Therefore, determining the ideal matrix for supporting CPCs and their derivatives is paramount.
In principle, the scaffold matrix should be biodegradable, immune-privileged, provide electrical and/or
mechanical properties for cell coupling and assembly, and support vascularisation [242,243]. Two types
of materials are typically employed in the production of scaffolds for tissue engineering: natural
matrices and synthetic matrices. This section will describe different types of scaffolds that have been
used in combination with CPCs and CPC-derived cardiomyocytes (Table 4).
7.1. Natural Scaffolds
Natural matrices have the advantage of being composed of native ECM cues that modulate cell
behavior [243,244]. These scaffolds can comprise pure ECM elements, like hydrogels made from natural
materials such as fibrin, alginate, gelatin, and collagen, or acellular tissue which displays the biochemical
and biomechanical properties (tensile strength and composition) of the native ECM tissue [245,246]. Three
independent studies used a fibrin patch seeded with CPCs (murine and human) to develop a tissue
construct, which was then tested in vivo [247–249]. Vallée et al. (2012) specifically utilized BMP2-primed
murine ESCs seeded onto fibrin matrices as single cells, small cluster and embryoid bodies [249]. These
constructs were then engrafted onto myocardial infarcted rat hearts, which led to a reduction in remodeling
and deterioration of cardiac functions. Seeded cells were identified by the expression of the cardiac genes
MESP1, NKX2.5, MEF2C, TBX6 and GATA4, speculating a CPC-related population. The transplanted
cells were also able to colonize the outer connective tissue where they differentiated into cardiomyocytes
and promoted neovascularization. The results from Vallée et al. (2012) encouraged two other studies to
apply their tissue engineering approach with human CPCs [247,248]. Bellamy et al. (2015) and Menasché
et al. (2015) seeded human CPCs, expressing the markers SSEA1 and ISL1, in a fibrinogen patch [247,248].
The two studies differed in the number of CPCs used, Bellamy et al. (2015) used 700,000 cells whereas
Menasché et al. (2015) used 4 million cells; and in the in vivo model chosen, myocardial infarction rats
and a 68-year-old patient suffering from severe heart failure, respectively. Improvement of contractility
and attenuation of ventricular remodeling was observed in both studies. It was also shown that these
benefits were likely a result of paracrine factors secreted by the transplanted CPCs rather than de novo
generation of tissue. Gaetani and colleagues (2012 and 2015) used 3D printing with SCA1+/CD105+ fetal
CPCs, which are referred to as human fetal cardiomyocyte progenitor cells (hCMPCs), and three types
of natural scaffolds (pure, RGD-modified alginate and a hyaluronic acid/gelatin-based matrix) [250,251].
The hCMPCs were able to migrate from the scaffolds, colonize the surrounding areas and form tubular-like
structures [250,251]. Another study by Christoforou et al. (2013) used murine iPSC-derived CPCs mixed
within a fibrin/Matrigel hydrogel that were applied in polydimethylsiloxane (PDMS) molds and cultured
for 14 days in vitro [157]. These CPCs expressed NKX2.5, GATA4, c-KIT and either FLK1 or SCA1 and
differentiated into mature cardiomyocytes that aligned into unidirectional myofilament and displayed
abundant electromechanical connections. This study also concluded that accessibility to oxygen and
nutrients within tissue constructs greatly affects integration of the implanted cells.
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Native ECM generally comprise of various components such as glycosaminoglycans (GAGs),
collagen, fibrinogen, hyaluronic acid and hydroxyapatite (HA) [246]. To mimic this, recent studies
have applied natural scaffolds generated from the decellularisation of tissues. This technique removes
any cells present in the tissue while preserving its original 3D architecture and ECM. Two studies have
combined decellularised scaffolds with iPSC-derived CPCs [252,253]. Lu et al. (2013) used human
iPSC-CPCs that were positive (low) for the marker KDR and negative for c-KIT to repopulate a whole
decellularised mouse heart [252]. The CPCs differentiated into cardiomyocytes, endothelial cells and
smooth muscle cells, and efficiency to a specific lineage could be changed with the addition of growth
factors. The recellularised scaffolds displayed vessel-like structures, spontaneous contraction, uniform
wave propagation in some regions, and the ECM seemed to stimulate proliferation of CPCs and
formation of wider myofilaments of cardiomyocytes. However, drawbacks of this study included the
uneven recellularisation of the heart constructs which led to weaker mechanical forces and incomplete
synchronization, and inability to generate cells of the conduction system and cardiac fibroblasts.
Although natural scaffolds retain the ultrastructure and biological information of the native tissue,
there is a risk of immunological reaction, disease transmission (in case of animal-derived materials)
and are generally variable in their physical properties [243,245].
7.2. Synthetic Scaffolds
The ideal synthetic scaffold should be biocompatible, degradable, display a surface that allows
for cell attachment, migration and differentiation, and a macrostructure that supports cell growth and
nutrient and waste exchange [245]. Structure and properties of synthetic scaffolds, like the associated
mechanics, chemistry and degradation rate, can be easily customised for the type of cells being
used [243,245,246]. Two studies employed self-assembling peptide nanofibres with CPCs and tested
the constructs in vivo [254,255]. Both studies used two distinct experimental designs: Padin-Iruegas et
al. (2009) seeded adult rat Lin− c-KIT+ CPCs onto nanofibres tethered with IGF1, whereas Tokunaga
et al. (2010) used adult mouse SCA1+ CPCs mixed with Puramatrix® (3D Matrix, Ltd.) (no tethered
factors). The CPCs in Tokunaga et al. (2010) nanofibres minimally contributed to de novo cardiomyocyte
generation and had no differentiation potential towards endothelial lineages [255]. The benefits
observed were associated to effects from paracrine signaling. On the other hand, Padin-Iruegas et al.
(2009) showed that continued IGF1 release from nanofibres enhanced CPC survival and proliferation,
and stimulated differentiation into cardiomyocytes, smooth muscle cells and endothelial cells [254].
Additionally, the regenerated cardiomyocytes were able to couple with resident cardiomyocytes, and
the smooth muscle cells and endothelial cells formed vascular structures. These studies demonstrated
that functionalising self-assembling peptide nanofibres can potentially support long-term CPC survival,
proliferation and differentiation, and lead to a more robust maturity of the CPC-derived cells, especially if
applied in the human CPC context. Li et al. (2011) used a solution made of mouse cardiosphere-derived
cells and degradable poly(N-isopropylacrylamide) hydrogel and performed in vitro testing of the
effects of scaffold stiffness and presence/absence of collagen on the cells’ functions [256]. The hydrogels
with medium stiffness and collagen were optimal for cardiosphere-derived cells differentiation into
cardiomyocytes, which displayed the highest expression of maturation genes (MYH6 and cTNT).
Unfortunately, there were no reports on the effects of the hydrogels on cardiosphere-derived cells
differentiation potential towards smooth muscle cells and endothelial cells. Liu et al. (2015) also
employed nanofibres with CPCs, but they used poly(l-lactic acid) and mouse ESC-derived CPCs [257].
These CPCs were positive for ISL1 and GATA4 and differentiated into the three cardiac lineages in both
in vitro and in vivo conditions. Additionally, differentiation potential towards endothelial lineages was
improved in vivo compared to that of in vitro. The scaffolds supported CPC survival, engraftment,
proliferation and integration with the host tissue, and stimulated the expression of intercellular coupling
proteins (connexin 43) and maturation of cardiomyocytes.
One study used a novel concept called “scaffold-in-scaffold” to promote human CPC growth and
differentiation in vitro [258]. The aim of this approach was to create a structure with different physical
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characteristics to better mimic the ECM microarchitecture. The multitexture 3D scaffold was composed
of a polyethylene glycol diacrylate (PEGDa) woodpile and a softer PEGDa hydrogel. Human LIN−
SCA1+ CPCs seeded on these scaffolds highly differentiated into cardiomyocytes, which aligned in an
orderly manner. However, robust cardiomyocyte maturation, such as sarcomeric organisation and
formation of gap junctions, was not achieved. In addition, there were no reports on the differentiation
potential towards other cardiac lineages.
Synthetic biomaterials are a great promise to constructing 3D microenvironments with adjustable
features. However, they still come with a few limitations, such as poor biocompatibility, incomplete
polymer degradation, and some toxicity, that will need to be addressed systematically to achieve better
cellular responses.
A significant trend that has been popular with human Pluripotent Stem Cell-Cardiomyocytes
(hPSC-CMs), has been the implementation of electrically-compatible scaffolds or biomaterials (in 2D
or 3D) compatible with standard electrophysiology measurements to stimulate hPSC-CM electrical
behavior and consequently its mature electrophysiological phenotypes (see Table 5). This would be a
strategy for exploration with CPCs as we improve our understanding of the CPC niche. Furthermore,
while most of the studies described above employed ESC-derived or putative CPCs on scaffolds,
studies using patient-specific CPCs from iPSCs or from transdifferentiation in engineered scaffolds to
model phenotypes are very rare. Therefore, with potential improvements in cardiac tissue engineering
and mechanistic understanding of responses in situ, the CPC niche can be exploited to assess normal
and disease-associated cardiac cell behavior to produce better regenerative outcomes (Figure 2).
Figure 2. Promising strategies to improve CPC characteristics and functionality. Strategies for
producing CPCs to date through reprogramming or transdifferentiation has been associated with
poor efficiency or lack of mechanistic insight to achieve the target population and desired functional
improvement. With a range of tools for genetic engineering or gene modulation, and with advances in
tissue engineering approaches, new strategies have been applied in this field to accelerate proliferation,
enhance differentiation, extend replicative lifespan or improve functionality or engraftment of CPCs
(detailed in Sections 6 and 7).
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8. In Vivo Applications of Human CPCs
The end-goal of in vitro and animal in vivo studies in CPC research is to provide enough evidence
regarding the efficacy and safety of cell therapies for further application in human trials. This is not
without the caveat that, despite promising results from in vitro and animal models, the translation to
clinical trials still suffer from serious inefficiencies in desirable outcomes over long term, costing billions
of dollars in the process [280]. Even though there is not yet an agreement on the CPC population that
displays the best regenerative capacity, a variety of CPCs have been used or are being used in clinical
trials, which are summarized in Table 6.
The first-ever clinical trial using CPCs, called SCIPIO (Stem Cell Infusion in Patients with Ischemic
cardiOmyopathy) used human LIN− c-KIT+ CPCs to improve postinfarction left ventricular dysfunction.
However, this study has now been retracted due to concerns about the randomisation and lack of integrity of
certain data [281,282]. In 2012, the randomised phase I trial CADUCEUS (CArdiosphere-Derived aUtologous
stem CELLs to reverse ventricUlar dySfunction) employed cardiosphere-derived cells to reduce scarring after
myocardial infarction [283]. These cells were obtained from endomyocardial biopsy specimens and were
transplanted into patients 1.5–3 months post-myocardial infarction using intracoronary infusion. The results
showed that the cells led to an improvement in viable heart tissue and a reduction of scarring. Differentiation
potential of cardiosphere-derived cells towards cardiac lineages remained to be elucidated and thus, it is
likely that the benefits observed in the CADUCEUS study were a result of paracrine factors. In the same
year, another phase I trial called ALCADIA (AutoLogous human CArdiac-Derived stem cell to treat Ischemic
cArdiomyopathy) used autologous human CPCs in combination with a controlled released of bFGF in patients
suffering from ischemic cardiomyopathy and heart failure [284,285]. These CPCs expressed the mesenchymal
surface markers CD105 and CD90 and were also derived from endomyocardial biopsy specimens. The cells were
injected intramyocardially and a biodegradable gelatin hydrogel sheet containing bFGF was then implanted on
the epicardium, which covered the injection sites areas. However, as in the case of the CADUCEUS study, the
benefits observed, such as attenuation of adverse ventricular remodelling and neovascularisation, were probably
due to paracrine mechanisms as there was no compelling evidence that the employed CPCs can differentiate
into cardiomyocytes in vivo [284,286]. A more recent trial published in 2018, named ESCORT (Transplantation
of Human Embryonic Stem Cell-derived Progenitors in Severe Heart Failure), used hESC-derived CPCs,
expressing the markers SSEA1/CD15 and ISL1, embedded in a fibrin gel [287]. The scaffold was then delivered
onto the epicardium of the infarct area. The aim of the study was to confirm the safety and feasibility of the
therapy rather than evaluating its regenerative effects in the patients. Further investigation will be needed to
thoroughly assess the benefits of the fibrin gel patch in severe heart failure.
There are also reports on phase I and II clinical trials assessing the use of autologous cardiosphere-derived
cells in paediatric patients suffering from hypoplastic left heart syndrome [288,289]. The phase I TICAP
(TranscoronaryInfusionofCArdiacProgenitorcells inpatientswithsingleventriclephysiology)demonstrated
that the approach was safe and feasible for improving cardiac function after 18 months [288]. The safety of
the therapy was also analysed at 36 months post-transplantation [290]. There was no tumour formation
and the initial observed benefits were enhanced, with attenuation of ventricular stiffness and improvement
of ventriculoarterial coupling. The results obtained from TICAP were further confirmed by the phase II
PERSEUS (Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease) [289]. Furthermore, the
therapy is currently being tested in a phase III trial (APOLLON) [291] and applied in paediatric patients
diagnosed with dilated cardiomyopathy (phase I trial TICAP-DCM: Transcoronary Infusion of CArdiac
Progenitor cells in paediatric Dilated CardioMyopathy) [292], for which results are still waiting.
Most trials involving CPCs come with limitations in employing small sample sizes or lack of
blinded assessment, which ultimately leads to inconclusive results regarding the therapies’ efficiency
in recovering from cardiac disorders. In addition, it is still inconclusive whether the positive results are
attributed to intracoronary infusion of CPCs themselves or from paracrine factors as speculated by
some trials. It will, therefore, be imperative to perform future clinical trials with a broader assessment of
study subjects and an established human reproducible model to better explore the CPCs’ regenerative
capacity in human hearts.
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9. Current Challenges and Limitations
There is still a lot of debate on the effect that CPCs play a role in cardiac regeneration and repair
in the context of diseases like MI, demonstrating increased left ventricular ejection fraction, decreased
infarct size, and an increase in hemodynamic function following infusion of autologous CPCs. Even
though there is a growing emphasis on the application of CPCs for cardiac regeneration, its impact is
still obscure, particularly owing to its heterogeneous nature and mechanistic silencing from deep-rooted
complexities associated with the nature of the cardiomyopathic disease. For example, there is still no
consensus regarding which CPC population is the ideal cell type for cell-based regenerative therapies
and which combination of markers accurately characterise CPCs. Additionally, the characteristic
epigenetic, gene, protein and secretome profiles of most CPCs remain unclear [19,41]. This could
elucidate how phenotypes and genotypes of CPCs alter throughout their development and their
effects on self-renewal and potency potentials. Furthermore, not many studies have investigated and
compared the therapeutic efficacy of different CPCs. The ideal CPC type should be able to tolerate
autologous transplantation, expand extensively in vitro, differentiate into mature cardiac cell subtypes
and integrate with the host cells [299].
Viral transduction remains the main approach applied in most reprogramming processes (both
in vitro and in vivo) as it shows the greatest efficiency. However, this is associated with a risk of genome
integration and activation of oncogenic genes. In addition, the currently developed protocols require
the use of both reprogramming and growth factors which substantially increases their complexity and
final cost. It is, therefore, imperative to develop a more effective and simpler gene transfer methods
that ensure cell therapies are safe and display a good cost-benefit ratio.
Furthermore, the populations of CPC-derived cells are heterogeneous and frequently represent
immature cells, which could potentially lead to arrhythmias, lower long-term stability and poor
integration when transplanted [3,300]. The mechanisms involved in cardiac lineage subtype
specification will need to be fully investigated and optimised to produce purer and more mature
populations of the desired cell types from the CPCs. With the growing pace of CRISPR strategies
and its potential to address limitations associated with genetic control and regulation, it will not be
surprising that this will be applied to CPCs for this purpose in the very near future.
Epigenetic profiles seem to strongly affect reprogramming efficiencies for both iPSCs and
transdifferentiation technologies. For example, using cells from non-cardiac tissue organs or aged
tissue negatively affects the cardiogenesis capability of iPSCs [301]. The success of reprogramming a
cell fate relies on the ability to overcome the several epigenetic barriers present in somatic cells. The
more distinct the donor somatic cells are from the cardiac tissue, the higher the number of epigenetic
barriers that need to be overcome and consequently, the harder it is to reprogram the cells. Therefore,
understanding the epigenetic regulatory mechanisms involved CPC formation might be vital to
improving reprogramming efficiency.
Another limitation in CPC research is that many studies have been performed in rodent models,
which display distinct cardiac anatomy and physiology from the human heart. Additionally, current
techniques developed using animal cells will need to be further validated for human context. For
example, the direct reprogramming protocol involving the three core cardiac genes GATA4, MEF2C
and TBX5 (also known as GMT) was demonstrated to induce mouse fibroblasts into cardiac cells, but it
was insufficient to convert human fibroblasts [164].
For future preclinical trials, the relationship between the number of CPCs and their effects on
cardiac regeneration and the appropriate frequency of administration of each cell therapy needs to be
further investigated [299]. In addition, molecules and/or cells are very often directly injected into the
heart during open-surgery. This is an invasive approach that could cause additional injury and pain
to the patients. Other less invasive methods, such as intracoronary and intravenous injection, have
been employed to deliver cells to the heart. However, these techniques rely on correct homing of cells
into the damaged tissue, and very often the delivered cells become trapped in other organs [302,303].
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Consequently, other delivery systems that are less aggressive and show the best efficacy and safety
need to be developed before CPCs can be applied in regenerative medicine strategies.
There are sufficient reports that support the existence of CPCs within specialized niche structures
in the myocardium [241]. For therapeutic applications, these CPCs can be isolated and cultured in vitro,
prior to transplantation into the affected heart or, the local microenvironment can be modulated to
recruit CPCs to the infarct area. Current biomaterial strategies (discussed in Tables 4 and 5) have
exploited both these methods for functional improvements but do not report complete recovery under
physiological conditions or pathological insults. This is evident in the lack of clinical trials with CPCs
using biomaterials (Table 6). This offers an opportunity to integrate engineering with mechanistic
modulation (perhaps through genetic engineering) to contextualize CPC behavior with disease factors.
The difficulties described above rely, to some extent, on the incomplete understanding of the
heart development and cardiac regeneration processes. Increasing this knowledge will clarify the
precise stoichiometry of the cardiac factors and optimal culture conditions to accurately mimic the
development of CPCs in vitro.
10. Final Thoughts—Controversies Surrounding CPCs
It does seem that the debate surrounding CPCs and adult heart repair is taking a full circle—it is
there, it is not there, it is there, etc? With the first evidence in rodents supporting the notion of c-KIT+
cells from bone marrow or adult heart to replace damaged myocardial tissue, from Piero Anversa’s lab,
and subsequent retractions of 31 papers from his group owing to unreliable data, it has encouraged
the field to challenge the theory by more robust techniques in mouse models [58,61,304,305]. Results
from such studies showed that cardiomyocyte generation from a c-KIT+ cells was an extremely rare
event. Notably, more recently, the data from Li et al. (2018) showed compelling evidence to support
endogenous stem cell to myocyte conversion in embryonic but not in adult heart [306].
Ironically, a more recent work in 2019, by Narino et al., has demonstrated that c-KIT expression
labels a heterogeneous cardiac cell population, with cells low in c-KIT expression enriched for CSCs
while c-KIT high expressers having endothelial/mast cell differentiation potential [307]. This study went
on to show that adult c-KIT-labeled CSCs in mouse “can be myogenic” and help to regenerate after injury
and to counteract effects of aging on cardiac structure and function, thus boldly suggesting that CSCs
as the bonafide endogenous source of cardiomyocytes in healthy/pathological heart. Consequently,
they identified c-KIT haploinsufficiency, generated usually in lineage-tracing studies, prevents efficient
labeling of true CSCs on one hand while affecting the regenerative potential of these cells on the other,
which perhaps could have been the oversight in the rival camp. Nevertheless, irrespective of the c-KIT
controversy, there is no denying that animal studies and clinical trials have appreciated the benefit of a
range of cell types for CPCs from many different sources through cellular transplantation approaches
([308–310] and Tables 1, 4 and 6). Furthermore, there is an emerging theory that injected/infused
CPCs can induce a reconditioning of the injured heart through paracrine signalling or that these cells
stimulate an acute inflammatory response when these cells die and are cleared, resulting in a secondary
acute healing response [311].
Therefore, as implied in Table 1, there is still no consensus on an endogenous CPC type that
is critical for myocardial repair and regeneration but there is growing consensus that regeneration
associated with these CPCs are not robust enough to repair severe myocardial damage such as in MI
(commented in [307]). While this review does not offer to bias the reader for one or the other theory, in
light of these recent studies, it offers the field impetus to interrogate other strategies and CPC sources
(like from stem cells or transdifferentiation of somatic cells) to provide mechanistic insights into how
CPCs can be more functionally significant in the context of cardiac regenerative medicine.
11. Future Directions
Heart failure patients are typically elderly, and suffer from chronic cardiomyopathies and associated
complications like diabetes, hypertension, etc. Notably, they possess CPCs with compromised regenerative
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potential, insufficient to recover lost cardiac function [312,313]. The propensity of CPCs to affect
cardiac repair is influenced by several factors, including genetics [314], epigenetic dysregulation [315],
environmental stress [315], disease progression and pathogenesis [316,317], heart load [318], medication,
and aging [319,320]. Nevertheless, discovery of CPC characteristics has revolutionized the conceptual
view of treatment for heart disease, supported by the capacity of CPCs to form functionally integrated
cardiomyocytes and vasculature [321]. Therefore, it is rational to enhance potential of CPCs from the
adult or reprogrammed cell sources prior to adoptive transfer into a damaged myocardium. Hence, CPC
research is gaining momentum to improve its feasibility for cardiac regenerative therapeutics. Advances
in this field are progressing towards combining optimised reprogramming approaches from iPSCs and
somatic cells with tissue engineering strategies. This will undoubtedly bring advances in genomics,
epigenomics, and proteomics of CPCs and their differentiated counterparts, to realise their full potential.
Future regenerative approaches might bring together genetic engineering (a very tested strategy in iPSCs),
the addition of multiple stimuli (mechanical, electrical and biochemical factors) and tissue engineering
approaches to develop a meticulously controlled system that maximises CPC regenerative capacity, and
that could potentially be applied in cell therapy, disease modelling, and drug screening (Figure 1).
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Abstract: Numerous studies have reported correlations between plasma microRNA signatures
and cardiovascular disease. MicroRNA-133a (Mir-133a) has been researched extensively for its
diagnostic value in acute myocardial infarction (AMI). While initial results seemed promising,
more recent studies cast doubt on the diagnostic utility of Mir-133a, calling its clinical prospects into
question. Here, the diagnostic potential of Mir-133a was analyzed using data from multiple papers.
Medline, Embase, and Web of Science were systematically searched for publications containing
“Cardiovascular Disease”, “MicroRNA”, “Mir-133a” and their synonyms. Diagnostic performance was
assessed using area under the summary receiver operator characteristic curve (AUC), while examining
the impact of age, sex, final diagnosis, and time. Of the 753 identified publications, 9 were included in
the quantitative analysis. The pooled AUC for Mir-133a was 0.73. Analyses performed separately on
studies using healthy vs. symptomatic controls yielded pooled AUCs of 0.89 and 0.68, respectively.
Age and sex were not found to significantly affect diagnostic performance. Our findings indicate
that control characteristics and methodological inconsistencies are likely the causes of incongruent
reports, and that Mir-133a may have limited use in distinguishing symptomatic patients from those
suffering AMI. Lastly, we hypothesized that Mir-133a may find a new use as a risk stratification
biomarker in patients with specific subsets of non-ST elevation myocardial infarction (NSTEMI).
Keywords: myocardial infarction; MicroRNA; Mir-133; coronary heart disease; biomarker;
meta-analysis
1. Introduction
Cardiovascular disease (CVD) is the leading cause of death in the United States [1] and accounts
for nearly $219 billion in spending annually and 647,000 deaths [2]. Coronary artery disease (CAD) is
the most prevalent form of CVD with upwards of 365,000 American mortalities each year, primarily as
a result of acute myocardial infarction (AMI) [2]. With over 800,000 Americans suffering AMIs
annually [3], early detection is crucial to improving clinical outcomes and decreasing mortality.
Currently used circulating biomarkers such as cardiac troponins and creatine kinase MB act as
sensitive and specific tests for myocardial damage, yet, they may be negative early in the process
of ischemia. Their increase in the setting of ST-elevation MI (STEMI), a process that nearly always
results from coronary plaque rupture and thrombosis formation, is usually reflective of the extent of
the infarct and approximates the mass of cardiomyocytes that damaged in the process of AMI. In the
setting of non-ST elevation myocardial infarction (NSTEMI), increases in different biomarkers may be
suggestive of a specific underlying pathophysiology, although data is limited on such associations.
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For instance, it was suggested that extreme levels of cardiac troponins are suggestive of total occlusion
(TO) of the culprit artery [4], but the results were not used to assess correlations with other entities of
myocardial injury, and data on such a possible association is limited. At present, biomarkers are not
used to differentiate specific coronary pathologies, or assess the extent of vascular occlusion, nor are
they used to detect non-CAD related myocardial cell damage [5].
Early reperfusion, usually through percutaneous coronary intervention (PCI) is a primary factor in
the prognosis and clinical outcome of AMI [6,7]. Although electrocardiographic signs of the ST segment
elevation are a sensitive and specific sign of coronary TO in the setting of STEMI, approximately
only 25.5–34% of NSTEMI patients were found to have TO [8,9]. Patients suffering from TO are
commonly underdiagnosed, receive delayed intervention, and have increased rates of complications
and mortality [8]. Additionally, it may be challenging to distinguish between NSTEMI resulting from
coronary atherosclerosis, and other processes of myocardial damage associated with inflammation,
microvascular damage, toxic injury, vasoconstriction, etc.
Thus, highly sensitive and specific circulating biomarkers capable of diagnosing AMI (and
specifically patients with TO) shortly after symptoms begin are of great clinical importance and may
reduce mortality as well as improve patient outcomes.
In recent years multiple circulating micro-RNAs (MiRNAs) have been identified and investigated
for their possible diagnostic and prognostic utility in CVD [10–14]. Specifically, Micro-RNA 133a
(Mir-133a) has been reported as a potentially powerful biomarker for AMI and CVD. Mir-133a is a
short non-coding RNA molecule, which serves to regulate target genes through post-transcriptional
suppression. It has been found that Mir-133a is critical for proper cardiac development, playing an
important role in early differentiation and cardiogenesis, as well as mediating various cardiac
processes including apoptosis, cardiac remodeling, hypertrophy, conductance, and automaticity [15].
Increased serum levels of Mir-133a have been observed in the setting of AMI and CVD. This is
most likely the result of damaged myocardium releasing Mir-133a during cellular lysis, or adjacent
border zone myocardium releasing Mir-133a containing vesicles in response to the cardiac insult [16].
The research on Mir-133a’s diagnostic potential, however, is strongly conflicted, with some papers
reporting weak correlations between circulating Mir-133a concentrations and AMI [10,17], and others
reporting strong correlations with excellent sensitivity and specificity [11,18–22]. In light of these
contradictory findings, this meta-analysis synthesizes data from existing literature in order to examine
the true potential of Mir-133a as a biomarker in AMI. Additionally, we analyzed the time frames in
which Mir-133a was quantified, and their effect on the increases in plasma concentration, to ascertain
whether Mir-133a may be useful as a very early diagnostic marker. Lastly, we compared the data of
STEMI patients with those of NSTEMI patients to determine if Mir-133a might be used to distinguish
between these two types of AMI. We hypothesized that TO in the setting of NSTEMI, and other specific
entities of myocardial injury, may be characterized by distinct Mir-133a increase patterns, and aimed to
evaluate the literature in that regard. Notably, correct identification of high risk NSTEMIs has a critical
impact on the course of treatment [8], and therefore Mir-133a may serve as a valuable biomarker in
this respect.
2. Materials and Methods
2.1. Search Strategy
Three electronic databases (Pubmed, Embase, and Web of Science) were searched for articles written
prior to December 1st, 2019 that included the terms microRNA, microRNA-133, and cardiovascular
disease, as well as common synonyms for these terms. The complete search strategy for all databases
can be found in the Supplementary Materials (Tables S1–S3) in accordance with PRISMA guidelines [23].
2.2. Inclusion and Exclusion Criteria
All papers retrieved in the literature search were subjected to the following criteria for inclusion:
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1. STEMI or NSTEMI was the clinical diagnosis in study patients.
2. The study was either case-controlled or a cohort.
3. Mir-133a was quantified from plasma using qRT-PCR with either SYBR or TaqMan probes.
4. Sample size, area under the standard receiver operator characteristic curve (AUC), location of
study, and maximum plasma sample collection time must be stated.
5. A sample size of 5 or more patients was required for each subgroup.
The following criteria were used for exclusion:
1. Papers written in languages other than English.
2. Reviews, meta-analyses, posters, and correspondence letters.
3. Experimental design based solely on animal models.
Studies meeting all the inclusion criteria and none of the exclusion criteria were used for the
quantitative analysis. If two or more included papers were based on the same clinical data, only the most
relevant study was included. Screening was performed in accordance with PRISMA guidelines [23].
The completed checklist can be found in the Supplementary Material (Table S4).
2.3. Data Extraction
All data used in this meta-analysis were extracted from the published versions of the included
papers, their supplementary materials, and their referenced sources. No unpublished data was
acquired for this analysis.
In papers where increases of Mir-133a were presented as a change in cycle threshold (ΔCT)
compared to a predetermined reference, or as ΔΔCT (ΔCT test sample–ΔCT calibrator sample),
fold change was calculated using 2ˆ(−ΔCT) or 2ˆ(−ΔΔCT). Additionally, when fold changes were
presented only for subgroups (for example STEMI and NSTEMI), the total fold change was calculated
using a weighted average based on the number of patients in each subgroup.
When the demographic characteristics of subgroups were not specified in the papers (i.e., mean age,
gender, etc.), it was assumed that they followed the same distribution as the larger group whose
characteristics were listed.
In several papers [10,24] quantitative data was presented graphically without exact numbers
being published. In these cases, the graphs and figures were digitized using GetData Graph Digitizer
software Ver. 2.26 in a blinded manner, and the averaged numeric values were used in this analysis.
2.4. Statistical Analysis
The Kruskal–Wallis H test was used to compare findings between the groups. Relations between
the dependent variables (fold change and AUC) and independent variables (percentage of STEMI
patients (%STEMI), time from onset, and patients’ age) were evaluated using linear regression analysis.
Correlation analyses were estimated according to the strength and direction of a linear relationship
between the two variables on a scatterplot (i.e., r). The number of patients was used as a frequency
weighted variable. A p-value of <0.01 was considered statistically significant. Pooled results were
expressed as mean and standard deviation for AUC and as mean and standard error of mean (SEM)
for fold changes. Analyses were performed using JMP version 7.0 (SAS Institute, Cary, NC, USA)
and MedCalc version 19.1.5 (MedCalc Software Ltd, Belgium). Forest plots were generated using
DistillerSR Forest Plot Generator (Evidence Partners, Ottawa, ON, Canada).
3. Results
3.1. Literature Search Results
The literature selection process is shown in Figure 1. In short, the search returned 1071 results.
After removal of duplicates 753 papers remained that were then assessed manually using titles and
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abstracts for: reviews, posters, meta-analyses, animal studies, and non-AMI related papers, which were
all excluded.
We further screened the remaining 55 papers for relevance using their full texts, excluding all
papers not written in English, papers, which did not publish their statistical data, and studies in which
non-plasma samples were used for the quantification of Mir-133a.
The remaining 23 eligible studies [10–12,16–22,24–36] were thoroughly analyzed and subjected to
the above inclusion criteria ultimately yielding 9 studies (Table 1) involving 2280 participants, with 943
AMI patients and 1337 controls that were included in the quantitative meta-analysis.
Records identified through database
Searching
(n = 71)
Medline (n = 266)
Embase (n = 727)
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Reviews and Meta analyses
Full text articles
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Figure 1. PRISMA flow chart of the study selection.
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3.2. Meta-Analysis Results
The most consistently reported value in all the included studies was AUC. The combined frequency
weighted analysis of this parameter yielded a pooled AUC of 0.73 (95% CI 0.68–0.79) for the eight
studies [10,11,17,19–22,24] in which a 95% confidence interval of the AUC was provided (Figure 2).
Figure 2. Forest plot of Mir-133a AUC values for the detection of AMI for each of the included studies.
Pooled AUC value of 0.73 (95% CI 0.68–0.79). It is important to note that 5 out of 8 studies yielded
AUC values greater than 0.86, yet, their overall weight was reduced by the relatively low number of
included subjects.
Further subgroup analysis was performed in order to determine whether the distinction between
STEMI and NSTEMI might account for some of the conflicting reports regarding increased Mir-133a
concentrations following AMI. Relying on six papers that reported the percentage of STEMI patients
in the study [17,18,20,21,24,37], and a linear regression model plotting Mir-133a fold as a function
of this percentage, we found a moderate correlation (r = 0.49), with a trend of increasing Mir-133a
concentration with higher percentages of STEMI patients (Figure 3a).
Furthermore, we compared subgroups from studies that reported data separately for STEMI or
NSTEMI patients [17,18,20,21,24] and found a significantly higher value (p < 0.001) of the Mir-133a
fold increase in STEMI patients vs. NSTEMI patients (11.6 ± 0.72 fold vs. 4.5 ± 0.14 fold, respectively;
Figure 3b). Unfortunately, nearly all of the studies did not provide AUC data for these subgroups,
and as such this parameter could not be analyzed.
Of the included studies, four [10,11,18,22] were controlled with non-AMI patients presenting with
symptoms of acute coronary syndrome (ACS), four used healthy volunteers [19–21,24], and one used
a mixed control population, with a majority of non-healthy recruits [17]. In order to assess whether
choice of control partially explains the discrepancies in reported AUC values for Mir-133a in AMI,
we compared these two groups using boxplots (Figure 4a). We found that the AUC was significantly
greater (p < 0.001) in studies that recruited healthy controls as opposed to those who used non-healthy
controls (pooled AUC of 0.89 ± 0.07 vs. 0.68 ± 0.14, respectively).
In the included studies there was diversity in the percentage of male participants and mean age.
To examine whether these factors impacted upon the reported results we used a linear regression
model and found that both age and gender had little effect upon the reported results (Supplementary
Figures S1 and S2).
Lastly, we divided the studies into two groups based on the reported time from onset of symptoms
until sample acquisition. Of the included studies, six were conducted such that all samples were
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acquired within 12 h [10,17,19–22], two reported sample acquisition within 24 h [11,24], and one did
not list a maximal time for sample acquisition and, as such, was not included in this analysis [18].
A significantly higher AUC value (p < 0.001) was found in the 24 h group when compared to the 12 h





Figure 3. Linear regression analysis of (a) a relative increase (in fold) of Mir-133a plotted as a function
of the percentage of patients in study with ST elevation myocardial infarction in composite groups.
(b) Boxplot comparison of fold change in subgroups of 100% STEMI patients vs. 0% STEMI. ** p < 0.001.
Figure 4. (a) Boxplot comparing AUC values based on control group characteristics (AUC was
0.89 ± 0.06 and 0.68 ± 0.14 when healthy or unhealthy controls were used, respectively), * p < 0.001.
(b) Boxplot comparing AUC values based on sampling time (AUC was 0.82 ± 0.05 and 0.71 ± 0.01 for
studies in which samples were acquired within 24 and 12 h, respectively). ** p < 0.001.
4. Discussion
AMI is a common and often deadly medical emergency. Presently, there is a great need for a
quick and accurate diagnosis of AMIs, as well as improved methods for the detection of high-risk
patients such as those with TO of the culprit artery, not presenting with STEMI. In the present study
the diagnostic value of Mir-133a was analyzed to determine whether it may serve as a biomarker for
very early detection of AMI, and to evaluate the contested claim that it may be useful in distinguishing
STEMI from NSTEMI.
179
Cells 2020, 9, 793
4.1. Mir-133a As an Early Biomarker for the Diagnosis of AMI
Historically, commonly used biomarkers for the diagnosis of acute myocardial infarction, such as
cardiac troponins and creatine kinase MB, were not effective at very early diagnosis of AMI (within
0–3 h) [5]. Today, with the advent of high-sensitivity cardiac troponin tests, AMI can be diagnosed
with reasonable accuracy even within the first hour [38,39]. Nevertheless, the search for additional
early biomarkers, especially ones with different underlying molecular mechanisms, may allow for
even greater sensitivity and specificity in shorter time frames.
To this end, early studies on Mir-133a reported high (>0.86, and as high as 0.95) AUC
values [11,18,19,21,22], while some of the subsequent studies found lower sensitivities and
specificities [10,17,24]. In this meta-analysis it was found that the pooled AUC for Mir-133a was 0.73
(95% CI 0.68–0.79). This value highlights its relatively weak sensitivity and specificity for the diagnosis
of AMI, especially when measured against current troponin based methods that have markedly greater
sensitivities and specificities [38,39]. Furthermore, it has yet to be shown whether Mir-133a, even in
combination with current biomarkers, offers any diagnostic advantage and as such, its clinical value
for the early diagnosis of AMI remains unclear. Notably, only two of the included papers suggested
threshold values for the optimal diagnosis of AMI [17,18], highlighting the current lack of standardized
values and measurements.
Additionally, we attempted to establish whether Mir-133a might be a more effective biomarker in
the earliest stages of AMI, as was reported by Ji et al., 2015 [24]. Unfortunately, it is difficult in practice
to determine how long after the onset of symptoms the samples are taken, and most studies did not
report precise time frames. Therefore, we were only able to subdivide the studies into two main groups:
(1) measurements made within 12 h [10,17,19–22] and (2) measurements made within 24 h [11,24].
The results of this analysis showed that, contrary to prior studies [11,24], measurements made within 24
h had a significantly higher pooled AUC. Regrettably, this does not settle the issue, as the distribution
of individual measurements within each study is unclear, and only two studies were included in the
24 h group. Yet, the fact that measurements conducted within 12 h from symptoms yielded AUC
values as high as 0.95 according to some reports [19], might be suggestive of Mir-133a’s potential as a
diagnostic tool in specific patient populations. Further research, with larger sample sizes, as well as
careful and repeated time measurements, are necessary in order to clarify the plasma concentration
dynamics of Mir-133a in various conditions associated with myocardial damage.
4.2. Mir-133a in Healthy and Unhealthy Controls
A significant methodological issue regarding research on the diagnostic potential of Mir-133a
is the choice of controls. As mentioned above, choices included healthy volunteers, patients with
comorbidities and acute chest pain, and mixed populations. We suspected that the reported AUCs
might have been greatly affected by the choice of controls, thus further obfuscating the clinical potential
of Mir-133a. After analyzing the studies separately, based on the controls used, we found, in agreement
with Jia et al. 2016 [17], that Mir-133a had a significantly higher (p < 0.001) pooled AUC of 0.89 ± 0.06
when healthy controls were used in comparison to 0.68 ± 0.14 in unhealthy. Hence, it may be concluded
that Mir-133a can more efficiently distinguish between AMI patients and healthy volunteers, but it is
not nearly as effective when testing patients presenting with symptoms of AMI. This may partially
explain the apparent discordance in the existing literature. As increases in Mir-133a concentration are
indicative of myocardial damage [30], it is reasonable to assume that a larger overlap will exist between
patients presenting with acute chest pain and AMI patients than between healthy volunteers and AMI
patients. For this reason, it may be concluded that Mir-133a might have greater diagnostic potential
in patients presenting without classic symptoms of cardiac distress. If true, it can be speculated
that Mir-133a might be of clinical importance in detecting troponin-based false-diagnosis of AMI in
certain populations [40]. Current medical literature contains little information on this topic, and this
speculation needs to be further evaluated in prospective studies.
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4.3. Mir-133a As a Biomarker that Distinguishes Between STEMI and NSTEMI
In addition to early diagnosis of AMI, a clinical need for the detection of NSTEMI with TO of the
culprit artery, as well as other serious cardiac conditions associated with a lack of ST segment elevation,
exists. Due to inherent limitations in the standard 12-lead ECG, a complete electrocardiographic
picture of the heart is not obtained. As a result, patients with acute occlusion of a coronary vessel may
present with NSTEMI, and, as studies have shown [8], patients suffering from complete culprit artery
occlusion presenting with AMI and no ST segment elevation are at a higher risk for mortality and
adverse cardiac events than their ST elevated counterparts. It is believed that this is primarily due
to the delay in identification and, as a result, establishment of reperfusion. Although several factors
have been suggested to aid in the identification of patients with TO (such as prolonged duration of
continuous chest pain, higher levels of the creatine kinase-MB fraction [41], and higher levels of high
sensitivity troponin [4]), currently a delay of more than 24 h before an invasive procedure is performed,
is common according to previous reports [8]. Furthermore, although patients with TO were reported
to have higher mean Global Registry of Acute Coronary Events (GRACE) scores compared to those
suffering subtotal occlusion (STO; 131 (range of 120–140) vs. 117 (range of 104–126); p = 0.032) [4],
these values are still lower than the proposed cutoff of 140, which serves as an indication for the
performance of PCI within 24 h according to accepted practice [8].
Consequently, it is of great importance to develop new and improved risk stratification tools that
will allow clinicians to recognize high risk NSTEMI patients, and specifically those with occult TO,
as early as possible.
Our results show that there was a trend of increasing Mir-133a plasma concentrations as
the percentage of STEMI patients in the study grew. Moreover, we found a significantly greater
increase (p < 0.001) in Mir-133a concentration amongst subgroups containing only STEMI patients
vs. only NSTEMI patients. These data corroborate the claims made by Devaux et al., 2015 [10] and
Ji et al., 2015 [24] that levels of Mir-133a are increased to a greater degree during STEMI as opposed to
NSTEMI, and contradict the results reported by Li et al., 2013 [19] who reported no significant difference
between the two. This difference in results may stem from the overall smaller sample size that was
used or the relatively small number of NSTEMI patients included in the report by Li et al., 2013 [19].
We hypothesize that specific entities of myocardial injury may be characterized by distinct
Mir-133a increase patterns. Yet, a concise meta-analysis of the literature yielded limited data in this
regard. The included studies on Mir-133a did not specifically evaluate those with TO and STO in
NSTEMI. Therefore, it is unknown whether NSTEMI patients with TO of culprit artery will present
with similar Mir-133a concentrations as the STEMI group, but if such a correlation can be found, it may
be used to identify these higher risk patients. Moreover, the underlying cause of myocardial damage in
the included studies was not reported, and so the cases likely include different entities of NSTEMI such
as myocardial infarction with nonobstructive coronary arteries (MINOCA), microvascular dysfunction,
and vascular anatomies with varying degree of occlusion. It is unknown whether these entities
may also present with markedly different Mir-133a elevation patterns, which might have diagnostic
importance prior to coronary angiography. Additionally, since the present NSTEMI groups may
contain a significant number of TO patients, it is possible that subanalysis of non-TO NSTEMI groups
will demonstrate an even greater relative increase in Mir-133a plasma concentration relative to the
TO group.
Further studies specifically designed to answer these questions are necessary in order to fully
assess Mir-133a’s diagnostic potential in this respect. Future studies should also focus on the correlation
between Mir-133a and other cardiac biomarkers in various populations of cardiac patients, as well as
on the association with plaque vulnerability. As such, it remains to be determined whether differences
in Mir-133a plasma concentration and elevation dynamics in NSTEMI may be used to identify different
underlying pathophysiologies, and whether these differences may be used to accurately stratify
risk groups.
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4.4. Study Limitations and Methodological Issues
During the systematic literature review we encountered several methodological issues that
hindered our ability to perform full comparisons between the data in each paper. It is our contention
that these differences in methods and designs are the primary cause of conflicting reports as to Mir-133’s
diagnostic ability. A prime example of this is the “endogenous control” used for the qRT-PCR analysis
of Mir-133a plasma concentration. Multiple studies used truly endogenous microRNAs such as
Mir-16, Mir-17, and U6 [11,18,24,27,29], though these controls, and especially U6, have been found to
vary markedly in the same patients [42,43] and therefore may be unsuitable as reference microRNAs.
Other studies used arbitrary CT values or the median CT for comparison [21,36], and multiple studies
used single or multiple C. elegans microRNA “spike ins” [10,12,17,19]. To further complicate the picture,
no uniform method of fold-change calculation was used. This resulted in non-standardized data,
which makes for a major limitation when attempting to perform comparisons or draw conclusions
from a meta-analysis. Furthermore, no standard protocol, equipment, or probes (SYBR/TaqMan) were
implemented. In this study we relied primarily on AUC values to avoid these limitations, but in the
case of distinguishing STEMI from NSTEMI only fold change data was available, so our conclusions in
that instance may be limited.
Another significant design issue is the selection of controls. As we showed above, the pooled
AUC value for Mir-133a was significantly greater in studies that used healthy controls as opposed to
unhealthy controls. This fact limits analyses conducted by combining these two groups, and likely
explains, at least in part, the large variations reported in the Mir-133a’s diagnostic ability.
Plasma concentration dynamics of Mir-133a in AMI are not yet fully understood. It is possible that
time is a key factor in Mir-133a’s sensitivity and specificity. Due to limited reporting of precise times in
the published literature, we were unable to conduct a thorough investigation of the impact that time
has on the reported results. Though we showed that Mir-133a’s AUC is actually increased in studies
with a longer duration from the onset of symptoms until sample acquisition, this conclusion is limited
because the time windows are large, and the timing of individual measurements is not reported.
The studies included in this meta-analysis ranged in number of subjects from 9 in the smallest to
233 in the largest. To account for these differences the studies were weighted according to their size (n).
While this is common practice, it does introduce a strong bias towards the larger studies, which also
limits the conclusions drawn in this analysis.
We have posited the hypothesis that a contributing factor to the difference between Mir-133a
plasma concentration in STEMI vs. NSTEMI is the degree of occlusion of the culprit artery, and therefore,
that Mir-133a may be used for NSTEMI risk stratification. Since there are varied species of NSTEMI
(MINOCA, TO, STO, etc.) that result from different underlying pathophysiologies that might each
effect Mir-133a concentrations differently, further studies assessing the causal relation between degree
of occlusion in NSTEMI and Mir-133a plasma concentration will be necessary to determine whether
this hypothesis is true.
Finally, in order to rigorously test the clinical potential of Mir-133a in the setting of AMI,
further studies will be needed with larger sample sizes, accurate timeline assessments, standardized
methods of Mir-133a plasma concentration quantification, use of accepted reference values, and
separate analyses based on subgroups.
5. Conclusions
Mir-133a has been investigated for its diagnostic potential for over a decade, yet a conclusive answer
as to its clinical applicability is still lacking. In this meta-analysis we found that Mir-133a does possess
a diagnostic ability (pooled AUC of 0.73), though it remains inferior to existing modalities [38,44].
Furthermore, we speculated Mir-133a may have an unrealized potential as a biomarker for the
identification of high risk NSTEMI patients, and we suggest that it may be useful for detecting specific
kinds of cardiac injuries and false-positive cardiac troponin increases. Further research will be needed
in order to determine Mir-133a’s clinical applicability in these various scenarios. Lastly, we highlighted
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several significant methodological issues that prevent accurate comparisons between studies in this
field and may be the cause of incongruent results.
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31. Hromádka, M.; Černá, V.; Pešta, M.; Kučerová, A.; Jarkovský, J.; Rajdl, D.; Rokyta, R.; Mot’ovská, Z. Prognostic
Value of MicroRNAs in Patients after Myocardial Infarction: A Substudy of PRAGUE-18. Dis. Markers
2019, 2019, 1–9. [CrossRef] [PubMed]
32. Eryilmaz, U.; Akgullu, C.; Beser, N.; Yildiz, O.; Omurlu, I.K.; Bozdogan, B. Circulating microRNAs in patients
with ST-elevation myocardial infarction. Anatol. J. Cardiol. 2016, 16, 392–396. [CrossRef] [PubMed]
184
Cells 2020, 9, 793
33. Corsten, M.F.; Dennert, R.; Jochems, S.; Kuznetsova, T.; Devaux, Y.; Hofstra, L.; Wagner, D.R.; Staessen, J.A.;
Heymans, S.; Schroen, B. Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in
Cardiovascular Disease. Circ. Cardiovasc. Genet. 2010, 3, 499–506. [CrossRef] [PubMed]
34. Jaguszewski, M.; Osipova, J.; Ghadri, J.-R.; Napp, L.C.; Widera, C.; Franke, J.; Fijalkowski, M.; Nowak, R.;
Fijalkowska, M.; Volkmann, I.; et al. A signature of circulating microRNAs differentiates takotsubo
cardiomyopathy from acute myocardial infarction. Eur. Heart J. 2014, 35, 999–1006. [CrossRef]
35. Gacon, J.; Kablak-Ziembicka, A.; Stepien, E.; Enguita, F.J.; Karch, I.; Derlaga, B.; Zmudka, K.; Przewlocki, T.
Decision-making microRNAs (MIR-124, -133a/b, -34a and -134) in patients with occluded target vessel in
acute coronary syndrome. Kardiol. Pol. 2016, 74, 280–288.
36. Dalessandra, Y.; Devanna, P.; Limana, F.; Straino, S.; Carlo, A.D.; Brambilla, P.G.; Rubino, M.; Carena, M.C.;
Spazzafumo, L.; Simone, M.D.; et al. Circulating microRNAs are new and sensitive biomarkers of myocardial
infarction. Eur. Heart J. 2010, 31, 2765–2773. [CrossRef]
37. Li, Y.; Ouyang, M.; Shan, Z.; Ma, J.; Li, J.; Yao, C.; Zhu, Z.; Zhang, L.; Chen, L.; Chang, G.; et al. Involvement
of microRNA-133a in the development of arteriosclerosis obliterans of the lower extremities via RHoA
targeting. J. Atheroscler. Thromb. 2014, 22, 424–432. [CrossRef]
38. Su, Q.; Guo, Y.; Liu, H.; Qin, Y.; Zhang, J.; Yuan, X.; Zhao, X. Diagnostic role of high-sensitivity cardiac
troponin T in acute myocardial infarction and cardiac noncoronary artery disease. Arch. Med. Res. 2015, 46,
193–198. [CrossRef]
39. Neumann, J.T.; Sörensen, N.A.; Ojeda, F.; Renné, T.; Schnabel, R.B.; Zeller, T.; Karakas, M.; Blankenberg, S.;
Westermann, D. Early diagnosis of acute myocardial inf1. Neumann, J.T.; et al. Early diagnosis of acute
myocardial infarction using high-sensitivity troponin i. PLoS ONE 2017, 12. [CrossRef]
40. Wang, A.Z.; Schaffer, J.T.; Holt, D.B.; Morgan, K.L.; Hunter, B.R. Troponin Testing and Coronary Syndrome in
Geriatric Patients With Nonspecific Complaints: Are We Overtesting? Acad. Emerg. Med. 2020, 27, 6–14.
[CrossRef]
41. Ho Jeong, M.; Ho Jung, D.; Hun Kim, K.; Seok Lee, W.; Hong Lee, K.; Joo Yoon, H.; Sik Yoon, N.; Youn
Moon, J.; Joon Hong, Y.; Wook Park, H.; et al. Predictors of total occlusion of the infarct-related artery in
patients with acute Non-ST elevation myocardial infarction. Korean J. Med. 2008, 74, 271–280.
42. Xiang, M.; Zeng, Y.; Yang, R.; Xu, H.; Chen, Z.; Zhong, J.; Xie, H.; Xu, Y.; Zeng, X. U6 is not a suitable
endogenous control for the quantification of circulating microRNAs. Biochem. Biophys. Res. Commun.
2014, 454, 210–214. [CrossRef]
43. Peltier, H.J.; Latham, G.J. Normalization of microRNA expression levels in quantitative RT-PCR assays:
Identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008, 14,
844–852. [CrossRef] [PubMed]
44. Gimenez, M.R.; Twerenbold, R.; Reichlin, T.; Wildi, K.; Haaf, P.; Schaefer, M.; Zellweger, C.; Moehring, B.;
Stallone, F.; Sou, S.M.; et al. Direct comparison of high-sensitivity-cardiac troponin i vs. T for the early
diagnosis of acutemyocardial infarction. Eur. Heart J. 2014, 35, 2303–2311. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





Cardioprotective Potential of Human Endothelial-
Colony Forming Cells from Diabetic and
Nondiabetic Donors
Marcus-André Deutsch 1, Stefan Brunner 2, Ulrich Grabmaier 2, Robert David 3, Ilka Ott 4
and Bruno C. Huber 2,*
1 Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Ruhr-University
Bochum, Georgstr. 11, D-32545 Bad Oeynhausen, Germany; mdeutsch@hdz-nrw.de
2 Department of Internal Medicine I, Ludwig-Maximilians-University, Campus Grosshadern, Marchioninistr.
15, D-81377 Munich, Germany; stefan.brunner@med.uni-muenchen.de (S.B.);
ulrich.grabmaier@med.uni-muenchen.de (U.G.)
3 Reference- and Translation Center for Cardiac Stem Cell Therapy (RTC), Rostock University Medical Center,
Department of Cardiac Surgery, Department Life, Light & Matter (LL&M), 18057 Rostock, Germany;
Robert.David@med.uni-rostock.de
4 Department of Internal Medicine, Division of Cardiology, Helios Klinikum Pforzheim, Kanzlerstraße 2-6,
D-75175 Pforzheim, Germany; ilka.ott@helios-gesundheit.de
* Correspondence: Bruno.Huber@med.uni-muenchen.de; Tel.: +49-89-44-000
Received: 14 January 2020; Accepted: 27 February 2020; Published: 2 March 2020
Abstract: Objective: The potential therapeutic role of endothelial progenitor cells (EPCs) in ischemic
heart disease for myocardial repair and regeneration is subject to intense investigation. The aim of
the study was to investigate the proregenerative potential of human endothelial colony-forming cells
(huECFCs), a very homogenous and highly proliferative endothelial progenitor cell subpopulation, in a
myocardial infarction (MI) model of severe combined immunodeficiency (SCID) mice. Methods: CD34+
peripheral blood mononuclear cells were isolated from patient blood samples using immunomagnetic
beads. For generating ECFCs, CD34+ cells were plated on fibronectin-coated dishes and were
expanded by culture in endothelial-specific cell medium. Either huECFCs (5 × 105) or control
medium were injected into the peri-infarct region after surgical MI induction in SCID/beige mice.
Hemodynamic function was assessed invasively by conductance micromanometry 30 days post-MI.
Hearts of sacrificed animals were analyzed by immunohistochemistry to assess cell fate, infarct size,
and neovascularization (huECFCs n= 15 vs. control n= 10). Flow-cytometric analysis of enzymatically
digested whole heart tissue was used to analyze different subsets of migrated CD34+/CD45+ peripheral
mononuclear cells as well as CD34−/CD45− cardiac-resident stem cells two days post-MI (huECFCs
n = 10 vs. control n = 6). Results: Transplantation of human ECFCs after MI improved left ventricular
(LV) function at day 30 post-MI (LVEF: 30.43 ± 1.20% vs. 22.61 ± 1.73%, p < 0.001; ΔP/ΔTmax
5202.28 ± 316.68 mmHg/s vs. 3896.24 ± 534.95 mmHg/s, p < 0.05) when compared to controls.
In addition, a significantly reduced infarct size (50.3 ± 4.5% vs. 66.1 ± 4.3%, p < 0.05) was seen in
huECFC treated animals compared to controls. Immunohistochemistry failed to show integration
and survival of transplanted cells. However, anti-CD31 immunohistochemistry demonstrated an
increased vascular density within the infarct border zone (8.6 ± 0.4 CD31+ capillaries per HPF vs.
6.2 ± 0.5 CD31+ capillaries per HPF, p < 0.001). Flow cytometry at day two post-MI showed a trend
towards increased myocardial homing of CD45+/CD34+ mononuclear cells (1.1 ± 0.3% vs. 0.7 ± 0.1%,
p = 0.2). Interestingly, we detected a significant increase in the population of CD34−/CD45−/Sca1+
cardiac resident stem cells (11.7 ± 1.7% vs. 4.7 ± 1.7%, p < 0.01). In a subgroup analysis no significant
differences were seen in the cardioprotective effects of huECFCs derived from diabetic or nondiabetic
patients. Conclusions: In a murine model of myocardial infarction in SCID mice, transplantation of
huECFCs ameliorated myocardial function by attenuation of adverse post-MI remodeling, presumably
through paracrine effects. Cardiac repair is enhanced by increasing myocardial neovascularization
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and the pool of Sca1+ cardiac resident stem cells. The use of huECFCs for treating ischemic heart
disease warrants further investigation.
Keywords: cardiovascular diseases; adult stem cells; cardiac regeneration; myocardial
infraction; angiogenesis
1. Background
Ischemic heart disease following acute myocardial infarction (AMI) is the leading cause of
morbidity and mortality in the Western world [1]. Most of the clinically approved therapeutics focus on
modulating hemodynamics to reduce early mortality but do not facilitate cardiac repair, which would
be needed to reduce the incidence of heart failure [2]. Therefore, the concept of cell-based therapies may
have the potential to transform the treatment and prognosis of heart failure through regeneration or
repair of injured cardiac tissue [3,4]. Most clinical trials have used bone marrow derived mononuclear
cells (BMCd), which have demonstrated inconsistent and, overall, modest efficacy [5].
In recent years, there has been an intense investigative effort to uncover the mechanism by which
transplanted stem cells preserve the function of infarcted hearts. Based on these findings, the attenuation
of ischemic cardiomyopathy after cell transplantation is not attributable to cardiomyocyte repopulation
or transdifferentiation. Rather, functional benefits after stem cell transplantation might be attributable
to an augmentation of the natural process of myocardial healing by paracrine signaling and promoting
neovascularization [6].
Endothelial progenitor cells (EPCs) are a minor population of mononuclear cells migrating from
the bone marrow into the bloodstream, which are able to home in on sites of injury and promote
neovascularization, which finally is associated with increased blood flow and tissue repair [7]. EPCs can
be isolated from peripheral or umbilical cord blood and culturing in vitro can produce two different EPC
types. These two distinct EPC subtypes have been named as early EPCs (eEPCs) and late outgrowth
EPCs (LOEPCs) or endothelial colony-forming cells (ECFCs). ECFCs comply with the definition of
bona fide EPCs and represent a well-characterized and homogeneous cell population of endothelial
origin with high proliferative capacity and inherent vasculogenic activity [8–10]. In vivo, their potential
has been investigated in different mouse models where ECFCs increased neovascularization and
tissue regeneration [11]. In a rat stroke model, ECFCs treatment was associated with reduced glial
scarring and increased functional recovery, which could be explained by stimulation of angiogenesis
and a marked reduction in apoptosis [12]. However, there are only a few studies investigating the
potential of human ECFCs to regenerate ischemic myocardium. To create a clinically relevant scenario,
which aims to address the effect of cell therapy after acute MI, we transplanted ECFCs from patients
with coronary artery disease (CAD) into immunodeficient SCID mice and employed functional studies,
immunohistology, as well as flow cytometry to assess their potential in facilitating cardiac regeneration.
2. Methods
2.1. Isolation and Culture of ECFCs
Human adult ECFCs were collected by leukapheresis after G-CSF-induced mobilization of CD34+
cells from diabetic (n = 9) and nondiabetic (n = 8) patients with coronary artery disease. The diagnosis
of diabetes was made in accordance with current guidelines (mean HbA1c 7.5% ± 0.3%).
For ECFC collection, mononuclear cells from leukapheresis were isolated by density gradient
centrifugation for 20 min at 1000× g (Ficoll-Hypaque, Seromed, Berlin, Germany). CD34+ cells were
isolated using immunomagnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) [13]. The purity
of the isolated CD34+ cells ranged between 86% and 99% as assessed by flow cytometry (EPICS XL,
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Couter, Hialeah, FL, USA). This study was approved by the Medical Ethics Committee of the Technical
University of Munich.
CD34+ cord blood (CB) and peripheral blood (PB) cells were cultured using a modified protocol
as described in [14]. Briefly, CD34+ cells from mobilized PB was cultured on 1% gelatin (Sigma,
Hamburg, Germany) or fibronectin (10 μg/cm2, Cellsystems, St. Katharinen, Germany) in Iscove’s
Modified Dulbecco’s Medium (IMDM, Gibco, Paisley, UK), with 10% horse serum and 10% fetal calf
serum (PAN-Biotech, Aidenbach, Germany) supplemented with penicillin/streptomycin (Gibco), 50
ng/mL recombinant human stem cell factor (SCF, R&D Systems, Abingdon, UK), 50 ng/mL vascular
endothelial growth factor (VEGF, R&D Systems), 20 ng/mL basic fibroblast growth factor (FGF-2, R&D
Systems), and 20 ng/mL stem cell growth factor (SCGFβ, Peprotech, London, UK). This medium (ECM)
was replaced 3 times a week. After 3 weeks, cells were adapted from ECM to the low-serum EGM-2
medium (Cellsystems). To analyze EC colony-forming units (CFU-EC), CD34+ cells were plated in a
limiting dilution series of cell concentrations in 24-well plates and treated as above. These multiwell
tissue culture plates were scored for the presence (“positive”) or absence (“negative”) of EC colonies
between 21 and 35 days. Adherent cells were cultured to confluence in 1% gelatin-coated chamber
slides (Nalge Nunc, Naperville, IL, USA). Cells were washed twice in phosphate-buffered saline
(PBS), fixed, and permeabilized using Fix and Perm (Dianova, Hamburg, Germany). Samples were
then incubated for 2 h with primary antibodies: antihuman specific CD31 (Sertotec, Raleigh, NC,
USA), anti-CD105, anti-CD144 (VE-cadherin, Coulter-Immunotech, Krefeld, Germany), anti-CD45 and
anti-vWF (Dako, Hamburg, Germany), anti VEGF-R2 (KDR-1 and KDR-2, Sigma), anti-Flt1, anti-Flt4,
anti-Tie-2 (Santa Cruz Biotechnologies Inc., Heidelberg, Germany), and CD146 (Chemicon, Limburg,
Germany). To visualize antibody binding (mouse and rabbit antibodies), the peroxidase-labeled
avidin-biotin method (Universal Dako LSAB®-Kit, Dako, Santa Clara, CA, USA) was used according
to the manufacturer’s recommendations. For goat primary antibodies, donkey antigoat antibodies
directly conjugated to peroxidase were used (Jackson Laboratories, Dianova, Hamburg, Germany).
Isotype-matched control antibodies (Coulter-Immunotech, Jackson Laboratories, Brea, CA, USA)
served as negative controls. In selected experiments, nuclear staining was performed with hematoxylin
staining solution (Merck, Darmstadt, Germany).
2.2. Animal Model
For this study, we used 8–12 weeks old male severe combined immunodeficiency (SCID)beige
mice (Charles River, Wilmington, MA, USA), which were kept under pathogen-free conditions. MI was
induced by surgical occlusion of the left anterior descending artery (LAD) through a left anterolateral
approach as described previously [15,16]. Briefly, animals were anesthetized with a mixture of
100 mg/kg ketamine (Sigma, St. Louis, MO, USA) and 5 mg/kg xylazine (Sigma) intraperitoneally.
Subsequently, they were intubated and artificially ventilated with room air at 200 breaths/min using a
mouse ventilator (HUGO SACHS, March-Hugstetten, Germany). A left anterolateral thoracotomy was
performed, and MI was induced by surgical occlusion of the left anterior descending artery (LAD)
with an 8-0 Prolene suture. Animal care and all experimental procedures were performed in strict
accordance with the German and National Institutes of Health animal legislation guidelines and were
approved by the local animal care committees (AZ 209.1/211-2531-117/02). The investigation conforms
to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996).
2.3. Cell Delivery
For cell delivery, a 15 μL suspension containing 5 × 105 human ECFCs or a 15 μL saline solution
was administered directly after LAD ligation by two injections in the border zone of the infarcted
myocardium using a 10 μL 32G Hamilton syringe (Reno, NV, USA). One injection was performed on
the medial and one at the lateral side of the infarcted area.
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2.4. Invasive Evaluation of Cardiac Function
For evaluation of myocardial function, mice of the previously described groups underwent
impedance-micromanometer catheterization. The method as well as data analyses were performed as
previously described in the literature [17,18]. Briefly, the animals were anesthetized with thiopental
(100 mg/kg intraperitoneal) and ventilated using a mouse ventilator (HUGO SACHS). After that, a 1.4
French impedance-micromanometer catheter (Millar Instruments, Houston, TX, USA) was introduced
into the left ventricle retrogradely via the right carotid artery, and pressure—volume loops were
recorded. The method was based on measuring the time-varying electrical conductance signal of
two segments of blood in the left ventricle from which total volume is calculated. Raw conductance
volumes were corrected for parallel conductance by the hypertonic saline dilution method [15].
2.5. Flow Cytometry of Nonmyocyte Cardiac Cells
We previously hypothesized that EPC may not be responsible only for the formation of new
vessels but may also recruit local cells [13]. Therefore, we performed flow cytometry in order to
evaluate the effects of cell transplantation on proangiogenic cardiac cell populations.
Hearts of the mice were investigated by flow cytometry (FACS) as described previously [19]. Briefly,
for cardiac FACS analyses, infarcted hearts of the mice were explanted at day 2 and retrogradely perfused
with saline (0.9% NaCl) to wash out circulating blood cells. Thereafter, a “myocyte-depleted” cardiac
cell suspension was prepared, incubating minced myocardium in 0.1% collagenase IV (Gibco, Co Dublin,
Ireland) for 30 min at 37 ◦C, lethal to most adult mouse cardiomyocytes. Cells from peripheral blood and
hearts were incubated for 40 min in the dark at 4 ◦C with the following fluoresceinisothiocyanate (FITC),
phycoerythrin (PE), and peridininchlorophyll-protein (PerCP) conjugated monoclonal antibodies:
CD45-PerCP, CD34-FITC, and CXCR4-PE (all from BD Pharmingen). A matching isotype antibody
served as control. Cells were analyzed by 3-color flow cytometry using a Coulter® Epics® XL-MCLTM
flow cytometer (Beckman Coulter, Brea, USA). Each analysis included 50,000 events.
2.6. Histology and Immunohistochemical Analyses
Infarct size was calculated as the average of four coronal sections sampled at 2 mm intervals from
the apex to the base using the following Equation (1) developed by Pfeffer et al. [20]:
In f arct Size =
Coronal In f arct Perimeter (Epicardal + Endocardial)
Total Coronal Perimeter (Epicardal + Endocardial)
× 100 (1)
infarct size 14 [coronal infarct perimeter (epicardial plus endocardial)/total coronal perimeter (epicardial
plus endocardial)] × 100. Infarct wall thickness was measured in Masson’s trichrome stained sections
by taking the average length of five segments along evenly spaced radii from the centre of the LV
through the infarcted free LV wall [15]. To assess the incorporation and phenotype of injected EPCs
in infarcted myocardium, we performed standard histological procedures (hematoxylin/eosin and
Masson Trichrome) and immunostaining, which was performed as follows:
For immunohistochemical analyses, hearts were fixed in 4% phosphate-buffered formalin overnight
and embedded in paraffin as described previously [15]. Before immunostaining, mounted tissue
sections were deparaffinized by rinsing 3× for 5 min in Xylene followed by 2× for 5 min 100%, 2× for
5 min 96%, and 2× for 5 min 70% ethanol rinses. Endogenous peroxidases were quenched in 7.5%
H2O2 in distilled water for 10 min. Following that, slides were rinsed in distilled water for 10 min and
twice in TRISbuffer (pH 7.5) for 5 min. Finally, sections were incubated at room temperature for 60 min
with either a primary antibody detecting vimentin (monoclonal mouse anti-human; Dako, Glostrup,
Denmark) or class I human leukocyte antigen (HLA) (monoclonal mouse anti-human HLA-A, B, C;
WAK-Chemie, Steinbach, Germany). Pretreatment was performed for 30 min (microwave 750 W)
using citrate buffer (10 mM, pH 6.0) for vimentin or a target retrieval solution (Dako) for HLA-A,B,C,
respectively. The detection system for vimentin and HLA-A, B, C was Dako REAL and APAAP mouse.
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2.7. Statistical Analyses
Results were expressed as mean ± SEM. Multiple group comparisons were performed by one-way
analyses of variance (ANOVA) followed by the Bonferroni procedure for comparison of means.
Comparisons between two groups were performed using the unpaired Student’s t-test. Data were
considered statistically significant at a value of p ≤ 0.05.
3. Results
3.1. Improvement of Cardiac Function after Intramyocardial Injection of Human ECFCS into Ischemic Myocardium
To investigate the regenerative potential of human ECFCs transplanted intramyocardially,
5 × 105 cells were injected directly after surgical occlusion of the LAD and functional parameters,
and histological and immunohistochemical data were collected. To assess the functional parameters,
pressure-volume relations of ECFC-treated and saline-treated hearts were measured at day 30 after MI
using conductance catheters (Figure 1). Heart rates did not differ significantly between the groups,
showing that experimental conditions such as anesthesia did not influence the measurements (data
not shown). At day 30 after MI, we detected a significant improvement in cardiac contractility
(Figure 1A; dPdt max: 5202.28 ± 316.68 mmHg/s vs. 3896.24 ± 534.95 mmHg/s, p = 0.03) in human
ECFC-treated mice compared to saline-treated animals. Moreover, compared to saline-treated control
animals, human ECFC-treated mice revealed significantly improved stroke work 30 days after MI
(CO 3470.70 ± 254.44 μL/min vs. 2006.71 ± 243.18 μL/min; p < 0.001, Figure 1B–D). Accordingly,
ECFC treatment was associated with improved LV ejection fraction (Figure 1E, LVEF 30.43 ± 1.20% vs.
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Figure 1. Improved myocardial function after human endothelial colony-forming cells (ECFC)
transplantation into ischemic myocardium. Bar graphs representing cardiac output (A), contractility (B),
and ejection fraction (E) in saline-treated animals (white bars) and ECFC-treated animals (black bars) 30
days after myocardial infarction (MI). Data represent mean ± SEM; n.s., not significant. Representative
pressure volume loops of saline-treated animals (C) and ECFC-treated animals (D) 30 days after MI.
3.2. Attenuated Infarct Remodeling after Transplantation of Human ECFCS into Ischemic Myocardium
After functional profiling, we performed histological analysis of explanted hearts at day 30
following MI and cell transplantation. As reported in prior studies [15,19], permanent occlusion of the
LAD artery resulted in a typical pattern of injury with transmural involvement of the myocardium
in regions supplied by the main branches of the left coronary artery. Histological analyses revealed
less pronounced thinning of the LV anterior wall after treatment with ECFCs (0.28 ± 0.08 mm vs.
0.20± 0.04 mm; not significant). However, this difference did not reach statistical significance. Infarction
size was significantly diminished among human ECFC-treated animals compared to control animals
30 days after MI (50.3 ± 4.5% vs. 66.1 ± 4.3%, p < 0.05, Figure 2). Thirty days post-MI, as assessed by
human-specific antibodies against HLA and vimentin, we were not able to detect any retained ECFCs
(data not shown).
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Figure 2. Attenuated infarct remodeling after human ECFC transplantation into ischemic myocardium.
(A) Bar graphs representing the size of infarction (%) in saline-treated animals (white bar) and
ECFC-treated animals (black bar) 30 days after MI. (B) Bar graphs representing anterior wall thickness
(mm) in saline-treated animals (white bar) and ECFC-treated animals (black bar) 30 days after MI. Data
represent mean ± SEM; n.s., not significant. (C) Representative Masson trichrome staining of infarcted
hearts 30 days after MI.
3.3. Increased Neovascularization after Intramyocardial Injection of Human ECFCS into Ischemic Myocardium
We hypothesized that attenuated cardiac remodeling after transplantation of ECFCs might
be a result of cell-induced enhanced neovascularization. Therefore, we performed anti-CD31
immunohistochemistry to analyze the extent of neovascularization in the border zone of animals
treated with ECFCs and control animals. Consistent with the smaller infarct size after ECFC therapy,
heart sections of these animals revealed a significantly increased capillary density at the infarct
border zone compared to the control animals (8.6 ± 0.4 vs. 6.2 ± 0.5, p < 0.001, Figure 3) 30 days
post-MI. In accordance to these data on enhanced neovascularization after cell transplantation in vivo,
we detected increased expression of the proangiogenic transcription factors HIF-1alpha and MMP-2 in
ECFCs compared to human umbilical vein endothelial cells (HUVEC) cells assessed by qPCR in vitro
(Figure S1A,B).
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Figure 3. Increased neovascularization after transplantation of human ECFCs into ischemic myocardium.
Histograms showing the numbers (A) and mean area (B) of CD31+ capillaries at the infarct border zone
of saline-treated control animals (white bars) and after ECFC transplantation (black bars) 30 days after
MI. Data represent mean ± SEM. (C) Representative immunohistochemical staining of CD31 (brown)
in infarcted hearts 30 days after MI.
3.4. No Enhanced Homing of BM-Derived Progenitor Cells after Human ECFC Injection into Ischemic Myocardium
Because circulating BMCs cells are known carriers of angiogenic growth factors, we sought to
address whether transplantation of ECFCs is able to attract BMCs from the peripheral blood to the
ischemic myocardium, thereby facilitating augmented neovascularization. To address this question,
we isolated a myocyte-depleted fraction of cardiac cells and performed flow cytometry respectively. In a
first step, we were interested in the amount of CD45+/CD34+ BMCs within the ischemic myocardium.
Transplantation of ECFCs was associated with increased number of cardiac homing of CD45+/CD34+
cells (1.1 ± 0.3% vs. 0.7 ± 0.1%), but the values did not reach statistical significance (Figure 4A,B). Next,
we further characterized CD45+/CD34+ cells utilizing the additional markers CD31, c-kit, Sca-1, CXCR4,
Flk-1, LFA-1, and VLA-4. Compared to PBS treated controls, transplantation of ECFCs increased the
number of all subfractions without reaching statistical significance (Figure 4C). Interestingly, among
the different subfractions, the CD45+/CD34+/Sca-1 and CD45+/CD34+/CXCR4+ showed the highest
enrichment (CD45+/CD34+/Sca-1 + 0.8 ± 0.1% vs. 0.5 ± 0.1% and CD45+/CD34+/CXCR4+ 0.6 ± 0.1% vs.
0.4 ± 0.1%).
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Figure 4. No enhanced homing of bone marrow (BM)-derived progenitor cells after human ECFC
injection into ischemic myocardium. (A) Bar graphs representing the percentage of CD45+/CD34+
stem cells in the ischemic hearts of control animals (white bar) and after ECFC transplantation (black
bar) 2 days after MI. Data represent mean ± SEM; n.s., not significant. (B) Representative flow
cytometry (FACS) analyses of CD45+/CD34+ cells in the heart of control animals (left) and after ECFC
transplantation (right) 2 days after MI. (C) Bar graphs representing the percentage of CD45+/CD34+
subpopulations in the ischemic hearts of control animals (white bars) and after ECFC transplantation
(black bars) 2 days after MI. Data represent mean ± SEM;n.s., not significant.
3.5. Increased Numbers of Sca-1 Positive Resident Cardiac Stem Cells after ECFCS Injection into Ischemic Myocardium
In recent years, there has been emerging evidence that the heart contains a reservoir of
resident cardiac progenitor cells [21]. These cells are positive for various markers, such as
c-kit or Sca-1. We hypothesized that these resident cells may play a role in the repair of
the injured heart, i.e., by secretion of angiogenic growth factors and contribution to improved
neovascularization. To investigate these cells, we analyzed the fraction of CD45−/CD34− cells
within the ischemic myocardium of control and ECFC-treated animals and further characterized
cells that additionally expressed c-kit or Sca-1. Transplantation of ECFCs significantly increased
the number of CD45−/CD34−/Sca-1+ progenitor cells 2 days after myocardial ischemia compared
to controls (11.70 ± 1.67% vs. 4.47 ± 1.71%, p < 0.05). In contrast, no difference in the number of
CD45−/CD34−/c-kit+ could be observed in ECFC-treated compared to control animals (0.33 ± 0.11% vs.
0.40 ± 0.06%; not significant). Results are depicted in Figure 5.
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Figure 5. Increased numbers of Sca-1+ resident cardiac stem cells after ECFC injection into ischemic
myocardium. (A) Bar graphs representing the percentage of Sca-1+ resident cardiac stem cells in
the ischemic hearts of control animals (white bar) and after ECFC transplantation (black bar) 2 days
after MI. Data represent mean ± SEM. (B) Representative FACS analyses of Sca-1+ resident cardiac
stem cells in the heart of control animals (left) and after ECFC transplantation (right) 2 days after MI.
(C) Bar graphs representing the percentage of c-kit+ resident cardiac stem cells in the ischemic hearts of
control animals (white bar) and after ECFC transplantation (black bar) 2 days after MI. Data represent
mean ± SEM; n.s., not significant.
3.6. No Difference in Therapeutic Effectiveness of ECFCS Derived from Diabetic or Nondiabetic Donors after
Transplantation into Ischemic Myocardium
To evaluate the hypothesis that diabetes mellitus may impair the protective potential of ECFCs,
we stratified cell donor patients into “diabetic” versus “nondiabetic”. Interestingly, there was no
statistical difference in the amount of CD45+/CD34+ BMCs within the ischemic myocardium between
animals treated with either ECFCs from diabetic or nondiabetic patients (1.1 ± 0.4 (non DM-ECFCs)
vs. 0.8 ± 0.2 (DM-ECFCs) vs. 0.7 ± 0.1% (control); for non DM-ECFCs vs. DM-ECFCs p = 0.18).
Furthermore, LV function assessed by catheterization revealed no significant difference between
animals transplanted with ECFC from diabetic or nondiabetic patients after MI. However, both ECFCs
from diabetic or nondiabetic patients were able to significantly improve cardiac contractility compared
to saline-treated control animals (dPdt max: 5154.65 ± 469.37 (non DM-ECFCs) vs. 5240.02 ± 447.51
(DM-ECFCs) vs. 3896.24 ± 534.95 (control) mmHg/s, for nonDM-ECFCs vs. DM-ECFCs p = 0.28;
CO: 3821.92 ± 238.14 (non DM-ECFCs) vs. 2006.71 ± 243.18 vs. 3236.54 ± 384.78 (DM-ECFCs);
for nonDM-ECFCs vs. DM-ECFCs p = 0.28; Figure 6).
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Figure 6. No difference in therapeutic effectiveness of ECFCs derived from diabetic or nondiabetic
donors after transplantation into ischemic myocardium. (A) Bar graphs representing the percentage of
CD45+/CD34+ stem cells in the ischemic hearts of control animals (white bar) after ECFC transplantation
from nondiabetic donors (black bar) and after ECFC transplantation from diabetic donors (grey bar) 2
days after MI. Data represent mean ± SEM; n.s., not significant. (B) Bar graphs representing cardiac
output and contractility (C) of control animals (white bar) after ECFC transplantation from nondiabetic
donors (black bars) and after ECFC transplantation from diabetic donors (grey bars) 30 days after
MI. Data represent mean ± SEM; n.s., not significant. (D) Bar graphs representing the percentage
of CD45+/CD34+ subpopulations in the ischemic hearts of control animals (white bar) after ECFC
transplantation from nondiabetic donors (black bars) and after ECFC transplantation from diabetic
donors (grey bars) 2 days after MI. Data represent mean ± SEM; n.s., not significant.
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4. Discussion
This study aimed to evaluate a proregenerative/reparative potential of human ECFCs in a murine
model of MI. Our main findings were the following: (1) transplantation of human ECFCs into
ischemic myocardium resulted in an improved cardiac function and reduced size of infarction 30 days
after MI; (2) the attenuated remodeling after ECFC transplantation was associated with enhanced
neoangiogenesis; (3) treatment with ECFCs increased the number of resident Sca-1+ stem cells without
significant homing of migrated BMCs; and (4) there was no difference in therapeutic effectiveness
between transplanted ECFCs derived from diabetic or nondiabetic donors.
In the present study, we used immunocompromised SCID animals to prevent cell death due to cell
rejection. However, 30 days after MI, we were not able to detect any transplanted cells by histological
analysis. Sheikh et al. [6] investigated recently the survival kinetics and gene expression changes of
transplanted BMMCs after transplantation into ischemic myocardium. Utilizing molecular-genetic
bioluminescence imaging, they demonstrated short-lived survival of cells following transplant,
with less than 1% of cells surviving by six weeks post-transplantation [6]. In line with these data,
Higuchi et al. [22] showed in a rat study of chronic myocardial ischemia that human EPCs transduced
with the sodium iodide symporter (NIS) gene for reporter gene imaging by (124)I-PET and labeled with
iron oxides for visualization by MRI showed poor cell engraftment after injection. The (124)I uptake
decreased on day three and was undetectable on day seven, which was confirmed by histological
analysis with CD31 and CD68 antibodies [22].
However, in accordance with previous preclinical [23,24] and clinical studies, we were able to see
functional improvement after transplantation of ECFCs into ischemic myocardium. These functional
effects were associated with an attenuation of adverse post-MI cardiac remodeling reflected by smaller
size of infarction and less pronounced thinning of the LV wall after treatment with ECFCs. Moreover,
our data showed an improved neovascularization reflected by a high number of CD31+ vessels at the
infarct border zone. It is an ongoing matter of debate how transplanted stem and progenitor cells
are able to increase neovascularization. On the one hand, it has been shown that EPCs are carriers of
proangiogenic cytokines and growth factors like VEGF, HGF, angiopoietins, and IGF-1 [25–27]. In this
regard, we detected increased expression of proangiogenic transcription factors HIF-1alpha and MMP-2
in ECFCs in vitro. Dubois et al. [28] investigated the paracrine activation after ECFC transplantation in
a pig model of acute MI. After infusion of autologous ECFCs, they observed decreased infarct size
and a greater vascular density, which was associated with higher levels of the proangiogenic placental
growth factor (PLGF) [28]. Likewise, in a rat model of transient middle cerebral artery occlusion
(MCAO), injection of ECFCs was associated with a reduction in the number of apoptotic cells and
an increase in capillary density at the site of injury. These effects were associated with an increased
expression of growth factors VEGF and IGF-1 in the infarct area 14 days after MCAO [12]. Furthermore,
neovascularization also increased cell survival, and decreased apoptosis is an important contributor
of cardio-protective paracrine effects after cell transplantation. In this regard, Kim et al. [29] showed
a significant decrease of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-
positive nuclei after transplantation of ECFCs compared to control animals in tissue sections collected
from the peri-infarct zones at day seven [29].
On the other hand, there is some evidence that migration and homing of BMCs as well as expansion
of resident cardiac stem cells beneficially influences cardiac remodeling after MI [3]. We used cardiac
FACS analysis to quantify the number of migrated CD45+/CD34+ BMCs after ECFC transplantation.
We were not able to see a significant increase in the absolute number of BMCs and their subpopulations.
However, we found a higher number of CD45−/CD34−/Sca-1+ cardiac-resident cells within the
myocardium of human ECFC treated animals injected with ECFCs. In the group of mice treated with
huECFC, we observed a more than 2-fold increase in the number of CD34−/CD45−/Sca1+ cells 2 days
after MI when compared to control animals. Sca1+ cells within the mouse heart have been described as
a multipotent stem cell population that are able to differentiate into cardiomyocytes, endothelial cells,
and smooth muscle cells in vitro and after cardiac grafting. In fact, more recently and in contrast to
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previous reports, it has been shown that adult Sca-1+ cardiac-resident cells appear to lack significant
cardiomyogenic potential [30]. Lineage tracing of Sca-1 expressing cells in the mouse heart revealed
only a very limited ability to significantly contribute new cardiomyocytes to the heart after MI in the
mouse. In fact, they demonstrated a mostly endothelial expression pattern in Sca-1mCmR26dTomato
hearts that colocalized with CD31 expression [31]. Tang et al. [32] by targeting endogenous Sca1+ cells
in Sca1-2A-CreER; R26-tdTomato mice through pulse labeling experiments showed that 94.25 ± 0.54%
tdTomato+ cells were CD31+ endothelial cells, indicating that most Sca1+ cells adopt an endothelial
cell fate during cardiac homeostasis. By immunostaining for tdTomato and VE-cad on post-MI murine
heart sections, they detected a substantial number of tdTomato+ coronary endothelial cells in the injured
region. Roughly, two thirds of VE-cad+ cells expressed tdTomato, whereas 91.77 ± 1.12% tdTomato+
cells expressed VE-cadherin in the injured myocardium. They concluded that Sca1+ cardiac progenitor
cells mainly differentiate into cardiac endothelial cells and fibroblasts but not cardiomyocytes during
cardiac homeostasis and after injuries. In a different experimental approach, Vagnozzi et al. [33]
generated Ly6a gene-targeted mice containing either a constitutive or an inducible Cre recombinase to
perform genetic lineage tracing of Sca-1+ cells in vivo. Similarly, they observed that the contribution of
endogenous Sca-1+ cells to the cardiomyocyte population in the heart was < 0.005% throughout all of
cardiac development, with aging, or after MI. Moreover, pulse labeling of Sca-1+ cells with an inducible
Ly6a-MerCreMer allele revealed that Sca-1+ cells rather represent a subset of vascular endothelial
cells that expand postnatally with enhanced responsiveness to pathological stress in vivo [33]. In our
study, huECFCs treatment were a potent stimulus for Sca-1+ endogenous angiogenic cells. Anti-CD31
immunohistochemistry confirmed improved neovascularization within the infarct border zone, thereby
contributing to protection of nonischemic areas. Sca1+ cells also have been described as differentiating
into fibroblasts that may positively act during the early phase of infarct healing, thereby mediating
positive effects on post-MI adverse remodeling.
In our study, we did not use specific cardiac stromal cell markers to define the phenotype of
CD45−/CD34−/Sca-1+ cells found in the myocardium (along with absence of CD31 expression). It must
be the goal of future studies to further characterize our population of Sca-1+ cells and to completely
rule out that they are not vessel-related cells or part of the mobilized pool from a noncardiac origin.
After we had established the cardioprotective potential of ECFCs, we further evaluated our
ECFC patient collective for cardiovascular risk factors and discovered that a fraction of these patients
had diabetes mellitus Typ II (DM Typ II) according to current guidelines. Interestingly, we were not
able to detect functional or cellular differences within the ischemic myocardium between animals
treated with either ECFCs from diabetic or nondiabetic patients. In this context, Tan et al. [34] injected
ECFCs of diabetic and healthy rabbits intramyocardially in diabetic rabbits. They found that injection
of transplantation of diabetic ECFCs was not able to rescue the ischemic myocardium of diabetic
rabbits. In comparison, transplantation of healthy ECFCs resulted in increased neovascularization
and paracrine activation. However, methodological differences might explain the different findings.
Tan et al. [34] used recipient animals with severe, untreated diabetes, suggesting that the recipient
environment plays an important role for the magnitude of therapeutical effects of cell-based therapies.
Likewise, others have reported that the dysfunction of diabetic ECFCs can be restored by improved
glycemic control [35,36].
A sole mechanism of action for ECFC beneficial effects remains to be elucidated. In some of these
studies, ECFCs facilitate vascular repair by directly integrating within the host vasculature, while in
others, vascular engraftment of these cells is low or completely absent [11]. Herein, we could show
that ECFC transplantation is associated with a secondary increase in Sca-1+ cardiac resident progenitor
cells and propose a novel proreparative mechanism of ECFC action.
In the present study, we were not able to perform noninvasive and repetitive analyses of the
animals because mice were sacrificed after invasive hemodynamic measurements and for histological
analyses. Therefore, it will be the goal of future studies to use noninvasive imaging techniques such as
cardiac MRI to facilitate serial assessments of cardiac function [37].
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The rapid donor cell death 30 days after transplantation seen in our study is consistent with
previous studies showing poor donor cell survival after transplantation of different cell types [6].
However, reporter gene PET imaging could be employed in future studies to monitor stem cell
survival in vivo. Likewise, molecular imaging will possibly help to unravel the mechanistic puzzle
about the contributory roles of inflammation, ischemia, apoptosis, anoikis, and autophagy after cell
transplantation [38].
5. Conclusions
In conclusion, in a murine model of myocardial infarction in SCID mice, transplantation of
huECFCs ameliorated myocardial function by attenuation of adverse post-MI remodeling, presumably
through paracrine effects. Cardiac repair was enhanced by increasing myocardial neovascularization
and the pool of Sca1+ cardiac resident stem cells without significant differences in the cardioprotective
effects of huECFCs derived from diabetic or nondiabetic patients. The use of huECFCs for treating
ischemic heart disease warrants further investigation.
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Abstract: Background: Bone marrow (BM)-derived stem cells with their various functions and
characteristics have become a well-recognized source for the cell-based therapies. However,
knowledge on their therapeutic potential and the shortage for a cross-link between distinct BM-derived
stem cells, primed after the onset of myocardial infarction (MI), seems to be still rudimentary. Therefore,
the post-examination of the therapeutic characteristics of such primed hematopoietic CD133+ and
mesenchymal CD271+ stem cells was the object of the present study. Methods and Results: The effects
of respective CD133+ and CD271+ mononuclear cells alone as well as in the co-culture model have
been explored with focus on their angiogenic potential. The phenotypic analysis revealed a small
percentage of isolated cells expressing both surface markers. Moreover, target stem cells isolated
with our standardized immunomagnetic isolation procedure did not show any negative alterations
following BM storage in regard to cell numbers and/or quality. In vitro network formation relied
predominantly on CD271+ stem cells when compared with single CD133+ culture. Interestingly,
CD133+ cells contributed in the tube formation, only if they were cultivated in combination with
CD271+ cells. Additional to the in vitro examination, therapeutic effects of the primed stem cells
were investigated 48 h post MI in a murine model. Hence, we have found a lower expression of
transforming growth factor βeta 3 (TGFβ3) as well as an increase of the proangiogenic factors after
CD133+ cell treatment in contrast to CD271+ cell treatment. On the other hand, the CD271+ cell
therapy led to a lower expression of the inflammatory cytokines. Conclusion: The interactions
between CD271+ and CD133+ subpopulations the extent to which the combination may enhance
cardiac regeneration has still not been investigated so far. We expect that the multiple characteristics
and various regenerative effects of CD271+ cells alone as well as in combination with CD133+ will
result in an improved therapeutic impact on ischemic heart disease.
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1. Introduction
In order to cover up the deficit of regenerative potential, new treatment approaches for cardiac
diseases are needed. Several studies suggest that approaches based on the application of stem cells may
be the future strategy in order to compensate the regenerative deficiency of the heart. As myocardial
infarction (MI) occurs due to the absent blood flow in the coronary arteries, the formation of new blood
vessels would be an essential prerequisite for the regeneration. Yet, in the search for suitable stem
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cell subtypes, various other properties are of interest as well. This includes cells that interfere with
pathological immune mechanisms as well as cellular mediators and chemokines that cause migration
and homing processes. Besides, it is of the tremendous importance whether the cells are proofed
to be safe in application. Furthermore, the cells can also be treated in advance in order to develop
desirable properties. As the CD133+ stem cell therapies and other approaches with hematopoietic
cells provide promising results, research has to examine more cell types in order to achieve additional
effects and thus to further improve the therapeutic measures. Until now, no stem cell-related cardiac
complications following intramyocardial transplantation of bone marrow (BM) derived stem cells
have been reported so that the therapy is considered to be safe [1]. In addition, the BM also contains
a population named after their ability to differentiate into various cell types of mesenchymal origin.
These multipotent stem cells are expandable and modifiable in cell culture and offer several distinctive
characteristics, which make them a promising therapeutic approach for damaged heart tissue [2].
Especially mesenchymal stem cells (MSC) are able to decrease infarct size and myocardial fibrosis [3].
Thereby, cardiac remodeling in total may be attenuated as well as the heart’s contractility improves [3].
Furthermore, MSC have paracrine effects that inhibit apoptosis of endothelial cells in hypoxic condition,
increase their survival, and thus stimulate angiogenesis processes [4]. As another advantage, MSC do
not express any antigens of histocompatibility and thus can be used in allogenic transplantation as
well. Quite the contrary, these cells even have immunomodulatory paracrine effects that counteract
inflammatory responses [5,6]. As inflammatory processes play a decisive role in the development
of chronic heart diseases and have a negative influence on the heart function, these effects may
also improve the therapy significantly. After the transplantation, MSC may be able to stimulate the
production of reparative growth factors, inhibit local inflammatory response, and replace damaged
cells [7]. Apart from these positive effects, difficulties with the practical application arise from the large
heterogeneity of MSC as well. Thus, it is uncertain to predict which exact cell type arises from the MSC
population after the application. Indeed, a study by Yoon et al. showed that the direct transplantation of
unselected BM cells into the infarcted myocardium induces significant intramyocardial calcification [8].
This clearly demonstrates the research demands in order to guarantee the safety of MSC as therapeutic
option. The development of methods for the identification and isolation of MSC subpopulations is
crucial for a determined specific function and a successful clinical application. A currently much
examined MSC subtype is characterized by the expression of the surface marker CD271. Several studies
showed that this marker is one of the most specific concerning BM derived MSC [9]. Thus, there may
be a particular suitability of CD271+ MSC for preselected cell products. CD271 enables prospective cell
isolation of MSC from BM derived mononuclear cells (MNC) [10] and have been shown to be essential
in the formation of the heart as they influence the survival of endothelial cells, vascular smooth muscle
cells, and cardiac myocytes. Furthermore, these proteins regulate angiogenesis and vasculogenesis by
autocrine and paracrine mechanisms [10–12].
Knowledge of the therapeutic potential attributable to distinct BM derived stem cell subtypes
primed due to MI of the donors is still greatly lacking. Therefore, this study intends to examine the
benefits of CD271+ and CD133+ stem cells. In this context, we have explored the effects of CD271+ cells
alone as well as in combination with CD133+ with the main focus on their angiogenic potential (in vitro
examination). Moreover, the therapeutic capacities of both primed BM stem cells were investigated
following cardiac ischemia/reperfusion in mice.
2. Materials and Methods
2.1. Bone Marrow Aspiration
Informed donors gave written consent to the aspiration of their BM according to the Declaration
of Helsinki. The ethical committee of the University of Rostock has approved the presented study
(registered as no. A201023) as of 29 April, 2010. BM samples were obtained by sternal aspiration
from patients undergoing coronary artery bypass grafting (CABG) surgery at Rostock University,
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Germany. Anticoagulation was achieved by heparinization with 250 i.E./mL sodium heparine
(B. Braun Melsungen AG, Melsungen Germany).
2.2. Cell Isolation (Single and Dual Method)
Mononuclear cells (MNC) were isolated by density gradient centrifugation using Lymphocyte
Separation Medium (LSM; 1.077 g/L, PAA Laboratories GmbH, Pasching, Austria). CD133+ and
CD271+ stem cells were enriched by positive magnetic selection using the magnet activated cell sorting
(MACS) system (Miltenyi Biotec, Bergisch Gladbach, Germany). In case of CD133+ direct labeling was
applied and indirect labeling for CD271+ cells (CD271-APC/anti-APC-microbeads; all Miltenyi Biotec).
Purified stem cells were appropriately employed in further in vitro and in vivo experiments. For the
dual method, the CD133+ population was isolated from the CD271– fraction and vice versa.
2.3. Phenotypical Characterization by Flow Cytometry
Cell fractions were suspended in cold MACS-buffer containing PBS, 2 mM EDTA and 0.5%
BSA. To reduce unspecific binding, FcR blocking reagent (Miltenyi Biotec) was added to all samples.
Cells were stained using the mouse anti-human-CD133-phycoerythrin (PE; 293C2), -CD34-fluorescein
isothiocyanate (FITC) and -CD271-allophycocyanine (all Miltenyi Biotec), -CD45-allophycocyanin-H7
as well as -CD45-Horizon-V500 (both BD Biosciences, Heidelberg, Germany) following incubation for
10 min in the dark at 4 ◦C. For optimal multicolor setting and correction of the spectral overlap single
stained mouse isotype antibodies were considered as controls. The gating strategy was performed
with matched isotype/fluorescence minus one control. After performing antibody staining 15 μM
4′,6-Diamidino-2-phenylindole (DAPI, Thermo Fisher Scientific, Waltham, MA, USA.) was added,
cells were incubated for 2 min and then immediately acquired by BD™ LSRII flow cytometer and
data were analyzed using FACS-Diva software, version 6.1.2 (both Becton Dickinson, Franklin Lakes,
NJ, USA). Purity and viability of all cell isolations were analyzed using near-IR live dead stain
(Thermo Fisher).
2.4. Angiogenesis Assay
Freshly isolated stem cells were prepared at 4 ◦C in an extracellular growth matrix using 100 μL
BD MatrigelTM Matrix (BD Biosciences) and 100 μL complete endothelial growth medium (EGM-2,
Lonza, Basel, Switzerland) per well of a 24-well-plate (Greiner Bio-One, Kremsmünster, Austria).
For the assay 100,000 CD133+ or CD271+ cells (single model) or both cell types in a ratio of 50,000 cells
each (co-culture model) were seeded per well. After 20 min polymerization of the matrix at 37 ◦C the
matrix 200 μL EGM-2was added carefully onto each well. The medium was changed every two days
for another 14 days.
2.5. Three Dimensional (3D) Microscopy Analysis
After two weeks the tube formation assays were conducted according to the criteria of network
length and count of nodal points. For this, z-stack images were acquired using the Zeiss high-resolution
microscope ELYRA PS.1 LSM 780 confocal imaging system and corresponding Zen2011 software (both
Carl Zeiss AG, Oberkochen, Germany). Z-Stack images are transversal slice images (two-dimensional)
of the 3D assay and thus allow representative analysis of their structures. For each well, five z-stacks
with ten images were taken and included into a final interpretation. The evaluation was performed
using the ImageJ free software (NIH, Bethesda, MD, USA). For better illustration, the different levels
of the z-stack were marked in different colors. Likewise, the amount of nodal points was counted,
respectively. In total, 900 images (n = 6) were analyzed and measured toward network length and
count of nodal points.
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2.6. Cell Tracking within Matrigel Matrix
In order to further investigate the cell networks accomplished in Matrigel matrix, immunofluorescence
staining was carried out on angiogenesis assay. For better discrimination and alterations within the matrix,
freshly isolated CD133+ cells were stained with the lipophilic cell permeable dye CFDA-SE as well as
CD271+ cells with the red fluorescent lipophilic tracer PKH26 (both Sigma-Aldrich, Saint Louis, MO, USA).
Additionally, both cell types were stained for nuclei discrimination with Hoechst 33324 (Thermo Fisher).
Acquisition and analyzes were performed using the Axiovert 40 CFL fluorescence microscope with Axio
Cam MRm ZEN software (both Carl Zeiss AG).
2.7. Immunofluorescence Staining within 3D Matrix
Mouse anti-human-CD29 allophycocyanin as well as -CD73-phycoerythrin antibodies (both BD
Biosciences) were diluted with EGM-2 in 1:10 ratio and incubated with the cells for 30 min. Afterwards,
the assays were washed with EGM-2. For each marker an isotype control was applied in the same
way in order to obtain a negative control. Additionally, both cell types were stained with Hoechst
33324. The analysis was performed by means of the Zeiss high-resolution microscope ELYRA PS.1
LSM 780 confocal imaging system and corresponding Zen2011 software Z-stack images were used for
3D reconstructions.
2.8. Gene Expression Analysis by Quantitative Real-Time-PCR
Cells derived from the single and co-culture models were collected after the termination of
the angiogenesis assay and have undergone lysis in TRIzol® reagent (Thermo Fisher). RNA was
extracted following the manufacturer’s instructions. For reverse transcription of total RNA amount
(2 μg) and cDNA synthesis, SuperScript® III Reverse Transcriptase (Thermo Fisher) and oligo (dT)15
Primers (Promega, Fitchburg, WI, USA) were used. Quantitative real time-PCR was performed
with StepOnePlusTM Real-Time PCR System (Applied Biosystems, Waltham, MA, USA) in TaqMan®
Universal Master Mix (Thermo Fisher) according to the instructions of the manufacturer. The expression
of the housekeeping gene ribosomal protein, large, P0 (human RPLP0, TaqManTM VIC® Endogenous
Control 4310879E) was used on each cell type. Similarly, human ACTA (alpha smooth muscle actin)
(TaqMan® Assay ID: Hs00909449_m1, FAM-MGB), NGFR (nerve growth factor receptor) (TaqMan®
Assay ID: Hs00609976_m1, FAM-MGB) and vWF (von Willebrand factor) (TaqMan® Assay ID:
Hs01109446_m1, FAM-MGB, all Thermo Fisher) were analyzed in duplicates and normalized to
RPLP0. Negative controls were included in each assay. Cycle thresholds (CT) for single reactions were
determined with StepOne™ Software 2.0 (formula: ΔCT mean = CT mean − CT mean RPLP0).
2.9. Animals
All animal procedures were in conformity with the guidelines from Directive 2010/63/EU of the
European Parliament on the protection of animals used for scientific purposes. The federal animal care
committee of LALLF Mecklenburg-Vorpommern (Germany) approved the study protocol (approval number
LALLF M-V/TSD/7221.3-1.1-088/11). Severe Combined Immunodeficiency beige mice (SCID beige; strain
CB17.Cg-PrkdcscidLystbg-J/Crl, female, 22 ± 2 g, Charles River, Sulzfeld, Germany) were randomly assigned to
4 groups: Healthy control (SHAM, n = 3), two MI groups with implanted human stem cells of the respective
source (MI133, MI271 each n = 3) and untreated MI control group (MIC n = 3).
2.10. Generation of Reperfused MI in Mice and Stem Cell Implantation
Mice were anesthetized with 50mg/kg Pentobarbital (Vetmedica GmbH, Ingelheim, Germany)
intraperitoneal injection. After thoracotomy and preparation, the left anterior descending coronary
artery (LAD) was ligated. After 45 min each mouse received an intramyocardial cell injection. For cell
treatment, 100,000 stem cells were suspended in 10 μL PBS containing 0.5% BSA and 2 mM EDTA and
mixed with an equal amount of reduced growth-factor BD MatrigelTM Matrix. The same experimental
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set-up was applied to control groups using cell suspension buffer and MatrigelTM for application.
Four injections, 5 μL each were given along the border of the blanched myocardium. Subsequently,
the ligation was removed. Healthy control (SHAM)-operated mice underwent identical surgical
procedures without left anterior descending coronary artery (LAD)-ligation.
2.11. Organ Harvesting
Mice underwent euthanization 48 h after intervention by cervical dislocation. Each heart was
removed, embedded in O.C.T.TM Compound (Sakura Finetek, Alphen aan den Rijn, Nederlands)
and snap-frozen in liquid nitrogen. For further examinations of the infarction area [13] and RT-PCR,
the heart tissue was divided into four horizontal levels from the apex to the base and cut into slices.
2.12. Immunofluorescence Staining within Tissue Sections
For immunofluorescence staining slices of cryosectioned hearts were fixed with 4% paraformaldehyde
(Sigma Aldrich) for 20 min at room temperature following treatment with M.O.M.TM Mouse Ig
Blocking Reagent and M.O.M.TM protein concentrate according to the instructions of Vector® M.O.M.TM
Immunodetection Kit (LINARIS GmbH, Mannheim, Germany). To identify human cells, monoclonal
anti-human-nuclei (Merck Millipore, Darmstadt, Germany) primary antibody as first and anti-mouse
Alexa-Fluor® 594 as secondary antibody was used. Nuclei were stained with DAPI and the tissue was
mounted using coverslip and Dako mounting medium (Dako, Santa Clara, CA, USA).
2.13. Gene Expression Analysis by RT2 Profiler PCR Array
Interlayers of the cryosectioned hearts were used for RNA-isolation, which was performed with
TRIzol® reagent. Reverse transcription as well as PCR were performed using RT2 Profiler PCR
Array Mouse Angiogenesis® kit (Qiagen, Germantown, MD, USA). According to the instructions of
the manufacturer an RT2 SYBR Green ROX qPCR Mastermix (Qiagen) was used. The expression of
the housekeeping genes ActB, B2M, GAPDH, GUSB, and HSP90AB1 as well as the gene panel were
analyzed in triplicates and normalized to the mean of all the housekeeping genes. No genomic DNA
was found in the samples. Moreover, we observed no apparent inhibition by any impurities that affect
the reverse transcription as well as the amplification of the gene-specific products.
2.14. Statistical Analysis
Statistical analysis was performed using SigmaStat (Version 3.5, Systat Software, San Jose, CA, USA)
and IBM SPSS Statistics for Windows (Version 22.0., IBM Corp., Armonk, NY, USA). Comparisons of
two experimental groups were performed using Mann–Whitney U test, when data were not normally
distributed (Shapiro–Wilk’s test) otherwise Student t-test was utilized. p values ≤0.05 were considered
as statistically significant.
3. Results
3.1. Immunomagnetic Separation of CD133+ and CD271+ Cells from BM
In order to optimize the procedure of cell isolation it had to be determined which impact the dual
isolation strategy has on the cell product quality. Therefore, the CD133+ population was isolated from
the CD271– fraction as well as vice versa. Thus, the quality of the cell populations resulting from
the isolation was compared with each other. The average volume achieved by BM aspiration was
approximately 53.8 mL. By the use of the manual immunomagnetic cell separation 150 × 106 MNC
were isolated on average. From these a mean of 0.42 × 106 viable CD133+ and 0.29 × 106 viable CD271+
cells were separated (Figure 1A). Furthermore, analysis revealed that the amount of CD133+ as well
as CD271+ cells showed a linear dependence on the initial amount of MNC that has been used for
isolation (Figure 1B).
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Figure 1. Quality of the immunomagnetic cell separation of CD271+ and CD133+ cells from fresh bone
marrow (BM). Mean cell numbers of mononuclear cells (MNC), CD133+, and CD271+ cells achieved by
magnet activated cell sorting (MACS) direct cell isolation (A). Linear dependence of CD133+ as well as
CD271+ cell numbers on the initial amount of MNC (linear regression plots: RCD133 = 0.821; RCD271 =
0.689; B). The percentage of the CD133/CD271 double-positive cells determined within the different
populations MNC, CD133+, as well as CD271+ cells using flow cytometry (C).
3.2. Flow Cytometric Characterization of Stem Cell Populations, Quality, and Storage
Furthermore, we have examined whether CD133+ and CD271+ cells form separate populations
within BM or if the surface proteins are also expressed simultaneously by an overlap population, which is
an important aspect in order to evaluate the feasibility of a combined therapeutic approach. Taking into
account that the majority of CD133+ cells express CD34+, MACS-purified CD133+ cells were co-stained
with CD34 antibody [14,15]. Moreover, the CD271+ population was co-stained for CD45 for further
distinguishing of the MSC subpopulation lacking the CD45 surface marker [16]. As demonstrated below,
0.04 ± 0.01% of BM-MNC co-expressed CD133 and CD271. This subpopulation represents 2.21 ± 0.43%
of total CD133+ stem cells and 4.65 ± 1.68% of total CD271+ stem cells (Figure 1C). As another aspect
of cell isolation, the impact of the dual isolation strategy was investigated. Therefore, the CD133+
population was isolated from the CD271− fraction and vice versa. The respective comparisons of the
qualities between the obtained subpopulations were conducted. We found that 1.14 ± 0.50% of the
isolated CD133+ population were positive for CD271, and 3.00 ± 0.99% of the isolated CD271+ cells
were also positive for CD133. At this point, no indication that the order of isolation has a negative or
significant influence on the quality or cell number was detected.
Additionally, the impact of the storage on the cell quality versus the quality of the fresh samples
was examined. In the clinical scenario, the BM samples reach the laboratory depending on the time
the heart surgery is performed, which cannot always be predicted precisely. Considering the fact that
one single MACS-isolation takes around five hours, the possibility of sample storage would make
experimental work much easier and effective. Furthermore, it is unavoidable that the cells undergo
storage for at least several hours due to processing and transportation. This applies for storage of BM
intended for mono-cell type isolation as well as for negative fractions assigned for dual isolations.
We could find that overnight storage of the initial material at 4 ◦C had no significant negative influence
on numbers or quality of the target cells resulting from the isolation (Table 1).
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Table 1. Influence of the storage (4 ◦C) and order of the isolation during the dual isolation of CD133+
or CD271+ cells on their cell numbers and quality. Single MACS isolations of CD133+ or CD271+ cells
were utilized on fresh (I) or stored (II) BM samples. For dual isolations, respective negative fractions
(III or IV) were stored and respective target isolations (CD133+ or CD271+) were conducted after
overnight storage.
CD133+ Stem Cells CD271+ Stem Cells
Count Purity Viability Count Purity Viability
×106 n [%] n [%] n ×106 n [%] n [%] n
Single isolation
I. Fresh BM 0.299 19 83.422 10 94.123 10 0.112 8 76.435 7 58.753 7
II. Storage BM 0.506 8 85.401 6 93.272 6 0.482 4 82.148 4 89.509 4
Dual isolation
III. Storage CD133– fraction 0.338 5 73.213 3 82.895 3 0.203 4 47.500 2 77.290 2
IV. Storage CD271– fraction 0.137 7 88.292 3 96.182 3 0.170 7 88.430 6 89.824 6
3.3. In Vitro Network Formation
In order to investigate to what extend the stem cells build networks of endothelial cells and
thus to evaluate their angiogenic capabilities, the isolated fractions of CD133+ and CD271+ cells were
cultivated in Matrigel and EGM-2. Matrigel was used to create a complex extracellular environment
with structural proteins like laminin, entactin, and collagen which resembles natural conditions. For the
purpose of stimulating the cell growth and endothelial differentiation EGM-2 was used as an endothelial
growth medium (Figure 2A). Each patient’s CD133+ and CD271+ cells were seeded separately in order
to compare their tendency to build network structures. Additionally, one assay consisting of both
cell types in equal amounts was created with the aim of investigating whether they influence each
other and alter the network formation. All assays contained cells of one patient only. The angiogenesis
assays were analyzed according to the criteria of network length and count of nodal points using
two-dimensional transversal slice images of the three-dimensional assay (Figure 2B) as well as in regard
with levels of the gene expression for ActA, NGFR, and vWF. This allowed representative analysis
of the structures (Figure 2C). The CD271+ cells formed well-defined, 3D networks within Matrigel
matrix, whereas CD133+ cells only have formed minimal networks in three out of six experiments
at all. The assays consisting of CD133+/CD271+ cells in co-culture also showed well-defined, 3D
networks. CD271+ cells generated networks with mean lengths of 81.20 ± 86.02 mm, combined
CD133+/CD271+ cell culture assays formed networks with 60.35 ± 44.81 mm in length, and CD133+
cells only formed 1.5 ± 4.74 mm of such network structure. Thus, in terms of network length CD271+
alone and assays of the co-culture consisting of CD133+/CD271+ cells were both significant compared
to CD133+ cells alone. Moreover, networks formed by CD133+/CD271+ cells in co-culture contained
the highest number of nodal points (893.2 ± 838.4), which revealed as significant when compared to
CD133+ cells alone (18.1 ± 75.4). The amount of nodal points built in CD271+ cell networks regarded
also as significant in comparison with those formed in CD133+ cell assay (639.9 ± 901 vs. 18.1 ± 75.4,
respectively). A quantitative mRNA-expression analysis demonstrated a 10-fold higher level of the
Actin assembly-inducing protein ActA in CD133+ cell monoculture compared to CD271+ cell influenced
assays (Figure 2D). No differences were observed between CD271+ and CD133+/CD271+ cell assays
for ActA, the NGFR as well as the angiogenic marker vWF genes expression (Figure 2E).
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Figure 2. In vitro angiogenesis assay. Schematic illustration of the network formation assay within
the Matrigel for testing of the angiogenesis potential (A). In contrast to CD133+ cells, a significant
formation of network length and highest number of nodal points in the network of CD271+ cells as well
as CD133+/CD271+ cell co-culture were observed (B). Representative phase contrast z-stack images of
the mono- and co-culture assays (C). CD133+ cell culture in Matrigel led to a 10-fold higher level of
ActA gene in comparison to CD133+/271+ cell co-culture (D). No differences were observed between
CD271+ and CD133+/271+ cell culture assays for ActA, NGFR, and vWF gene expression (E). Mean ±
SD; * p ≤ 0.015 vs. CD133, Mann–Whitney U test.
3.4. Identification of Stem Cell Phenotype
In order to further investigate the cell networks accomplished in Matrigel, respective
immunohistochemical analysis was carried out. Therefor cells were labelled with different fluorescent
dyes, allowing the structures to become more perceptible and differentiable. In this regard, the assays
containing both cell types in co-culture were of particular interest. By using different dyes for the stem
cell subpopulations the staining should reveal whether both cell types take part in building the network
structures and to which extent. The CD133+ and CD271+ cells have been labelled with CFDA-SE
and PKH 26, respectively. Both fluorescent dyes could be detected within the network structures.
Figure 3A shows a colocalization of CFDA labelled CD133+ cells and PKH26 labelled CD271+ cells
at nodal points of the CD133+/CD271+ cell co-culture angiogenesis assay but no connections were
observed within the CD133+ mono cell assay. Of note, the true CFDA-SE fluorescent signals come
from inside of the cellular extensions (Figure 3B) although CD133+ cell monocultures built minimal
networks. In turn, it demonstrates that CD133+ cells form networks when cultured with CD271+ cells.
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To obtain information on the stem cell differentiation degree and phenotypic fate within the network,
differences in the extent and distributions of the subpopulations in those assays have been tested.
At this, the cells were positive for CD29 (Figure 3C). The same applies to the staining of CD271+ cell
culture with CD73 (Figure 3D). Conversely, the staining with CD271 antibody and its isotype control
were both negative. Based on these results, the CD133+/CD271+ cell co-culture network showed
CD73 expression (Figure 3E). Additionally, no signals for CD73 were detectable in assays lacking
network formation.
Figure 3. Representative images illustrate cellular interactions within the network structure.
Colocalization of CFDA-SE labelled CD133+ cells (green) and PKH26-labelled CD271+ cells (red)
at nodal points of the CD133+/CD271+ cell co-culture angiogenesis assay but with very rare or no
connections of CD133+ cell culture were observed (A). Although CD133+ cell cultures built minimal
networks and true CFDA-SE fluorescent signal originate inside the network structures (B). 3D-image
of a vital mesenchymal cell network was taken 2 weeks after seeding (C). CD271+ cell (D) as well as
CD133+/CD271+ cell co-culture (E) angiogenesis assays were stained with CD73-PE antibody (red) and
counterstained for nuclei with Hoechst dye (blue).
3.5. In Vivo Angiogenic Benefit
Currently, animal experiments are necessary to evaluate the effects of stem cell therapies on the
infarcted hearts. The complex pathophysiological processes have to be taken into account, as the
intact circulation, vegetative nervous system, and cellular interactions of the entire organism are
essential to guarantee reliable scientific results. By the use of a small animal model, applied stem cells
were investigated regarding their capability to differentiate as well as which gene expression patterns
were associated. For quantitative assessment of the angiogenic benefit we performed Real-Time-PCR
assays using the RT2 Profiler PCR Array Mouse Angiogenesis® kit. The ΔΔCT method was used to
calculate fold-differences in target gens compared to the SHAM operation. Following CD133+ cell
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treatment (MI133) we observed a significant lower expression of the inflammatory cytokine TIE1
(Tyrosine kinase with immunoglobulin-like and EGF-like domains) and fibrotic marker TGFβ3 and
a significant improvement of the pro-angiogenic factors such as CXCL1 and CXCL2 compared to MIC
as well as MI271 group (Figure 4A). After CD271+ cell treatment we found a lower expression of the
inflammatory cytokines IL1β, IL6, CCL11, and TIMP1 in contrast to a significant increase after CD133+
stem cell treatment versus MIC and the angiogenic factor VEGFC (vascular endothelial growth factor)
was significantly improved compared to MI133 (Figure 4B). We were able to find the transplanted
human cells 48 h after transplantation at the border of the infarct (Figure 4C).
Figure 4. Angiogenic benefit 48 h after myocardial infarction (MI). Data show a significant lower
expression of fibrotic markers as well as significant improvement of pro angiogenic factors after
CD133+ cell treatment compared to MIC as well as MI271 group (A). Lower expression of inflammatory
cytokines after CD271+ stem cell treatment in contrast to significantly increase after CD133+ stem
cell treatment as well as significantly improvement of the pro angiogenic factor VEGFC (vascular
endothelial growth factor) after CD271+ cell treatment. (B). Mean ± SD normalized to SHAM operation;
* p ≤ 0.05 vs. MIC; # p ≤ 0.05 vs. MI271 (t-test). Representative images of CD271+ cell derivatives
illustrate the engrafted human stem cells 48 h post transplantation (C).
4. Discussion
Our present study predominantly relied on investigation of angiogenic capabilities of primed
human CD133+ and CD271+ BM derived stem cells alone and in a co-culture in vitro as well as in mice
using combined cell transplantation post MI. Recently, we already have demonstrated the beneficial
therapy when a single administration of stem cells was applied [13].
First, we were able to achieve suitable isolation protocols and storage parameters. The results
from the manual immuno-magnetic cell separation in combination with flow cytometric analysis
revealed relatively few CD133+ and CD271+ cells within BM. Moreover, a linear dependence between
target stem cells and the initial amount of MNC has been found (Figure 1B). However, the initial cell
numbers and percentages differed eminently within the patient’s cohort [17,18].
Whether CD133 and CD271 are separate subsets or co-expression exists, is an important aspect in
order to evaluate the feasibility of a combined therapeutic approach. In conclusion, CD133+ CD271+
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double-positive cells are represented at a higher proportion within the CD133+ as well as the CD271+
cells than within the total MNC fraction (Figure 1C). Nevertheless, only a small percentage of isolated
cells express both surface markers. During magnetic cell separation no selective enrichment or
depletion of double or single positive cells took place. Therefore, the separation of the two populations
is considered to be sufficient for this study and the investigation of their separate and combined effects.
In clinical setting, autologous stem cells may be transplanted 24 to 30 h after BM aspiration [19].
A recent study by our laboratory closely investigated the impact of short-term storage on human
CD133+ cells. At this, we used standardized non-freezing storage conditions even for up to 72 h.
We have shown that cell number as well as metabolic activity decreased after 30 h, although no
significant alterations were observed in cell viability at this point over the time. In line with that,
also present results do not indicate a negative influence of storage on cell numbers or quality (Table 1).
This applies to storage of BM as well as for negative fractions intended for dual isolation.
In the present study, we have characterized the phenotype of both stem cells types. The flow
cytometric strategy relied on our previous work [13,15]. Cultivated MSC are often characterized by the
expression of several surface marker including CD73, CD105, and CD44 as well as the absence of others,
including CD45 and CD34 [2,13]. In our analysis the expression of CD73 and CD105 was significantly
increased on CD271+ cells compared to remaining BM subtypes. We have already detected a favorable
survival pattern, improved healing performance, and a more robust preservation of cardiac function for
CD105+ cells in infarcted hearts [20]. Therefore, the increased expression of CD105 on the CD271+ cell
population can be expected to have a positive influence on the angiogenic potential. Whereas most of
cultivated MSC do not express CD45, the largest proportion of freshly isolated CD271+ cells expressed
CD45dim - a surface marker that has been correlated to mesenchymal colony formation by Cuthbert
and coworkers [16]. The percentage of CD45- cells was small and showed considerable fluctuations
between patients. In conclusion, the most frequent population in purified CD271+ cells presumably
consists of mesenchymal progenitors [13]. Of note, as our recent flow cytometric observation revealed,
the same CD271+ MSC used for the present study have undergone phenotypic alterations toward
a pericytic phenotype [13]. This is in agreement with the observation by Kutcher and coworkers and
Bellagamba and associates [21,22].
Proliferative capacity of MSC is associated with their clonogenic properties. In accordance
with Quirici and coworkers [10], colony-formation was only detected in MNC and CD271+ fraction,
but neither in CD271– nor in CD133+ population [13]. The ability to proliferate is a major contributor
to the impacts and effectiveness of stem cells in clinical applications. This applies to various functions
such as differentiation into specialized mature cells as well as self-renewal or angiogenic processes.
Although CD133+ HSC do not show colony formation in CFU-F assays, they have been demonstrated
to proliferate and generate offspring with endothelial characteristics in CFU-EC assays [19]. CFU-EC
acquire the functional phenotype of EC and also show typical gene expression including vWF [19]
and angiogenic factors such as FGF3, PDGFB, and others [23]. Furthermore, we detected a significant
augmentation of EC-colonies after hypoxic preconditioning of CD133+ cells and thus assumed that
hypoxia may lead to the differentiation of CD133+ cells towards endothelial lineage [23]. Our results
indicate that in vitro network formation relies on CD271+ cells. Since CD133+ cells alone rarely build
network structures at all, it is remarkable that they will nevertheless contribute to the network, if they
are cultivated in combination with CD271+ cells (Figure 2). The fluorescence images provided evidence
for this contribution as both fluorescent signals were detected from within the networks (Figure 3).
Noteworthy, we previously observed similar network formation also in co-culture when primed cardiac
CD45- CD44+ DDR2+ MSC from MI-induced rats were setup together with endothelial cells [24].
Immunoflorescence staining indicated a strong expression of CD73 marker within the networks built by
CD271+ as well as CD133+/CD271+ cells of the angiogenesis assays. CD73 is often referred to us the MSC
phenotype [25,26]. CD133+ cell networks also expressed CD73 whereas the maker was not detected on
CD133+ cells that did not form network structures. For this study the involvement of the marker in
angiogenic processes is of particular importance. At this, CD73 does not only seem to be associated with
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cells that are involved in angiogenesis, but appears to play a crucial role in the process itself. A study
by Wang and associates found that capillary-like structures were formed more in CD73+/+ pulmonary
microvascular endothelial cells (PMEC) than in CD73−/− PMEC in vitro. In accordance with that they
also observed that the extent of tumor angiogenesis as well as the tumor size was greater in CD73+/+
mice compared to CD73−/− mice in vivo. Furthermore, CD73 expression decreased the adhesion of EC
to collagen IV and promoted migration. Thus, they concluded that CD73 contributes to EC forming new
vessels especially in cancer conditions [27]. A study by Allard and associates demonstrated that both
tumor and host-derived CD73 are involved in these processes. In fact, tumor-derived CD73 enhances
the production of vascular endothelial growth factor (VEGF) by tumor cells whereas host-derived
CD73 is required for in vivo angiogenic responses. Furthermore, they also confirmed that EC require
CD73 expression for tube formation and migration [28]. Consequently, measures against CD73 have
been shown to impair angiogenesis in tumors [28,29]. However, Böring and associates stated that CD73
deficiency has no effect on angiogenesis in their mice model of hind limb ischemia [30]. Thus, it is
not certain if the angiogenic effect applies on tumor tissue only and might be different in non-tumor
environment. The increased expression of CD73 especially on CD271+ cells may have positive impact
on the angiogenic potential of the stem cell treatment. We were able to show that CD271 network
structures express ActA and thus a marker for muscular differentiation. This expression was 10 fold
higher in assays consisting of CD133+ cell cultures (Figure 2D). To simulate network formation in vitro,
we used Matrigel as a 3D framework. Interestingly the CD133+ cell culture in Matrigel led to a 10-fold
higher level of ActA (α-SMA) gene in comparison to the CD133+/271+ cell co-culture. However, Lu and
associates observed that following culture in endothelial cell-promoting environment CD133+ cells
did not produce endothelial-like cells that expressed α-SMA, but only HUVEC and CD34+ progenitor
cells [31]. As we have already shown recently, flow cytometric analysis of the CD133+ cell product
isolated from sternal BM (similar patient’s disease baseline as in the present study) was characterized
by the co-expression of approx. 80% of CD34 marker [15]. Therefore, detected ActA mRNA levels in
our CD133+ cell angiogenesis assay seem to be reasonable. Interestingly, CD133+ αSMA+ phenotype
was found only in association with blood vessels of cancer-associated fibroblasts [32], confirming the
linkage of α-SMA expression to endothelial-like origin and cell activation. Furthermore, the possible
reason of less or comparable ActaA mRNA levels with a CD271+ cell culture for the CD133+/CD271+
cell co-culture might be explained by the phenotypical alterations of CD133+ hematopoietic stem
cells when applied together with MSC and/or due to the maintained undifferentiated state of MSC in
co-culture model [33,34]. Hence, these in vitro co-culture conditions may have a reducing effect on the
α-SMA mRNA levels in total.
Moreover, we examined mRNA expression profiles using the infarcted area of heart cross sections.
In line with recent observations of the proliferative capacities and induction of regenerative pathways,
demonstrated by our group [24], the present study focused on testing of possible angiogenic potential in
the early phase post MI. On the one hand in a murine model, the switch between the early inflammatory
and the proliferative phase eventuate 2-4 days after MI [35]. At the same time, neovascularization of
surrounding, viable myocardium in the infarct border zone is also crucial during this process of tissue
remodeling, although angiogenesis occurs in the granulation tissue that will ultimately form the infarct
scar [36]. On the other hand, a complete engraftment and no significant differences in the retention of
both cell subsets were evident in the hearts 48 h following MI as shown in our own previous work [13].
Indeed, in a recent long term study using the identical human stem cell types as well as the identical
mouse model we did observe functional improvement [13].
Recently, we could show the co-localization of CD133+ cell derivatives with functional blood
vessels 3 weeks post transplantation. This direct impact of CD133+ stem cells on angiogenesis was
not detected for CD271+ cells, suggesting different cellular mechanisms for cardiac regeneration [13].
Coherently, indications of the present study 48 h after MI reveal positive effects of the stem cell
therapy regarding angiogenesis. The expression of the pro-angiogenic cytokines Cxcl1 and Cxcl2
has been significantly increased in the CD133+ cell treated animal group, whereas the MI271 group
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showed less expression (Figure 4A). However, the same applies to the expression of IL1B and IL6
as well as Timp1 [37] (Figure 4B). Al-Amran and co-workers demonstrated that down-regulation
of Cxcl2 results in decrement in myocardial neutrophil infiltration, which is associated with less
reactive oxygen species and reactive nitrogen species formation after global ischemia reperfusion
apoptosis [38]. Therefore, we assume, that CD133+ cell therapy may have a valuable impact on
a moderate course of the neutrophil-mediated tissue injury [39], although, we only could observe
a significant lower TGFβ3 mRNA level of this fibrotic marker in MI133 therapy group when compared
with MI271 [40]. Our long term follow up experiments revealed unanticipated data. Subsequently,
both cell therapy groups led to a decreased collagen deposition at the infarction border as well as
improved vessel infiltration of scar tissue compared to the MIC group [13,40–42]. Again, these data
show possible different cellular mechanisms for angiogenic effects mediated via CD133+ vs. CD271+.
Furthermore, many existing in vitro studies confirmed the involvement of TGFβ in the activation of
cardiac fibroblasts. Nevertheless, the in vivo functioning has not completely been explained because
of the complexity and the context-dependent signaling cascades [40]. Interestingly, mRNA levels for
pro-inflammatory interleukins (see above) within MI133 therapy group were significantly enhanced,
while TGFβ3 levels were rather reduced. Since IL-6 bears pleiotropic properties, a possible switch
from pro- into anti-inflammatory or even immunomodulatory signaling cascades, would be in favor
for a respective therapy. Importantly, it has been shown, that both IL-6 with TGFβ play a crucial role in
the shift between inhibitory Tregs and pro-inflammatory Th17 cells and this is associated with their
ratio at all [43].
Finally, we have observed significantly increased mRNA levels of the pro angiogenic factor
VEGFC after CD271+ stem cell treatment compared to MI133 group (Figure 4B). It is known that
MSC promotes angiogenesis by releasing VEGF [44–46]. Accordingly, Liu and associates observed
enhanced cardiac function, increased perfusion and angiogenesis in vivo using MSC as a VEGF delivery
system [47]. Collectively, analysis of hearts of the MI271 therapy in the early ischemic phase revealed
rather immunomodulatory fate of CD271+ stem cells.
5. Limitations
It must be stated that the present study and the generated data rely on a relatively small sample
size. Thereby, sternal bone marrow for the present study was obtained from patients with CABG
surgery. In general, we were able to perform standard quality control experiments at a high sample
size (Sections 3.1 and 3.2). However, downstream use of these samples served to address various
related projects, resulting in a limited sample size for the respective specific experiments.
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Abstract: Heart diseases such as myocardial infarction and myocardial ischemia are paroxysmal and
fatal in clinical practice. Cardiomyocytes (CMs) differentiated from human pluripotent stem cells
provide a promising approach to myocardium regeneration therapy. Identifying the maturity level of
human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) is currently the main challenge for
pathophysiology and therapeutics. In this review, we describe current maturity indicators for cardiac
microtissue and microdevice cultivation technologies that accelerate cardiac maturation. It may
provide insights into regenerative medicine, drug cardiotoxicity testing, and preclinical safety testing.
Keywords: human pluripotent stem cell; cardiomyocytes; ventricular; cardiac tissue engineering;
maturation
1. Introduction
It is well-acknowledged that significant differences in hearts exist between human and model
organisms. These morphological and physiological differences can lead to complex problems, such as
low pathological reproducibility in clinical practice [1]. On the other hand, human pluripotent stem
cells (hPSCs), including human embryonic stem cells (hESCs) and human-induced pluripotent stem
cells (hiPSCs), benefitting from the property of indefinite proliferation in vitro and the capacity to
differentiate into different types of somatic cells, are a promising tool in biomedical applications.
Compared with the transdifferentiation of human somatic cells, the differentiation of hPSCs seems to
be more efficient in terms of productivity, safety, and cost. The rapid development of hPSC research
in the past few decades has made it possible to utilize hPSC-derived cardiomyocytes in large-scale
cardiac tissue engineering directly.
Several effective protocols have been successfully developed to induce hPSCs to become
cardiomyocytes. Embryoid body (EB) was first used in the differentiation of cardiomyocytes from
hESCs and hiPSCs; however, its effectiveness and reproducibility were found to be problematic because
of serum quality instabilities and heterogeneous EB sizes [2]. Differentiation protocols developed using
serum-free and compound-defined media were subsequently used and improved the efficiency and
reproducibility of cardiomyocytes generated from EBs. Engineering approaches to the production
of homogeneous EBs emerged several years ago [3,4]. This method produced more homogenously
sized EBs compared with conventional methods that used 96-well plates, and it was also appropriate
to scale-up. Because of the limitations of EB protocols, monolayer three-dimensional (3D) approaches
have drawn increasing attention over the past several years. Uniform hESC colonies were plated on
Matrigel via a microcontact approach and the size range was optimized for maximizing mesoderm
formation and cardiac induction. The method of activation of canonical Wnt signaling by the glycogen
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synthase kinase-3 (GSK-3) inhibitor (CHIR99021) followed by inhibition of Wnt signaling via Inhibitor
of Wnt Production 2 (IWP2) or Inhibitor of Wnt Production 4 (IWP4) were found to be sufficient to
produce numerous functional cardiomyocytes from multiple human pluripotent stem cell lines in two
weeks without exogenous growth factors or genetic manipulation in adherent culture or suspension
culture system [5–7]. Paul et al. designed a cardiomyocytes differentiation strategy by using a medium
including three components: RPMI-1640, L-ascorbic acid 2-phosphate, and rice-derived recombinant
human albumin [8]. It is essential for cardiac development in vitro through an appropriate addition of
different growth factors, including fibroblast growth factor-2 (FGF-2), transforming growth factor-β
(TGF-β), superfamily growth factors activin A, bone morphogenetic protein-4 (BMP-4), vascular
endothelial growth factor (VEGF), and dickkopf WNT signaling pathway inhibitor 1 (DKK-1). All of
these factors were found to assist human pluripotent stem cells generate myocardial precursor cells
and cardiomyocytes when added in order [9].
In clinical practice, patient-derived hiPSC-CMs are an optimal disease model for personalized
medicine involving inherited cardiac diseases and stem cell therapies to repair or replace injured
heart tissues. hiPSC-CMs can be used to model several heart diseases, including Duchenne
muscular dystrophy [10], Leopard syndrome [11], long QT syndrome [12], Timothy syndrome [13],
Fabry disease [14], Danon disease [15], and familial hypertrophic cardiomyopathy [16]. In addition,
hiPSC-CMs from mitochondrial cardiomyopathy of Barth syndrome (BTHS) have been used to
generate a platform for pathogenesis and medical therapeutics. This cardiomyopathy model shows
irregular sarcomeres, abnormal myocardial contraction, and defective heart function; more importantly,
it mimics mitochondrial functional impairment caused by a mature cardiolipin defect [17]. Masahide
et al. constructed a Torsade de Pointes (TdP) arrhythmias model from hiPSCs to mimic a patient’s
disease condition and provide a chance to study the mechanisms of TdP generation and develop an
anti-arrhythmias drug test [18]. Overexpression of CDK1, CDK4, cyclin B1, and cyclin D1 efficiently
induced cell cycle progress in at least 15% of post-mitotic murine and human cardiomyocytes [19].
Nutlin-3a can selectively activate the p53 signaling pathway and induce cell apoptosis of DNA-damaged
iPSCs except for DNA-damage-free cells. These iPSC-CMs were engrafted into an ischemic mouse
heart to enhance mouse cardiac beating [20]. This technology may bring about potential benefits for
patients with a cardiac disease in clinical medicine.
However, evidence indicates that cardiomyocytes differentiated by these approaches are not as
mature as an adult phenotype, thus they may not be able to reflect the physiological response of the
adult heart accurately. In addition, with respect to cardiac tissue engineering, cardiomyocytes that
more closely resemble those of the native myocardium would contribute more to myocardial repair.
For example, as cardiovascular diseases predominantly occur in elderly humans, immature hPSC-CMs
may cause modeling to be imprecise and futile [21]. In this review, we discuss the state of current
approaches to obtaining more mature cardiomyocytes.
2. Characteristics of Mature and Immature Cardiomyocytes
The maturation level of human cardiomyocytes is crucial to clinical therapy. Immature
cardiomyocytes fail to maintain full cardiac function and may lead to an aberrant remodeling of cardiac
wall and cardiomyocyte hypertrophy because of differences in cell size, myofibrillar switch, conduction
velocity, metabolism, and calcium handling between the two statuses. Table 1 briefly summarizes some
typical physiological and chemical differences between mature human cardiomyocytes and immature
hPSC-CMs and provides criteria for defining mature cardiomyocytes [22–25]. For a review of the
details, we refer the reader to the work of Xiulang Yang et al. [23].
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Table 1. Distinctions between mature human cardiomyocytes (CMs) and immature CMs.
Mature CMs Immature CMs
Structure
Structure Rod-shaped Round and irregular
Alignment Orderly Disorderly
Nucleation 20–30% binuclear or polynuclear Slightly binuclear
Beating Quiescent Spontaneous
Length–width ratio 5–10:1 1–3:1
Sarcomere banding Z discs, I band, H band, A band, M band Z discs, I band
Sarcomere length 2.2 μm 1.6 μm
Troponin
cTnT, high β-MHC/α-MHC, high
MLC2v/MLC2a, high cTnI/fetal ssTnI,
Titin isoform N2B, ADRA1A
cTnT, low β-MHC/α-MHC,
nondeterministic MLC2v/MLC2a,
low cTnI/fetal ssTnI, Titin isoform
N2BA
SRP High CSQ, PLN, RYR2, SERCA/ATP2A2 Low CSQ, PLN, RYR2,SERCA/ATP2A2
T-tubules Present Not present
Mitochondria Regularly distributed; 20–40% of cellvolume Irregularly distributed; paucity
LGJ Intercalated discs Circumferential
Biochemistry Metabolism Fatty acid β-oxidative Glycolysis and lactate
Biophysical Force 40–80 mN/mm
2 for muscle lines
μN range for a single cell
0.08-4 mN/mm2 for 3D cultivation
nN range for a single cell
Electrophysiology
Capacitance 150 pF 10–30 pF
RMP −80 to −90 mV −20 to −60 mV
Upstroke velocity 100–300 V/s 10–50 V/s
Conduction velocity 60 cm/s 10–20 cm/s
APA 100–110 mV 70–120 mV
cTnT, Cardiac troponin T2; β-MHC, Myosin heavy β chain; MLC2v, Myosin light chain 2 ventricular isoform;
MLC2a, Myosin light chain 2 atrial isoform; ADRA1A, Adrenoceptor α1A; cTnI, Cardiac troponin I3; CSQ,
Calsequestrin; PLN, Phospholamban; RYR2, Ryanodine receptor 2; SERCA/ATP2A2, Sarco/endoplasmic reticulum
calcium transport ATPases; SRP, Sarcoplasmic Reticulum Proteins; T-tubule, Transverse tubule; RMP, Resting
Membrane Potential; LGJ, Location of Gap Junctions; APA, Action Potential Amplitude.
3. Approaches to Obtaining Mature Cardiomyocytes
In order to obtain more mature and functional hPSC-CMs, the provision of a similar physiological
microenvironment in the process of cardiomyocyte development may be a feasible adult direction.
In recent years, academics have performed various experiments to stimulate cardiomyocyte maturity,
including biophysical, biochemical, electrophysiological, and mechanical experiments.
3.1. Biophysical and Biochemical Factors
Several practicable methods have been used to promote the maturation of cardiomyocytes,
including long-term cultivation, a specified material, a three-dimensional culture, a microfluidic
system, a co-culture with other cells following transplantation to model organisms, a dynamic
sustainability system, drugs, and metabolic regulation.
Long-term cultivation and stiff matrix have been shown to enhance human pluripotent
stem cell-derived cardiomyocyte sarcomere formation, calcium handling, and ion channel protein
expression [26,27]. Collagen-coated polyacrylamide gels with an elastic moduli of 10 kPa have been
shown to lead to aligned sarcomeres in comparison with a stiffer substrate [28]. Mihic et al. generated
human-engineered cardiac tissues from hESC-CMs in a large gelatin. Human-engineered cardiac
tissues were subjected to a cyclic stretch and their cell size increased, their Z discs were organized, and
the Connexin-43 expression increased significantly [29]. Biohybrids of collagen and pristine graphene
increased the metabolic activity of human pluripotent stem cell-derived cardiomyocytes and enhanced
sarcomere structures [30].
Three-dimensional (3D) culture systems can mimic the native cardiomyocyte microenvironment
in vivo to support the maturation of cardiomyocytes. Tulloch et al. generated 3D human-engineered
cardiac tissues from hPSC-CMs in collagen that was seeded into a channel with a silicon floor plus
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nylon mesh anchors. After seven days, myofibril and Z-disc alignment increased [31]. Lee et al. used
3D bio-print collagen to obtain a human heart tissue model that possessed synchronized contraction
and directional action potential propagation [32]. hESC-CMs in 3D patches exhibited more mature
characteristics, including significantly faster conduction velocities and longer sarcomeres as compared
with two-dimensional (2D) monolayers. The conduction velocities of these cardiac patches increased
significantly as the purity of the cardiomyocytes increased [33]. Human cardiac muscle patches
transplanted into swine were shown to prominently improve left ventricular function and myocardial
stress, promote myocardial hypertrophy, and reduce myocardial apoptosis [34]. It was shown that a
3D culture suppressed smooth muscle -actin content and increased the expression of several cardiac
markers [35].
Microfluidic systems can be used to study disease and organoid models. In recent years,
combinations of microfluidic systems and functional human myocardium have been developed for
drug cardiotoxicity testing [36]. Flow culture systems provide continuous gas and nutrient exchange
to induce cardiomyocyte maturation. Dynamic cultures result in an enhancement in sarcomeric
protein expression, an increase in size, augmentation of the contraction force, and a higher conduction
velocity [37].
In addition, mixtures of human primary or human-induced pluripotent stem cell-derived
cardiomyocytes (hiPSC-CMs), fibroblasts, and endothelial cells have been used to obtain vascularized
functional myocardium. This improvement has allowed us to introduce blood flow into cardiomyocyte
cultivation systems and paves the way to cardiomyocyte metabolism and maturation [38]. Human
cardiomyocyte patches, through several types of cells derived from hPSCs, were shown to enhance the
capacity for excitation contraction coupling, calcium handling, and force generation. Moreover,
Johannes and co-workers found that co-transplantation of hESC-derived epicardial cells and
cardiomyocytes could double the cardiomyocyte proliferation and augmented angiogenesis between
the graft and the host simultaneously [39]. Triiodothyronine is essential to myosin heavy chains (MHCs)
and Titin isoform switchover in normal cardiac development. Addition of triiodothyronine was shown
to compel immature cardiomyocytes to show several maturation characteristics [40]. The co-inhibition
of HIF1 (hypoxia-inducible factor 1) and lactate dehydrogenase A promoted the function maturation of
hPSC-CM as mitochondria prefer to conduct oxidative phosphorylation rather than aerobic glycolysis
and resulted in sarcomere length increase and contraction stress enhance [41].
These biophysical and biomedical approaches promote the growth and proliferation of immature
cardiomyocytes and the formation of adult-like cardiac tissue with an organized ultrastructure, longer
sarcomeres, more intensively developed mitochondria, more T-tubules, a more mature oxidative
metabolism, and more rapid calcium handling.
3.2. Electrophysiological Stimulation
The spontaneous beating of cardiomyocytes is directly regulated by the cells of atrio-ventricular
nodes in vivo. A combination of 3D cultivation with 6 Hz of electrophysiological stimulation
was shown to markedly increase myofibril ultrastructural organization and cardiomyocyte size,
elevate the conduction velocity, and improve both electrophysiological and calcium ion handling in
hPSC-CMs [42]. Electrophysiological stimulation of 2 Hz was used to culture hESC-CMs in a 3D
matrix, and significant improvements in contraction and calcium handling were obtained [43]. Chiu
et al. found that an electrical field with a symmetric biphasic square and strengths of 2–5 V/cm at
a frequency of 1 Hz could enhance the hallmarks of cardiomyocyte maturation in vitro [44]. Thus,
the maturation process of cardiomyocytes in vitro progresses more quickly when accompanied by
optimized electrophysiological stimulation.
More and more researchers are becoming aware of the fact that electrophysiological stimulation
can promote the maturation of hPSC-CMs. However, it remains hard to compare the results from
different assays as a universal and gold standard is currently lacking. Besides this, it is obvious
that diverse electric field intensities and stimulation frequencies, hPSC cell types, and cultivation
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conditions can lead to differences in the maturation of cardiomyocytes. Thus, there may be benefits to
establish a compatible platform to assess the maturation process, and make comparisons in different
stimulation models.
3.3. Mechanical Stress
Functional cardiomyocytes are linked to varieties of cells and structure in vivo. These structures
provide the cells with anchors to contract and contribute to physiological hypertrophy. Mechanical
loading may be the efficient factor with the most potential when considering the explosion of research
in this area in recent years. Mechanical stress increases cells’ size and improves the contraction
force that is associated with hypertrophic growth. Jianzhong et al. devised a system for assembling
muscle-powered microdevices based on precise manipulation of materials to monitor muscle tissue
function [45]. Furthermore, periodic stretching of hPSC-CMs in a 3D structure mixture was shown to
cause faster force production, higher calcium influxes, an increased expression of β-MHC and cTnT [35].
Schmelter et al. demonstrated that cyclic mechanical stretching activated the Reactive Oxygen Species
(ROS) signaling pathway and enhanced the differentiation of ESCs into cardiomyocytes [46]. Ronaldson
et al. formed cardiac grafts from early stage iPSC-derived cardiomyocytes and trained them via cyclic
mechanical stress for several weeks. After one month, the grafted cardiomyocytes showed adult-like
gene expression profiles, increased sarcomere length, enhanced density of mitochondria, the presence
of T-tubules, metabolism switch, and functional calcium handling [47]. Table 2 summarizes some
typical engineered approaches to the maturation of human and rodent cardiomyocytes.
Table 2. Different methods for maturing cardiomyocytes.
Stimuluses Cultured Cell Types Maturation Conditions Reference
Electric stimulation
Hes3 hESCs
After 4 days of culturing in the presence of
electric field stimulation (a 6.6 V/cm, 1 Hz, and
2 ms pulse), hESC-CM elongation and
troponin-T enhancement.
[48]
Hes2 and Hes3 hESCs
and CDI-MRB
HR-I-2Cr-2R hiPSCs
Biowires increased myofibril ultrastructural
organization, elevated conduction velocity,




C25 hiPSCs 2 Hz in the first week and 1.5 Hz thereafter,developed 1.5-fold contractile forces. [49]
hiPSC-CMs
(ReproCardio 2)
Efficient electrical stimulations were formed by
a hydrogel-based microchamber with organic
electrodes. The large interfacial capacitance of




Neonatal Rat Heart Cells
Engineered heart muscle was subjected to
electric stimulation at 0, 2, 4, or 6 Hz for 5 days
and engineered flexible poles facilitated
auxotonic contractions by straining.





After the first contraction was observed, tissue
was immediately subjected to 21 days of
increasingly intense electromechanical strain.
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Table 2. Cont.
Stimuluses Cultured Cell Types Maturation Conditions Reference
Mechanical loading
HES2 hESCs
Cyclical stretching produced Cardiac troponin
T elevation, cell elongation, and an increase in
gap junction.
[29]
IMR90 ESCs and IBJ
hiPSCs
Compared to a 2D culture, a 3D environment
increased the number of cardiomyocytes and
decreased the number of smooth muscles. With
cyclic stress, expression of several cardiac
markers increased, including β-myosin heavy
chains and cardiac troponin T.
[35]
Mechanical loading and
vascular co-culture H7 hESCs
Cyclic stress enhanced cardiomyocyte
hypertrophy and proliferation rates
significantly and endothelial cells showed the
formation of vessel-like structures.
[31]
Textile based-culturing UTA.04602 hiPSC
Gelatin-coated polyethylene
terephthalate-based textiles were used as the
culturing surface. hiPSC-CMs showed
improved structural properties.
[53]
Substrate stiffness Neonatal Rat VentricularMyocytes
Substrates of varying elastic moduli were
fabricated. Cardiomyocytes matured on 10 kPa
gels were similar to the native myocardium and
generated a greater mechanical force and the
largest calcium transients.
[28]
Mechanical loading can improve the rate of maturation of hPSC-CMs and contractile properties.
All these characteristics reflect the state of maturity of these cells. However, there is little published
data about the real-time monitoring of cardiomyocyte development; to date, the shortage of clinical
feedback has slowed its application.
4. Conclusions
In this review, we summarized the approaches that have been adopted to improve the maturity
of hPSC-CMs under different conditions. Human embryonic cardiac development and postnatal
physiological hypertrophy processes are difficult to study because of species specificity and the lack of
availability of human heart tissues. Mature hPSC-CMs may reflect the pathological state in adults
more accurately and serve as preferential disease models for clinical use.
With the rapid development in this multidisciplinary field, our understanding of the maturation
of human cardiomyocytes has been growing in recent years. Many studies on the maturation of
cardiomyocytes have been published in multiple journals in the last decade. Some methods have been
applied to successfully produce adult-like cardiomyocytes with respect to the biochemical indicators;
however, the remaining methods still need improvement. Current hurdles include achieving adult-like
cardiomyocytes with angiogenesis and organized, mixed assemblies of multi-layer 3D heart tissues.
A real-time assessment system is required to compare different approaches and obtain an optimized
maturation status in hPSC-CMs. Besides this, in order to monitor feedback from cell and tissue signals,
we may need an electrophysiological surveillance system that can regulate the differentiation and
maturation of cardiomyocytes in real time in clinical practices. A mature and functional human
cardiac model in vitro could play a role in myocardial tissue development research, cardiotoxicity
drug screening, and clinical therapies.
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Abstract: Multipotent adult mesenchymal stromal cells (MSCs) could represent an elegant source for
the generation of patient-specific cardiomyocytes needed for regenerative medicine, cardiovascular
research, and pharmacological studies. However, the differentiation of adult MSC into a cardiac
lineage is challenging compared to embryonic stem cells or induced pluripotent stem cells. Here we
used non-integrative methods, including microRNA and mRNA, for cardiac reprogramming of adult
MSC derived from bone marrow, dental follicle, and adipose tissue. We found that MSC derived from
adipose tissue can partly be reprogrammed into the cardiac lineage by transient overexpression of
GATA4, TBX5, MEF2C, and MESP1, while cells isolated from bone marrow, and dental follicle exhibit
only weak reprogramming efficiency. qRT-PCR and transcriptomic analysis revealed activation of a
cardiac-specific gene program and up-regulation of genes known to promote cardiac development.
Although we did not observe the formation of fully mature cardiomyocytes, our data suggests
that adult MSC have the capability to acquire a cardiac-like phenotype when treated with mRNA
coding for transcription factors that regulate heart development. Yet, further optimization of the
reprogramming process is mandatory to increase the reprogramming efficiency.
Keywords: mesenchymal stromal cells (MSC); mRNA; miRNA; cardiac reprogramming; cardiac
differentiation
1. Introduction
Mesenchymal stromal cells (MSC) represent a multipotent cell population capable to differentiate
into different cell types [1]. They are an easily-accessible cell source as they can be isolated at high
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yields from various kinds of human tissue, such as umbilical cord, bone marrow, dental pulp, adipose
tissue, placenta, etc. [1]. The common mesenchymal cell types that emanate from MSC are osteocytes,
chondrocytes, and adipocytes [2]. Due to their plasticity, MSC are considered as one of the most
important cell types for the application in regenerative medicine as demonstrated by a huge number
of pre-clinical studies and several clinical trials [3,4]. In addition, MSC mediate immunomodulatory
and immunosuppressive effects that promote wound healing and tissue repair, while showing no
teratoma formation post transplantation [5]. Nowadays, it is commonly accepted that the observed
therapeutic impact induced by MSCs is mainly based on the secretion of paracrine factors rather than
on the differentiation into cardiomyocytes.
In recent years, MSC have also been utilized for the generation of mesenchymal as well as
non-mesenchymal cell lineages, including neuron-like, hepatocyte-like, and cardiac-like cells [6–10].
Despite these promising results, the differentiation of human MSC into fully mature cardiomyocytes
bearing all their respective phenotypical and functional characteristics is difficult [11–15]. As MSC
are located in various tissues, they represent a heterogeneous progenitor cell population dependent
on the tissue source and the individual donor [16]. This heterogeneity could explain the variety
in differentiation characteristics [17–19]. Therefore, it remains to be investigated which type of
MSC favorably undergoes cardiac trans-differentiation, thus, is a suitable candidate for cardiac
reprogramming strategies. Detailed knowledge about the cardiac differentiation potential of specific
MSC populations is even more important as some studies showed enhanced therapeutic effects
following cardiovascular lineage commitment of MSC [12].
The development of an approach to efficiently control the cardiac differentiation of MSC would be a
crucial step for the production of patient-derived cardiomyocytes without any ethical concerns. As such,
they can also serve as a model system, beneficial for basic cardiovascular research, drug screening,
and translational applications. Currently, several re/programming strategies exist to guide the
mesenchymal and non-mesenchymal differentiation of MSC, such as treatment with small molecules
and cytokines, exposure to metabolic stress, co-culture experiments, or overexpression of regulatory
proteins [20–24]. For the potential clinical use, transient, non-integrative reprogramming approaches
are preferred to prevent permanent alterations of the genome and to reduce tumorigenic risk.
Small non-coding RNAs, like microRNAs (miRNA) and chemically modified messenger RNA (mRNAs)
allow the manipulation of cell behavior for a limited period of time, e.g., triggering (trans)-differentiation
by activation of lineage-specific molecular pathways. Some studies have already shown that alteration
of gene expression using selected miRNAs can induce cardiac differentiation of MSC to a small
extent [15,25,26], while data about mRNA-based cardiac reprogramming is still lacking.
Unlike multipotent MSCs, pluripotent stem cells (PSCs) have been demonstrated to efficiently
differentiate into cardiomyocytes, characterized by a profound sarcomere organization and spontaneous
beating behavior [27]. Yet, these PSC-derived cardiomyocytes typically still represent an immature cell
type, resembling a neonatal cell stage rather than an adult phenotype [28,29]. The common cardiac
programming approaches used to guide cardiac differentiation of PSCs mainly relies on the application
of cytokines and small molecules [30,31]. However, PSCs bear tumorigenic risk due to genome
modification (induced pluripotent stem cells, iPSC) and provoke ethical concerns (embryonic stem
cells, ESC). Therefore, increasing the efficiency of cardiac programming of MSC would be beneficial for
cardiovascular research, including their therapeutic use.
Here, we examined whether MSC derived from different sources, including bone marrow (BM),
dental follicle and subcutaneous adipose tissue can be driven towards a cardiac lineage using a transient
reprogramming strategy based on miRNA and mRNA transfection. According to our results, adipose
tissue-derived MSC (adMSC) were found to be the most susceptible cell type for this reprogramming
approach, as shown by enhanced expression of cardiac markers. At the same time, we observed the
activation of transcriptome pathways involved in cardiac development following mRNA treatment.
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2. Material and Methods
2.1. Cell Culture
BM-derived MSC (BM MSC) were obtained by sternal aspiration from donors undergone coronary
bypass graft surgery. Anticoagulation was achieved by heparinization with 250 i.E./mL sodium heparin
(Ratiopharm, Ulm, Germany). Mononuclear cells were isolated by density gradient centrifugation
on 1077 Lymphocyte Separation Medium (LSM; PAA Laboratories, Pasching, Germany). MSC were
enriched by plastic adherence and sub-cultured in MSC basal medium supplemented with SingleQuot
(all Lonza, Cologne, Germany) and 1% Zellshield (Biochrom, Berlin, Germany).
Isolation of adMSC was performed by liposuction of healthy individuals. The extracted tissue was
treated with collagenase for 30 min, followed by several filtrations and washing steps. The detailed
process of adMSC isolation has been already described previously [32].
Dental follicle stem cells (DFSCs) were isolated from dental follicles of extracted wisdom teeth
before tooth eruption. Following tooth removal, the follicle was removed and subjected to enzymatic
treatment as presented earlier [33]. Upon tissue digestion, cells were seeded on tissue flasks and
obtained by plastic adherence. DFSCs were maintained in DMEM-F12 (Thermo Fisher, Waltham, USA)
supplemented with 10% FCS and 1% Zellshield.
All three types of stromal cells were maintained at 37 ◦C and 5% CO2 humidified atmosphere.
Medium was changed every 2–3 days. Sub-cultivation was performed when cells reached a confluency
of ~80–90%.
All donors have given their written consent for the donation of their tissue according to the
Declaration of Helsinki. The study was approved by the ethical committee of the Medical Faculty of
the University of Rostock (registration number: bone marrow A2010-23; renewal in 2015; adipose
tissue: A2013-0112, renewal in 2019, dental tissue: A 2017-0158).
2.2. Fluorescence-Activated Cell Sorting
The expression of cell surface markers was quantified by flow cytometric analysis. Stromal cells
were labelled with antibodies CD29-APC, CD44-PerCP-Cy5.5, CD45-V500, CD73-PE, CD117-PE-Cy7,
PerCP-Cy5.5 CD90 (BD Biosciences, San Jose, USA), and CD105-AlexaFluor488 (AbD Serotec, Oxford,
UK). Respective isotype antibodies served as negative controls. A measurement of 3 × 104 events was
carried out using BD FACS LSRII flow cytometer (BD Biosciences).
To evaluate miRNA and mRNA uptake efficiency, cells were treated with different amounts
of Cy3-labeled Pre-miRNA Negative Control #1 (AM17120, Thermo Fisher) or GFP-mRNA (Trilink,
San Diego, USA) and analyzed by flow cytometry 24 h post transfection. To detect cytotoxicity,
cells were labelled with Near-IR LIVE/DEAD fixable dead cell stain kit (Molecular Probes, Eugene,
USA). Analysis of flow cytometry data, including gating, was conducted with the FACSDiva software,
Version 8. (Becton Dickinson).
2.3. Cardiac Reprogramming
For cardiac reprogramming, 1 × 105 cells/well were seeded on 0.1% gelatin-coated 6 well
plates and cultured to 80% confluency. We transfected 40 pmol of each miRNA (Pre-miR™ hsa-miR-1,
Pre-miR™hsa-miR-499a-5p, Pre-miR™hsa-miR-208a-3p, Pre-miR™hsa-miR-133a-3p, all Thermo Fisher)
with Lipofectamine® 2000 according to the manufacturer’s instructions (Thermo Fisher). Transfection
of custom-made mRNA (Trilink) was performed with Viromer Red® transfection reagent (Lipocalyx,
Halle, Germany). Cells were either transfected with 2 μg MESP1 or with a combination of 1 μg GATA4,
1 μg MEF2C and 1 μg TBX5. One day after transfection of miRNA or mRNA, cells were subjected to
two different medium conditions. For cardiac induction medium I (card ind. I), cells were incubated in
RPMI, supplemented with B27 without insulin (Thermo fisher) for 7 days, followed by incubation
in RPMI containing B27 +insulin/- vitamin A (Thermo Fisher) for another 21 days. Additionally,
culture medium was supplemented with ascorbic acid (Sigma Aldrich, St. Louis, USA) and Wnt
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pathway targeting small molecules, including 6 μM CHIR99021 (days 1–2), and 5 μM IWP-2 (days
4–5) (both Stemcell Technologies). For cardiac induction II (card ind II), a commercially available
cardiomyocyte differentiation kit was used according to the instructions given by the manufacturer
(Thermo Fisher, A2921201).
2.4. IF Staining and Calcium Imaging
To verify multipotency, BM-MSC, DFSC and adMSC were subjected to in vitro differentiation
towards osteogenic, chondrogenic and adipogenic lineages using the Mesenchymal Stem Cell Functional
Identification Kit (R & D). Differentiation was induced by maintaining cells under different culture
conditions according to the manufacturer instructions for 20 days. Subsequently, cells were fluorescently
labelled to detect fatty acid-binding protein 4 (FABP4), Aggrecan and Osteocalcin to visualize successful
differentiation into adipocytes, chondrocytes, and osteocytes.
For labelling of cardiac markers, cells were seeded on coverslips and fixed with 4% PFA. Antibody
staining was performed as described elsewhere [34]. Cells were labelled with anti sarcomeric α-actinin
(abcam, ab9465), anti-NKX2.5 (Santa Cruz, sc-8697), anti-TBX5 (abcam, ab137833) and anti-MEF2C
(Santa Cruz, sc-313).
To visualize intracellular calcium, cells were cultured on 8 well chamberslides (Ibidi). Three days
after seeding, cells were incubated with the calcium sensitive dye Cal520 (AATBioquest) for one hour
at 37 ◦C and subjected to fluorescence microscopy. All fluorescence images were acquired using Zeiss
ELYRA LSM 780 (Zeiss, Oberkochen, Germany).
2.5. RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction
Isolation of cellular RNA was performed using the NucleoSpin® RNA isolation kit (Macherey-
Nagel, Düren, Germany) according to the manufacturer instructions. The concentration and purity
of isolated RNA was assessed with NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific).
Subsequently, cDNA synthesis was performed with a High-Capacity cDNA Reverse Transcription
Kit (Thermo Fisher Scientific). The reverse transcription reaction was conducted using the MJ Mini™
thermal cycler (Bio-Rad).
Quantitative real-time PCR for cardiac marker genes was carried out using the StepOnePlus™
Real-Time PCR System (Applied Biosystems, Foster City, USA) with following reaction parameters
(StepOne™ Software Version 2, Applied Biosystems, Germany): start at 50 ◦C for 2 min, initial
denaturation at 95 ◦C for 10 min, denaturation at 95 ◦C for 15 s and annealing/elongation at 60 ◦C
for 1 min with 40 cycles. A qPCR reaction contained: TaqMan® Universal PCR Master Mix (Thermo
Fisher), respective TaqMan® Gene Expression Assay, UltraPure™ DNase/RNase-Free Distilled Water
(Thermo Fisher), and 30 ng of the respective cDNA. The following target gene assays were used:
ACTN2 (Hs00153809_m1); MYH6 (Hs01101425_m1) TBX5 (Hs00361155_m1); TNNI3 (Hs00165957_m1),
GJA1 (Hs00748445_s1); HPRT (HS01003267_m1) (all Thermo Fisher). Obtained CT values were
normalized to HPRT and data were calculated as fold-change expression, related to untreated
control cells.
2.6. Microarray Analysis
RNA integrity was analyzed using the Agilent Bioanalyzer 2100 with the RNA Pico chip kit
(Agilent Technologies). 200 ng of isolated RNAs were subjected to microarray hybridization as
described in [35]. Hybridization was performed on Affymetrix ClariomTM D Arrays according to the
manufacturer’s instructions (Thermo Fisher).
Analysis of the microarray data was conducted with the provided Transcriptome Analysis Console
Software from Thermo Fisher (Version 4.0.1, Waltham, USA). The analysis included quality control,
data normalization, and statistical testing for differential expression (Limma). Transcripts were
considered as significantly differentially expressed with a fold change (FC) higher than 2 or smaller
−2, false discovery rate (FDR) < 0.05, and p < 0.05. The pathway analyses were conducted based
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on a gene set enrichment analysis using Fisher’s Exact Test (GSEA) on the Wiki-Pathways database.
Only significant pathways have been selected.
2.7. Statistical Analysis
Data are presented as mean ± SEM, obtained from three patients for each MSC type. Preparation
of graphs and statistical analysis was performed using SIGMA Plot software (Systat Software GmbH,
Erkrath, Germany). Statistical significance was considered as * p ≤ 0.5, ** p ≤ 0.05, *** p ≤ 0.001.
3. Results
3.1. Characterization of Isolated MSC
Initially, we performed flow cytometric analysis to investigate the presence of common
mesenchymal surface markers in isolated MSC. The obtained data indicated a high expression
of CD29, CD44, CD73, CD105 and CD90, while very low levels were detected for CD117 and CD45,
indicating that stem cells possess properties of MSC (Figure 1A,B).
Figure 1. Phenotype-related and functional characterization of mesenchymal stromal cells (MSC): (A)
Flow cytometric measurements revealed a high expression of common MSC surface markers (CD29,
CD44, CD73, CD90, CD105), while very low levels were found for hematopoietic surface markers
(CD45 and CD117). Representative flow cytometry charts of adipose tissue-derived MSC (adMSC)
demonstrate the expression level of surface markers. Blue histograms represent measurement of CD
surface marker with corresponding isotype control, shown in red. (B) Tri-lineage differentiation assay
indicated adipogenic, osteogenic, and chondrogenic differentiation of MSC. Detection of adipocytes was
performed by labelling of FABP4, while osteocytes and chondrocytes were identified by fluorescence
staining of osteocalcein and aggrecan, respectively. Scale bar: 50 μm. Results in (A) are shown as mean
± SEM, obtained by analysis of three different donors for each MSC cell type.
MSC characteristics were further confirmed by a functional assay that demonstrated the
multilineage differentiation capability of all three cell types. Upon incubation in lineage-specific
induction medium, the cells were capable to differentiate into adipocytes, chondrocytes, and osteocytes,
as shown by fluorescence labelling of specific differentiation markers (Figure 1B). As expected,
adMSC were found to profoundly express FABP4, if compared to osteocalcin and aggrecan labelling.
In contrast, DFSCs favored chondrogenic differentiation indicated by strong fluorescence intensity of
aggrecan staining.
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Next, we compared the different MSC by analyzing their gene expression profiles using a
microarray platform. The obtained data allowed us to compare the transcription profile among both,
individual donors and MSC derived from different tissue. Boxplots of signal intensity distributions for
each performed microarray are shown in Figure 2, indicating good data quality prior (blue) and after
(red) normalization of the gene expression data (Figure 2A). A principal component analysis (PCA) was
performed to show the common clustering of the triplicates (Figure 2B, blue, red and purple) as well as
the differences of tested cell types, each represented by three different donors. We found that stromal
cells from BM, adipose, and dental tissue are clearly distinct with respect to their transcriptomic profile.
Interestingly, we detected a high donor-dependent variety of the gene expression for MSC derived
from human BM (Figure 2B), suggesting a potential donor-specific impact on the efficacy of cardiac
programming. A total of 1685 differentially expressed genes were detected, while 13 genes were shared
by all MSC populations (Figure 2C). Most differentially expressed transcripts (679) have been found
between MSCs obtained from BM and adipose tissue, suggesting a higher gene profile related diversity
within these two MSC populations (Figure 2D). A list of differentially expressed genes between all
MSC types is given in Table S1.
 
Figure 2. Comparative microarray analysis of undifferentiated dental follicle stem cells (DFSCs),
bone marrow (BM) MSC, and adMSC. (A) Comparison of signal intensity for .cel files (blue) and .chp
files (red) after normalization demonstrates sufficient data quality. (B) MSC from different sources are
clearly distinct in regard to their transcription profile. A high patient-dependent variety was found for
BM MSC, while adMSC and DFSCs demonstrate a more homogenous distribution. (C) Venn diagram
visualizes expressed genes overlapping between different MSC cell types. (D) The numbers of up- and
down-regulated transcripts is significantly differentially expressed in all three cell types.
3.2. Reprogramming of MSC Using miRNA and Cardiac Induction Cell Culture Conditions
In order to induce cardiac reprogramming, cells were cultured under two different medium
conditions (see Section 2.3), separately or in combination with myocardial miRNAs (myo-miRNAs),
that have been previously shown to induce cardiac differentiation in fibroblasts (miR-1, miR-499a,
miR-208a, and miR-133a) [36]. As the efficiency of miRNA-based reprogramming largely depends on
proper intracellular miRNA uptake, we evaluated miRNA transfection conditions using Cy3-labelled
miRNA. Depending on the amount of transfected miRNA, uptake efficiencies of ~80–95% were
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achieved in all three cell types tested (Figure 3A). Importantly, only minimal cytotoxic effects were
observed following transfection of miRNA (Figure 3B).
 
Figure 3. miRNA transfection and programming efficiency in MSC. (A) Uptake of miRNA was
determined using Cy3-labelled miRNA and flow cytometry. (B) Detection of dead cells revealed
low cytotoxicity induced by miRNA transfection. (C) Relative expression of cardiac marker genes
among all tested cell types, four weeks after transfection and cultivation under different culture
conditions. Reprogramming efficiency with cardiac induction medium I, II and myo-miRNAs (miR-1,
miR-499, miR-208, miR-133) resulted in an up-regulation of cardiac specific markers in all types of
MSC, while most profound up-regulation was found for cardiac induction medium II. Among tested
MSC, the strongest increase of cardiac gene expression was observed for adMSC. Note, no beneficial
effects on cardiac programming were observed following myo-miRNA transfection. Data are shown as
mean ± SEM, obtained from three donors for each MSC type. Statistical analysis was performed using
ANOVA test, followed by Bonferroni post-hoc analysis. * p ≤ 0.5, ** p ≤ 0.05, *** p ≤ 0.001.
The success of myo-miRNA-based cardiac reprogramming was determined by qRT-PCR analysis
of cardiac specific marker genes four weeks post transfection. Compared to control cells, cardiac
induction medium II was found to be the most effective treatment leading to an induction of α-actinin,
TBX5, GJA1, and cardiac Troponin I. While the level of α-actinin mRNA was strongly increased in all
three cell types, a less pronounced effect was observed for cardiac Troponin I (Figure 3C). Notably,
adMSCs showed the highest expression levels of cardiac marker genes after the treatment with
cardiac induction medium II, when compared to MSCs obtained from dental follicle as well as BM,
and therefore have been identified as the preferred candidate for our cardiac programming approach.
Surprisingly, our data also revealed that transfection with myo-miRNAs did not provoke an
additional, beneficial effect on the expression of cardiac markers. Likewise, the cardiac induction
medium containing RPMI and small molecules (Figure 3C, card induction I) did not promote the
cardiac differentiation of MSC.
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3.3. mRNA-Based Reprogramming of adMSC
As the transfection of miRNA did not further improve cardiac differentiation, we asked whether
the application of modified mRNAs might boost the reprogramming efficiency in adMSC, which had
been found to be the most promising cell type for the differentiation towards the cardiac lineage
(Figure 3).
For mRNA-based programming of adMSC, cells were either transfected with single MESP1 mRNA
or with a combination of GATA4, MEF2C, and TBX5 mRNA (GMT). First, mRNA transfection and
translation efficiency were determined with mRNA encoding GFP to evaluate the optimal amount
of mRNA showing strong expression while causing minimal cytotoxic effects. As demonstrated by
flow cytometry and fluorescence microscopy, approximately 80% of cells express the GFP protein 24 h
post transfection with 1 μg of mRNA (Figure 4A–C). Considering the increasing cytotoxicity when
higher amounts of mRNA are transfected, reprogramming experiments were performed with 1–2 μg
of individual mRNA (Figure 4D).
Analysis by qRT-PCR showed that both MESP1 and GMT transfection resulted in elevated levels
of selected cardiac marker genes, compared to untreated control cells (Figure 4E). The most prominent
incline of gene expression was observed for α-actinin, which was confirmed on the protein level by
immunostaining showing a faint signal in cells treated with MESP1 and GMT mRNAs (Figure 4F).
Additional antibody staining of early cardiac transcription factors demonstrated the expression of
MEF2C and NKX2.5 on the protein level in GMT treated cells (Figure 4G and Figure S1). Interestingly,
a profound increase of the expression level was also found for TBX5 that has been used for mRNA
transfection in the GMT-treated group, verified by fluorescence microscopy (Figure S1).
Moreover, we observed differences of the intracellular Ca2+ concentration between treated groups.
Following labelling of intracellular Ca2+, GMT transfected cells demonstrated a more intensive
fluorescence signal than observed for MESP1 treated cells and the control group (Figure S2).
To obtain a deeper understanding of the mRNA-induced effects on the gene expression profile of
treated adMSC, we conducted a microarray analysis of cells that underwent cardiac reprogramming.
The signal intensity values detected on each microarray had a similar spread after normalization,
indicating a well-suited data quality for further downstream data analysis (Figure 5A). The PCA plot
visualizes the differences in gene expression among treated groups, showing that control cells (blue)
share a high similarity regarding their transcription profile (Figure 5B). In contrast, reprogramming
with cardiac induction medium II (red), MESP1 (green), and GMT (purple) mRNA induced a
strong donor-dependent alteration of gene levels, however, the treatment specific groups remain
distinguishable from each other.
The numbers of significant total up-regulated and down-regulated transcripts are represented in
Figure 5C, indicating a distinct change of gene expression following cardiac reprogramming. The highest
number of genes differentially expressed was found in MESP1 (6669 transcripts) and GMT (5649) treated
cells. Interestingly, more transcripts are down-regulated than up-regulated in most of the comparisons.
The corresponding Venn diagram (Figure 5D) compares the significantly expressed genes of the
three different reprogramming approaches related to untreated control cells. The largest amount of
transcripts (2828 transcripts, 33.6%) was found to be commonly regulated by all three treatments.
The second largest proportion of differentially expressed genes is shared by GMT vs. Control and
MESP1 vs. Control (1816 transcripts, 21.6%). Notably, the largest unique set of transcripts was found in
cells transfected with MESP1 mRNA (1660 transcripts, 19.7%). A detailed comparison of up-regulated
(Figure 5E, red) and down-regulated (Figure 5E, green) genes among these three reprogrammed groups
indicates that the differences between MESP1 and GMT treatment vs. cardiac induction medium
II are more profound (189 up-regulated, 276 down-regulated transcripts), while MESP1 and GMT
only showed one differentially up-regulated transcript that was not previously up-regulated in other
comparisons (Figure 5E). A detailed list of differentially expressed genes found in all reprogrammed
groups is shown in in Table S1.
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Figure 4. mRNA-based cardiac programming of adMSC. (A) Concentration-dependent expression
of transfected mRNAs was evaluated with mRNA coding GFP. The quantative flow cytometry
analysis demonstrated maximum transfection efficiency of ~80% when ≤ 1000 ng mRNA were
applied. (B) Representative scatterplots of control cells (left) and cells transfected with GFP mRNA
(right). (C) Corresponding microscopy images of cells expressing GFP following mRNA treatment.
(D) Cytotoxic effects were only induced when mRNA amounts higher than 1000 ng were used for
transfection. (E) Compared to untreated control cells, higher gene expression levels of selected cardiac
markers were detected for all reprogramming conditions, in particular forα-actinin. (F) Immunolabeling
of cells using anti α-actinin antibody results in a faint fluorescence signal in cells transfected with MESP1
and GATA4, MEF2C, and TBX5 (GMT) mRNAs, Scale Bar: 25 μm. (G) Moreover, GMT treated cells
also demonstrated protein expression of MEF2C, an early cardiac transcription factor. Flow cytometry
and qRT-PCR data are shown as mean ± SEM, obtained from three different donors. Statistical analysis
was performed using one-way ANOVA. * p ≤ 0.5, ** p ≤ 0.05, *** p ≤ 0.001.
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Figure 5. Transcriptome based comparison of reprogrammed adMSC. (A) Quality control of microarray
data. Box plot of signal intensity of performed microarrays on .cel (blue) and .chp files normalization (red)
confirm good data quality. (B) Principal component analysis (PCA) demonstrates clustering of treated
groups, clearly showing the impact of respective reprogramming conditions on the transcriptomic
profile compared to control cells (blue). Yet, cells subjected to MESP1 (green), GMT (purple) or cardiac
induction medium II solely (red) remain distinguishable. (C) Up-and down-regulated transcripts and
corresponding Venn diagram (D) showing the impact of reprogrammed cells compared to control.
Most differentially expressed transcripts were regulated by all three reprogramming treatments (2828
genes), while 1816 transcripts are shared by GMT vs. control and MESP1 vs. control. (E) Detailed
comparison of common and distinct up-regulated (red) and down-regulated (green) transcripts among
the three reprogrammed groups. The differences found for optimized medium vs. MESP1 and GMT
transfections are much more prominent than the differences between MESP1 and GMT.
These data indicate a strong change of gene expression when cells are subjected to cardiac
induction medium II, with more distinct effects induced by mRNA transfections.
To evaluate the influence of the differentially expressed genes on important cardiac development
pathways, we integrated our microarray gene expression data into the WikiPathways database
and identified significantly enriched pathways for “heart development” (Figure 6A) and “cardiac
progenitor differentiation” (Figure 6B). The pathway visualization indicates proteins mainly involved in
cardiac development, while up-regulated and down-regulated transcripts of respective programming
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treatments are labelled in red and green, respectively. As shown in Figure 6, cardiac induction
medium II as well as mRNA programming by MESP1 and GMT influence the gene expression
profile of several key transcription factors and signaling molecules involved in cardiac differentiation,
such as IGF, VEGF, TBX5, GATA4 and HAND2 (Figure 6A,B). Most changes on pathway genes were
induced by GMT treatment (92%), followed by MESP1 (60%) and cardiac induction medium (52%).
Additional immunofluorescence labelling of GMT treated cells, confirmed the expression of early
cardiac transcription factors, including NKX2.5, TBX5 and MEF2C (Figure 4G and Figure S1)
 
Figure 6. The impact of reprogramming on cardiac-differentiation pathways. Up-regulated and
down-regulated transcripts of respective programming conditions are labelled in red or green color.
(A,B) Strongest up-regulation of transcripts involved in cardiac development ((A) heart development,
(B) cardiac progenitor differentiation) was mainly found in GMT reprogrammed cells, followed by
MESP1 treatment and cardiac induction medium II. Key cardiac transcription factors and signaling
molecules were significantly up-regulated, including TBX5, GATA4, MEF2C, HAND2, BMP4, and IGF.
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Taken together, the results obtained by microarray analysis clearly indicate that reprogramming
with cardiac induction medium II and mRNA induced a strong alteration of the transcription patterns
with high similarity in mRNA transfected cells compared to cells cultured in cardiac induction
medium solely.
4. Discussion
In vitro generated cardiomyocytes are an important tool for cardiovascular research, as they can
be utilized for disease modelling or for the development of drug screening assays to assess the cardiac
toxic risk of established or newly synthesized drugs [37–39]. Moreover, promising preclinical data
suggests the therapeutic potential of generated cardiomyocytes for the treatment of cardiac diseases to
overall improve heart regeneration and function [40,41]. Although several stem cell types are available
to produce cardiac cells, the ideal source of stem cells remains elusive as each has its own advantages
and drawbacks. Adult MSC can be easily isolated from human donors in large quantities, possess
immunomodulatory properties and can be propagated in vitro [12]. Further, they can overcome certain
limitations that have been attributed to PSCs, including ESC and iPSC. In contrast to ESC, MSC do not
provoke any ethical concerns [12,37,38]. Moreover, pre-clinical studies demonstrated a tumorigenic
potential of ESC and iPSC-derived cell products that has not been observed for MSC to date [42–45].
However, other pre-clinical and clinical trial data showed that the transplantation of iPSCs-derived
cardiomyocytes did not result in teratoma formation [46–48]. These different outcomes might be
associated with the transplantation of residual undifferentiated cells along with the PSC product that
increases the possibility of tumorigenesis. In this regard, the therapeutic use of PSC requires the
establishment of differentiation protocols allowing the generation of highly pure PSC-derived cell
types, e.g., cardiomyocytes [49]. The major advantage in comparison to adult stem cells is the cardiac
differentiation potential of ESCs and iPSCs. So far, PSC have been found to be the only stem cell type
capable to differentiate into functional, premature cardiomyocytes showing pronounced sarcomere
organization, contraction capacity, and subtype specific ion channel composition [50,51]. Thus, for the
generation of cardiomyocytes applied in regenerative medicine PSC are currently superior to MSC as
no efficient cardiac reprogramming strategies have been developed for adult stem cells yet.
The successful cardiac differentiation of human MSC into fully mature cardiomyocytes is by
far more challenging. Adult cardiomyocytes are characterized by a specific cell shape, structural
organization, ion channel composition and mechanical properties; important features that need to be
addressed when generating stem cell-derived cardiac cells [52]. Former reports led to contradictory
results about the programming efficiency of MSC. While some reports described spontaneous beating
associated with the formation of sarcomeric protein structures, other studies failed to generate
cardiac-like cells from adult MSC [53–57].
One reason for this might be attributed to the fact that MSC may represent a heterogeneous
stem cell population with different functional and phenotype-related properties as well as varying
therapeutic potential [58]. A notion that is supported by our microarray data, indicating a high
diversity of the expressed transcripts among MSC obtained from BM, dental pulp and adipose tissue
(Figure 2). Likewise, our functional data revealed cell type-dependent differentiation capacity of
tested MSC (Figure 1). Previous studies have also reported distinct characteristics between MSC
from different sources regarding surface marker expression, proliferation rate, and differentiation
potency [17,19,58,59]. For example, adMSC were observed to favor osteogenic differentiation and
demonstrate higher proliferation when compared with DSFCs [18,60]. Moreover, our results suggest
that these different biological characteristics of MSC could have an impact on the selected strategy
and efficiency of cardiac programming as adMSC demonstrated a more pronounced incline of cardiac
marker expression than BM MSC and DFSCs (Figure 3). In line with these data, Kakkar et al. recently
described human adMSC to be a better choice for cardiac programming using a combination of
small molecules and cytokines. Compared to BM MSC, adMSC exhibited a higher expression of
α-actinin, troponin and connexin43 following cardiac induction with 5-Azacytidine and TGF-β1 [61].
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Similarly, a comparative study revealed that adMSC expressed significantly more cardiomyocyte
specific biomarkers as DFSCs following cardiac programming with cytokine supplemented culture
medium [11]. The impact of MSC origin on programming capability was also shown for non-cardiac
cell lineages like hepatocytes and smooth muscle cells [59,62].
Myo-miRNA based programming has been successfully applied for the conversion of cardiac
fibroblasts, into cardiomyocytes [36]. For MSCs, cardiac induction by miRNA is less efficient as shown
by different groups [25,63,64]. For example, it was demonstrated that transfection with miRNA-1-2
promote the expression of GATA4, NKX2.5 and cardiac Troponin in BM MSCs [15]. Similarly, miR-149
and miR-1 were found to slightly trigger myocardial differentiation, albeit without formation of
sarcomere structures or beating activity [25,65]. We did not observe any additional effects on the
expression of selected cardiac marker genes following miRNA treatment. This might be attributed to
the fact that the miRNA concentrations used in this study are not sufficient to significantly increase the
expression level of cardiac-specific genes, although uptake efficiency for miRNA was about 80%. In this
regard, some studies have used viral vectors to ensure constitutive overexpression of miRNA [25,64].
Given that miRNAs have a very short half live, transient transfection approaches, as used in our study,
might be less effective.
Proper cardiac development requires the activation and inhibition of many different pathways
modulated by several transcription factors [66]. MESP1 was shown to drive cardiovascular fate
of stem cells during embryonic development, while the combination of GATA4, MEF2C and TBX5
was described to induce the cardiac differentiation of murine and human fibroblasts, leading to
spontaneously contracting cells with cardiomyocyte-like expression profile [67–70]. Therefore, we have
concluded that this approach might be applicable to reprogram human adMSC. Using an mRNA-based
setting we induced the overexpression of GATA4, MEF2C, and TBX5 as well as MESP1, which provoked
an incline of genes involved in cardiac differentiation (Figure 4). To our knowledge this combination of
transcription factors has not been applied before to induce cardiac differentiation of human adMSC.
In contrast to our strategy, most of the previous studies performed overexpression of transcription factors
by application of retro- or lentiviral systems. For example, in a study by Wystrychowski et al., adMSC
from cardiac tissue were treated with seven transcription factors, including GATA4, MEF2C, MESP1,
and TBX5, that resulted in an elevated number of cells positive forα-actinin and troponin [71]. However,
no clear sarcomere structures have been observed, suggesting a premature cardiac progenitor state.
Similarly, forced expression of another factor of the T-box family, TBX20, provokes an up-regulation of
sarcomeric proteins, without cardiomyocyte specific sarcomere organization [72]. These data are in
line with our observations as we could also detect a moderate signal for α-actinin, albeit without the
presence of sarcomere structures (Figure 4).
Yet, our programming approach leads to a strong induction of the key cardiac transcription
factors GATA4, MEF2C, MESP1 and TBX5, which corresponds to the transfected mRNAs used for
programming. However, it is known that mRNAs underlie fast turnover, suggesting that mRNA
transfection activated the expression of its endogenous counterparts [73,74]. At the same time,
the current study demonstrates that mRNA transfection boosts the cardiac programming effects
induced by culture conditions targeting important signaling pathways such as the WNT cascade.
The manipulation of signaling pathways by cytokines and small molecules is the most common
methodology to generate large amounts of PSC-derived functional cardiomyocytes [30,31]. In addition,
the overexpression of transcription factors, like Tbx3 and MESP1, can influence cell fate decision
in PSCs [75,76]. While these techniques allow highly efficient programming of ESCs and iPSCs,
we observed significantly less programming efficiency for MSCs in the current study. However,
the comparison of programming protocols used for PSCs and multipotent stem cells is difficult due
to their different developmental stages and resulting culture conditions prerequisites. Yet, it was
shown that cytokines like BMP4, IL and TGF improve cardiac development of human and non-human
MSCs [57,77]. However, the cardiomyocyte-like cells derived from these programmed MSCs lack
profound sarcomere formation, beating activity and physiological maturation [78,79]. This is in
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accordance to our data indicating that mRNA transfection could promote the expression of early
cardiac proteins, while differentiation efficiency and elaboration of a terminal cardiac phenotype is
profoundly limited when compared to PSC differentiation protocols [27,31].
Together with previous studies of adMSC overexpressing transcription factors, our results
demonstrate the feasibility of mRNA-based cardiac reprogramming of MSC. However, the absence of
sarcomere structures and spontaneous cell beating suggests a yet quite incomplete reprogramming,
leading to an immature cardiac cell type. Hence, there is an urgent need for further optimization.
Since mRNAs are degraded over time, multiple transfection steps might increase the reprogramming
efficiency, a strategy that is already applied for the generation of iPSCs from adult cells [74,80].
Moreover, proportions of GATA4, MEF2C, and TBX5 protein expression has been described to play a
crucial role for the quality of cardiac reprogramming [81], thus, different ratios of transfected mRNA
could positively influence the outcome of reprogrammed adMSC. This will have to be addressed in
future studies as the impact of mRNA ratios and mRNA concentration on cardiac programming might
be affected in a donor specific manner. Former data already demonstrated donor-to-donor variability of
MSC functional potential, including differentiation capacity [82,83]. Beside age and gender, underlying
diseases are known to influence cellular properties of MSCs [82]. This is supported by our microarray
results, showing a large variety of the transcription profile of BM MSCs that have been obtained
from patients suffering from cardiovascular diseases. On the contrary, adMSCs and DFSCs derived
from healthy donors shared similar transcription patterns, suggesting same programming conditions
required to induce cardiac development. Nevertheless, it is recommended to adapt mRNA conditions
for each individual patient to obtain maximum programming efficiency.
In addition, more comparative studies are required to identify and characterize MSC subtypes
most susceptible for specific transdifferentiation towards the respective desired target cells, including
non-mesodermal and mesodermal cell types such as cardiomyocytes.
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Abstract: Fabry disease (FD) is a rare inherited disorder characterized by a wide range of systemic
symptoms; it is particularly associated with cardiovascular and renal problems. Enzyme replacement
therapy and pharmacological chaperone migalastat are the only approved and effective treatment
strategies for FD patients. It is well documented that alpha-galactosidase A (GLA) enzyme activity
deficiency causes globotriaosylceramide (Gb3) accumulation, which plays a crucial role in the
etiology of FD. However, the detailed mechanisms remain unclear, and the lack of a reliable
and powerful disease model is an obstacle. In this study, we created such a model by using
CRISPR/Cas9-mediated editing of GLA gene to knockout its expression in human embryonic stem cells
(hESCs). The cardiomyocytes differentiated from these hESCs (GLA-null CMs) were characterized by
the accumulation of Gb3 and significant increases of cell surface area, the landmarks of FD-associated
cardiomyopathy. Furthermore, we used mass spectrometry to compare the proteomes of GLA-null
CMs and parental wild type CMs and found that the Rab GTPases involved in exocytotic vesicle release
were significantly downregulated. This caused impairment of autophagic flux and protein turnover,
resulting in an increase of reactive oxygen species and apoptosis. To summarize, we established a FD
model which can be used as a promising tool to study human hypertrophic cardiomyopathy in a
physiologically and pathologically relevant manner and to develop new therapies by targeting Rab
GTPases signaling-related exosomal vesicles transportation.
Keywords: Fabry disease; human embryonic stem cells; CRISPR/Cas9 genomic editing; Mass
spectrometry proteomic analysis; hypertrophic cardiomyopathy; disease model
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1. Introduction
Approximately 3–5% of inherited hypertrophic cardiomyopathies result from lysosome storage
disorders [1]. One of these cardiomyopathies is Fabry disease (FD), which is caused by
alpha-galactosidase A (GLA) deficiency leading to accumulation of globotriaosylceramide (Gb3)
in several tissues. FD is particularly manifested in renal and cardiovascular dysfunctions [2]. A number
of in vivo and in vitro studies revealed that the loss of GLA results in left ventricular hypertrophy
and develops into heart failure, myocardial infarction and life-threatening arrhythmias due to Gb3
deposition. The levels of Gb3 and its deacylated derivative, globotriaosylsphingosine (lyso-Gb3) in
plasma and tissues are used as diagnostic biomarkers of FD, and are applied for the screening/monitoring
of FD patients by liquid chromatography-tandem mass spectrometry (LC-MS/MS) [3–6]. However, the
limited sample volume and variable levels of lyso-Gb3 in different matrices makes the quantitation
very challenging [7]. Furthermore, the detailed mechanism of how Gb3 accumulation results in
hypertrophic cardiomyopathy still needs to be elucidated. In order to develop new therapeutic
strategies for FD-associated vasculopathy, it is essential to understand the underlying pathogenesis
mechanisms, as well as to discover the potential prognostic biomarkers.
Previously, we generated CRISPR/Cas9-edited GLA-null human HEK293 cells; however, this
cell line may not be an appropriate model with which to study pathological events occurring
in cardiomyocytes [8]. The pluripotent stem cells, including embryonic stem cells (ESCs) and
induced pluripotent cells (iPSCs), offer a great potential for modelling human diseases as they can
be differentiated into the tissue affected by the pathology. Although several FD-specific iPSC lines
have been obtained from patients carrying different GLA gene mutations, which claimed to be useful
for FD cardiomyopathy research [9,10], one major limitation of such approach is the influence of
variable genetic background, which can be significant even for monogenic, dominant and highly
penetrant disease in FD [11,12]. Currently, CRISPR/Cas9 emerges as a powerful genome editing
technique, providing the opportunity to efficiently delete genes to establish isogenic cells [13–15].
Therefore, our strategy in this study was to generate GLA knockout in human pluripotent stem cells by
CRISPR/Cas9-mediated gene editing, and compare them with the parental cells of the same genetic
background to study the mechanisms of FD-associated cardiomyopathy.
Recently, it became increasingly clear that lysosomal storage disorders have an impact on
autophagic dysfunction [16]. Dysregulated ceramide metabolism can trigger cytotoxic signaling
cascades, including apoptosis and necroptosis, missorting and accumulation of these sphingolipids
in the membrane subdomains may destabilize lipid bilayer and cause their permeabilization [17].
Exosomes are small vesicles secreted upon fusion of multivesicular endolysosomal compartments
with the plasma membrane and are derived from the intraluminal vesicles (ILVs) of those organelles.
Exosomes may participate in the control of cellular homeostasis by promoting the release of intracellular
harmful components, including proteins, lipids or nucleic acids. Emerging evidence from the studies
of normal development, as well as multiple disease studies, is beginning to reveal a coordinated
exosome–autophagy response that functions to maintain homeostasis through lysosomal degradation
and release of cellular cargo [18–20]. However, little effort has been made to investigate the impact of
autophagic dysfunction in FD on biogenesis and secretion of exosomes.
In the current study, we applied CRISPR/Cas9-mediated genomic editing to deplete GLA expression
in ESC-derived cardiomyocytes to recapitulate FD cardiac hypertrophy in vitro and performed
proteomic analysis by LC-MS/MS. We identified that Rab GTPase signaling-related vesicle secretion
is the factor that may initiate or exacerbate the development of FD-associated cardiomyopathy.
Such information will be extremely important for potential application in the prevention of and in
interventions for the adverse effects of the cardiac hypertrophy in FD patients.
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2. Materials and Methods
2.1. CRISPR/Cas9 Plasmid Construction and Transfection
The CRISPR/Cas9 with T2A-eGFP co-expression vector pSpCas9(BB)–2A-GFP (PX458) was a
gift from Feng Zhang (Addgene plasmid). The exon 1 of GLA was selected for guiding RNA design
and the sequence (5′-AGGAACCCAGAACTACATCT-3′) was cloned into PX458 (abbreviated as
GLA-Cas9-GFP) as previously described [8]. The GLA-specific targeting plasmid was transfected into
hESC line (WA09) by electroporation using Nucleofector System (Lonza, Basel, Switzerland) following
the manufacturer’s protocol. Briefly, hESC cells were cultured to 80–90% confluence, then harvested
and washed with PBS without Ca2+ and Mg2+. Approximately 4 × 105 cells were resuspended in
the pre-mixture solution with 2 μg GLA-Cas9-GFP plasmid, and the optimized protocol (program
B016) was used for electroporation. The cells were plated on Matrigel-coated 6-well plate in mTeSR1
medium containing 10 μM Y27632. 48 h later, the proportion of cells expressing EGFP was enriched
by flow cytometry using FACSCalibur (BD Biosciences, San Jose, CA, USA). Three days later, cells
were detached with TrypLE (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA), separated into
single cells and seeded with a density of 1 cell/well of a 96-well dish.
2.2. Analysis of CRISPR/Cas9-Induced Mutations in GLA Gene
To identify the presence of indels in GLA gene, the genomic DNA was extracted and used for
PCR amplification of the target site with the primer pair 5′-CACACACCAACCTCTAACGATACC-3′
(forward) and 5′-CCAGGAAAGGTCACACAGAGAAAG-3′ (reverse). PCR products were TA-cloned
into pGEM-T Easy vector (Promega, Madison, WI, USA). Subsequently, DNA from the clones #19 and
#27 was sequenced using T7 forward and Sp6 Reverse primer. Vector NTI software was used to align
the results of sequencing and determine the indel spectra in GLA target site.
2.3. hESC Culture and Differentiation to Cardiomyocytes
The hESCs were cultured on tissue culture dishes coated with Geltrex (Life Technologies, Thermo
Fisher Scientific) in mTeSR1 culture medium (STEMCELL Technologies, Vancouver, BC, Canada) with
daily media changes. The cells were passaged every 3–4 days using Accutase (STEMCELL Technologies).
The undifferentiated phenotype of the hESCs was checked daily using a light microscope. In order to
differentiate hESCs to cardiomyocytes, they were dissociated by Versene (Life Technologies, Thermo
Fisher Scientific), resuspended in mTeSR1 + 5 μM Y27632 and seeded onto Geltrex-coated plates at a
density of 3 × 105 cells/cm2 and grown for the next four days with daily medium change. Following
that, the cells were treated with 6 μM CHIR99021 (Selleckchem, Houston, TX, USA) in insulin-free
RPMI/B27 medium (Life Technologies) for 24 h. The medium was replaced with basal medium for
another 2 days. At day 3, the culture medium was subsequently replaced with 5 μM IWP-2 (Tocris
Bioscience, Minneapolis, MN, USA) in insulin-free RPMI/B27 for 48 h. On day 7, the culture medium
was changed to RPMI/B27 containing insulin (Life Technologies, Thermo Fisher Scientific), and the
culture medium was refreshed every 3 days thereafter.
2.4. Alkaline Phosphatase Staining
Cells were washed in PBS twice, fixed with 80% alcohol for at least 2 h at 4 ◦C, followed by soaking
in ddH2O for 2–3 min, and 100 mM Tris-HCl (pH 8.2–8.5) for 5 min. Alkaline phosphatase substrate
working solution (Vector Laboratories, Burlingame, CA, USA) was added for 1 h and stained colonies
were visualized under light microscope.
2.5. Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated with TRIzol reagent (Invitrogen, Thermo Fisher Scientific) and quantified
by spectrophotometry at 260 nm. 3 μg of total RNA was reverse transcribed using SuperScript III
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Reverse Transcriptase (Invitrogen, Thermo Fisher Scientific) at 55 ◦C for 1 h into complementary DNA,
which was then used as the template for subsequent PCR reactions. The PCR reactions were run with
the following cycling conditions: 94 ◦C for 5 min, followed by 25 or 30 cycles at 94 ◦C (denaturation)
for 30 s, 58–62 ◦C for 30 s (annealing), 72 ◦C for 45 s (synthesis). The primer sequences are shown
in Supplementary Tables S1 and S2. Amplified RT-PCR products were analyzed on 2% agarose gels
and visualized using ethidium bromide staining and SPOT camera system (Diagnostic Instruments,
Sterling Height, MI, USA).
2.6. Immunofluorescence Staining
First, the cells were rinsed in PBS and fixed with 1% (v/v) paraformaldehyde for 10 min followed
by treatment with 70% ethanol (v/v) for 10 min at room temperature. The cells were permeabilized with
0.1% NP-40 (Sigma-Aldrich, St. Louis, MO, USA) for 20 min, then washed twice with PBS. To block
cells, blocking solution (0.3% BSA and 5% serum in PBS) was applied for 30 min. Cells were incubated
with primary antibodies in the blocking solution overnight at 4 ◦C, washed three times in PBS, then
stained with secondary antibodies at 1:200 in PBS for 1 h at room temperature. Cells were washed
three times in PBS, and nuclei were stained with Hoechst 33,342 (Life Technologies, Thermo Fisher
Scientific) at 1:5000 in PBS for 5 min at room temperature. Prior to imaging, cells mounted with
SlowFade Gold Antifade Mountant (Millipore, Sigma, Burlington, MA, USA). Images were obtained
using fluorescent microscopy and a digital camera. Antibody for characterization of pluripotency is
listed in Supplementary Table S3.
2.7. Measurement of Cardiomyocyte Size
The size of iPSC-derived cardiomyocytes was evaluated by measuring the cell area. Twenty
days after cardiac induction, the spontaneously beating embryoid bodies were dissociated into single
cells using Accutase™ (STEMCELL Technologies). These cells were then plated onto gelatin-coated
dishes for further experiments and analysis. Subsequently, the cellular images of cTnT-positive cells
were recorded at days 30, 40 and 60 post-induction of differentiation using FV10i confocal microscope
(Olympus, Tokyo, Japan). The pixel area of cTnT-positive cells was measured and analyzed using ImageJ
software package (NIH). About total two hundred cells were analyzed in five independent experiments.
2.8. Western Blotting
Cells were lysed in RIPA lysis buffer (0.5M Tris-HCl, pH 7.4, 1.5M NaCl, 2.5% deoxycholic
acid, 10% NP-40, 10 mM EDTA, protease inhibitor), and the protein lysates were subjected to
SDS-PAGE followed by electroblotting onto a PVDF membrane. Membranes were probed with the
following primary antibodies: α-galactosidase A, TSG101 (GeneTex, Irvine, CA, USA), CD63 (Santa
Cruz Biotechnology, Dallas, TX, USA), Calnexin (Abcam, Cambridge, MA, USA) GDRID2, VPS36,
VTI1A (Proteintech Group, Wuhan, Hubei, P.R.C), LC3 (Novus Biologicals, Centennial, CO, USA),
Rab11 and GAPDH (Cell Signaling Technology, Denver, MA, USA). The bands were visualized by
chemiluminescence detection reagents.
2.9. Lipid Extraction
The cells were grown to confluency on 150 mm cell culture dishes and harvested by scraping
into 700 μL PBS. The cell suspension was transferred into 16 mm × 100 mm glass tubes, and 1 mL
chloroform and 2.4 mL methanol were added. After water bath sonication, protein was precipitated by
centrifuging at 2400× g for 30 min. The supernatant was transferred to a new glass tube and 4.5 mL
chloroform and 1.2 mL 0.9% NaCl were added. The sample was centrifuged at 900× g for 5 min.
The upper aqueous phase was discarded, and the lower organic phase was washed twice with 2 mL
methanol and 0.8 mL 0.9% NaCl. The lower phase was extracted using a 1 mL glass syringe (Hamilton,
Reno, NV, USA) and transferred to a new glass tube. Lipids were dried under a stream of nitrogen.
252
Cells 2019, 8, 327
2.10. Quantification of Gb3 by Thin Layer Chromatography (TLC)
First, 100 nmole of total phospholipid was applied to a silica high performance TLC plate
(Sigma-Aldrich, St. Louis, MO, USA). The plate was first developed in a solvent system consisting of
chloroform/methanol (98:2), and air-dried. The plate was then developed in a solvent system consisting
of chloroform/methanol/acetic acid/water (61/31/5/3) and air-dried. Plates were submerged in 8% cupric
sulfate pentahydrate in water/methanol/H3PO4 (60:32:8), and charred for 10 min at 150 ◦C, or were
sprayed with 1% orcinol in 11% H2SO4 and charred at 130 ◦C for 5 min. Plates were scanned and
densinometry measured using ImageJ software. Lipids were quantified by running Gb3 standards on
a plate (Matreya LLC, State College, PA, USA).
2.11. Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Analysis
LC-MS/MS analysis was performed using Orbitrap Mass Analyzer (Thermo Fisher Scientific),
according to the manufacturer’s protocol. Briefly, each sample of digested peptides was reconstituted
in 20 μL of 0.1% formic acid. Peptides were first separated by the nanoflow HPLC on Agilent 1100
(Agilent Technologies, Santa Clara, CA, USA) using C18 column (Agilent Technologies) with a flow
rate of 0.4 μL/min, and were ionized after passing through the nanospray tip (New Objective, Woburn,
MA, USA). LC gradient for the LC-MS/MS system ramped from 2–40% ACN in 120 min, and the
system was set up for automated data-dependent acquisition, with a mode of 200–2000 m/z full scan for
the maximum three most intense peaks from each Orbitrap MS scan. Peptides with +2 or +3 charge
were further subjected to CID. Spectra were obtained in raw data files with Xcalibur (version 2.0 SR2).
Protein identification was accomplished by TurboSEQUEST (Thermo Fisher Scientific) using the UniProt
database. A protein was confirmed once three peptides with Xcorr >2.5 were matched in sequencing.
2.12. Transmission Electron Microscopy
The morphology of differentiated cardiomyocytes was characterized using JEM-2000 EX II
transmission electron microscope (JEOL, Tokyo, Japan). The cardiomyocytes were covered with
400 mesh carbon-coated copper TEM grid. After 15 min, the grid was tapped with filter paper to
remove the excess water followed by staining with 1% phosphotungstic acid (Sigma-Aldrich) for
20 min. The samples were allowed to air-dry for 24 h and then observed under TEM.
2.13. Array-Based Comparative Genomic Hybridization (CGH-Array
Genomic DNA was isolated and intermittently sonicated using a Digital Sonifier 450 sonicator
probe (Branson Ultrasonics, Danbury, CT, USA). DNA samples were amplified using the GenomePlex
WGA kit (Thermo Fisher Scientific). Genomic DNA ULS Labeling Kit (Agilent) was used to label
the amplified DNA with either Cy3 or Cy5. As recommended by Agilent, 2.0–2.5 μg of amplified
DNA was used as the input starting material for each labeling reaction. Scanning and image analysis
were conducted according to Agilent Oligonucleotide Array-based CGH for Genomic DNA analysis
Protocol (version 4.0). Microarrays were scanned using an Agilent G2565BA DNA Microarray Scanner
(Agilent). Agilent Feature Extraction software (v9.1.3) was used to extract data from raw microarray
image files. Agilent CGH Analytics software (v3.4) was used to visualize, detect and analyze the
aberration patterns from CGH microarray profiles.
2.14. Exosome Isolation and Characterization
Exosomes were isolated from cell culture supernatants using Total Exosome Isolation Reagent
(Thermo Fisher Scientific) following the manufacturer’s protocol. Culture media samples were
centrifuged at 2000× g for 30 min to remove cells and debris. The supernatant was transferred to
sterile tubes and an exosome precipitation solution was added at a 2:1 ratio. Samples were mixed
and left overnight at 4 ◦C. Samples were then centrifuged at 10,000× g for 60 min and supernatant
carefully removed. The precipitated exosome pellets were re-suspended with PBS and either used
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immediately or stored at −80 ◦C until required. Immunoaffinity capture assay was used to characterize
the purity of exosomes using CD63 antibody-conjugated dynabeads. Exosomes were incubated with
antibody-conjugated dynabeads overnight and washed by PBS containing 0.1% BSA two times. Further,
CD63 PE-conjugated antibody was used to stain the exosome-bound dynabeads. All samples were
examined by flow cytometry using FACSCanto System (BD Biosciences) and FACSDIVA software was
used to analyze the population of exosomes.
2.15. Quantification of Isolated Exosomes
Acetylcholinesterase activity assay was performed using EXOCET Exosome Quantitation Kit
(System Biosciences, Palo Alto, CA, USA). Isolated exosomes were re-suspended with PBS and lysed
with lysis buffer. Each sample was incubated at 37 ◦C for 5 min and mixed with reaction buffer
in 96-well plates. Mixed samples were incubated for 20 min at room temperature and quantified
by spectrophotometry at OD 405 using standard samples containing known numbers of exosomes.
The final number of exosomes was converted to micrograms, per the manufacturer’s guideline.
To characterize exosomes, isolated exosome preparations were re-suspended with PBS and analyzed
using Zetasizer Nano dynamic light scattering system (Malvern Instruments, Malvern, UK).
2.16. Mitochondrial Superoxide Stress Quantification
Mitochondrial superoxide production was quantified using MitoSOX Red mitochondrial
superoxide indicator (Thermo Fisher Scientific) according to the manufacturer’s protocol. Briefly, the
cells were incubated with 5 μM MitoSOX Red in the culture medium in the dark for 60 min at 37 ◦C.
Stained cells were counterstained as desired and mounted and analyzed by fluorescent microscopy.
2.17. Annexin V Staining
Cells were washed once with PBS and analyzed using FITC Annexin V Apoptosis Detection Kit
(BD Biosciences) according to the manufacturer’s protocol.
2.18. GLA Enzyme Activity Assay
Cells were washed twice with 1X PBS and were lysed in 60 μL lysis buffer (27 mM sodium citrate,
46 mM sodium phosphate dibasic, 0.5% Triton X-100). 10 μL of cell lysate was added to 50 μL assay
buffer containing 6 mM 4-methylumbelliferyl-α-d-galactopyranoside (Sigma-Aldrich) and 117 mM
N-acetyl-D-galactosamine (Sigma-Aldrich) and incubated at 37 ◦C for 1 hr. The 4-methylumbelliferone
(Sigma-Aldrich) dissolved in methanol was used as standard ranging from 0.15 μM to 5000 μM.
Thereafter, 70 μL glycine-carbonate solution (pH 10.8) was then added to stop the reaction and
fluorescence was detected by microplate reader (em/ex = 365/448 nm). The enzyme activity was
normalized by protein concentration of cell lysate.
2.19. Statistical Analysis
The quantifiable data are presented as the means ± standard deviation (SD) and compared with
Student’s t-test by GraphPad Prism 6 (GraphPad Prism Software). * p < 0.05, ** p < 0.01, *** p < 0.005
and **** p < 0.001.
3. Results
3.1. CRISPR/Cas9-Mediated Knockout of Expression of GLA in hESCs
In order to investigate the functions of GLA and its therapeutic potential for FD, we performed
CRISPR/Cas9-mediated gene editing to knock out expression of this gene in human embryonic stem
cells (hESCs). The procedure was similar to that described in our previous work, where we established
the GLA-null HEK293 cell line [8]. Briefly, the GLA-specific single-guide RNA (sgRNA) was designed
by using Optimized CRISPR Design tool (http://crispr.mit.edu/) to introduce the frameshift mutations
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in exon 1 of GLA gene as shown in Figure 1A. The parental male hESC line H9 (WA09) was transfected
with Cas9-encoding plasmid with EGFP reporter, along with the sgRNA. Following the transfection,
the proportion of the successfully transfected EGFP-expressing cells was enriched by FACS, and these
cells were seeded to 96-well dishes to obtain pure colonies. Out of 36 wells where the single cells were
seeded, the clones #20 to #24 and #28 did not grow up. The remaining 30 colonies were screened for
GLA protein expression by western blotting (Figure 1B). The GLA protein expression was completely
ablated in four clones (#3, #19, #26, and #27) and partially suppressed in two (#25 and #31) (Figure 1B).
By performing preliminary differentiation of these clones into cardiomyocytes (CMs), we found that
clone #26-derived CMs displayed slight GLA expression, which could be due to contamination with
parental non-edited cells, therefore, this clone was excluded from further analysis (Supplementary
Figure S1A). GLA mRNA levels in these CM clones were not significantly decreased as compared
to the control, only in clone #27-derived CMs mRNA levels were downregulated by approximately
50% (Supplementary Figure S1B). On the other hand, GLA enzyme activity was completely absent
in clones #3, #19, and #27, which was consistent with the complete absence of GLA protein in these
cells (Supplementary Figure S1C). Subsequently, the mutations introduced by CRISPR/Cas9 were
identified by Sanger sequencing in the remaining GLA-knockout hESC clones #3, #19, and #27. Clone #3
displayed mixed genetic background at the target site, due to putative non-homogeneous population,
therefore, it was also excluded from the analysis. (Supplementary Figure S1D). Two of GLA-null hESC
clones were selected for the following study because they were hemizygous for 2 bp deletion (clone
#19) and 1 bp insertion (clone #27) (Figure 1C). T7 Endonuclease I (T7E1) was used to confirm the
presence CRISPR/Cas9-introduced mutations in the GLA gene, whereby the cleaved mismatch products
were detected in clones #19 and #27 (Figure 1D). On the other hand, T7E1 assay revealed that there
were no CRISPR/Cas9-introduced mutations in the potential off-target genes predicted by Optimized
CRISPR Design tool (Suppl. 2). Therefore, by conducting the CRISPR/Cas9-mediated genome editing,
we successfully established two GLA-null hESC clones.
Figure 1. CRISPR/Cas9-mediated knockout of expression of GLA in hESCs. (A) Schematic
depiction of sgRNA-guided Cas9 target site within exon 1 of GLA gene. The sgRNA sequence
(5′-AGGAACCCAGAACUACAUCU-3′) is labeled in blue font and PAM recognition sequence
highlighted in red. The gRNA targeting site in the GLA exon 1 region is highlighted in green
and the double-strand breaking site is indicated by the red arrowheads. The start codon is highlighted
in yellow. (B) Western blot screening of 30 CRISPR/Cas9-corrected clones for expression of GLA
protein. H9 cells were used as wild type parental control. GAPDH used as a loading control.
(C) Sanger sequencing analysis confirming two nucleotides deletion and one nucleotide insertion in
CRSIPR/Cas9-edited hESC clones #19 and #27, respectively. (D) T7E1 digestion assay of the mutants at
the target site in GLA gene. The mismatch T7E1 cleavage products are marked with white arrowheads.
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3.2. Characterization of GLA-Null hESC Clones
To confirm the pluripotency status of the established GLA-null hESC clones #19 and #27, several
stemness markers were detected by RT-PCR, thus confirming that CRISPR/Cas9-mediated GLA knockout
did not significantly influence the pluripotency gene expression in hESCs (Supplementary Figure
S3A). Both GLA-null hESC clones displayed typical pluripotent morphology features, including small
and tightly packed cells, high nucleus to cytoplasm ratio, and positive alkaline phosphatase activity
(Supplementary Figure S3B). The expression of pluripotency markers OCT4, NANOG, TRA-1-60 and
TRA-1-81 was verified by immunofluorescence staining (Figure 2A). Both null-GLA hESC clones were
able to spontaneously differentiate in vitro into embryoid bodies expressing markers of three germ
layers: HNF3β of endoderm, α-SMA of mesoderm, and nestin of ectoderm (Figure 2B). Both clones
exhibited normal karyotypes (Figure 2C). To summarize, both established GLA-null hESC clones
exhibited normal stem cell properties, and therefore, were suitable for differentiation into FD-specific
cardiomyocytes to investigate the mechanisms of involvement of GLA deficiency in the pathology of
FD cardiomyopathy.
Figure 2. Characterization of CRISPR/Cas9-edited GLA-null hESC clones. (A) Immunofluorescence
staining demonstrating the protein expression of pluripotency markers OCT4, TRA-1-60, NANOG
and TRA-1-81 in GLA-null hESC clones #19 and #27. Nuclei stained with DAPI. (B) Embryoid
body formation assay showing differentiation of GLA-null hESC clones #19 and #27 into three germ
layers: endoderm immunoreactive for HNF3β, mesoderm immunoreactive for α-SMA, and ectoderm
immunoreactive for nestin. Nuclei stained with DAPI. (C) Representative karyograms GLA-null hESC
clones #19 and #27. Visualization was performed using Agilent CytoGenomics software.
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3.3. Recapitulation of FD-Specific Cardiac Abnormalities in GLA-Null Cardiomyocytes
Given the fact that CM hypertrophy is one of the symptoms of FD-associated cardiomyopathy,
we examined whether GLA-null CMs could recapitulate such features. hESCs were differentiated
into CMs according to the conventional CM differentiation protocol [21]. Both GLA-null CMs and
CMs derived from the parental H9 hESCs (H9 CMs) exhibited spontaneous contractions as early as
twelve days following initiation of cardiac differentiation. Noticeably, no significant differences in
the efficiency of cardiac differentiation were observed between GLA-null CMs and H9 CMs, which
suggested that the GLA deficiency did not significantly affect the differentiation of hESCs to CMs.
The accumulation of Gb3 in CMs is the most prominent hallmark of FD-associated cardiomyopathy.
Compared with H9 CMs, GLA-null CMs accumulated more Gb3, as was demonstrated by transmission
electron microscopy (Figure 3A) and thin layer chromatography (Figure 3B). GLA protein was not
expressed in #19 and #27 GLA-null CM clones at day 60 of differentiation (Figure 3C). Cardiac
hypertrophy is often accompanied by reactivation of fetal genes which are active during fetal cardiac
development and quiescent in adult hearts [22]. We measured the expression level of several of such
genes by qRT-PCR and showed that atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP),
but not troponin T (TnT) were upregulated in GLA-null CMs compared to H9 CMs. In addition,
GLA-null CMs were characterized by shifted balance between α- and β-cardiac myosin heavy chain
(MYH6/MYH7 ratio) expression, which is a common response to cardiac injury and a hallmark of
cardiac hypertrophy [23] (Figure 3D). Immunofluorescent staining of cardiac troponin T (cTnT) revealed
that GLA-null CMs were of significantly larger size (26% ± 9.7%, p < 0.001) as compared to the control
H9 CMs (Figure 3E,F), which was consistent with the phenotype of FD-associated cardiomyopathy.
In summary, we have shown that CRISPR/Cas9-edited hESC-derived GLA-null CMs recapitulated the
typical phenotype features of FD-affected CMs and, therefore, could be a useful model to study the
FD-associated cardiomyopathy.
3.4. Proteomic Analysis of GLA-Null CMs
To further investigate the potential mechanism of FD-related cardiomyopathy, we used proteomic
analysis. We focused our analysis to the genes that where downregulated by GLA knockout, i.e., whose
function was negatively affected. By applying LC-MS/MS, we identified 60 proteins downregulated in
GLA-null CMs as compared to H9 CMs with a false discovery rate (FDR) below 0.01. By performing gene
ontology (GO) analysis using FatiGO software [24], we found that these 60 proteins were significantly
enriched in cellular component GO terms related to extracellular vesicle transportation, secretion, and
exocytosis (Figure 4A,B). Among the downregulated proteins involved in regulated exosome release
were Ras-Related Protein Rab-11 (RAB11), Rho GDP-dissociation inhibitor 2 (GDIR2, ARHGDIB),
VPS36 and VTI1A (Supplementary Table S4). The levels of these proteins were validated and quantified
by western blotting; they were shown to be downregulated in GLA-null CMs (Figure 4C,D).
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Figure 3. Recapitulation of FD-specific cardiac abnormalities in GLA-null cardiomyocytes. (A) TEM
images showing the ultrastructure of parental type (H9) and GLA-null CMs. The red arrowheads
indicate the multilayered lysosomal structure. (B) Gb3 content in parental (H9) and GLA-null CMs
(clones #19 and #27) analyzed by TLC. (C) Western blot showing lack of expression of GLA in clones
#19 and #27 of GLA-null CMs as compared to the parental wild type CMs and hESCs (H9). Connexin
43 (Cx43) and NANOG served as cardiomyocyte and pluripotency markers, respectively. GAPDH
used as a loading control. (D) qRT-PCR analysis of expression several fetal heart markers in CM clones
#19 and #27. The results are expressed as fold change relative to H9 CMs. (E) Immunostaining of cTnT
showing significantly enlarged size of GLA-null CMs compared to H9 CMs. (F) Quantification of area
size of GLA-null CMs (green columns) and H9 CMs (blue columns). At least 200 cells were analyzed
individually and statistical difference is p < 0.001.
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Figure 4. Proteomic analysis of GLA-null CMs. (A) The most enriched cellular component GO
terms in the list of 60 genes downregulated in GLA-null CMs. (B) Visualization of the most enriched
cellular component GO terms using REVIGO software. (C) Western blot showing expression of the
mediators of vesicular trafficking in GLA-null CMs #19 and #27 as compared to wild type control
(H9). GAPDH served as a loading control. (D) Quantitation of expression of proteins annotated as
the mediators of vesicular trafficking. The data are presented as mean ± standard deviation error
bars from three independent experiments. (D) Flow cytometric analysis of CD63 expression in H9-
and GLA-null CM-derived exosome isolated with magnetic beads directly from cell culture medium.
(E) Quantification of exosome numbers in the supernatant from H9 and GLA-null CMs.
3.5. GLA-Null CMs Secrete More Exosomes Than H9 CMs
Given the fact that the proteome analysis revealed changes in proteins involved in vesicle
secretion, we further investigated whether the exosome biogenesis was affected in GLA-null CMs.
The exosomes were isolated from the culture medium, and their identity was confirmed by electron
microscopy. Multivesicular bodies were observed and exhibited the typical characteristic cup-shaped
morphology (Supplementary Figure S4A) and size (diameter between 50 and 150 nm). Exosome
size was measured by the Nanosight tracking system (Supplementary Figure S4B) and their identity
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was confirmed by detecting expression of exosomal markers TSG101 and CD63 (Supplementary
Figure S4C). Quantification of exosome though CD63 PE-conjugated fluorescence by flow cytometry
analysis revealed that at higher CD63 positive levels in exosomes derived from GLA-null CMs
compared to H9 CMs (Figure 4D). Next, we investigated the number of isolated exosomes from H9
and GLA-null CMs. Interestingly, GLA-null CMs produced significantly larger number of exosomes
than H9 CMs (10.8 × 108 vs. 5.1 × 108, p < 0.001) (Figure 4E). These results indicate that GLA-null CMs
increased the production and secretion of exosomes.
3.6. Vesicle Turnover Impairment Induces Cardiotoxicity in GLA-Null CMs
Several studies have shown that the molecular machinery and regulatory mechanisms are shared
between exosome biogenesis and autophagy [25,26], suggesting that these two processes are intimately
linked. Since the proteomic analysis revealed the downregulation of components of vesicular trafficking
machinery in GLA-null CMs, we hypothesized that dysfunctional autophagy pathway may underlie the
impairment of cellular homeostasis in FD-related cardiomyopathy. To investigate whether autophagy
flux impairment plays a role in cardiac phenotype of FD, we used western blotting to analyze the
expression of autophagy markers LC3-I and LC3-II. The levels of these proteins were monitored in
a time course of four hours after induction of autophagy with HBSS medium, and it was revealed
that LC3-II accumulated by two hours after autophagy induction in both H9 and GLA-null CMs
indicating to initiation of autophagy flux (Figure 5A,B). However, after four hours of autophagy
induction, LC3-II levels dropped significantly in H9, but remained high in GLA-null CMs, signifying
the digestion of autophagosome by lysosomes in the former and the block of autophagy flux in the latter
(Figure 5A,B). Previous studies have indicated that undigested material within the autophagosome,
including dysfunctional mitochondria, may be a source of free radicals, which in turn can result in
cellular dysfunction and apoptosis [27,28]. Mitochondrial integrity and turnover play an important
role in CM bioenergetics and function. MitoSOX Red staining demonstrated significant activation of
mitochondrial superoxide production in GLA-null CMs (Figure 5C). The quantification of the MitoSOX
Red staining intensity indicated that mitochondrial superoxide production in GLA-null CMs was
3.4-fold higher than that in H9 CMs (Figure 5D). To assess CM apoptosis, annexin V assay was used.
GLA-null CMs displayed 4-fold increase in staining with annexin V in comparison with H9 CMs
(Figure 5E,F). Furthermore, we observed significant 2-fold increase of lactate dehydrogenase (LDH),
a marker of necrosis, in the supernatant derived from GLA-null CMs (Figure 5G). Collectively, our
results demonstrate that GLA-null CMs were characterized by autophagy impairment and active
mitochondrial ROS production that caused apoptosis and necrosis.
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Figure 5. Vesicle turnover impairment induces cardiotoxicity in GLA-null CMs. (A) Western blot
showing expression of LC3 protein isoforms (LC3-I and LC3-II) in a time course of induction of
autophagy with HBSS medium. GAPDH was used as a loading control. (B) The expression levels of
LC3-II were measured by using ImageJ and the quantification results presented as mean ± standard
deviation error bars from three independent experiments. (C) Staining of mitochondrial ROS in
GLA-null CMs and H9 control CMs with MitoSOX Red. (D) MitoSOX Red fluorescence intensity
quantified by flow cytometry presented as mean ± standard deviation from three independent
experiments. (E) Flow cytometry analysis of annexin V-positive cells in populations of GLA-null
and H9 CMs. (F) Quantitation of annexin V-positive cells. (G) The level of LDH secreted by H9 and
GLA-null CMs. The data are presented as a fold change relative to H9 control. These data are presented
as mean ± standard deviation error bars from three independent experiments.
4. Discussion
The lysosome storage dysfunction (LSD) is the major factor in etiology of inherited hypertrophic
cardiomyopathy, including FD; however, the underlying mechanisms of FD-associated cardiomyopathy
are not fully understood. In order to expand the therapeutic strategies for FD, the construction of
in vitro disease models using primary human cells is essential and unavoidable. Whereas the patients’
cells can be used to directly model the effects of drugs on humans, their availability and capacity for
expansion are limited and finite compared to in vitro derived cell lines, especially for vital organs such
as heart and brain. These drawbacks restrict the capacity of these models to faithfully simulate human
disease. By comparison, ESCs can sidestep these limitations and thus provide a powerful and versatile
tool for disease therapy, as well as basic research. Combined with the advancements in genome editing
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technology though CRISPR/Cas9, it is now possible to model human diseases in a physiologically,
pathologically, and genetically relevant manner.
Mass spectrometry-based proteomics has been recognized as a powerful tool with a potential to
uncover detailed changes in protein expression [29]. To date, most of the proteomics studies performed
on FD patients examined FD-affected renal tissue or plasma; however, few studies of protein expression
have used FD-affected human heart tissue [30,31]. Although it has been revealed that Gb3 accumulation
induces endothelial KCa3.1 degradation in Gla-knockout mice through clathrin and Rab5C, which are
the critical components of endosome maturation machinery [32], the proteomic profiling performed in
our study revealed that GLA knockout led to the downregulation of Rab GTPases, including RAB11
subfamily, which are involved in recycling from an endosomal compartment to the plasma membrane,
and was shown to contribute to exosome secretion in neuronal cells [33], although the molecular
mechanism of RAB11 function in exosome secretion has yet to be deciphered, especially regarding
its downstream effectors. On the other hand, our proteomic profile also revealed downregulation
of Rho GDP-dissociation inhibitor 2 (GDIR2) in GLA-null CMs. This observation is consistent with
previously published clinic proteomic profiles, where PBMCs isolated from FD patients were analyzed,
and among the downregulated proteins were calnexin, Rho GDP-dissociation inhibitor 1 (GDIR1),
Rho GDP-dissociation inhibitor 2 (GDIR2), chloride intracellular channel protein [34]. Rho GDIs play
an important role in regulating Rho GTPases, which are members of the Ras superfamily of GTP
binding proteins that participate in the regulation of cytoskeleton and other cellular functions including
proliferation, differentiation, and apoptosis [35,36]. Rho GDI is ubiquitously expressed and binds to all
Rho family proteins, including RhoA [37]. The small G-protein RhoA regulates the actin cytoskeleton,
and its involvement in cell proliferation has also been established. In cardiomyocytes grown in vitro,
RhoA induces hypertrophic cell growth and gene expression [38,39]. In vivo, however, cardiac-specific
overexpression of RhoA leads to development of heart failure [40,41]. These correlated evidences
suggest that exosome secretion regulated by Rab GTPase/RhoGDI signaling pathway may utilize as a
target for the potential therapeutic strategy for FD-associated cardiomyopathy.
FD is characterized by failures of cellular autophagy associated with accumulation of glycogen
granules and intracytoplasmic vacuoles that contain autophagic material. Impairment of autophagic
flux in FD, which was manifested as defects of autophagosome maturation in renal endothelial cells and
mesangial cells [42,43]. Autophagy is an evolutionary conserved process of self-degradation of cellular
components by autophagosomes, which are delivered to the lysosomal machinery. Several studies have
shown that starvation-induced autophagy reduces exosome secretion due to the fusion of multivesicular
bodies with autophagic vacuoles [44]. In contrast, cellular stresses, such as senescence and ER stress,
increase exosome secretion [45,46]. It is not clear why cells respond to stress by releasing more
exosomes, but this could be an alternative way of eliminating waste products. The secreted exosomes
may be targeted to and degraded by phagocytes, but they may also have other destinations. Exosomes
secreted as waste are likely to affect neighboring cells and possibly induce pathological conditions.
Another possibility is that cells may communicate with neighboring cells about intracellular stress by
increasing exosome release. Therefore, preventing waste accumulation and rescuing the autophagic
ability in FD-affected CMs may be utilized as another therapy approach for FD cardiomyopathy.
It has been observed that exosomes derived from CMs harbor a variety of mRNAs, miRNAs and
proteins, which may be transferred to the adjacent endothelial cells and modulate their function [47].
Interestingly, exosomes derived from ESCs/iPSCs were shown to possess regenerative power on
CMs by augmenting and modulating endogenous repair mechanisms [48,49]. Emerging evidence
from the studies of normal development, as well as multiple disease studies, revealed that exosome
secretion and autophagy act in a coordinated manner to maintain homeostasis through lysosomal
degradation and/or release of cellular cargo [50]. Therefore, considering the role of exosomes in
physiological and pathological conditions, strategies that interfere with the release of exosomes and
impair exosome-mediated cell-to-cell communication could potentially be exploited therapeutically in
FD cardiomyopathy.
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The objective of the present study was to explore the influence of Gb3, a lysosomal glycolipid
accumulating in FD-affected cells, on modulation of cellular vesicle cycling and the possible mechanism
underlying cardiomyopathy. We demonstrated that disruption of GLA with CRISPR/Cas9 resulted
in the complete ablation of GLA protein expression in hESCs. Results from this study may provide
mechanistic insights into how Gb3 accumulation modulates vesicles formation, particularly the
autophagy flux in CMs. Such information may be extremely important for potential application in
prevention and intervention of adverse effects of FD-associated cardiomyopathy.
5. Conclusions
To summarize, in the present study we show that CRISPR/Cas9-mediated GLA knockout of
hESC-derived CMs can serve as an in vitro FD model for studying hypertrophic cardiomyopathy. Here,
we adopted CRISPR/Cas9-mediated genomic editing to successfully generate GLA-deficient hESC
clones (Figure 1). These GLA-deficient hESC clones displayed the properties of pluripotency, and were
differentiated into CMs, which exhibited the typical biochemical and pathological abnormalities
of FD including ablated GLA expression, enlarged cellular size, increased expression of cardiac
hypertrophy genes and Gb3 accumulation. Therefore, these GLA-null CMs clones recapitulated the
typical characteristics of FD-associated cardiomyopathy (Figures 2 and 3). To determine the global
protein expression changes involved in the hypertrophic response to GLA deficiency, we used proteomic
analysis and demonstrated markedly reduced expression of proteins involved in cytoskeleton dynamics
and secretion of extracellular vesicles (Figure 4). Since exosome biogenesis and autophagy are highly
interrelated processes, we have shown that GLA knockout led to autophagic impairment, which resulted
in increase of mitochondrial ROS production and cell death (Figure 5). Additional investigation of the
role of autophagy in FD is highly promising for the development of novel chemical modulation-based
therapeutic approaches that may be more economically viable than traditionally-used ERT.
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Abbreviation
LSD lysosomal storage disease
FD Fabry disease
Gb3 globotriaosylceramide
α-Gal A α-galactosidase A
ERT enzyme replacement therapy
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Abstract: The lymphocyte function-associated antigen 1 (LFA-1) is a member of the beta2-integrin
family and plays a pivotal role for T cell activation and leukocyte trafficking under inflammatory
conditions. Blocking LFA-1 has reduced or aggravated inflammation depending on the inflammation
model. To investigate the effect of LFA-1 in myocarditis, mice with experimental autoimmune
myocarditis (EAM) were treated with a function blocking anti-LFA-1 antibody from day 1 of disease
until day 21, the peak of inflammation. Cardiac inflammation was evaluated by measuring infiltration
of leukocytes into the inflamed cardiac tissue using histology and flow cytometry and was assessed by
analysis of the heart weight/body weight ratio. LFA-1 antibody treatment severely enhanced leukocyte
infiltration, in particular infiltration of CD11b+monocytes, F4/80+macrophages, CD4+ T cells, Ly6G+
neutrophils, and CD133+ progenitor cells at peak of inflammation which was accompanied by an
increased heart weight/body weight ratio. Thus, blocking LFA-1 starting at the time of immunization
severely aggravated acute cardiac inflammation in the EAM model.
Keywords: myocarditis; inflammation; leukocytes
1. Introduction
Myocarditis is a major cause of heart failure in young adults. Infections with cardiotropic
viruses represent the most common etiology of myocarditis in the Western World. Release of cardiac
self-antigens can subsequently lead to breakdown of heart-specific tolerance tissue and can evolve into
autoimmune-mediated inflammation sustaining the disease upon eradication of the virus. Sustained
cardiac inflammation may eventually lead to cardiac remodeling and end-stage heart failure with
dilation of the ventricles and deteriorating contractility of the cardiac muscle, a condition called
inflammatory dilated cardiomyopathy (DCMi) [1]. We recently showed that neutrophils play a critical
role for cardiac inflammation in the experimental autoimmune myocarditis (EAM) mouse model
which resembles the immunological and histopathological features of post-viral heart disease [2,3].
In this model, cardiac inflammation was induced by administration of a cardiac peptide together
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with complete Freund’s adjuvant which triggered an autoimmune response with a peak of leukocyte
infiltration at day 21 after immunization. We demonstrated that targeting neutrophil extracellular
traps (NETs), a process by which neutrophils expel their nuclear DNA together with antibacterial
proteins, thereby maintaining tissue inflammation, can substantially reduce cardiac inflammation
in the EAM mouse model [2,4]. In order to undergo NET formation in the inflamed cardiac tissue,
neutrophils must be recruited from the blood stream into the tissue by crossing the endothelial barrier
of the cardiac vasculature. The neutrophil recruitment cascade consists of consecutive events including
capturing of free-flowing neutrophils, rolling, adhesion, adhesion strengthening, intraluminal crawling,
and transmigration [5]. The lymphocyte function-associated antigen 1 (LFA-1, CD11a/CD18) and the
macrophage 1-antigen (Mac-1, CD11b/CD18), adhesion molecules of the beta2-integrin family, are
of fundamental importance for neutrophil adhesion and subsequent recruitment into the inflamed
tissue [6]. LFA-1 also acts as an important adhesion molecule for other leukocyte subsets during
the recruitment process, e.g., for T cells. Beyond its role for leukocyte recruitment, the interaction
of LFA-1 on T cells with its ligand (the intercellular molecule-1 (ICAM-1)) on antigen-presenting
cells like dendritic cells can provide a co-stimulatory signal for T cell activation. It has been shown
that LFA-1 signaling influences differentiation of T cells into specific effector subsets. Engagement
of LFA-1 on T cells can activate the Notch pathway promoting Th1 differentiation and suppressing
generation of Th17 cells and regulatory T cells [7]. LFA-1 has been investigated as target in different
autoimmune diseases. In psoriasis, an antibody targeting LFA-1 resulted in significant improvement
of plaque psoriasis in patients with moderate to severe disease [8]. In contrast, in the experimental
autoimmune encephalomyelitis (EAE) model, infiltration of leukocytes into the spinal cord and the
brain was substantially enhanced in LFA-1-/- mice which was accompanied by increased disease
severity suggesting that LFA-1 was protective in this model [9]. The role of LFA-1 in myocarditis is
unclear. In this study, we set out to investigate the role of LFA-1 in myocarditis using the EAM model.
2. Materials and Methods
2.1. Mice
Male wild-type mice (8 weeks) on a BALB/c background were obtained from Charles River (Sulzfeld,
Germany). Animals were fed a standard chow diet ad libitum with free access to water. All animal
experiments were approved by the Regierung von Oberbayern (55.2-1-54-2532-48-2014), Germany.
2.2. EAM Model
To induce EAM, a purified synthetic peptide of the cardiac myosin heavy chain alpha
(Ac-RSLKLMATLFSTYASADR, Caslo, Kongens Lyngby, Denmark) emulsified in complete Freund’s
adjuvant (CFA, Sigma-Aldrich, St. Louis, MO) was applied subcutaneously (200 μg of cardiac peptide
per mouse) at day 1 and day 7. Equal volumes of CFA + PBS were administered for sham controls.
In order to block LFA-1, we used a chimeric rat-mouse IgG1 anti-mouse CD11a monoclonal antibody
(muM17, Genentech, San Francisco, CA) which was previously described [10]. The antibody was
applied subcutaneously (5 μg/g body weight) starting from day 1 once a week until day 21. Control
animals were treated with a matching IgG1 isotype antibody (Genentech, San Francisco, CA) or PBS.
Sham-immunized controls were treated with PBS. On day 21, mice were sacrificed and hearts were
subsequently removed for analysis.
2.3. Histology and Heart Weight/Body Weight Ratio
To evaluate the cardiac tissue histologically, mouse hearts were rinsed with PBS and fixated
with PFA 4% (Roth, Karlsruhe, Germany). Analysis of the heart weight/body weight ratio was
conducted using a microbalance (CP64-0CE, Sartorius, Göttingen, Germany) after carefully removing
the pericardium, connective tissue, and vascular remains. Thereafter, hearts were dehydrated in
a graded series of ethanol concentrations and subsequently embedded in paraffin (Sigma-Aldrich,
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St. Louis, MO, USA). To evaluate infiltration of leukocytes, sections were stained with hematoxylin
(Roth) and eosin (Roth, H&E, day 21). The established EAM score (0: no inflammatory infiltrates; 1:
small foci of <100 inflammatory cells between myocytes; 2: larger foci of >100 inflammatory cells;
3: >10% of a cross section shows infiltration of inflammatory cells; 4: >30% of a cross section shows
infiltration of inflammatory cells) was used to evaluate leukocyte infiltration semi-quantitatively as
previously described [2]. Analysis was performed in a blinded manner.
2.4. Flow Cytometry
To study infiltration of different leukocyte subsets into the cardiac tissue, flow cytometry was
performed at day 21. The hearts were removed, perfused with PBS, subsequently cut in small pieces,
and incubated with Liberase (Roche, Basel, Switzerland) for 45 min at 37 ◦C. Next, the suspension
was mixed gently, filtered through a 40 μm cell strainer, and subsequently suspended in PBS. Cells
were stained with a APC-conjugated rat anti-mouse CD11b antibody (clone M1-70, BD, Franklin
Lakes, NJ), PE-conjugated rat anti-mouse Ly6G antibody (clone 1A8, Biolegend, San Diego, CA, USA),
PerCP-conjugated rat anti-mouse CD45 antibody (clone 30F-11, BD), PB-conjugated rat anti-mouse
CD4 antibody (clone RM4-5, BD), an APC rat anti-mouse F4/80 antibody (clone BM8, Biolegend) and
FITC-conjugated rat anti-mouse CD133 antibody (clone EMK08, ThermoFisher, Waltham, MA, USA).
Experiments were performed using a Gallios flow cytometer (Beckman Coulter, Krefeld, Germany).
FlowJo software (TreeStar, Ashland, OR) was used to analyze data.
2.5. Statistical Analysis
Data shown represent the mean ± SEM. A Kolmogorov-Smirnoff test was conducted to test for
normal distribution. As data were not normally distributed, a Kruskal Wallis test with pairwise
comparison and Dunn-Bonferroni correction for multiple testing was applied for all statistical tests.
An alpha level of 5% was considered as statistically significant. All data was analyzed using SPSS
version 26.
3. Results
To investigate the role of LFA-1 for cardiac inflammation in myocarditis, we evaluated leukocyte
infiltration and the heart weight/body weight ratio in the EAM model after blocking LFA-1. We targeted
LFA-1 using a chimeric rat-mouse anti-mouse antibody from day 1 until day 21 during the course
of EAM. Leukocyte infiltration into the inflamed cardiac tissue, which was analyzed histologically
using a semi-quantitative score (referred to as EAM score), was significantly increased at day 21
in immunized mice without antibody treatment (PBS) or with isotype control antibody treatment
compared to sham-immunized mice, as expected. Strikingly, leukocyte infiltration was substantially
enhanced after blocking LFA-1 compared to mice treated with PBS or the matching isotype control
antibody suggesting that LFA-1 suppressed leukocyte infiltration into the inflamed cardiac tissue in
EAM (Figure 1a,b). The heart weight/body weight ratio was altered accordingly (Figure 1c).
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Figure 1. Blocking lymphocyte function-associated antigen 1 (LFA-1) aggravated cardiac inflammation
in experimental autoimmune myocarditis (EAM): (a) Representative cross sections of heart tissue of
sham-treated control mice, vehicle-treated EAM mice (PBS), anti-LFA-1-treated EAM mice as well as
isotype control-treated mice on day 21. (b) EAM score (c) as well as evaluation of the heart weight/body
weight ratio at day 21 after induction of EAM (EAM) or sham immunization (sham). EAM mice were
treated with an anti-LFA-1 antibody (anti-LFA-1), a matching isotype control (isotype ctrl), or PBS as
indicated, with n = 8 for sham group; n = 18 for EAM groups; * p < 0.05; ** p < 0.01; *** p < 0.001; n.s.,
not significant. Kruskal Wallis test followed by Dunn-Bonferroni post hoc test. Data are presented as (b)
individual data points or (c) median with interquartile range, whiskers indicate 95% confidence interval.
Next, we determined whether infiltration of specific leukocyte subsets into the cardiac tissue in
EAM would be affected by the blockade of LFA-1 in EAM. For this purpose, we administered the
LFA-1 blocking antibody or the matching isotype or PBS for control from day 1 until day 21 and
subsequently determined the percentage of infiltrated leukocyte subsets of all cells using flow cytometry.
The percentage of infiltrated leukocytes determined by CD45+ cells was substantially enhanced by
blockade of LFA-1 compared to PBS or the isotype control antibody (Figure 2a). To evaluate the specific
leukocyte subsets affected by targeting LFA-1, we also stained for CD4, CD11b, F4-80, Ly6G, and CD133.
Blockade of LFA-1 significantly increased the infiltration of all CD4+ T cells (Figure 2b). Moreover,
infiltration of CD45/CD11b cells (mainly consisting of monocytes and neutrophils) was significantly
elevated in LFA-1 antibody-treated mice compared to control mice (Figure 2c). Accordingly, an
increased percentage of infiltrated F4-80+ cells resembling monocytes/macrophages was observed after
blocking LFA-1 compared to control conditions (Figure 2d). Moreover, LFA-1 antibody treatment led to
a higher number of neutrophils in the inflamed cardiac tissue (Figure 2e). Finally, the fraction of CD133+
progenitor cells, which represent the cellular source of TGF-β mediated fibrosis, was increased after
LFA-1 blockade compared to PBS control albeit not reaching a statistical significant difference compared
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to isotype control (Figure 2f). These findings imply that blocking LFA-1 substantially promoted
leukocyte infiltration into the inflamed cardiac tissue affecting CD4+ T cells, monocytes/macrophages,















Figure 2. Infiltration of different leukocyte subsets is enhanced by blocking LFA-1: Flow cytometric
analysis of leukocyte subpopulations in the inflamed cardiac tissue on day 21 after induction of EAM.
Diagrams display the percentage of leukocytes (a, CD45) and leukocyte subpopulations (b, CD4;
c, CD45/CD11b; d, F4-80; e, CD45/CD11b/Ly6G; f, CD45/CD11b/CD133) of all cells after blocking LFA-1
(anti-LFA-1) compared with the matching isotype control antibody (isotype ctrl) or PBS. n = 18 for PBS,
n = 17 for anti-LFA-1 and isotype ctrl. * p < 0.05; ** p < 0.01; *** p < 0.001; n.s., not significant. Kruskal
Wallis test followed by Dunn-Bonferroni post hoc test. Data are presented as median with interquartile
range, whiskers indicate 95% confidence interval.
4. Discussion
Blocking LFA-1 or the absence of LFA-1 in different autoimmune diseases revealed a protective or
detrimental role of this adhesion receptor depending on the autoimmune disease [8,9]. Moreover, the
time-point of targeting LFA-1 may also have an enormous impact on the course of the particular disease.
Our findings showed that biological blockade of LFA-1 from day 1 until day 21 substantially enhanced
leukocyte infiltration into the inflamed cardiac tissue in the EAM model compared to immunized
mice treated with an isotype antibody or PBS. Infiltration of inflammatory cells was accompanied by
a dramatic increase of the heart weight/body weight ratio which is a very robust marker for cardiac
inflammation indicating that blocking LFA-1 significantly promoted acute myocarditis in this model.
Interestingly, all immunized mice treated with the anti-LFA-1 antibody showed the full phenotype of
myocarditis (EAM score ≥ 3) whereas a significant percentage of mice generally develop only mild
disease (EAM score ≤ 1). Analysis of different leukocyte subpopulations revealed that infiltration of
CD4+ T cells, monocytes/macrophages, and neutrophils was enhanced after blocking LFA-1 compared
to control conditions suggesting that all investigated leukocyte subsets were affected. In addition,
we observed a numerical but not statistical significant increase of CD133+ progenitor cells after
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targeting LFA-1 which have been shown to promote fibrosis by expression and release of TGF-β [11].
These findings may point to a profibrotic phenotype after blocking LFA-1 in the EAM model.
The underlying mechanism of our preliminary findings remains unclear. As described above,
LFA-1 serves as adhesion receptor in particular for neutrophils and T cells. In a peritonitis mouse
model, blocking LFA-1 significantly reduced neutrophil recruitment into the peritoneal cavity [12]. The
contribution of LFA-1 for neutrophil adhesion and subsequent recruitment depend on the tissue and
the predominating inflammatory stimuli in the particular inflammatory setting [13]. The importance
of LFA-1 for T cell adhesion and extravasation is also tissue-dependent as T cells also use the very late
antigen-4 (VLA-4) as adhesion receptor [14]. Furthermore, the relevance of VLA-4 or LFA-1 may also
depend on the T cell subset in specific inflammatory settings [15]. However, as we did not observe
reduced but substantially enhanced CD4+ T cell infiltration, we did not assume reduced recruitment
of a specific T cell subset in our model.
In line with our study, aggravated leukocyte infiltration was observed in LFA-1-deficient mice
in the EAE model which was caused by an impairment of the generation of regulatory T cells and
subsequent expansion in the absence of LFA-1 [9]. Enhanced CD4+ T cell infiltration into the spinal
cord was also observed by targeting LFA-1 in the EAE model [15]. Whether blocking of LFA-1 also
impacted expansion of regulatory T cells in the EAM model requires further investigation.
As described above, LFA-1 engagement can promote Th1 cell and suppress Th17 cell
differentiation. Interferonγ-producing Th1 cells represent the predominant T cell subset in autoimmune
myocarditis [16]. However, depletion of IL-17 reduced severity but did not prevent EAM, suggesting
that both subsets contribute to the inflammatory milieu in the EAM model [17]. Blocking LFA-1 could
potentially impact the fate of T cells towards Th17 effector cells thereby changing the inflammatory
setting. However, the mechanism of enhanced cardiac inflammation in myocarditis after blocking
LFA-1 still needs to be determined.
In summary, targeting LFA-1 substantially enhanced infiltration of neutrophils, monocytes/
macrophages, CD4+ T cells and potentially CD133+ progenitor cells and thereby promoted cardiac
inflammation in the EAM model. These findings suggest that engagement of LFA-1 may prevent
excessive inflammation in myocarditis.
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Abstract: Cellular inflammation following acute myocardial infarction has gained increasing
importance as a target mechanism for therapeutic approaches. We sought to investigate the effect of
syngeneic cardiac induced cells (CiC) on myocardial inflammation using 18F-FDG PET (Positron
emission tomography)-based imaging and the resulting effect on cardiac pump function using cardiac
magnetic resonance (CMR) imaging in a mouse model of myocardial infarction. Mice underwent
permanent left anterior descending coronary artery (LAD) ligation inducing an acute inflammatory
response. The therapy group received an intramyocardial injection of 106 CiC into the border zone of
the infarction. Five days after myocardial infarction, 18F-FDG PET was performed under anaesthesia
with ketamine and xylazine (KX) to image the inflammatory response in the heart. Flow cytometry of
the mononuclear cells in the heart was performed to analyze the inflammatory response. The effect
of CiC therapy on cardiac function was determined after three weeks by CMR. The 18F-FDG PET
imaging of the heart five days after myocardial infarction (MI) revealed high focal tracer accumulation
in the border zone of the infarcted myocardium, whereas no difference was observed in the tracer
uptake between infarct and remote myocardium. The CiC transplantation induced a shift in 18F-FDG
uptake pattern, leading to significantly higher 18F-FDG uptake in the whole heart, as well as the
remote area of the heart. Correspondingly, high numbers of CD11+ cells could be measured by
flow cytometry in this region. The CiC transplantation significantly improved the left ventricular
ejection function (LVEF) three weeks after myocardial infarction. The CiC transplantation after
myocardial infarction leads to an improvement in pump function through modulation of the cellular
inflammatory response five days after myocardial infarction. By combining CiC transplantation and
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the cardiac glucose uptake suppression protocol with KX in a mouse model, we show for the first
time, that imaging of cellular inflammation after myocardial infarction using 18F-FDG PET can be
used as an early prognostic tool for assessing the efficacy of cardiac stem cell therapies.
Keywords: inflammation; 18F-FDG PET; cardiomyocytes; cardiac induced cells; cardiac function;
non-invasive imaging
1. Introduction
Inflammatory activity of the innate immune system following myocardial infarction substantially
influences remodeling after myocardial infarction (MI) and the evolution of heart failure [1]. Therefore,
anti-inflammatory therapies have been under intense investigation since the early 1970s. Yet, none
of the clinical trials testing pharmacological strategies aiming at unspecific reduction of myocardial
inflammation has proven successful [2]. The main reason for these disappointing findings is the
complexity of the well-orchestrated activity of different leukocyte populations. The amplitude and
duration of inflammation and the timely and spatial resolution within the heart define the quality of the
scar following MI and the amount of tissue loss rather than the mere extent of inflammation [1]. Hence,
the concept of suppressing inflammation has changed to a further elaborated concept of “modulating
cellular inflammation”. The balance of pro- and anti-inflammatory immune cells and their recruiting
mechanisms are discussed as both therapeutic and prognostic targets [1]. Further understanding
of this intricate cellular immune response to myocardial ischemia in a translational setting requires
non-invasive molecular imaging tools. The 18F-FDG PET (Positron emission tomography) using
specific protocols for suppressing glucose uptake in cardiomyocytes has recently been introduced to
detect cellular inflammation following MI in both patients and C57BL/6 mice [1,3–5]
Protocols to suppress physiological myocardial 18F-FDG uptake require low-carbohydrate diet
the day before imaging followed by a 12 h fasting period and intravenous application of heparin before
the actual scan [3]. In mice, myocardial glucose metabolism can be effectively suppressed by replacing
the commonly used anaesthetic isofluorane for a ketamine/xylazine-based protocol [1].
However, to our knowledge, no studies have used these protocols for measuring therapeutic
effects of therapies aiming at improving myocardial healing following MI. Therefore, we implanted
syngeneic cardiac induced cells committed to the cardiac lineage in order to improve post-MI cardiac
function in 129Sv mice as measured my cardiac magnetic resonance (CMR). Cellular inflammation
was detected by 18F-FDG PET in vivo and by post-mortem flow cytometry in both infarcted and
remote myocardium.
We hypothesize that PET-based imaging and quantification of cellular inflammation can be used as
a molecular imaging tool for both quantification and spatial distribution of monocytes and as an early
prognostic tool to predict the effect of cardiac stem cell therapies modulating post-MI inflammation.
2. Materials and Methods
2.1. Stem Cell Culture and Cardiovascular Differentiation
W4 murine embryonic stem cells (mESCs), originally isolated from the 129S6 mouse strain [6],
were grown according to standard protocols as described previously [7]. In brief, cells were cultured
in DMEM supplemented with 15% FBS Superior (Biochrom AG, Berlin, Germany), 1% Cell Shield®
(Minerva Biolabs GmbH, Berlin, Germany), 100 μM non-essential amino acids, 1000 U/mL leukemia
inhibitory factor (Phoenix Europe GmbH, Mannheim, Germany) and 100 μM β-mercaptoethanol
(Sigma-Aldrich GmbH, Steinheim, Germany) at 37 ◦C, 5% CO2, and 20% O2. For cardiovascular
differentiation we used cardiogenic differentiation medium, containing IBM (Iscove’s Basal Medium,
Biochrom AG) supplemented with 10% FBS Superior, 1% Cell Shield®, 100 μM non-essential amino
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acids, 450 μm 1-thioglycerol (Sigma-Aldrich GmbH), and 213 μg/mL ascorbic acid (Sigma-Aldrich
GmbH), as described previously [7,8]. Cardiovascular differentiation was initiated by hanging-drop
culture for two days at 37 ◦C, 5% CO2, and 20% O2. 400 cells per drop were plated on the cover of a
square petri dish and grown for 2 days to start formation of embryoid bodies (EB). Afterwards, EB
were grown additional four days in suspension culture [9] and then harvested for transplantation and
PCR analysis. These cells will be referred to as cardiac induced cells (CiC). They were cultured till day
30 for beating foci analysis.
2.2. Animal Model
The present study was approved by the federal animal care committee of the Landesamt für
Landwirtschaft, Lebensmittelsicherheit und Fischerei Mecklenburg-Vorpommern (LALLF, Germany)
(registration no. LALLF M-V/TSD/7221.3-1.1-054/15). The 129S6/SvEvTac were bred in the animal facility
of the Rostock University Medical Center and maintained in specified pathogen-free conditions. The
mice had access to water and standard laboratory chow ad libitum and received humane care according
to the German legislation on protection of animals and the Guide for the Care and Use of Laboratory
Animals (NIH publication 86–23, revised 1985), and all efforts were made to minimize suffering. Mice
were anaesthetized with pentobarbital (50 mg/kg, intraperitoneal). Following thoracotomy, the left
anterior descending coronary artery (LAD) was ligated to induce acute myocardial infarction. The MI
group received an intramyocardial injection of 10 μL PBS mixed with 10 μL Growth Factor Reduced
Matrigel™Matrix (Corning, Berlin, Germany). The MI induction plus cell transplantation (MIC) group
received a suspension of 1 × 106 syngeneic in PBS (10μL) mixed with 10 μL Growth Factor Reduced
Matrigel™Matrix. Injections of 4 × 5 μL were given along the infarct border. The injection site was
controlled visually at the time of transplantation [10].
Healthy mice (n = 33) were divided into 7 groups for 18F-FDG PET imaging 5 days following MI
using different protocols for anaesthesia:
(1) no intervention, isofluorane (n = 2)
(2) no intervention, ketamine/xylazine (n = 2)
(3) MI group, isofluorane (n = 4)
(4) MI group, ketamine/xylazine (n = 6)
(5) MIC group, ketamine/xylazine (n = 7)
Cardiac function was assessed in separate groups three weeks following MI by cardiac MRI:
(6) MI only (n = 6)
(7) MIC (n = 6)
Flow cytometric analysis was performed in separate groups (MI, n = 5 and MIC, n = 5).
2.3. qRT-PCR
RNA was isolated from the cells using the NucleoSpin® RNA isolation kit (Macherey-Nagel,
Dueren, Germany). First strand cDNA was then synthesized using the cDNA synthesis kit (Thermo
Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. The qPCR reaction
was then carried out with the Taqman® Universal PCR Master Mix (Thermo Fisher Scientific) and
performed on a StepOnePlus Real-Time PCR system (Applied Biosystems, Foster city, CA, USA).
Primers of the following target genes: Pou5f1 (Mm00658129_gH), cTnnt2 (Mm01290256_m1), MesP1
(Mm00801883_m1), and Nkx2.5 (Mm01309813_s1) were purchased from Thermo Fisher Scientific. Gene
expression values of the target genes at day 6 were then normalized to the housekeeping gene Hprt
(Mm00446968_m1; Thermo Fisher Scientific) and compared relative to the expression values at day 0
using the ΔΔCt method for relative quantifications.
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2.4. Beating Foci Analysis
The number of beating foci per EB was analyzed from day 7 to day 30 of differentiation. The EB
were observed under a microscope (Carl Zeiss, Oberkochen, Germany) and the beating foci per each
EB were then visually analyzed using the ZEN2011 software (Carl Zeiss).
2.5. Flow Cytometry
Single cell cardiac monocyte suspensions were prepared for flow cytometry, as previously
described [11] Briefly, the remote and infarct tissue of the heart was dissected and enzymatically
digested separately in HBSS with Ca2+ and Mg2+(450 U/mL collagenase type I, 125 U/mL collagenase
type XI, 120 U/mL DNase I, 60 U/mL hyaluronidase, all Sigma-Aldrich) for 30 min at 37 ◦C. The digested
samples were then passed through a 100 μm filter and centrifuged to enrich for mononuclear cells.
Red blood cells were then lysed using erythrocytes lysis buffer (eBioscience, San Diego, CA, USA) and
the digest was then washed and suspended in MACS® buffer (PBS, 2 mM EDTA, 0.5% BSA). Samples
were then labeled using Zombie Aqua dye (BioLegend, San Diego, CA, USA.), washed, resuspended
in MACS buffer containing FCR Block (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), and
stained (see Table 1 for antibody list). Stained samples were then analyzed on a BD FACS LSR II®
running BD FACS Diva software (version 6.1.2, Franklin Lakes, NJ, USA). The various immune cell
populations in the heart tissue were then assessed, as described in Figure 1.








CCR2 475301 R and D
MHC-II AF6-120.1 Biolegend
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Figure 1. Gating strategy for identifying the different immune populations in the heart. Mononuclear
cells expressing CD45 were gated and doublets (FSC-W vs. FSC-A) were excluded. Dead cells
were excluded by Zombie aqua. The live single CD45+ cells were then grouped into R1, CD11b+
myeloid cells (CD45+/CD11b+/CD11c−); R2, dendritic cells (CD45+/CD11b+/CD11c+); and R3, NK
cells (CD45+/CD11b−/CD11c−/NK1.1+) based on their relative expression of CD11b and CD11c.
R5, neutrophils (CD45+/CD11b+/CD11c-/Ly6Ghi) were then excluded from R1 based on their Ly6G
expression. The remaining R4 monocytic cells were then further characterized into R6, Ly6Chi or
commonly known as M1 cells (CD45+/CD11b+/CD11c−/Ly6Glo/Ly6Chi); R7, Ly6Clo or commonly known
as M2 cells (CD45+/CD11b+/CD11c−/Ly6Glo/Ly6Clo) based on their Ly6C expression; and into R8,
fetal liver HSC-derived resident macrophages (CD45+/CD11b+/CD11c-/Ly6Glo/CCR2−/MHC-IIhi); R9,
monocyte derived macrophages (CD45+/CD11b+/CD11c-/Ly6Glo/CCR2+/MHC-IIhi); R10, monocytes
(CD45+/CD11b+/CD11c−/Ly6Glo/CCR2+/MHC-IIlo); and R11, yolk sac-derived resident macrophages
(CD45+/CD11b+/CD11c−/Ly6Glo/CCR2−/MHC-IIlo) based on their CCR2 and MHC-II expression. These
CCR2 and MHC-II gated populations were then back gated on R6 and R7 and their relative contribution
to the M1 (Ly6Chi) and M2 (Ly6Clo) cells was assessed.
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2.6. PET Imaging
For the PET study, mice of the groups 1,3, 6, and 7 were anaesthetized by inhalation of isoflurane
(4% for induction and 1% to 2.5% maintenance during preparation and scanning), whereas mice of the
groups 2,4, and 5 were anaesthetized by i.p. injection of ketamine/xylazine (ketamine 84 mg/kg and
xylazine 11.2 mg/kg) 20 min before tracer application. All PET/CT scans were performed on a small
animal PET/CT scanner (Inveon MM-PET/CT, Siemens Medical Solutions, Knoxville, TN, USA) [12]
according to a standard protocol: Mice were injected intravenously with a dose of approximately
10 MBq 18F-FDG via a custom-made micro catheter placed in a tail vein. After an uptake period
of 60 min, mice were imaged in prone position for 20 min. During the imaging session, respiration
of the mice was controled and core body temperature was constantly kept at 38 ◦C via a heating
pad. For attenuation correction and anatomical reference, whole body CT scans were acquired.
CT images were reconstructed with a Feldkamp algorithm. The PET images were reconstructed
with the three-dimensional (3D) iterative ordered subset expectation maximization reconstruction
algorithm (3D-OSEM/OP-MAP) with the following parameters: 4 iterations (OSEM), 32 iterations
(MAP), 1.7 mm target resolution, and 128 × 128 matrix size. Reconstruction included corrections for
random coincidences, dead time, attenuation, scatter, and decay.
2.7. PET Image Analysis
Image analyses were performed using an Inveon Research Workplace (Siemens, Knoxville, TN,
USA), as described previously [13]. PET (Positron emission tomography) and CT (Computerized
tomography) images were fused by the use of an automated volumetric fusion algorithm and then
verified by an experienced reader for perfect alignment. Consecutively, standardized representative
volumes of interest (VOI) were manually placed in the remote area and in the infarcted region as well
as the whole heart guided by anatomical landmarks, as described in detail in Figure 2. Correct VOI
positioning was visually verified in axial, coronal, and sagittal projection.
Carimas 2 software (Turku PET Centre, Turku, Finland) was used for generating polar maps of
the left ventricle according to the manual provided by the developer. Results are presented using
17-segmental standardized myocardial segmentation.
Figure 2. Representative images visualizing our volumes of interest (VOI) positioning strategy:
(A) Myocardium of healthy mice anaesthetized with isofluorane can be clearly delineated and served
as a reference for VOI positioning. (B and C) Anaesthesia with ketamine/xylazine. A VOI of 5 μL was
positioned in both anterolateral wall (infarct area, green) and remote area (inferobasal, blue). Thereby
both anatomical landmarks form the CT scan and the image of healthy myocardium (A) was used.
2.8. Cardiac Magnetic Resonance Imaging
Cardiac magnetic resonance (CMR) measurements were performed on a 7 Tesla small animal
MRI system (BioSpec 70/30, maximum gradient strength 440 mT/m, Bruker BioSpin Gmbh, Ettlingen,
Germany) equipped with a 1H transmit volume coil (86 mm, volume resonator) and a 2-by-2 receive-only
surface coil array (both Bruker BioSpin GmbH). After induction of anaesthesia using 2% to 3.5%
isoflurane in oxygen, animals were placed in a supine position on a dedicated mouse bed and surface
coil was placed on the chest of the mice. Respiration rate and body temperature were monitored
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using an MR-compatible small animal monitoring and gating system (Model 1030, SA Instruments,
Inc., Stony Brook, NY, USA), and stable body temperature was maintained by a warm water heating.
Anaesthesia was maintained during the experiment with isoflurane oxygen (1.5% to 2%) to achieve a
respiration rate of about 35 to 55 breaths.
After planning sequences, for the short axes view final images of the left ventricular ejection
fraction (LVEF) measurements were acquired using a IntraGate gradient-echo cine sequences (IntraGate
Cine-FLASH) in six short-axis planes completely covering the left ventricle. Acquisition parameters
included: echo time (TE) 2.38 ms, repetition time (TR) 5.89 ms, flip angle 15◦, 14 frames per cardiac cycle,
oversampling 140, averages 1, field of view (FOV) 29.4 × 25.2 mm, matrix size 211 × 180, resolution
in-plane 0.14 × 0.14 mm, slice thickness 1 mm, and scan time per slice 2 min.
2.9. Cardiac Magnetic Resonance Analysis
LVEF was assessed from the cine sequences using the freely available software Segment v2.0 R5165
(Medviso, Lund, Sweden) (http://segment.heiberg.se) [14]. The left ventricular (LV) endocardium in
these slices was manually segmented to exclude the papillary muscles. The volumes of these segments
were then integrated along the six planes of the LV and LVEF was then calculated from their summated
end systolic and end diastolic volumes.
2.10. Statistics
All data are presented as mean values ± standard deviation (SD). Flow cytometric data and qPCR
values are presented as mean values ± standard error of mean. Student’s t-test was used for statistical
analysis of parametric data and the Mann–Whitney test was used for nonparametric analysis of flow
cytometric data. Values of p < 0.05 were considered statistically significant.
3. Results
3.1. Cardiac Induced Cells Show Increased Cardiac Markers and Beating Activity During Differentiation
In order to ascertain the differentiation status of the cells, we examined the expression of various
markers at the beginning and at day six of differentiation (Figure 3A). We observed the expression
of early cardiac markers such as MesP1, Nkx2.5, and cardiac troponin (cTnnt2). They were increased
several fold at day six, whereas the expression of the pluripotency marker, Pou5f1 (also known as Oct4),
was strongly decreased. This indicates the cardiac lineage commitment of the cells. We also investigated
the beating activity of the cells along the differentiation process to determine their functional capability
(Figure 3B). In accordance with the strong induction with the induction of the cardiac markers, the
cells were robustly beating and the number of beating foci per EB consistently increases over time till
day 30 of differentiation. Therefore, these cardiac-induced cells have committed to the cardiac lineage
with the potential to form beating cells in the host after transplantation.
Figure 3. Cont.
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Figure 3. Characterization of cardiac-induced cells: (A) Analysis of mRNA expression after six days of
cardiac differentiation shows a decrease of the pluripotency marker Oct4, whereas cardiac markers
are upregulated. The mRNA expression was normalized to the expression of the house keeping gene
hprt. Values are expressed as fold increase as compared with day 0. Values are presented as mean ±
SEM. (B) Starting at day 7 of the cardiac differentiation protocol, beating foci per embryoid bodies (EB)
were counted until the end of differentiation (n = 3). Values are presented as mean ± SD. p-value was
calculated using the student t-test.
3.2. Impact of Anaesthesia on the FDG-Uptake Pattern in the Infarcted Heart
First, we examined if the myocardial glucose uptake suppression protocol established by Thackeray
et al. [5] for C57BL/6 J mice can be applied in the mouse strain 129Sv used in our study on healthy mice
(Figure 4).
Figure 4. Representative images of healthy mice anaesthetized with isofluorane (upper row)
and ketamine/xylazine (lower row). Uptake of 18F-FDG is effectively suppressed by the use of
ketamine/xylazine as can be seen in axial, coronal, and sagittal planes, as well as the polar maps.
Secondly, 18F-FDG PET was performed five days after permanent LAD ligation. Under anaesthesia
with isofluorane, the highest tracer accumulation was detected in the viable myocardium, whereas
ketamine/xylazine (KX) led to accentuated tracer accumulation within the border zone (Figure 5).
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Figure 5. Sample axial, coronal, and sagittal myocardial 18F-FDG images at five days post-surgical
myocardial infarction (MI) induction. Isofluorane leads to high tracer accumulation in the healthy
myocardium, whereas the infarcted area can be clearly identified as an area of low glucose metabolism
(upper row). When using ketamine/xylazine, the most intense tracer accumulation is detected in the
area of the border zone, whereas 18F-FDG uptake in healthy myocardium remains suppressed.
The 18F-FDG uptake was significantly reduced by the use of ketamine/xylazine as compared with
isofluorane for anaesthesia in the whole heart (5.2 ± 0.7% ID/g vs. 46.1 ± 11.2% ID/g; p = 0.02) and both
remote (4.1 ± 0.6% ID/g vs. 79.3 ± 22.7% ID/g; p < 0.0001) and infarcted myocardium (4.35 ± 0.4% ID/g






















Figure 6. Regional quantitative analysis of 18F-FDG uptake five days after myocardial infarction in the
whole heart, the infarct and the remote myocardium. Mice were anaesthetized with isofluorane or
ketamine/xylazine, respectively. Values are presented as mean ± SD. p-value was calculated using the
student t-test.
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With KX, there was no difference in tracer uptake between remote and infarcted myocardium
(4.1 ± 0.6% ID/g vs. 4.4 ± 0.4% ID/g; p = 0.5). In contrast isoflurane lead to significantly higher 18F-FDG
uptake in the remote as compared with the infarcted myocardium (79.3 ± 22.7% ID/g vs. 11.6 ± 6.0%
ID/g; p = 0.001).
3.3. FDG-Uptake Pattern is Fundamentally Changed by Cell Transplantation
We then compared 18F-FDG uptake patterns in untreated to animals treated with CiC therapy
(MIC) using the ketamine/xylazine protocol (Figures 7 and 8). Transplantation of embryoid bodies
containing 106 syngeneic cardiac induced cells following acute myocardial infarction led to an increase
in 18F-FDG uptake in the remote myocardium as compared with the MI group (10.7 ± 4.3% ID/g
vs. 4.1 ± 0.6% ID/g; p = 0.003) (Figure 9). Interestingly, tracer accumulation in the center of the
infarcted area was not altered by cell therapy (4.3 ± 1.4% ID/g in MIC vs. 4.4 ± 0.4% ID/g in MI;
p = 0.9). Furthermore 18F-FDG uptake in the whole heart was significantly increased in the MIC group
(8.0 ± 2.9% ID/g vs. 5.2 ± 1.1% ID/g; p < 0.05).
Figure 7. Sample axial, coronal, and sagittal myocardial 18F-FDG images at five days post-surgical
MI induction and MI induction plus cell transplantation (MIC). Mice were anaesthetized with
ketamine/xylazine. The MI group showed intense tracer accumulation in the border zone, whereas in
cell-treated animals the highest tracer accumulation was found in the remote area.
Figure 8. Representative 17-segment tomographic polar maps visualizing distinctive differences of
FDG-distribution in the left ventricle between the groups. The apex is in the middle and the anterior
wall at top, the inferior wall at bottom, the septum in left and the lateral wall in the right. High tracer
uptake is visualized by the yellow colors, lower upake by red and black. (A) MI group anaesthetized
with isofluorane, the infarct region shows low FDG uptake as compared with remote myocardium; (B)
MI group anaesthetized with ketamine/xylazine, the most intense FDG uptake came in the border zone;
and (C) MI + cardiac induced cells (CiC) group anaesthetized with ketamine/xylazine shows a change
of the FDG uptake to a pattern, which is similar to (A) with low FDG accumulation within the infarct
region and highest uptake in the remote area.
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Figure 9. Regional quantitative analysis of 18F-FDG uptake five days after myocardial infarction in
the whole heart, infarct, and remote myocardium. Both MI and MIC group were anaesthetized using
ketamine/xylazine. Values are presented as mean ± SD. p-value was calculated using the student t-test.
3.4. Improvement of Cardiac Function Through Cell Therapy Assessed by CMR
In order to assess the value of 18F-FDG-based imaging of cellular inflammation post-MI as an early
predictor of functional outcome following cardiac cell therapy, cine CMR was performed three weeks
after LAD ligation in separate groups. LVEF was significantly reduced by LAD ligation as compared
with healthy animals (24.2 ± 4.1% vs. 59.3 ± 3.7%; p < 0.001). Cell therapy led to a significant increase
of LVEF (31.7 ± 3.5% vs. 24.2 ± 4.1%; p = 0.007) (Figure 10). From this we conclude, that the change in
the 18F-FDG uptake pattern, as described above, is a valuable early predictor of therapeutic efficacy.
Figure 10. Improved cardiac function after transplantation of embryonic stem cells (ESC) derived
CiC following acute myocardial infarction at 3 weeks following MI. (A) Magnetic resonance imaging
analyses of infarcted animals receiving either CiC (MIC) or matrigel and healthy animals and (B) left
ventricular ejection fraction was significantly higher in CiC animals vs. control animals (n = 6, p-value
was calculated using the student t-test).
3.5. Modulation of the Immune Response Through Cell Therapy Assessed by Flow Cytometry
In order to identify the immune response within the myocardium, we analyzed the mononuclear
cell (MNC) suspension isolated from the remote and infarct area of the hearts of 129Sv mice five days
after MI or MIC (Figure 1).
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We observed a significantly higher percentage of NK cells (CD45+/CD11b−/CD11c+/NK1.1+) in
the infarct area (0.82 ± 0.04 vs. 0.56 ± 0.03; p = 0.01) as compared with the remote area in MI mice. Cell
therapy influences the various immune subpopulations differently in infarct and remote areas of the
heart. On the one hand, cell therapy led to a significantly higher percentage of CD11b+ myeloid cells
(Figure 11A) in the remote area (49.28 ± 3.92 vs. 31.17 ± 2.72; p = 0.01) of MIC hearts as compared with
MI hearts. This agrees well with the increased 18F-FDG uptake observed in the remote area of MIC
mice (Figure 9), which has been attributed mainly to CD11b+ cells [1]. On the other hand, cell therapy
led to a decrease in the percentage of NK cells (Figure 11A) in the infarct area (0.41 ± 0.05 vs. 0.82 ±
0.04; p = 0.007) when compared to MI hearts.
Figure 11. Effect of CiC transplantation on the percentage of various immune cell subpopulations in
the heart based on flow cytometric analysis. Mice were subjected to MI/MI+ cells and the remote and
infarct area of the hearts were dissected, digested, and the isolated mononuclear cells were stained
using various antibodies. These immune cell populations were then characterized using the gating
strategy described before and represented as three major groups. (A) CD11b+ and NK cells, (B)
populations based on their CCR2/MHC-II expression, and (C) contribution of the populations towards
the M1 (Ly6Chi) and M2 (Ly6Clo) cells, n = 5. Values are represented as mean ± SEM. Significance was
calculated using the Mann–Whitney test.
Interestingly, we also observed various differences in various CD11b+ subpopulations based on
their relative CCR2 and MHC-II expression between the MI and MIC groups (Figure 11B,C).
In the remote area, cell therapy led to an increase in the percentage of fetal liver HSC-derived
resident macrophages (4.68 ± 1.03 vs. 1.29 ± 0.32; p = 0.05) and an increase in the percentage of
monocyte-derived macrophages (50.48 ± 3.24 vs. 24.35 ± 4.54; p = 0.007), and their relative contribution
to the percentage of M1 (Ly6Chi) (58.48 ± 5.41 vs. 28.11 ± 7.72; p = 0.01) and M2 (Ly6Clo) (47.28 ± 3.95
vs. 23.39 ± 3.38%; p = 0.007) cells along with a subsequent decrease in the percentage of monocytes
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(24.33 ± 5.61 vs. 44.36 ± 5.62; p = 0.05) and their relative contribution to the percentage of M1 (Ly6Chi)
(33.76 ± 6.9 vs. 67.85 ± 7.22; p = 0.03) and M2 (Ly6Clo) (13.25 ± 1.74 vs. 32.71 ± 3.56; p = 0.007) cells as
compared with MI.
In the infarct area, we observed an increase in the percentage of fetal liver HSC-derived resident
macrophages (4.68 ± 1.03 vs. 1.29 ± 0.32; p = 0.05) as well as monocyte-derived macrophages (57.46 ±
4.37 vs. 38.89 ± 8.13) and their relative contribution to the percentage of M2 (Ly6Clo) (51.44 ± 2.47 vs.
33.25 ± 6.6%; p = 0.03) cells with a subsequent decrease in the percentage of monocytes (18.88 ± 5.99 vs.
32.25 ± 6.88; p = 0.05) and their relative contribution to the percentage of M1 (Ly6Chi) (27.6 ± 7.59 vs.
47.4 ± 10.04; p = 0.05) and M2 (Ly6Clo) (8.39 ± 1.17 vs. 25.85 ± 6.15; p = 0.007) along with a decrease in
the percentage of yolk sac-derived resident macrophages (20.16 ± 2.43 vs. 27.95 ± 2.15; p = 0.05) as
compared with the MI group.
Therefore, CiC transplantation in the heart increases the CD11b+ cells in the remote area of
the heart while favoring an increase in the MHC-IIhi subset of CD11b+ cells (monocyte derived
macrophages and fetal liver HSC-derived resident macrophages) in both the infarct and remote areas.
4. Discussion
Translational cardiovascular research has evolved at an incredible pace within the last decade and
resulted in significantly higher survival rates after acute myocardial infarction. In contrast to highly
efficient approaches based on early revascularization and pharmacological prevention of adverse
ventricular remodeling, replacement of irreversibly lost cardiomyocytes has not been achieved yet,
despite huge efforts in the field of regenerative medicine.
Recently, cellular inflammation following ischemic myocardial injury has been identified as a
key player in the process of myocardial healing. Thereby, the local distribution patterns of specific
monocyte and macrophage subpopulations have been proposed to determine the quality of myocardial
healing [15,16].The vast majority of data has been obtained from rodent studies because their hearts
can easily be excised for in vitro experiments such as flow cytometric measurements of single cells
suspensions. Most researchers focus on the invasion of two distinct macrophage subpopulations,
usually referred to as M1 and M2 macrophages. The early M1 macrophage subset is attracted to the site
of myocardial injury via CCL2, expressing pro-inflammatory mediators and proteases for degradation
of infarcted tissue. Subsequently, M2 macrophages are recruited via CX3CL1 for mediating synthesis
of extracellular matrix and angiogenesis [3]. However, the M1/M2 classification does not adequately
explain the complete spectrum of macrophage phenotypes. Recently, macrophages which do not
express CCR2 in the neonatal heart have been shown to regenerate the infarcted tissue [15] while
the adult heart involves CCR2+ monocyte-derived macrophages also taking part in the remodeling
process [17].
Preclinical studies have examined the effect of therapeutic applications, such as stem cell
injections, to modify the qualitative and quantitative composition of the post infarct cellular immune
response [18–20]. This modulation of the innate cellular immune response resulted in improved cardiac
pump function, reduction of scar size, and adverse remodeling [18]. Findings from a meta-analysis by
our group have ascribed high therapeutic potential to cardiovascular cell preparations [21]. Therefore,
we sought to transplant ESC-derived cardiac induced cells to improve myocardial healing and also
investigate whether they influence the ischemic cellular immune response.
The above-mentioned experiments are based on post-mortem analyses such as flow cytometry
and immunohistochemistry of excised organs, and thus have been restricted to preclinical research.
However, clinical translation requires methods that allow in-vivo visualization and quantification of
inflammatory cells. Lee et al. established 18F-FDG PET for imaging the inflammatory cell activity in
the heart, based on suppressing glucose metabolism in myocytes [1]. Interestingly, anaesthesia with
ketamine/xylazine is both sufficient and highly effective in reducing glucose uptake in cardiomyocytes,
hence, enabling visualization of inflammatory activity in the heart [1]. According to Lee et al.,
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18F-FDG uptake at the site of myocardial inflammation related to the content of local CD11b+
monocyte/macrophage concentration in C57BL6 mice [1], at day 5 after MI induction.
On the basis of these findings by other groups, we hypothesized the following:
(A) Distribution pattern of CD11b+ myeloid cells at day five after MI induction can be modified by
intramyocardial transplantation of CiC;
(B) This change can be visualized and quantified by 18F-FDG PET using ketamine/xylazine
anaesthesia;
(C) The specific 18F-FDG uptake pattern correlates with functional outcome as measured by cardiac
magnetic resonance imaging.
We were able to replicate the glucose uptake suppression protocol based on anaesthesia with
KX [5] in 129sv mice and achieved an almost 88% reduction in the glucose uptake in the whole
myocardium as compared with isoflurane anaesthesia. We did not find any significant difference in the
18F-FDG uptake levels between the remote and infarcted myocardium using KX anaesthesia, which is
in line with findings from Thackeray et al. [4,5]. Furthermore, intense focal tracer uptake was localized
in the border zone. Similarly, Lee et al. also reported accentuated FDG uptake in the border zone
corresponding to high numbers of infiltrating CD11b+ cells [1]. Despite visual assessment of this high
focal tracer accumulation, quantitative analysis in this region was only performed by Thackeray et al.
However, their VOI positioning strategy remains unclear from the manuscript. This might be due to
a certain overlap of the border zone to the adjacent regions which makes demarcation of the border
zone difficult. In order to produce comparable data in this aspect, VOI positioning strategies should be
provided in future studies.
Interestingly, transplantation of 106 cardiac induced cells after MI significantly increased FDG
uptake in both the whole heart and the remote myocardium, but not in the infarct region. Moreover,
CiC transplantation led to a 7% improvement in LVEF three weeks after MI. The magnitude of LVEF
improvement is well in line with previous reports [21]. Therefore, we conclude that the change in the
myocardial 18F-FDG uptake pattern represents a valid tool for early PET-based in vivo prediction of
myocardial healing post MI.
A deeper investigation of the immune response in the heart five days after MI using flow cytometry
revealed an increase in the percentage of CD11b+ cells and a shift towards increased monocyte-derived
macrophages in the remote area of cell-treated mice. We also observed a reduction in the yolk
sac-derived resident macrophages in the infarct area of cell-treated mice. We did not however observe
a shift in the M1/M2 polarization phenotype, as observed in previous studies involving MSCs [18].
It is interesting to note that increased monocyte-derived macrophages and reduced yolk sac-derived
macrophages in the heart have been previously attributed to adverse cardiac remodeling and scar
formation [17]. However, these studies did not involve the transplantation of cells into the infarcted
heart and it is well known that the gene expression profile and the characteristics of the immune cells
are affected based on their location in the myocardium and the cells they interact with [22].
However, unbiased expression profiling of these cells over various time points and under the
influence of CiC has yet to be carried out. The influence of CiC transplantation on the immune response
in the heart has not been studied until now and our work suggests possible new mechanisms and
targets for improving the efficiency of CiC.
The 18F-FDG-based imaging strategies for myocardial inflammation are highly attractive and
have been applied in a clinical setting despite some limitations, which have yet to be overcome [3].
Both cardiomyocytes [4] and infiltrating inflammatory cells [23] in the setting of acute myocardial
injury possess high levels of glucose metabolism. Metabolism of healthy cardiomyocytes is mainly
based on fatty acid oxidation, whereas ischemia triggers increased anaerobic glycolysis, which requires
much higher rates of glucose [24]. This might hamper direct correlation of focal 18F-FDG uptake
and high concentration of CD11b+ cells in the infarcted region. The use of KX for anaesthesia has
been shown to reduce serum insulin levels in rodents, thus, preventing translocation of GLUT4 to
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membranes of cardiomyocytes and reducing 18F-FDG uptake [25]. In contrast, leucocyte glucose influx
in a setting of acute inflammation depends more on GLUT1 and GLUT3, which are expressed and
translocated independently of insulin [26]. Whereas, this KX protocol is well suited for preclinical
research, different strategies are used for suppression of myocardial glucose uptake in patients including
prolonged fasting, dietary modifications, and heparin loading before imaging [27]. This might hamper
straightforward translation of imaging protocols established in rodents to clinical application.
Furthermore, the transplantation of CiC adds more complexity to its use in imaging the
myocardium. It becomes difficult to attribute the observed 18F-FDG uptake pattern to the inflammatory
cells alone since the ability of CiC to alter the cardiac metabolism is poorly understood. It is, therefore,
difficult to delineate the relative contribution of 18F-FDG uptake between the host cardiomyocytes,
immune cells, and the CiC. The heterogeneity of the inflammatory response and the relative 18F-FDG
uptake between the different immune cell populations is also clearly not understood. Further research
is necessary to understand metabolic changes in the different cells involved in healing myocardium.
Nevertheless, this is the first study to investigate 18F-FDG-based PET imaging of inflammation as
an early indicator for assessing long term therapeutic efficiency in a rodent model of acute myocardial
infarction. Furthermore, the current work illustrates the benefit of CiC transplantation to improved
cardiac function after MI possibly through its beneficial modulation of the innate inflammatory
response. Using such non-invasive techniques in the field of translational research will foster a better
understanding of the inflammatory response and how its modulation could lead to altered cardiac
function. It is also a valuable tool for monitoring various immune modulation and cell therapies and
broadens the horizon for understanding the mechanisms of these therapeutic strategies.
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CiC cardiac induced cells
mESCs murine embryonic stem cells
MI myocardial infarction
EB embryoid bodies
LAD left anterior descending coronary artery
FOV field of view
VOI volumes of interest
CMR cardiac magnetic resonance
LV left ventricle
LVEF left ventricular ejection fraction
SD standard deviation
SEM standard error of mean
MNC mononuclear cell
KX ketamine/xylazine
PET positron emission tomography
CT computerized tomography
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Abstract: Three dimensional (3D) printing, which consists in the conversion of digital images into a
3D physical model, is a promising and versatile field that, over the last decade, has experienced a
rapid development in medicine. Cardiovascular medicine, in particular, is one of the fastest growing
area for medical 3D printing. In this review, we firstly describe the major steps and the most common
technologies used in the 3D printing process, then we present current applications of 3D printing
with relevance to the cardiovascular field. The technology is more frequently used for the creation of
anatomical 3D models useful for teaching, training, and procedural planning of complex surgical
cases, as well as for facilitating communication with patients and their families. However, the most
attractive and novel application of 3D printing in the last years is bioprinting, which holds the
great potential to solve the ever-increasing crisis of organ shortage. In this review, we then present
some of the 3D bioprinting strategies used for fabricating fully functional cardiovascular tissues,
including myocardium, heart tissue patches, and heart valves. The implications of 3D bioprinting in
drug discovery, development, and delivery systems are also briefly discussed, in terms of in vitro
cardiovascular drug toxicity. Finally, we describe some applications of 3D printing in the development
and testing of cardiovascular medical devices, and the current regulatory frameworks that apply to
manufacturing and commercialization of 3D printed products.
Keywords: 3D printing; 3D model; bioprinting; cardiovascular medicine; heart; myocardium;
heart valves
1. Introduction
Three dimensional (3D) printing is a technique used to transform digital images in a physical
3D model by fusing or depositing material layers. The materials deposited can be powders, plastics,
ceramics, metals, liquids, or even living cells, making the process extremely versatile [1,2]. The first
technology for 3D printing, called stereolithography, was introduced in 1986 by Charles Hull [3].
From its invention, 3D printing has been largely developed, mostly in the last decades, and nowadays
several techniques are available, with applications spanning from the industrial to the medical field [4].
In medicine, 3D printing is utilized for several purposes such as teaching, surgical planning,
development of novel and/or personalized implantable devices, and also for creating scaffolds for tissue
engineering and artificial functional tissue regeneration [5]. Since its first introduction, the application
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of 3D printing has greatly expanded mainly in the maxillofacial and orthopedic sectors [6]. With regard
to the cardiovascular field, one of the most popular clinical uses of 3D printing is related to the possibility
to create 3D printed heart models. These personalized models are proven to be particularly useful in
pre-operative planning and pre-surgical simulation of complex cardiac interventions, intra-operative
orientation for improving clinical decision-making, medical education and training, and communication
in medical practice [7]. In this review, we firstly introduce the 3D printing process and technologies
with relevance to cardiovascular medicine. Then, we present some cases of patient-specific 3D printing
applications in cardiovascular pre-operative training and pre-surgical planning. Since 3D bioprinting
currently represents the most attractive application of 3D printing in the healthcare sector, we then
introduce methods for 3D bioprinting and the most commonly used bioinks. This review subsequently
covers the applications of 3D bioprinting in the cardiovascular field through categories that include
myocardium, heart valves, and cardiac patches for drug screening. In the last section, we describe
current regulatory frameworks that USA and EU apply to 3D printed products. Finally, we summarize
the major limitations of 3D printing and bioprinting, and the future directions that will enable the
translation of these technologies to personalized therapeutic and pharmaceutical applications.
2. Process and Technologies of Cardiovascular 3D Printing
Generating a 3D model is a complex process comprising the sequential stages of diagnostic images
acquisition, digital modeling, and 3D printing (Figure 1) [8]. Close collaboration between physicians,
imagers, and engineers is therefore fundamental to obtain a functional and accurate 3D printed model.
The first step in the 3D printing process is the acquisition of accurate volumetric images formed by
contiguous multiple slices that provide a dataset. Medical images suitable for 3D printing must have
high contrast between adjacent structures, low noise, and high spatial resolution [9]. The methods
usually employed to acquire cardiovascular imaging data are computed tomography (CT) and magnetic
resonance imaging (MRI), but in some cases also 3D transthoracic echocardiography (TTE) or 3D
transesophageal echocardiography (TEE) are utilized [10]. Since the quality of the imaging sourcing
data is fundamental to obtain precise 3D models, it is essential to evaluate the advantages and
limitations of each imaging modality prior to acquiring patient images for 3D modeling. CT represents
the preferred imaging technique for 3D printing, because it can provide sub-millimetrical resolution of
tissues. In the cardiovascular field, CT is an advantageous option for modeling both intracardiac (atria
and ventricles) and extracardiac (great vessels) structures [11]. In addition, CT is able to clearly identify
bone and pathologic calcium deposition, and to image patients with pacemakers, artificial valves and
metal implants that are not compatible with MRI scanning [12]. However, the major limitation of CT is
the exposure to radiation caused by the emission of X-rays, which has been correlated with increased
risk of cancer [13]. On the other hand, MRI allows the acquisition of high-resolution images without
the employment of ionizing radiation. This imaging modality is mostly employed for visualizing soft
tissues; for example, it has been used for the creation of heart chambers and vasculature 3D models,
and for the reconstruction of intracardiac tumors [14]. However, a limitation of MRI in comparison to
CT includes a lower spatial resolution that limits its use for the evaluation of coronary arteries or the
small morphological features within heart valve complexes [12]. 3D echocardiography is a widely
available, relatively low-cost ultrasound imaging technique which, similarly to MRI, lacks ionizing
radiation. 3D echocardiography is a valuable tool to 3D model ventricular chambers, cardiac valves,
and the interatrial septum; however, it is subjected to artifacts and it is not suitable for visualizing
extracardiac structures, such as the aorta and pulmonary arteries [15].
The second step in the 3D printing workflow is segmentation, namely, the delineation of
appropriate regions of interest for creating patient-specific and highly accurate models of organs and
tissues. In cardiovascular 3D printing, this process aims at discriminating the cardiovascular structures
of interest, excluding irrelevant noncardiac structures, such as bone and lung [9]. Segmentation is a
multi-step process. Prior to segmentation, the acquired diagnostic imaging dataset is exported into
a digital imaging and communication in medicine (DICOM) format, which can be universally used
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in digital modeling softwares without the need for file type conversion [16]. Several medical image
segmentation softwares are available; some of these are open-source and freely accessible, while others
are commercial, licensed products. From the DICOM dataset, the target anatomic geometry is identified
and segmented based on properties such as contrast or brightness [17]. As a result, segmentation
masks are created such that pixels with the same intensity range are grouped and converted into 3D
digital models using rendering techniques. These segmented digital models are then exported out
in the standard tessellation language (STL) file type, which is the industry standard for 3D objects
and 3D printing software [17]. Nevertheless, STL files do not contain color information and in order
to print in multiple colors, a different file format will need to be used. For example, virtual reality
modeling language (VRML) and additive manufacturing file format (AMF) provide multiple color
and material options [18]. Once segmentation is completed, the final 3D digital model may be further
modified within computer-aided design (CAD) software. The main post-processing adjustments of the
3D model are: Repairing errors and discontinuities that sometimes arise in the image segmentation
and exporting processes, smoothing of the surface of the model due to scaling errors resulting from the
resolution of the original medical image, and addition of other structures or elimination of unneeded
parts from the segmented model [19].
The last step is the actual printing, and in this context it is important to identify the best type of
technology and materials in relation to the final purpose, considering complexity, durability, and quality
of the model to be obtained. Currently, several 3D printing technologies are available; the most
frequently reported with potential applications in cardiovascular medicine are stereolithography
(or vat polymerization), powder bed fusion (or selective laser sintering), material extrusion
(or fused fiber filament/fused deposition modelling), and material jetting (or polyjet printing) [10,19].
Stereolithography and powder bed fusion technologies use a laser to fuse multiple layers of print
material [17]. In particular, stereolithography uses ultraviolet laser light to harden the surface layer
made of photopolymeric liquid resin, whereas powder bed fusion uses a laser to heat and fuse a bed of
powdered printing material without requiring any support structure. In contrast, material extrusion
and material jetting technologies use a nozzle or jet, respectively, to lay down a liquefied print material,
which then solidifies before a new layer is built [17]. In detail, the extrusion technique creates 3D
models by extruding thermoplastic materials or bioinks filaments layer by layer. Material jet printers,
instead, produce 3D models by jetting thin layers of photopolymers that are instantly hardened by
ultraviolet light, and allow the incorporation of multiple-materials and colors simultaneously. Once
the print is completed, post-processing may also be required, which often includes cleaning to remove
residual debris and support material and sanding if smooth surfaces are needed [14].
Figure 1. Cardiovascular 3D printing workflow includes acquisition of imaging data, segmentation,
imaging modeling, and actual 3D printing. Reprinted with permission from Vukicevic et al. [12].
Copyright© 2020 American College of Cardiology Foundation.
3. 3D Printing for Teaching and Surgical Training in Cardiovascular Medicine
In modern medical schools, the use of 3D models is emerging as a successful novel tool to support
and complement the classic methods for anatomy teaching and demonstration [20,21]. The creation
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of 3D models starting from a clinical dataset of images allows the realization of teaching models
of normal and abnormal anatomy. Traditionally, cardiac morphology teaching is carried out using
samples collected during cadaveric dissection or heart transplantation in pathological patients [18].
Nonetheless, the scarcity of these specimens, associated with the fact that these do not represent all
possible heart diseases, makes 3D models more promising educational resources [18]. Interestingly,
3D models can be fabricated with materials that mimic the real consistency of tissues and they can be
scaled to any size. In addition, these 3D models can be printed with different colors, variable material
hardness, and even layered texturing if needed to reproduce sophisticated or unusual cardiovascular
pathology (Figure 2). Another aspect not to be underestimated is the possibility for several generations
of students to handle, manipulate and experience such anatomical variations because 3D printed
models are reusable and safe. Consequently, there is no need of special laboratories, instruments,
or equipments, such as cadaveric specimens, whose availability is becoming increasingly difficult due
to logistical, financial and ethical issues [21–24].
Figure 2. (A) Multi-material and multi-colored patient-specific 3D printed heart for educational
purposes and communication with patients. LV, left ventricle. Reprinted with permission from
Vukicevic et al. [12]. Copyright© 2020 American College of Cardiology Foundation. (B) Four models
for surgical practice and training. Reprinted with permission from Yoo et al. [18]. Copyright© The
Author(s) 2016.
3D printed anatomical models are great resources also for surgical and pre-operative training,
thanks to the patient-specific information which can be obtained from the model. In particular,
3D printed models are considered more helpful than virtual reality (VR) and 3D digital images when
visualizing complex cases. Indeed, VR and 3D digital imaging do not always demonstrate spatial
relationships efficiently and may not always provide an accurate representation of the anatomy [24,25].
The use of such 3D printed models allows a realistic simulation of the surgical procedure to be
performed before the actual surgery, thus acting as a surgical guide. If, on one hand, the trainees
can learn, practice and repeat surgical procedures until they feel confident, the experienced surgeons,
on the other hand, can use 3D printed models for developing new procedures or improving their
surgical skills for rare diseases. This is especially true for certain rare congenital heart diseases (CHD),
where each patient has a different intracardiac and extracardiac anatomy, such as the chest wall and
the relation of the heart to the chest wall. In all these cases, 3D printed models can lead to better
pre-operative planning [26,27]. Other advantages of training using 3D models include a reduction in
operation time and the possibility to predict intra-operative complications and plan management as
required [21]. The use of 3D printed models can ease the communication not only within the clinical
staff but also with patients and their family [28]. For example, the patient’s cardiovascular pathology
and the intended or previously performed surgical procedure can be more easily understood when it
is explained using 3D printed models [18].
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Several cases of patient-specific 3D printing applications in cardiovascular pre-operative training
have been reported. Recently, Bateman and coworkers at the University of Minnesota described three
case studies in which heart 3D printed models resulted fundamental to evaluate the most appropriate
surgical procedure [14]. The first case concerned a patient with dextrocardia that needed the placement
of a left ventricular epicardial pacing. Because of the patient’s anomalous anatomy, a 3D model was
requested to highlight the paths of the coronary arteries across the myocardium of the left ventricle
(LV), finally permitting to practice a minimal invasive surgical approach. The second case was about a
patient with a very complex congenital heart disease accompanied by a complex vascular anatomy that
requested heart transplantation. The creation of a detailed 3D printed model allowed to determine
the best donor and recipient preparation to plan for the implantation of a normal anatomic heart into
an anomalous cardiac vascular anatomy. In the last case study, two conjoined sisters attached from
chest to navel had to be separated. 3D printed models of the two hearts revealed a previously unseen
myocardial connection and led the surgeons to change the surgical procedure. These three case studies
demonstrate that the close collaboration between the University of Minnesota’s Academic Health
Center and relevant departments of engineering has created an excellent environment for developing
projects based on the clinical application of 3D printing in the cardiovascular field.
Patients with non-valvular atrial fibrillation (AF) undergoing left atrial appendage (LAA)
occlusion can benefit from the advantages of 3D printing. LAA occlusion represents an alternative
to anticoagulation for stroke prevention in patients with AF. In the retrospective and prospective
analysis described by Fan and colleagues on 107 patients undergoing LAA occlusion, the creation
of patient-specific 3D models from 3D TEE imaging data was associated with improved procedural
safety and efficacy [29]. In particular, the use of such models offered outcome-relevant information
anticipating the complexity of the surgical procedure, permitting to choose the best size device, thus
improving intraprocedural performance and safety.
Motwani and colleagues reported a case where a 63-year-old man, several years after a
cardiovascular intervention, developed a severe aortic regurgitation (AR) and needed to be re-operated
for the closure of paravalvular leak (PVL) [30]. After evaluation with coronary angiography and
echocardiography, the multi-disciplinary team decided to proceed with the transcatheter percutaneous
closure of the PVL, which is a relatively novel procedure characterized by a small range of closure
devices and limited sizing guidance. The creation of 3D models from CT images allowed to test
different closure devices and to evaluate the best anatomical fit without interference with adjacent
structures. After these bench tests, surgeons acquired high pre-procedural confidence with a particular
closure PLD-W device. At 2 months from the intervention, the device remained well-seated with only
trivial AR, and the patient returned to his active lifestyle without symptoms.
Over the last years, 3D printing has been demonstrated particularly helpful in the pre-surgical
planning of minimally invasive procedures, such as mitral valve (MV) repair surgery [31–33]. Minimally
invasive procedures are considered as very complicated, and reconstructive MV surgery is particularly
challenging due to variation in valve pathologies. In addition, the possibility of surgeons to practice
is limited and most of the pre-surgical training is conducted by assisting and performing real
operations [34]. Various surgical repair techniques exist (e.g., annuloplasty, leaflet plasty, chordae
plasty), which may address different parts of the valve [35]. Vukicevic and coworkers created
patient-specific 3D MV models with different materials starting from TEE and CT imaging datasets.
The authors stated that the material properties of such models facilitated functional evaluation of novel
trans-catheter MV repair strategies, thus providing surgeons a realistic tool for surgical training [31].
More recently, Engelhardt and colleagues produced for the first time 3D printed MV silicone models
containing the full MV apparatus of specific patients, that is the annulus, leaflets, chordae tendineae,
and papillary muscles [33]. Then, twelve surgeons performed various surgical techniques, such as
annuloplasty, neo-chordae implantation, and triangular leaflet resection, judging the realism of the
valves very positively.
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As mentioned above, 3D printed models result particularly helpful for a variety of complex CHD,
including double-outlet right ventricle (DORV), atrial septal defect (ASD), and ventricular septal defect
(VSD). Treatment of these conditions is generally surgical closure, although percutaneous approaches
with closure devices are considered a safe alternative [10]. 3D printing has valuably aided in the
spatial navigation of occluder devices during the operation and in optimizing patch sizing. In last
years, a broad range of complex congenital heart anatomies have been reconstructed and 3D printed
to enhance surgical planning (Figure 3) [36–39]. The Royal Brompton Hospital was the first to use
images from cardiac MRI to replicate signs of scarring in 3D heart models for better understanding
and improving treatments for CHD patients with arrhythmias [28]. In their models, scar tissues are
printed with rigid, colored material for better visualization, allowing cardiologists to decrease invasive
diagnostic cardiac catheterization procedures and to choose the best surgical procedures in relation to
the patient conditions.
Despite the evidence that 3D printing could be very useful in teaching and clinical consultations,
as well as in pre-operative planning and decision-making, additional studies are needed to determine
whether 3D printed models are cost-effective and can reliably improve clinical outcomes before they
become part of routine clinical practice.
Figure 3. (A) 3D model printed to visualize the complex anatomy and aid surgical planning of a
four-month-old patient with superoinferior ventricles, atrial septal defect (ASD), ventricular septal
defect (VSD), left lung collapse, leftward shift of the heart, and compression of the left mainstem
bronchus. (B) A 3D model obtained from cardiac MRI of an eight-month-old patient with situs inversus,
dextrocardia, double-outlet right ventricle (DORV), and L-malposed great arteries was printed to guide
next steps in surgical management. Reprinted with permission from Anwar et al. [39]. Copyright©
2020 Elsevier.
4. 3D Bioprinting for Cardiovascular Applications
The increase of organ requirement for transplantation and the ever-decreasing availability of donor
has driven research to try to create biological substitutes mimicking native tissues to restore or replace
multi-functioning organs. Therapies based on tissue engineering and regenerative medicine represent
a potential solution for the organ donor shortage [40]. The traditional tissue engineering strategy is
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based on the incorporation of stem cells into natural or synthetic scaffolds that, in the presence of
appropriate growth factors, direct cell proliferation and differentiation into 3D functioning tissues [41].
This approach has generated some significant successes in the past decades both in research and clinical
applications, including myocardial tissue, vessel, and heart valve [42–45]. Nevertheless, complex 3D
organs, such as kidney, liver, lungs, and heart, require precise multi-cellular structures with vascular
network integration.
The new frontier of tissue engineering is to exploit 3D printing for functional organ reproduction.
For this purpose, a special 3D printing method, named bioprinting, has been developed. 3D bioprinting
was first introduced by Klebe in 1988, who used the term ‘cytoscribing’ for describing the technique of
the precise placement of cells on a substrate using a computer-controlled inkjet printer or graphics
plotter [46]. Currently, bioprinting refers to the 3D printing of biocompatible materials, cells,
and biomolecules into complex 3D functional living tissues [47]. The bioprinting fabrication process is
highly controllable, allowing precise positioning of various biomaterials and living cells simultaneously
according to the natural compartments of the target tissue or organ. When compared with traditional
tissue engineering techniques, 3D bioprinting offers additional important advantages, such as high
precise cell placement and high digital control of speed, resolution, cell concentration, drop volume,
and diameter of printed cells [48,49].
Based on the working principles and depending on the type of tissue to be fabricated, methods
for 3D bioprinting include laser-assisted bioprinting, inkjet bioprinting, microextrusion bioprinting,
and integrated approaches (Figure 4) [50]. Inkjet-based bioprinting, the most common method for 3D
printing of live cells, is a non-contact technique in which living cells are printed in the form of droplets
through cartridges instead of seeding them on scaffolds [49]. The mechanism used to generate the
picolitre droplets can be thermal, piezoelectric, laser-induced, or based on pneumatic pressure. Thermal
inkjet bioprinting has been shown to be more biocompatible to the living system comparing to the
other inkjet bioprinting technologies, because cells are always maintained and protected in an aqueous
environment during the printing process [40]. The presence of such a water-based environment also
allows the printer to freely deliver from single cell to multiple cells, by simply regulating the bioink
concentration and the printed patterns.
Figure 4. Schematic representation of 3D bioprinting technologies. (A) Laser-assisted bioprinting,
(B) inkjet bioprinting, and (C) microextrusion bioprinting. Reprinted from Visscher et al. [50]. Copyright
© 2020 Elsevier Ltd. All rights reserved.
Ink development is considered as one of the most challenging aspects in the bioprinting process.
An ideal bioink should be highly biocompatible to hold live cells, mechanically stable after printing,
and it should provide high resolution during printing [51]. Other important requirements for selecting
a bioink for 3D bioprinting are permeability to oxygen and other gases, nutrients, and metabolic wastes,
low cost, industrial scalability, and immunological compatibility [52].
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The bioinks most commonly used in the 3D bioprinting are cell-laden hydrogels, decellularized
extracellular matrix (ECM)-based solutions, and cell suspensions [53]. Hydrogels are hydrated networks
of crosslinked polymers, in which cells can be encapsulated in 3D when the hydrogel undergoes
gelation [54]. Over time, the scaffold biomaterial biodegrades and is replaced by cell-secreted
ECM proteins; therefore, the encapsulated live cells grow occupying the space to form predesigned
tissue structures [52]. These cell-laden hydrogel bioinks can be natural polymers, such as agarose,
alginate, chitosan, collagen, gelatin, fibrin, and hyaluronic acid (HA); synthetic, such as pluronic
and polyethylene glycol (PEG); or a combination of both. In any case, all hydrogel formulations
require printing of a polymer solution followed by subsequent physical or chemical crosslinking [53].
Hydrogels are particularly attractive not only for their ability to accommodate live cells, but also for
their adjustable chemical, mechanical and biodegradation properties, and the good resolution that
can be achieved during printing [52]. Furthermore, hydrogels show low cytotoxicity and structural
similarity to the native ECM. For cardiovascular bioprinting, soft bioinks can recapitulate the native
elastic modulus, reliably mimicking the native physical properties of cardiac tissues and vasculature in
the body.
Another bioink option is decellularization of allogenic or xenogenic tissues, which contain a
variety of proteins, proteoglycans, and glycoproteins [48]. The use of decellularized ECM as bioinks
offers the possibility to recreate more complex biologically and biochemically microenvironments,
that mimic tissue specific ECM composition or resident cytokines [55]. Decellularized ECM-based
bioinks are produced from the tissue of interest by removing the cells by sequential physical, chemical
and enzymatic treatments while preserving an intact ECM [56]. The obtained ECM is then crushed
into a powder and dissolved in a buffer solution to formulate the bioink for 3D printing. A polymer
could be used as carrier to increase the solubility, to modify the viscosity, or to induce or increase
post-crosslinking of the bioink [53]. Although decellularized ECM bioinks provide novel opportunities
to fabricate tissue specific constructs, the decellularization process requires multiple steps, making
it a costly approach. In addition, the use of decellularized ECM raises other concerns that must be
addressed, such as immunogenicity and toxicity [57,58].
Other bioink materials recently explored in 3D bioprinting are cell aggregates. In cell aggregate
configurations, the living cells are printed directly in a process resembling the normal embryonic
growth. These approaches are emerging as an alternative to scaffold-based bioprinting [59]. One of
the main advantages of the scaffold-free bioprinting is that problems related to the biomaterials’
compatibility are avoided; on the other hand, cell–cell interactions play a crucial role in tissue
formation. Another attractive property of scaffold-free bioprinting is its efficiency, as the speed can be
comparable or even higher than other forms of bioprinting [60]. Nevertheless, the time of pre-printing
preparations tend to be longer when compared with scaffolds-based approaches. For this reason,
scaffold-free-methods are preferable for smaller, cell-heterogeneous, matrix-poor tissues where the
continuous intercellular communication is important. Cell aggregates can be classified into tissue
spheroids, cell pellets, and tissue strands [61]. Tissue-spheroids are 3D organized clusters of cells
generally 200–400 μm in diameter that, once placed near each other, fuse into a living material thanks to
surface tension forces [62]. These spheroids possess the ability to organize as organoids in native tissue,
and 3D bioprinting can be used for their precise assembling [59]. Substantial body of evidence has
indicated that preformed cell spheroids have been assembled in cartilage, bone, and cardiac muscle-like
constructs [59].
Despite the complexity of the cardiac tissue, 3D bioprinting is emerging as one of the most advanced
techniques for creating cardiovascular implants possessing biomimetic features that recapitulate both
the native physiochemical and biomechanical characteristics of the cardiovascular system. In the
following paragraphs, we present some of the 3D bioprinting strategies used for fabricating functional
cardiovascular tissues, including myocardium, heart tissue patches, and heart valves.
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4.1. 3D Bioprinting of Functional Myocardium
The myocardium is the thick intermediate muscular layer of the heart wall responsible for
contraction and relaxation of the heart [63]. The myocardium contains 2–4 billion cardiomyocytes
(CMs), that account for roughly 75% of the heart volume, although they represent only about 33% of
the total cell number [64]. CMs associate with nonmyocyte cells, that is endothelial cells (ECs), smooth
muscle cells (SMCs), and fibroblasts (FBs), generating an intricately organized 3D structure.
Most causes of heart failure are attributable to CMs deficiencies, and aging itself is associated
with the loss of about 1 g of myocardium per year in the absence of specific heart disease [65]. CMs
have a limited regenerative capacity, and during the progression of heart failure, also the cardiac ECM
is modified and replaced by scar tissue [66]. Therefore, combining procedures aiming at regenerating
both the CMs population and the ECM could improve the effectiveness of cellular therapy. In effect,
over the years several tissue engineering strategies have been employed to create new myocardium that
is electrically and mechanically integrated into the heart. The first successful contractile myocardium
was fabricated in the late 1990s using chick embryonic CMs seeded onto a collagen scaffold [67]. Over
the years, other myocardial tissue engineering procedures have been successfully explored to replace
ECM in patients with ischemic heart disease or heart failure. For example, in the study of Chachques
and colleagues, a biodegradable 3D collagen type I matrix was seeded with bone marrow cells (BMC)
(250 ± 28 × 106 cells), then grafted on the infarcted LV of 10 patients with chronic ischemic heart disease
following autologous implantation of BMC (250 ± 28 × 106 cells) on the scarred area (Figure 5A,B) [68].
Long-term results showed that a combined cell transplantation and matrix scaffolds approach offer
further benefits with respect to cell therapy alone. Apart from being considered feasible and safe,
this tissue-engineered approach improved the efficiency of cellular cardiomyoplasty. In addition,
the cell-seeded collagen matrix allowed to normalize cardiac wall stress in injured regions, thus
limiting ventricular remodeling and improving diastolic function. Subsequent studies combined the
use of biodegradable cell-seeded hybrid scaffolds with synthetic mesh wrap devices for the creation
of bioartificial myocardium and cardiowrap bioprostheses for ventricular support and myocardial
repair (Figure 5C) [69,70]. In advanced heart failure patients, having large dilated ventricles, complete
cardiac wrapping is associated with bioprosthetic helical myocardial bands, that follow the anatomical
heart configuration of native muscular ventricular bands (Figure 5D). The role of such cardiopatches,
complete wrap bioprostheses and helical myocardial bands is to reduce size and fibrosis of infarct
scar, limit ventricular spherical dilatation, and recover elliptical LV shape. This positive chamber
remodeling should contribute to improve diastolic filling and myocardial conditions by angiogenic,
antiapoptotic and regenerative mechanisms. Preclinical studies in 18 sheep demonstrated that a
cardiopatch manufactured using porous elastomeric polycaprolactone (PCL) 3D membrane filled with
peptide hydrogel and stem cells improves myocardial infarct scars [71]. PCL elastomer was chosen for
its good mechanical properties, namely flexibility and adaptation to curved surfaces, such as those
of ventricles. The elastomeric membrane externally covered the heart surface, having advantageous
restraining effects on ventricle dilation. In addition, a capillary network developed between the
inserted scaffold and the heart.
These works provided the input for the development of scaffold-based 3D bioprinting works
(Figure 6A). The bioinks mostly used to 3D bioprint myocardial tissue include alginate, collagen, gelatin,
HA, and decellularized ECM [62]. Not only the choice of a suitable matrix, but also an appropriate
cell source is critical for an effective cardiac regenerative therapy (Figure 6B). In this context, cardiac
progenitor cells (CPCs) seem to be a promising cell population due to their natural differentiation
potential to the cardiac lineages [72]. Nevertheless, during the years, other cell populations different
from CMs have been used for brioprinting cardiac tissue models, including embryonic stem cells
(ESCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs). The advantages
in using these cell types is that most of them is produced pre-clinically and is safe and effective in
clinical practice [48].
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Figure 5. Schematic representation of the surgical procedure combining (A) the intra-infarct implantation
of bone marrow cells (BMC) followed by (B) the fixation of a BMC-seeded collagen matrix onto the
epicardial surface. Reprinted from Chachques et al. [68]. Copyright© 2020 The Society of Thoracic
Surgeons. (C) Cardiowrap bioprostheses with helical loops, that follow (D) the anatomical heart
configuration (native muscular ventricular bands). Modified from Chachques et al. [69]. Copyright©
2020 Informa UK Limited.
Figure 6. Schematic representation of 3D bioprinting of the myocardium, showing (A) the methods
and (B) the cell types. Reprinted from Ong et al. [62]. Copyright© 2020 Chin Siang Ong et al.
Gaetani and coworkers used the method of pressure-based extrusion to bioprint a patch of human
cardiac-derived cardiomyocyte progenitor cells (CMPCs) (30 × 106 cells/mL) on a scaffold made
from alginate, which was characterized by precise pore size and microstructure [66]. The authors
demonstrated the cardiogenic potential of this patch, determined by mRNA upregulation of the
early cardiac transcription factors NK2 homeobox 5 (Nkx2.5), Gata-4, myocyte enhancement factor
2C (Mef-2c), and of the late cardiac marker Troponin T (TnT) by these cells 7 days post-printing.
Furthermore, the printed cells were able to migrate from the alginate matrix to a matrigel layer, forming
tubular like structures. Few years later, the same group bioprinted a myocardial patch consisting
of human CMPCs (30 × 106 cells/mL) suspended in a scaffold made of HA and gelatin, then treated
10–12 weeks aged infarcted mice [73]. After 4 weeks from implantation, the scaffold proved to be an
excellent vehicle to support cell survival, engraftment, and differentiation, finally improving mouse
cardiac function (Figure 7A–C).
In order to bioprint 3D functional cardiac tissue constructs with improved conductive properties,
Zhu and coworkers recently developed an attractive bioink containing an electrically conductive
component [74]. To do this, the authors incorporated gold nanorods (GNRs) into a CMs- and
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cardiac FBs-laden hydrogel (1:1.5 × 106 cells/mL), consisting of gelatin methacrylate (GelMA) and
alginate pre-polymer solutions. GelMA is a degradable hydrogel composed of gelatin, which is
the denatured form of collagens, that has been tunably substituted with methacryloyl groups [53].
In addition, the presence of integrin-binding motifs and matrix metalloproteinase(MMPs)-sensitive
groups make GelMA a biomaterial highly bioactive [75]. The advantage of using alginate, instead,
is represented by its ability to maintain the viscosity of the bioink for a long period of time at a
room temperature [76]. After 5 days of culture, both the CMs and cardiac FBs were successfully
embedded within the GelMA/alginate bioprinted construct loaded with GNRs, and displayed good
cell spreading [74]. One week later, the two cell populations entirely colonized the printed construct,
forming a uniform and interconnected tissue layer. Compared to the constructs without GNRs, the
presence of a conductive nanomaterial in the GelMA/alginate bioink further improved the electrical
propagation between adjacent CMs, as evidenced by higher expression of the gap junction protein
Cx-43 after 14 days and higher synchronized contraction of the bioprinted construct.
An important challenge in the 3D bioprinting technology remains the vascularization of constructs,
that is the ability of building in vessels that are capable of anastomosing with host vessels following
implantation [77]. With the aim to construct a stable vasculature, Gaebel and colleagues used a polyester
urethane urea (PEUU) cardiac patch for bioprinting two types of human cells, ECs (4 × 106 cells) and
MSCs (2 × 106 cells), in a defined arrangement mimicking the vasculature [78]. It has been reported
that co-implantation of vascular ECs and MSCs could enhance the stability of the neovascularization
of ECs [79]. The authors reported better cell viability and increased vessel formation after 8 days of
culture when compared to randomly seeded patches. However, the most interesting finding of this
study was that the 3D bioprinted cardiac patch was able to promote the creation of a vascular network
8 weeks after implantation in infarcted rat hearts, enhancing vessel formation also in the border zone
of myocardial infarction. Furthermore, significant improvements of heart function were observed
following implantation of the bioprinted constructs in the infarcted area.
In some other recent studies, bioinks derived from cardiac decellularized ECM have been developed
for 3D bioprinting and appeared to be promising biomaterials in the repair of myocardial dysfunction
and for the delivery of stem cells. For example, Pati and colleagues successfully decellularized the
LV of porcine heart ECM with a combination of physical, chemical, and enzymatic processes [80,81].
The resulting heart decellularized ECM possessed levels of collagen and glycosaminoglycans similar
to those of the native ECM, thus providing a viable environment for 3D bioprinting. By using a
multi-head tissue/organ building system, the authors printed the obtained ECM with rat myoblast
cells, producing a tissue that had a myocardial-like organization. The 3D bioprinted constructs further
supported differentiation and maturation of encapsulated cells, as demonstrated by the expression
level of the cardiac-specific genes fast myosin heavy chain (Myh6) and alpha-sarcomeric actinin (Actn1)
during 14 days study-period. In agreement with gene expression results, immunofluorescence analysis
confirmed the presence of Myh6 in the cell-printed constructs. Jang and collaborators produced a heart
decellularized ECM from the LV of 6-month-old Korea domestic pigs [55]. They used three different
bioink formulations to develop pre-vascularized stem cell patch. In detail, 2 layers of PCL were made
up to provide mechanical support. Then, bioink I, containing 5 × 106 human CPCs/mL, and bioink
II, containing 5 × 106 human MSCs/mL supplemented with 10 μg/mL vascular endothelial growth
factor (VEGF), were alternatively printed on the PCL supporting layer. After printing, vitamin B2 was
used for the crosslinking process by exposition to ultraviolet radiation. The result of this dual stem
cell 3D printed structure was a tissue with stiffness similar to native myocardium, in which the cells
were able to proliferate and differentiate. In addition, the developed stem cell patch promoted strong
vascularization and tissue matrix formation when implanted for 28 days into 7-weeks-old balb/c nude
mice. Another interesting example of 3D bioprinting involving two different stem cell populations
comes from the recent work of Park and colleagues, who employed a multipronged approach for
simultaneously restoring cardiac function and vessel formation in infarcted rat hearts [82]. To do this,
they intramyocardially injected CMs derived from human iPSCs (iPSCs-CMs) (1 × 106 cells/rat), and
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epicardially implanted human MSCs-loaded patch (MSCs-PA) (1 × 106 cells/mL) generated from pig
heart decellularized ECM. Epicardial patch carrying human MSCs improved vascular regeneration
through prolonged secretion of angiogenic paracrine factors, but more importantly it promoted
the engraftment, viability and maturation of the injected human iPSC-CMs, ultimately leading to
restoration of cardiac function in infarcted-induced hearts.
Another group combined cardiac decellularized ECM hydrogel with GelMA and pediatric human
CPCs (3 × 106 cells/mL) to print a patch to be used for pediatric patients suffering from right-ventricular
(RV) failure or for adult myocardial dysfunction [83]. The presence of GelMA allowed for printability of
the CPCs/cardiac ECM bioink through hydrogel polymerization via cooling to 10 ◦C, followed by white
light radical polymerization and incubation at physiological temperatures. The authors demonstrated
that the human CPCs cells in GelMA-cardiac ECM patches improved cardiogenic differentiation
and angiogenic potential at 3 and 7 days when compared to cells in GelMA-only patches. In vivo,
the printed GelMA-cardiac ECM patches remained attached to rat hearts epicardially, and vessels were
formed after 14 days, indicating their integration with the native myocardium [83]. The importance of
cardiac ECM as a component of bioinks was also underlined by Das and colleagues, who created bioinks
with porcine heart tissue-derived ECM or collagen for encapsulating neonatal rat CMs (2× 107 cells/mL)
using an extrusion-based 3D bioprinter [84]. The patches were then cultured for a month in dynamic
or static conditions with the aim to evaluate the structural arrangement of CMs and their subsequent
gene expression. From a molecular point of view, heart tissue-derived ECM cultured under dynamic
conditions promoted enhanced expression of cardiac specific genes, like cardiac TnT, Myh6, and Actn2,
compared with the static condition during the 14-day study period. This was also true for genes
encoding the proteins responsible for cell–cell adhesion, cell-matrix interaction (integrins), formation
of basement proteins (laminins), and guidance of matrix remodeling events (MMPs). Furthermore,
microscopic images revealed that CMs in decellularized ECM cultured dynamically exhibited a more
aligned, uniform, and rod-like structural arrangement of the cardiac regulatory protein TnT with
sarcomeric integrity compared to the respective static counterpart (Figure 7D–F). The results of this
work would indicate that both matrix and microenvironment can be decisive factors for cell–cell and
cell–matrix interactions, thus influencing engineered heart tissue maturation.
In a very recent work by Noor and colleagues, a biopsy of omental tissue was taken from patients,
then the cells were reprogrammed to become iPSCs and differentiated to CMs and ECs, whereas the
ECM was processed into a personalized hydrogel serving as a bioink for 3D printing [85]. The bioinks
were then 3D printed for generating vascularized patches (2 × 107 iPSCs/mL and 2 × 107 ECs/mL)
and complex cellularized structures. Structure and function of the patch was evaluated in vitro, while
cardiac cell morphology was assessed after transplantation in between two layers of rat omentum,
revealing elongated CMs with massive actinin striation. This work has demonstrated for the first
time the possibility to engineer vascularized cardiac patches that fully match the immunological,
biochemical, and anatomical properties of any individual.
As mentioned before, scaffold-free techniques are being increasingly developed because problems
associated with using biomaterials, such as immunogenicity, fibrous tissue formation, biomaterial
degradation, toxicity of degradation products, are avoided. One of the first work is the one of Atmanli
and Domian, who addressed the need of a scaffold using a microtextured polydimethylsiloxane
(PDMS) stamp to guide the microarchitecture of murine ventricular progenitor cells (CVPs) printed by
microcontact printing [86]. Although this experiment did not test the in vivo therapeutic properties
of the bioprinted myocardium, it nonetheless represents a pivotal early step in scaffold-free 3D
bioprinting of myocardial tissue. Later, Ong and coworkers 3D bioprinted cardiac patches by mixing
cell cardiospheres (33 × 105 cells/cardiosphere) composed of human iPSCs-CMs, FBs, and ECs at
different ratios [87,88]. The assembling of cardiospheres resulted only when iPSCs or iPSC-CMs were
co-cultured with at least 15% ECs or FBs. Patches of all cell ratios showed spontaneous beating,
ventricular like action potential and uniform electrical conduction spontaneously within 3 days of
bioprinting. By increasing FBs percentage, lower conduction velocities and longer action potential
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duration were recorded, suggesting some inhibition of electrical coupling of CMs by these cells.
Nevertheless, after 1 week from implantation onto nude heart rats, all the bioprinted patches engrafted
well on to the myocardium and were vascularized, indicating the regenerative potential of such a
scaffold-free 3D bioprinting approach (Figure 7G–M). The applications of 3D bioprinting in the cardiac
patches’ fabrication discussed in this paragraph are listed in Table 1.
Figure 7. Examples of 3D bioprinting of myocardium using (A–C) cell-laden scaffolds,
(D–F) decellularized heart ECM, and (G–M) cell-free scaffolds. (A) Human CMPCs 3D bioprinted in a
scaffold made of HA and gelatin are alive (green) 2 hours after printing, (B) express the proliferation
marker Ki-67 (red) after 7 days in culture, and (C) are visible in infarcted mice 4 weeks after
transplantation. Reprinted from Gaetani et al. [73]. Copyright © 2020 Elsevier Ltd. (D) Schematic
representation of 3D bioprinted cardiac decellularized ECM cultured under static and dynamic
conditions. (E) confocal microscopy images of immunostaining for cardiac TnT (green) synthesized
by CMs in 0.6%, and (F) 1.2% ECM cultured statically and dynamically for 14 days. Reprinted
from Das et al. [84]. Copyright © 2020 Acta Materialia Inc. Cardiospheres form in 24 hours and
start beating in 48 hours when iPSCs-CMs:FBs:ECs were co-cultured at (G) 70:15:15 or (H) 45:45:10
ratio. (I) Transplantation of 3D bioprinted cardiac patches (iPSCs-CMs:FBs:ECs 70:15:15) onto the
anterior surface of the rat heart. (L) Anterior aspect of the heart explanted 1 week after implantation.
(M) Confocal microscopy images of immunostaining for human nuclear antigen (HNA) (magenta),
wheat germ agglutinin (WGA) (green), and DAPI (blue) showing the presence of human cells (white
arrows) in native rat myocardium. White dotted line demarcates the cardiac patch (left) from the native
rat myocardium (right). Reprinted from Ong et al. [88]. Copyright© 2020 Springer Nature.
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alginate human CMPCs 1 (30 × 106/mL) extrusion-basedbioprinting
cells were able to migrate out of the alginate
matrix and fully colonize a matrigel layer,
forming tubular-like structures in vitro
[66]
HA 2 and gelatin human CMPCs (30 × 106/mL) extrusion-basedbioprinting
the scaffold was able to support cell survival,
engraftment, and differentiation; in addition,
it improved cardiac function after epicardial
transplantation in a mouse model of
myocardial infarction
[73]
GelMA 3 and alginate
incorporating GNRs 4
CMs 5 (1 × 106/mL) and cardiac
FBs 6 (1.5 × 106/mL)
extrusion-based
bioprinting
the presence of a conductive nanomaterial
(GNRs) into the hydrogel improved the
electrical propagation between adjacent CMs,
that finally resulted in a synchronized
contraction of the bioprinted construct in vitro
[74]
PEUU 7 human ECs
8 (4 × 106) and
human MSCs 9 (2 × 106)
laser-based
bioprinting
co-implantation of ECs and MSCs in a defined
printed pattern enhanced the vascularization of
the construct and improved cardiac function
after acute myocardial infarction in rats
[78]
decellularized ECM 10
from the LV 11 of
porcine heart




the construct possessed a microarchitecture
having a native-like organization [80,81]
decellularized ECM
from the LV of
6-month-old Korea
domestic pig
human CPCs 13 (5 × 106/mL)
and human MSCs (5 × 106/mL)
extrusion-based
bioprinting
the use of two different bioink formulations,
one containing CPCs and the other made of
MSCs supplemented with VEGF 14,




from the LV of
porcine heart
CMs derived from human
iPSCs 15 (1 × 106/rat) and
human MSCs (1 × 106/mL)
extrusion-based
bioprinting
the strategy of intramyocardially applying
CMs derived from human iPSCs-CM and
epicardially implanting a cardiac patch
containing human MSCs significantly
improved cardiac function and vessel
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pediatric patients suffering from RV 16 failure,
or for treating adult myocardial dysfunction
[83]
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from the LV of porcine
heart or collagen
neonatal rat CMs (2 × 107/mL) extrusion-basedbioprinting
the culture conditions (dynamic versus static)
are decisive factors for the structural
arrangement of CMs, and affect gene









possibility of generating vascularized patches
that fully match the immunological,




cardiospheres (33 × 105
cells/cardiosphere) composed of
human iPSCs-CMs, FBs and ECs
at different ratios
3D bioprinting
on a needle array
the biomaterial-free 3D printed cardiac patch
produced from human iPSCs showed
spontaneous beating, electrical integration of
the cardiospheres, and in vivo engraftment
and vascularization
[87,88]
1 cardiomyocytes progenitor cells; 2 hyaluronic acid; 3 gelatin methacrylate; 4 gold nanorods; 5 cardiomyocytes; 6
fibroblasts; 7 polyester urethane urea; 8 endothelial cells; 9 mesenchymal stem cells; 10 extracellular matrix; 11 left
ventricle; 13 cardiac progenitor cells; 14 vascular endothelial growth factor; 15 induced pluripotent stem cells; 16 right
ventricle; 17 cardiomyocytes derived from human induced pluripotent stem cells.
4.2. 3D Bioprinting of Heart Valves
In addition to myocardial damage, heart valves disfunction represents another significant cause of
heart failure [89]. Anatomically, heart valves consist of three leaflets and a root wall, mainly containing
valve interstitial cells (VICs), SMCs, and valvular endothelial cells (VECs) [46]. These cells populate
the valves in precise spatial locations having different flexure strength and stiffness [90]. The leaflets
are indeed tri-layer structures, each characterized by unique ECM composition: the collagen-rich
fibrosa layer, the intermediate proteoglycan-rich spongiosa, and the elastin-rich ventricularis [91].
These three layers continuously flaps, resulting in a closure and opening of the valve, and are subjected
to shear stress and periodic loading and unloading. The roots, on the other hand, are annular structures
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providing support to the leaflet and serving as a base to be integrated with the major blood vessels of
the heart [92]. In valve heart diseases, the valves become either too contracted to open-up entirely or
incapable to close effectively. Currently, valve replacement surgeries are the only option for the vast
majority of patients; these strategies usually employ mechanical or biological prosthetic valves [93].
Mechanical valves have high durability; however, the thrombogenicity of such valves is a major concern,
forcing patients to take blood-thinning drugs for the rest of their lives. On the other hand, biological
prosthetic valves suffer from other complications, including immune rejection and degeneration over
time, thus requiring a possible reoperation after 10–20 years [93].
3D heart valve bioprinting has been explored as an alternative technology to traditional mechanical
or biological prosthetic valve replacements, and also possesses further benefits over standard tissue
engineering methods [94]. The advantages offered by 3D bioprinting include the possibility to
generate a mechanically heterogeneous structure with spatial control of valve cells, therefore accurately
replicating the complex biomimetic architecture of heart valves. Hydrogels are promising scaffold
materials for bioprinting heart valves, due to their high physicochemical and mechanical tunability,
and permeability to nutrients and waste for encapsulated cells. In addition, hydrogels can be designed
to mimic biological properties of soft tissue heart valve scaffolds with high spatial precision [95,96].
Nonetheless, despite considerable efforts have been made in this field, it is still challenging to achieve
completely controlled regional and spatial composition to bioprint the complex 3D structure of heart
valves. Below, we report some examples of the most recent attempts of heart valves 3D bioprinting
described in the literature.
Duan and colleagues experienced different types of hydrogel bioinks for creating 3D bioprinted
valves. In one of their study, a 3D bioprinted aortic valve conduit was created by encapsulating human
aortic root SMCs and porcine aortic VICs (1 × 107 cells/mL) in alginate/gelatin hydrogels (0.05 and
0.06 g/mL, respectively), using a dual syringe system to mimic the structure of valve root and leaflet,
respectively [97]. Both cell types showed high cell viability after encapsulation within the hydrogel
discs, being over 80% after 7 days from printing. Furthermore, encapsulated SMCs expressed elevated
alpha-smooth muscle actin (αSMA), a contractile filament protein, whereas VICs expressed elevated
vimentin, a protein typically present in FBs and other mesenchymal cells [98,99]. In a subsequent work,
the same authors used human aortic VICs (HAVICs) (5 × 106 cells/mL) suspended in methacrylated-HA
(Me-HA)/methacrylated-gelatin (Me-Gel) hybrid hydrogel solutions (4% w/v of Me-HA, and 6%, 10%,
12% w/v of Me-Gel) to bioprint a tri-leaflet valve [100]. In detail, the heart valve root was printed
with acellular hydrogel, while the leaflet was printed with the Me-HA/Me-Gel hydrogels suspended
with HAVICs. Cells in all the hydrogel formulations maintained a post-printing viability of over 90%
after 7 days, without significant difference in proliferation rate. By increasing Me-Gel concentration
resulted in lower stiffness and higher viscosity, facilitating cell spreading, and better maintaining
HAVICs fibroblastic phenotype. Histological and biomolecular analysis showed significant expression
of αSMA, vimentin, periostin, and collagen type I, demonstrating that the cells proliferated normally
post-printing and secreted their own ECM (Figure 8). However, both the studies described here
were short-term works (7 days), and the printed constructs did not completely fulfil the mechanical
performance of native valve tissue.
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Figure 8. Example of 3D bioprinting of heart valve conduit with encapsulation of human aortic VICs
(HAVICs) within the leaflets. (A) The valve conduit bioprinted using 4% w/v Me-HA/10% w/v Me-Gel
hydrogels has inner diameter of 20 mm, outer diameter of 26 mm, height of 8 mm for valve root,
and three leaflets with radius of 10 mm. (B) The bioprinted valve conduit shows an intact structure
after photo-crosslinking and 7 days of static culture. (C) Cross-sectional view of Live/Dead image
showing that nearly all encapsulated cells are alive from the surface to more than 300 μm below the
surface. (D) Immunofluorescence images of the encapsulated HAVICs showing positivity for αSMA
(red), vimentin (green), and nuclei (blue) after 7 days of culture. (E) Masson’s Trichrome staining of
bioprinted leaflets showing that more intense blue color is found around the encapsulated HAVICs,
indicating the newly deposition of collagen. Reprinted from Duan et al. [100]. Copyright© 2020 Acta
Materialia Inc.
In the 3D bioprinting process, a high degree of geometric control and shape fidelity of an hydrogel
construct can be achieved by using photo-crosslinking [101]. Light exposure is generally sufficient to
solidify the hydrogel structure, and it can be performed during printing or post-fabrication of the whole
construct [102]. Kang and colleagues tested several parameter combinations of photoinitiator type
and concentration, and light intensity for optimizing cell viability during 3D bioprinting in a mixture
of methacrylated gelatin/poly-ethylene glycol diacrylate/alginate (MEGEL/PEGDA/alginate) [102].
The two compared photoinitiators were Irgacure 2959 and VA086: Irgacure 2959 was chosen because
it is one of the most widely used in contact with cells, whereas VA086 has been reported to be less
cytotoxic than Irgacure [103–105]. As cell source, the authors used HAVICs, human aortic valve sinus
smooth muscle cells (HASSMCs), and human adipose derived mesenchymal stem cells (HADMSCs)
(2.5 × 106 cells/mL). The encapsulated cell population that responded better to increased concentrations
of photoinitiator was the HADMSCs. When using 0.25–1.0% w/v VA086, 0.025–0.1% w/v Irgacure 2959,
and 365 nm light intensity 2–136 mW/cm2 for encapsulating cells in the the MEGEL/PEGDA/alginate
bioink, cell viability was 95% for HASSMCs, 93% for HAVICs, and 93% for HADMSCs. The major
findings of this work were the identification of different parameters that can be combined for optimizing
the viability of different cell populations within 3D bioprinted hydrogels. Some positive examples of
other cell types are coming from applications in neuroscience and neurosurgery, where cells grown
in either two-dimensional (2D) or 3D systems offer exciting opportunities in both basic [106] and in
concrete regenerative tasks [107,108].
3D bioprinting has been successfully used also for generating 3D models of calcific aortic valve
disease (CAVD) recapitulating leaflet layer biomechanics [109]. As mentioned above, the healthy aortic
valve (AV) is composed of three semilunar leaflets, each comprising three stacked layers with its own
ECM composition [91]. With the progression of CAVD, the leaflets of the AV become fibrotic and calcify
as their constituent cell population of VICs undergo myofibrogenic and osteogenic differentiation [91].
308
Cells 2020, 9, 742
In their study, Van der Valk and colleagues bioprinted a model of CAVD encapsulating human VICs
(10 × 106 cells/mL) in GelMA/methacrylated HA (HAMA) hydrogels followed by UV crosslinking with
the photoinitiator lithium phenyl-2,4,6-trimethylbenzoylphosphinate [109]. The 3D printed hydrogels
with encapsulated VICs were then cultured with osteogenic factors for promoting the formation of
microcalcifications. The exposition to osteogenic stimuli for 14 days effectively caused the formation of
microcalcific nodules; nevertheless, negligible levels of apoptosis were measured in the encapsulated
cells, thus suggesting that calcification was not related to cell death by apoptotic processes. In this study,
the authors additionally quantified the compressive mechanical properties of each of the AV leaflet
layers, finding that the ventricularis showed an intermediate Young’s modulus (26.9 kPa) between
the fibrosa and the spongiosa layers (37.1 kPa and 15.4 kPa, respectively). The findings of this work
have established for the first time a novel 3D model for the study of valvular mechanobiology and
could also facilitate high-throughput drug screening for CAVD in a biologically-relevant environment.
3D bioprinting applications for the generation of heart valve models discussed in this paragraph are
summarized in Table 2.






human aortic root smooth
muscle cells (SMCs) 1
(1 × 107/mL) and porcine
aortic valve interstitial cells
(VICs) 2 (1 × 107/mL)
extrusion-based
bioprinting
the use of a dual syringe system,
each containing a defined cell population
(SMCs or VICs), allowed for the creation of a
3D printed aortic valve conduit complete of




5 (5 × 106/mL) extrusion-basedbioprinting
a heart valve conduit was bioprinted with
acellular root and three leaflets encapsulating
HAVICs; by varying the concentration of the
hydrogel formulations it was possible to




HAVICs, human aortic valve
sinus smooth muscle cells
(HASSMCs) 7, and human
adipose derived
mesenchymal stem cells
(HADMSCs) 8 (2.5 × 106/mL)
extrusion-based
bioprinting
variable combinations of photoinitiator
type (Irgagure 2959 versus VA086) and
concentration, and light intensity
(2–136 mW/cm2) can be used to optimize
cell viability during 3D printing for
multiple cell types
[102]
GelMA/HAMA 9 human VICs (10 × 106/mL) extrusion-basedbioprinting
a 3D model of calcific aortic valve disease
(CAVD) 10 was created recapitulating leaflet
layer-specific mechanical properties which is
useful for studying the valvular
mechanobiology and for high-throughput
drug screening
[109]
1 smooth muscle cells; 2 valve interstitial cells; 3 methacrylated-hyaluronic acid; 4 methacrylated-gelatin; 5 human
aortic VICs; 6 methacrylated gelatin/poly-ethylene glycol diacrylate/alginate; 7 human aortic valve sinus smooth
muscle cells; 8 human adipose derived mesenchymal stem cells; 9 gelatin methacrylated/methacrylated HA; 10 calcific
aortic valve disease.
4.3. 3D Bioprinted Heart Tissue Patches for Drug Screening
An increasingly widespread opinion believes that 3D printing can offer great potential also in
pharmaceutics for the discovery and development of new drugs, as well as for advances in drug
delivery strategies [94]. Drug discovery represents the preclinical phase of the entire process, and it
consists in testing thousands of compounds to select few candidates with possible beneficial effects
against the clinical target diseases. The drug development phase involves further validation of the
selected drug in terms of absorption, distribution, metabolism, excretion (ADME), toxicity, dosage, and
treatment modalities, as well as interaction with other molecular compounds [110]. Drug development
is a multistep process that involves phase I-III clinical trials, review and approval by the Food and
Drug Administration (FDA), phase IV clinical trials, followed by launch in the market, and post-market
surveillance by FDA.
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About 94% of the drugs that passed the preclinical trials fail in the clinical phase [111]. It is
believed that this is mainly attributable to inadequate screening in preclinical trials, most of which
are still performed on traditional 2D monolayer culture systems that miss the native 3D extracellular
microenvironment [112]. Furthermore, the efficacy and toxicity of drugs evaluated in animal studies do
not always predict the response in human patients [113]. For example, during both the preclinical and
clinical stages of drug development, cardiotoxicity remains a major cause of failure, thus representing
the primary reason for the retraction of pharmaceuticals from the market [114]. The use of 3D
engineered tissue platforms could overcome these problems, and 3D bioprinting, in particular, could
play a key role in both the drug discovery and development phases. 3D bioprinted tissues could
produce results similar to those obtained in in vivo tests, thus representing valuable platforms for
conducting drug toxicity analysis in vitro.
In the cardiovascular field, most of the efforts toward developing drug discovery and screening
platforms have focused on recreating microtissues of the left ventricular myocardium, the site of most
cardiac pathologies and the primary pumping chamber of the heart [115]. For example, Zhang and
colleagues developed a novel hybrid strategy based on 3D bioprinting to engineer endothelialized
myocardial tissues [116]. In their work, the authors directly encapsulated ECs (1 × 107 cells/mL)
within an alginate/GelMA bioink through a combination of extrusion and photocuring processes
(Figure 9A). In approximatively 2 weeks of culture, the ECs gradually migrated toward the microfiber
peripheries, organizing in a confluent layer of endothelium, and formed a pattern resembling the
blood vessel walls (Figure 9B). This bioprinted microfiber scaffold was then seeded with rat-derived
CMs (1 × 106 cells/mL) (Figure 9C). The CMs adhered and spread on the surface of the microfibers
across the entire thickness of the scaffolds, and strongly expressed the contractile Actn1 protein and
the intercellular conductive connexin-43, as demonstrated by immunostaining analysis. In addition,
the CMs-populated constructs started beating spontaneously and synchronously after 48 hours of
culture. In order to construct the endothelialized-heart-on-a-chip device and evaluate cardiovascular
drug toxicity, a microfluidic perfusion bioreactor was generated. The endothelialized microtissue was
tested with the common anti-cancer drug doxorubicin, which demonstrated dose-dependent effects
towards both CMs and ECs. In particular, the beating rate of the CMs decreased to 70.5% and 1.62%,
and the levels of von Willebrand factor (vWF) secreted by the ECs were reduced to 76.0% and 35.3%
6 days after exposure to 10 μM and 100 μM doxorubicin, respectively (Figure 9D,E). In the same study,
the authors adopted a similar fabrication method and drug toxicity test on endothelialized human
iPSCs-derived CMs microtissue, with results that were comparable to those observed in the rat-derived
microtissue, thus suggesting potential translational for personalized drug screening.
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Figure 9. Example of 3D bioprinted heart tissue patches used for drug screening. (A) Schematic
representation of the extrusion-based 3D bioprinting system used to generate microfibrous
alginate/gelatin methacrylate (GelMA) scaffolds encapsulating endothelial cells (ECs), that (B) in
approximatively 2 weeks form a vascular bed through migration of cells to the peripheries of the
microfibers. (C) Cardiomyocytes (CMs) are then seeded into the interstitial space of the endothelialized
scaffold. The doxorubicin dose-concentration response is evaluated as (D) relative beating rate of
CMs and (E) relative expression levels of von Willebrand factor (vWF) in ECs. Reprinted from
Zhang et al. [116]. Copyright© 2020 Elsevier Ltd.
More recently, Lind and coworkers designed cardiac microphysiological devices via multi-material
3D bioprinting by sequentially using six functional bioinks based on highly conductance, piezoresistive,
and biocompatible soft materials [117]. After printing, the devices were seeded with human iPSCs-CMs
(220 K/cm2), which self-assembled into laminar tissues mimicking the structure of the native heart.
Such a fabricated system allowed the authors to perform dose response studies of cardiac drugs that
influence contraction strength or beat rate directly inside a cell incubator. In particular, the L-type
calcium channel blocker verapamil and the β-adrenergic agonist isoproterenol were investigated.
The engineered microtissue displayed inotropic responses to verapamil and isoproterenol, comparable
to data obtained from engineered 3D neonatal rat ventricular myocardial tissues and isolated postnatal
whole rat hearts, therefore demonstrating the potential of this model as a drug screening platform.
In another study, Wang and colleagues 3D bioprinted a functional cardiac tissue mimicking the
structural, physiological, and functional features of native myocardium [118]. The authors used a
fibrin-based composite hydrogel as bioink to print primary CMs (10 × 106 cells/mL) isolated from
infant rat hearts. Bioprinted cardiac tissue constructs exhibited spontaneous synchronous contraction
in culture, and positivity to Actn1 and connexin 43, indicating the generation of uniformly aligned
and electromechanically coupled cardiac cells. The authors then evaluated physiologic responses of
these bioprinted cardiac tissues to known cardiac drugs, the androgen agonist epinephrine and the
androgen antagonist carbachol after 3 weeks of culture. Calcium imaging analysis was used to quantify
spontaneous beating of bioprinted cardiac tissues, revealing that epinephrine increased the beating
frequency from 80 to 110 beats per minute (BPM), whereas carbachol decreased the beating frequency
to 40 BPM. Interestingly, the authors demonstrated the reversible effects of these drugs when these
were removed from the bioprinted cardiac tissues, thus indicating their effectiveness in testing the
physiological response of cardiac drugs.
As mentioned above, 3D bioprinting could be useful also for the development of drug delivery
strategies [94]. Some current applications of 3D printing in drug delivery systems include implant
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surfaces (i.e., orthopedic implants) modified with drug-eluting solutions [119,120], medical devices
(i.e., stent or catheter) containing and eluting drugs [121], and 3D printed delivery devices providing
personalized drug release profiles [122]. 3D bioprinting applications for drug screening discussed in
this paragraph are summarized in Table 3.
Table 3. Applications of 3D bioprinting for drug screening.
Bioink Cell (Concentration) Drug Tested Significance Ref.
alginate/GelMA 1
human ECs 2
(1 × 107/mL) and





response was evaluated in the
endothelialized-myocardium-on-a-chip
both as beating rate in CMs and as
relative expression levels of
vWF 4 in ECs
[116]
dextran, TPU 5, CB 6:TPU,







the engineered microtissues displayed
inotropic responses to verapamil and
isoproterenol comparable to data
obtained from engineered 3D neonatal
rat ventricular myocardial tissues and













the bioprinted cardiac tissues
physiologically responded to the
tested cardiac drugs by modulating
the CMs beating frequency; reversible
effects of the drugs were observed
once these were removed from the
bioprinted tissues, thus confirming
the effectiveness of these constructs as
in vitro 3D tissue models
[118]
1 gelatin methacrylated; 2 endothelial cells; 3 cardiomyocytes; smooth muscle cells; 4 von Willebrand factor;
5 thermoplastic polyurethane; 6 carbon black nanoparticles; 7 silver particle-filled, polyamide; 8 polydimethylsiloxane;
9 cardiomyocytes derived from human induced pluripotent stem cells; 10 hyaluronic acid.
5. 3D Printing for Testing and Realizing New Heart Devices
Another important application of 3D printing is the development and testing of medical devices.
With regard to the cardiovascular field, one of the first studies was the one of Kalejs and von Segesser,
who created an aortic root model made of common house-hold silicone, then started to use this model
in in-vitro valved stents testing, integrating the aortic root in an artificial circulatory loop [123]. Biglino
and coworkers, instead, imaged a tract of descending aorta of a 29-year-old volunteer 50 mm in length
with MRI, then used the polyjet technique for printing models having different wall thickness (0.6,
0.7, 0.8, 1.0, and 1.5 mm) but constant internal diameter (15.5 mm) [124]. These models of descending
aorta were then subjected to compliance tests through gradual increase and decrease of the internal
volume in order to track pressure variations. Two critical cases of vascular anatomies were then
selected for evaluating the practicability of the method, after the identification of a range of material’s
distensibility. The first case concerned an adult patient affected by severe pulmonary regurgitation
and dilated right ventricular outflow tract (RVOT), whereas the second case was about a pediatric
patient with hypoplastic left heart syndrome (HLHS) and aortic coarctation (2.7 mm narrowing).
Good anatomical finishing was qualitatively obtained for both models, suggesting their usefulness for
device implantation and testing (Figure 10A). Later, Mashari and colleagues acquired TEE images of a
patient subjected to a percutaneous MitraClip® operation, which is a minimally invasive procedure
to reduce the mitral regurgitation, for creating a 3D MV model [125]. Hemodynamic tests were then
carried out on this 3D model by insertion in a pulse duplicator chamber loaded with a fluid mimicking
the blood (Figure 10B). Paulsen and colleagues used a 3D printed left heart simulator to compare
two different conduits for valve-spearing aortic root replacement [126]. The simulator was efficient
to show the comparability of straight tubular and Valsalva grafts in terms of gross hemodynamic
and coronary blood flow, however it revealed that the two conduits differ considerably in terms of
biomechanics. 3D printing also resulted effective in realizing personalized occluders for the treatment
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of CHD using new biodegradable materials. As an example, Sun and coworkers produced a 3D printed
biodegradable occluder made of a copolimer composed by poly-L lactic acid, trimethylene carbonate
and glycolide [127]. Such a 3D printed model was then tested both in vitro and in vivo in a rabbit
model, demonstrating good results in terms of safety, reliability and biocompatibility.
Figure 10. Examples of 3D printed models for device testing. (A) 3D printed right ventricular outflow
tract (RVOT) model used for physical insertion of a stent-graft for assessing patient’s suitability for the
device. Reprinted from Biglino et al. [124]. Copyright© 2020, Springer Nature. (B) Silicone 3D printed
mitral valve (MV) incorporated into (C) a pulse-duplicator chamber filled with a blood mimicking fluid
for hemodynamic testing. Reprinted from Mashari et al. [125]. Copyright© 2020 Elsevier Inc.
6. Regulatory Considerations and Commercialization of 3D Printed and 3D Bioprinted Products
The 3D printing industry is a rapidly expanding field, and it has been estimated that the global
market for 3D printed devices will reach around $34.8 billion with a compound annual growth rate
(CAGR) of 23.2% during the forecast period 2019–2024, while that of 3D bioprinting will be near
$1.647 million with a CAGR of 20.4% by the end of 2024 [128,129]. For this reason, it is necessary
that regulatory agencies around the world will soon try to establish quality standards before devices
manufactured with 3D printing technologies become part of common clinical practice.
Worldwide, the regulatory requirements for a given type of medicinal product depend strictly
on its classification. In the USA, medicinal products are categorized as drugs, biologics, or medical
devices [130]. Each type of product is regulated by a different center within the FDA: The center for
drug evaluation and research (CDER), the center for biologics evaluation and research (CBER), or the
center for devices and radiological health (CDRH), respectively. The FDA regulatory agency in the
USA considers 3D printed devices in the same way to traditional medical devices, and therefore subject
them to the same regulatory requirements and submission information [131]. The CDRH classifies
medical devices into three classes, on the basis of the intended use of the device, the indications for
use, and the risk level to patient or user (Figure 11) [131]. Medical devices of Class I have a minimal
harm potential to the patient or user, require general controls without clinical trials and are exempt
from the regulatory process, meaning there is no need for proof of safety or efficacy. Medical devices
of Class II have a moderate risk to the patient or user, require both general and special controls, and
most of them need also filing a premarket notification, known as 510 (k), for notifying the FDA the
intent of marketing. A 510 (k) is obtained when the device proves to be safe, effective, and substantially
equivalent to a device already legally marketed that is not subjected to premarket approval [131].
Finally, Class III includes those medical devices that support or sustain human life, are generally
implanted, and thus require clinical trials or other evidences before the most rigorous premarket
approval. If a Class III device presents only minor changes from an already approved device, named
predicate device, it may not need the stringent premarket approval; on the contrary, all novel devices
that do not have a predicate device are automatically classified as Class III devices [130,132].
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Figure 11. Classification of medical devices in the USA and in the EU.
In the EU, products are categorized as medicinal products (drugs or biologics) or medical devices,
and they have their own unique regulatory processes [133]. With establishment of the EU, approval
processes for medical devices followed a path of harmonization; nevertheless, medical device regulation
does not fall solely to any one agency. Indeed, national competent authorities (NCAs) are responsible
to designate and audit notified bodies (NBs), which are independent commercial organizations that
contract with device manufacturers to supply these certifications for a fee [134]. NBs assess and
assure conformity with requirements of the relevant European commission (EU) directives. Once NBs
demonstrate the device meets requirements for conformity, the NBs issue a conformité européenne
(CE) mark, and the device can be marketed in any EU member state [135]. Differently from the USA,
medical devices in the EU are classified into four classes: class I, class IIa, class IIb, and class III
(Figure 11) [136]. Class I are low risk medical devices, and only require a self-declaration of conformity
by manufacturers without the involvement of NBs. In contrast, and similarly to what happens in the
USA, medical devices of Classes IIa, IIb, and III require clinical and/or nonclinical evidence to support
their approval.
In December 2017, the FDA released a guidance document entitled “Technical Considerations
for Additive Manufactured Medical Devices”, with the aim to outline technical considerations for
manufacturing 3D printed devices, and containing recommendations for testing and characterizing
such devices [137]. As already discussed in a dedicated section of this review, the technical workflow
for manufacturing 3D medical devices involve several steps (Figure 12). The aspects of 3D printing
addressed in the guidance document focused on device design, materials control, printing and
post-printing validation; examination of printing parameters; assessment of physical and mechanical
characteristics of final devices; and biological and safety considerations of final devices in terms
of cleaning, sterility, and biocompatibility [137]. It has to be remembered that 3D printed medical
devices, like those traditionally manufactured, must meet quality system requirements across all the
production process.
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Figure 12. Technical workflow for manufacturing 3D printed medical devices.
Over the years, more than 80 3D printed medical devices have been approved by the FDA’s
center CDRH through 510(k) process [138]. Most of these devices are used in dental, orthopedic and
cranio-maxillofacial fields (i.e., dental crowns, hearing aids, bone tether plates, skull plates, hip cups,
spinal cages, facial implants, and screws), and are produced using powder bed fusion techniques
(83%), stereolithography (12%), extrusion (3%), and jetting (2%) [138,139]. A postmarket analysis
of the FDA’s approved devices, conducted on the manufacturer and user facility device experience
(MAUDE) database, evidenced that the principal reasons for product-related adverse events were
improper size or incompatibility with other components of the device (46%), device fracture or shaving
(45%), incorrect device size for the patient (5%), implant wear (2%) and incorrect device implanted
(2%) [138]. To be fair, we have to say that many of these adverse events are common to medical devices
manufactured with the traditional techniques.
As for 3D printed products containing biological components, no defined regulations currently
exist, since these products cannot be simply classified as medical device, biologic, or drug, but can rather
be considered both medical devices and biologics [140]. Indeed, combination products are products
comprising two or more regulated components, that is drug-device, device-biologic, drug-biologic or
drug-device-biologic [141]. A combination product is for example one in which living cells (biologics)
are combined with a synthetic scaffold matrix (medical device) that provides physically support for the
growth of new tissue [133]. The legislation applied to these products depends on their classification,
which is determined by several factors, mainly by the way in which the finished product achieves its
intended medical purpose and by its primary mode of action (PMOA) [133]. In the USA, the office of
combination product (OPC) assigns combination products to the most appropriate FDA center [142].
If the PMOA of a cell-based medicinal product is provided by the biological cellular constituent,
then the product is regulated as biologics by CBER in the USA, and as combined advanced-therapy
medicinal products (ATMPs) in the EU [140,142]. On the other hand, if the therapeutic effect derives
from the device component, the combination product is considered a Class III medical device in the EU.
Regarding 3D bioprinted products, their classification mainly depends on whether these devices are
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mass-produced or custom-made. In current practice, custom-made devices, which are manufactured
in accordance with a specific prescription for a specific individual, are exempt from normal quality
system requirements or conformity assessment requirements by most regulatory bodies in both in the
USA and in the EU [143,144].
The technical workflow for 3D bioprinting medical device is similar to that seen for 3D printing,
although additional steps are included in the manufacturing process, such as selection of a design
approach, cell type, and biological material [138]. Consequently, additional technical considerations
need to be taken into account respect to 3D printed medical devices. These include, for example,
printing parameters (printing temperature, resolution, and speed) or material selection. Mechanical
and physicochemical properties, biocompatibility, as well as vascularization and biological function
of the finished product are other parameters to be evaluated. Although 3D bioprinting technologies
are largely still in the research and development stage, urgent regulatory and manufacturing process
considerations are required to meet the growing global interest and needs of such 3D printed products.
7. Current Limitations, Future Perspectives, and Conclusions
3D printing attracted remarkable attention of the scientific community due to its high versatility,
and in recent years the technology has considerably expanded also to the cardiovascular medicine.
3D printing allows the complex cardiac anatomy to be accurately replicated using materials resembling
human heart tissues. For this reason, 3D printed heart models could serve as an excellent tool
in facilitating medical education, pre-operative planning, and communication between doctor and
patients or their family. Nevertheless, cardiac surgeons and cardiologists agree with the fact that these
3D printed heart models should only be used to complement the current diagnostic tools. This is
particularly true when creating a model for cardiovascular pre-surgical planning, where an error
made during segmentation of an image data set could have devastating consequences. In addition,
there is still no statistical data currently available to demonstrate the real clinical value of these 3D
printed models. Another obstacle that limits diffusion and routine application of 3D printing in clinical
practice is related to its high cost. Further investigations are needed to analyze the cost-benefit of 3D
printing for creating anatomical models. Interestingly, a recent work demonstrated that 3D printed
heart models produced with low cost materials (A$50) show efficiency and precision similar to models
created with high cost materials (A$300) [6]. Another limitation to overcome in a near future is the
availability of the 3D printing technology in situ; most research hospitals, indeed, have access to
facilities through academic collaborators. Building a 3D printing laboratory would require planning in
hardware, software and dedicated staff [145].
Currently, the most advanced application of 3D printing is 3D bioprinting, which has the great
potential to engineer highly organized functional tissues and/or organs with complex geometries
and tailored components for widespread applications, including transplantation, drug discovery and
development, and disease modelling. The most ambitious goal of the 3D bioprinting technology,
however, is the realization of customized devices for clinical applications. In the cardiovascular
field, fabrication of 3D bioprinted functional tissues greatly depends on the availability of biomimetic
materials recapitulating native heart ECM and electrical conductivity properties. Although several
specialized 3D bioprinters have been developed to fabricate various types of 3D heart tissues,
such as myocardium and heart valves, bioprinting technology still faces many technical challenges.
Some of the main efforts focus on obtaining high resolution distribution of cells, while minimizing
their loss and maximizing cell–cell interactions. The ideal bioprinter should have resolution in the
submicron range to allow bioprinting of a matrix with an orientation able to direct the alignment of
cardiovascular cells [146]. Achieving the proper cellular composition is another issue in cardiovascular
3D bioprinting [62]. As emerged in different studies discussed in the manuscript, alteration of the
composition of nonmyocyte cells, such as FBs and ECs, strongly influences the function, vascularization
and vitality of the 3D bioprinted cardiac tissue.
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Another crucial aspect to consider in 3D bioprinting relates the development of an ideal cardiac
bioink, possessing appropriate stiffness and cell microenvironment, and controllable degradation rate.
At the time of this writing, hydrogels are among the most used bioprintable materials for cardiovascular
applications, as they provide good support for cells. Nevertheless, hydrogels do not contain specific
ECM proteins for certain cell types, thus not fully reflecting the native environment of the heart.
In addition, although hydrogels encapsulate and confine cells, they limit cell–cell interactions, and do
not allow to obtain the same high cell density as native tissues. Another important shortcoming is the
instability of hydrogels during the bioprinting process: Increasing hydrogel concentration improves
its mechanical properties, but simultaneously limits biological activities [147]. Use of decellularized
heart ECM as bioink material represents an alternative solution in 3D bioprinting, although further
optimization is still needed. Besides the fact that decellularization is a tedious process, the native
ECM loses its mechanical integrity and some of the biochemical properties when homogenized,
and toxic residues can remain after the decellularization process. In addition, cells seeded on the
decellularized ECM produce MMPs that rapid degrade the bioink [147]. Despite the advancements in
scaffold-free techniques, limitations still exist also in the use of tissue spheroids for 3D bioprinting.
Some are technical difficulties related to the printing process: The nozzle used to load tissue spheroids
should be large enough to hold the spheroids inside and allow extrusion without clogging, since
these structures do not have a homogeneous size and can be easily deformed or broken. Furthermore,
necrosis can occur in the core of tissue spheroids, but this can be overcome by proper vascularization.
Considering that each type of bioink has its own advantages and disadvantages over others, a future
winning strategy could involve the combination of bioinks composed of multiple and complementary
biomaterials. This in turn would require the development of hybrid systems integrating different but
compatible bioprinting technologies. At present, the majority of the 3D bioprinting techniques require
post-processing of the printed product through crosslinking. In most cases, this step complicates the
workflow and leads to a potential deterioration in the quality of the final product [148]. For these
reasons, there is an urgent need to improve material design or the printing technology itself for
preventing the post-printing step.
As discussed in the manuscript, another challenge in 3D bioprinting is the achievement of early
vascularization of tissue constructs, which is fundamental for exchange of materials and oxygen supply,
and consequently for improving vascular integration with the host cardiovascular system. Supply of
oxygen to 3D printed tissue constructs could be addressed by generation of oxygen biomaterials that,
together with conductive elastomers, could be the future of 3D bioprinted cardiac tissues. In addition,
the development of 3D printed bioreactors that can integrate electrical and mechanical stimulation
could represent another potential area for generating functional heart tissues [149].Advancements in
3D bioprinting technologies will also be dependent on the capability to accelerate large-scale tissue
constructs production in a rapid manner. At the moment, only extrusion-based bioprinting has the
potential to produce volumetric human-scale tissues but this method lacks speed and resolution.
A final challenge in this field is the conduction of long-term studies for evaluating cell viability after
printing, cell phenotypic changes and their biological functionality, as many works published so far are
short-term studies. Long-term studies could better assess the biological safety and fidelity of constructs
before clinical trials. In this context, immunogenicity of the 3D bioprinted construct is an issue that has
to be addressed as well.
A future area of research is undoubtedly 4D printing, which essentially combines a 3D printing
technique with smart materials that can respond to external stimuli, thereby reshaping or changing their
function over time [150]. To do this, 4D printing employs hydrogels responsive to, i.e., temperature,
pH, light, electric or magnetic field, or shape-memory polymers [151]. The most intriguing aspect
of 4D bioprinting is the possibility to create sophisticated high resolution dynamic and animated
structures, otherwise inaccessible with the current static 3D bioprinting techniques. Nonetheless,
an aspect that should be carefully considered in 4D printing is the presence of a stimulus that may
have a negative effect on living cells. At the moment, 4D printing of cardiac tissue is still in its early
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stages, but we believe that it can give the opportunity to generate dynamic structures better mimicking
the types of tissue structures in vivo. It is hoped that in a near future these important major challenges
and regulatory issues could be addressed to enable the translation of the technology to personalized
therapeutic and pharmaceutical applications.
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Abstract: Regular physical activity with aerobic and muscle-strengthening training protects against
the occurrence and progression of cardiovascular disease and can improve cardiac function in heart
failure patients. In the past decade significant advances have been made in identifying mechanisms of
cardiomyocyte re-programming and renewal including an enhanced exercise-induced proliferational
capacity of cardiomyocytes and its progenitor cells. Various intracellular mechanisms mediating
these positive effects on cardiac function have been found in animal models of exercise and will
be highlighted in this review. 1) activation of extracellular and intracellular signaling pathways
including phosphatidylinositol 3 phosphate kinase (PI3K)/protein kinase B (AKT)/mammalian target
of rapamycin (mTOR), EGFR/JNK/SP-1, nitric oxide (NO)-signaling, and extracellular vesicles;
2) gene expression modulation via microRNAs (miR), in particular via miR-17-3p and miR-222;
and 3) modulation of cardiac cellular metabolism and mitochondrial adaption. Understanding the
cellular mechanisms, which generate an exercise-induced cardioprotective cellular phenotype with
physiological hypertrophy and enhanced proliferational capacity may give rise to novel therapeutic
targets. These may open up innovative strategies to preserve cardiac function after myocardial injury
as well as in aged cardiac tissue.
Keywords: physical exercise; cardiac cellular regeneration; microRNA (miR); Akt signaling;
cardiomyocyte proliferation; cardiac hypertrophy; cardioprotection
1. Introduction
Physical exercise has been shown to be protective against cardiovascular diseases (CVD),
the leading cause of death worldwide [1]. Despite remarkable progress in medical, interventional,
and surgical treatment options of CVD over the last years, prevention will be more and more vital
for healthcare systems in an aging society. An alarming increase in the incidence of CVD-associated
diseases such as insulin resistance, type II diabetes mellitus, and obesity demand altered lifestyle
behaviors including dietary changes [2], cessation of smoking [3], and frequent physical exercise which
all reduce risks for CVD clearly. The American Heart Association (AHA) therefore recommends at
least 150 minutes of moderate-intensity aerobic activity or 75 minutes of vigorous aerobic activity or a
combination of both per week as well as a moderate- to high-intensity muscle-strengthening activity
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on at least 2 days per week [4]. The beneficial effects on the cardiovascular system apply not only to
young and healthy individuals [5] but also to patients with distinct cardiovascular risk factors or overt
CVD and seem to decline after detraining [6,7]. Most importantly, exercise seems to be protective
against myocardial ischemia-reperfusion injury [8].
Different acute and chronic changes in autonomic regulation, cardiac metabolism, signaling
pathways, and protein expression in exercising hearts leading to cardiac growth and cellular
reprogramming have been discovered over recent years. Especially, the beneficial effects of sports
in heart failure and stable angina pectoris on patient outcomes, hospital admission, quality of life,
and exercise capacity have been demonstrated [9–11]. However, the exact mechanisms of how physical
activity delays the development of cardiovascular diseases remain unclear.
Physiologically, the heart can adapt to chronic exercise in order to meet the enhanced oxygen
demand of the body, a process called ‘remodeling’. Exercise above three hours per week results in a
significantly lower resting heart rate as well as significantly higher maximum oxygen uptake (
.
VO2)
and left ventricular mass [12]. Aerobic training thus promotes physiological cardiac hypertrophy and
can contribute to a preserved cardiac function. This has high clinical impact as training can counteract
declined cardiac function to a certain extent in injured as well as in aging hearts.
Physiological hypertrophy is initiated via humoral factors and mechanical stress leading to changes
in intracellular cardiac signaling to affect gene transcription, protein translation and modification,
and metabolism [13]. These intracellular responses at a molecular level are different to those seen in
pathological hypertrophy. In this context, exercise-modulated gene expression and cell signaling might
protect the heart from further injuries and continuous maladaptive remodeling processes. Further
understanding and identification of pathways responsible for physiologic exercise-induced adaption
resulting in a cardioprotective phenotype with physiological hypertrophy and proliferation might help
to identify triggers for physiologic/cardioprotective and pathologic/maladaptive remodeling that could
potentially be used therapeutically to maintain cardiac function after ischemic or infectious injury of
the heart as well as in aging hearts.
In the following review, we highlight these cellular mechanisms of cardiac remodeling in response
to physical exercise with a focus on signaling pathways and microRNAs.
2. Cardiac Cellular Changes in Exercise
2.1. Cellular Regeneration and Physiological and Pathological Hypertrophy
Injuries to the heart such as biochemical stress, toxins, infections, or ischemia require regeneration
in order to maintain proper cardiac function. In contrast to most other cells, however, adult mammalian
cardiomyocytes lose the ability to proliferate resulting in a low cellular turnover rate of 0.3 to 1%
per year in the heart [14,15]. Although pioneering reports lately showed that adult mammalian
cardiomyocyte proliferation could potentially be targeted via highly conserved signaling cascades
such as peroxisome proliferator-activated receptor delta (PPARδ) agonist carbacyclin (induction of
PPARδ/PDK1/protein kinase B (Akt) pathway) [16], extracellular matrix (ECM) protein agrin [17],
or Hippo-Yap pathways [18], this very low cellular turnover is insufficient to achieve sufficient cardiac
regeneration after cardiac injury.
Instead of regeneration with full restoration of organ function, hypertrophy, and fibrotic healing
with incomplete functional recovery occur in the heart in response to injury. Regarding hypertrophy,
one has to distinguish physiologic hypertrophy (proportional growth of length and width with
proportional chamber enlargement) in response to exercise and pathologic concentric (relatively greater
increase in width with disturbed contractile elements) as well as eccentric hypertrophy (relatively
greater increase in length) in response to injury [19,20].
In this context sports have been shown to induce physiologic cardiac hypertrophy. In mouse
models exercise induced inhibition of the transcription factor C/EBP beta and increased expression of
CBP/p300-interacting protein with ED-rich carboxy-terminal domain-4 (CITED4) resulting in cardiac
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hypertrophy and proliferation, and contributed substantially to resistance against adverse cardiac
remodeling and subsequent heart failure [21]. CITED4 has been demonstrated to mediate its effect
on hypertrophy and recovery after ischemic injury due to its regulation of mammalian target of
rapamycin (mTOR) signaling [22]. Cardiac cell proliferation, per se, does not seem to be necessary
for exercise-induced cardiac growth but is highly required as a protective mechanism counteracting
ischemia/reperfusion injury [23]. In addition to an enhanced proliferation and division of differentiated
cardiomyocytes exercise such as swimming activates C-kit and Sca1 positive cardiac progenitor cells.
These adult cardiac progenitor cells provide a certain potential of self-renewal and support myocardial
regeneration [24]. This positive effect of sports on stem cell recruiting has been detected in the heart and
the vascular system: Exercise-induced activation of cardiac and endothelial progenitor cells protects
the heart, the coronary, and vascular system and attenuates the decline in arterial elasticity mediating
positive effects on hypertension [25–27]. Administration of exogenous stem cells has been linked
myocardial repair and regeneration in cardiac diseases and could be a potential therapeutic option in
the future [28].
Nevertheless, even though these recent reports show that cardiomyocytes are at least to some
degree capable of proliferation, adult hearts mainly respond to exercise and stress with an increase
in cell size. Athletes’ hearts are consequently characterized by a benign increase in heart mass as an
effect of regular training. This physiological transformation with increases in cardiac mitochondrial
energy capacity has to be distinguished from pathological cardiac growth due to e.g., hypertension
with diminished contractile function, ATP deficiency, and mitochondrial dysfunction [13,29,30].
Both physiological and pathological hypertrophy are associated with higher heart mass and size.
Pathological hypertrophy, however, is associated with increased interstitial fibrosis, apoptosis, and loss
of cardiomyocytes. It shows fetal gene expression, altered cell signaling, and a different metabolism
with decreased fatty acid metabolism which results in cardiac dysfunction with increased risk of
heart failure and sudden cardiac death compared to physiological cardiac hypertrophy in exercised
hearts [19,20]. Activation of fetal genes is as mentioned above one of the prominent changes found
in pathological cardiac hypertrophy. Alterations in gene expression patterns in hypertrophic hearts
resemble patterns found during fetal cardiac development and involve regulations on transcriptional,
posttranscriptional, and epigenetic level. This reactivation of a fetal gene program in failing hearts has
been nicely reviewed by Dirkx et al. [31].
Physiological “benign” hypertrophy declines after long-term detraining with significant reduction
in cavity size and normalization of wall thickness whereas pathological “malign” hypertrophy
persists [32].
Reports of sudden cardiac deaths (SCD) among young athletes have gained pronounced attention
in the media as well as in research over the past years and have initiated the debate whether there is
a threshold between benign “healthy” hypertrophy and malignant “unhealthy” hypertrophy with
pathological conditions due to regular high-intensity exercise. To date, there is no clear evidence that
healthy athletes without an underlying cardiovascular disease or a genetic cardiomyopathy have an
increased risk of SCD [33], although recent data reveals that the leading finding associated with SCD
among athletes is actually a structurally normal heart (unexplained autopsy-negative sudden cardiac
death) [34].
Nevertheless, there is strong evidence for beneficial effects of regular aerobic and
muscle-strengthening activity despite the association with mild cardiac hypertrophy.
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2.2. Animal Models of Exercise
To experimentally study exercise-induced cellular cardiac alterations and their effects on
cardiovascular health, aging, and response to injury, various animal models of physical exercise
have been developed over the years using zebrafish, rodents, and large animals (rabbits, dogs, pigs,
goats, sheep, and horses). Exercise modalities mainly include swimming or treadmill and wheel
running [35].
The zebrafish as an animal model has gained broad attention in the field of exercise and regeneration
physiology of the heart in the past years [36,37]. Unlike mammals, adult zebrafish hearts are capable of
proliferation in case of cardiac injury and therefore represent a valuable model to study cardioprotection,
regeneration, and aging [38,39]. This plasticity of the zebrafish heart has been demonstrated in injured
hearts [40,41] as well as in intensified swimming-trained hearts [36] and revealed useful insights in
cardiac remodeling processes and their cellular basis.
Rodents, especially rats and mice, are the most frequently used species to investigate effects
of sports on cardiovascular system due to several advantages: Short gestation periods, syngeneic
strains, relatively low housing costs, and easily reproducible experiments [42]. Most importantly,
however, exercise-induced cardiac hypertrophy in mice shows physiological cardiac responses similar
to those seen in humans [43] which makes them a valuable pre-clinical model. Rodent exercise models
therefore have been widely used to study effects on cardiac hypertrophy as well as regeneration
and aging: Broad insights in aging processes including telomere shortening have been gathered in
exercising mice and rats [44]. Physical activity has been highly useful to study exercise-induced
cardiac hypertrophy and to distinguish it from its pathological form [35] as observed e.g., in mouse
models of aortic constriction [45]. These models revealed alterations in intracellular signaling such as
Akt/mTOR/S6K1/4EBP1 pathways [46–48]. In rodents, treadmill running is predominantly used as this
modality allows to adjust different intensities including interval training as well as modulations in
inclination, speed, and duration. These intensity-controlled treadmill workouts provide reproducible
cardiac hypertrophy and increase heart weights by 12–29% and cardiomyocyte dimensions by 17–32%
in mice [49]. Beneficial effects on cardiovascular function mediated by treadmill running with high
intensity interval training (HIIT) or long-term aerobic exercise before myocardial infarction include for
example significantly reduced infarct sizes as well as an increased induction of anti-apoptotic effects in
cardiac cells [50,51].
In contrast, larger animals are rather infrequently used compared to rodent models to study
exercise-induced effects on the heart due to higher costs and efforts in housing and experimental
procedures. Nevertheless, especially pigs closely resemble human coronary and vascular anatomy,
hemodynamic physiology, and electrophysiology [52]. Thus, pigs could be used to investigate
exercise-induced cardiac effects. In this context, for example, improvements in myocardial contractile
function and in collateral capacity after physical activity were detected in an ischemic porcine model [53].
2.3. Major Signaling Pathways in Exercise-Induced Cardiac Remodeling
Over the past years different signaling pathways have been identified mediating cardioprotective
cardiac growth and adaption as well as damage repair and attenuating cellular aging in response
to physical exercise. Figure 1 provides an overview of cellular reprograming in cardiomyocytes in
response to physical exercise.
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Figure 1. Schematic overview of cellular reprogramming in cardiomyocytes in response to physical
exercise. Activation of receptor tyrosine kinases (RTKs) such as ErbB2/4 via growth factors
(e.g., insulin-like growth factor 1 (IGF-1) or Neuregulin-1) enhance phosphatidylinositol 3 phosphate
kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTor)/ glycogen synthase kinase
3 beta (GSK3β) signaling which leads to proliferation, physiological hypertrophy, and cardiac repair
mechanisms in response to injury. Beta3-adrenergic receptor (β3-AR) activation enhances endothelial
nitric oxide synthase (eNOS) and subsequently intracellular nitric oxide (NO) levels which increases
contractility and decreases fibrosis as well as pathological hypertrophy. Changes in miR expression
influence intracellular signaling pathways (including Akt and eNOS), mediate apoptosis and cell cycle
progression and influence cardiac compliance and fibrosis via alterations in collagen production and
matrix metalloproteinase (MMP) expression. Sports induces mitochondrial renewal and decreases
apoptosis via changes in B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein (Bax) ratio. Activation of
adenosine monophosphate-activated protein kinase (AMPK) attenuates pathological hypertrophy and
decrease profibrotic remodeling. Paracrine secretion of extracellular vesicles containing miR mediate
I/R injury as well cellular apoptosis.
2.3.1. Akt-Signaling
The cellular key pathway in the regulation of physiological cardiac hypertrophy in response
to exercise include phosphatidylinositol 3 phosphate kinase (PI3K) and Akt with their respective
downstream signaling. These pathways are activated by extracellular growth factors such as insulin-like
growth factor 1 (IGF-1) that has been linked to cardiac disease especially heart failure as it influences
cardiac hypertrophy and contractile function [54]. This has been further demonstrated in rodents with
heart failure where insulin-like growth factor-1 enhances ventricular hypertrophy and function [55]
and suppresses apoptosis of cardiomyocytes [56]. Acute and chronic physical activity increase the
local IGF-1 levels further confirming an important role in response to physical exercise but the precise
role of IGF-1 is still not completely understood [57].
Mullen et al. identified PI3K and Akt signaling as crucial in the development of physiological
(due to exercise) but not pathological (due to pressure overload) hypertrophy in mice [58]. These
protective effects of enhanced PI3K signaling have been further demonstrated in dilated and
hypertrophic cardiomyopathy with exercise and increase PI3K activity prolonging survival in a model
of dilated cardiomyopathy up to 20% [59]. This implies that PI3K is essential for exercise-induced
cardioprotection. Delivery of a constitutively active PI3K vector as a gene therapy can improve
function of the failing heart in mice [60]. Akt acts as effector kinase downstream of PI3K and further
activates mTOR signaling. Exercise training seems to be associated with activation of the Akt/mTOR
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pathway in contrast to pressure overload which is associated with its inactivation. This particular
pathway may be one of the key regulators to distinguish between physiological and pathological
cardiac hypertrophy. This cardiac growth is further mediated via downstream effectors of mTOR,
including S6Kinase 1 and 4EBP1, as they play a crucial role in regulating protein biosynthesis, cell
cycle progression, and hypertrophy [61,62].
Alterations of PI3K/Akt signaling is not only initiated via extracellular growth factors but also
via changed intracellular microRNAs (miR) levels. miR-124 cluster among others suppress PI3K and
are decreased in response to physical exercise leading to an enhanced activation of PI3K [63]. These
changes mediated by miRNAs will be further elucidated in the next section.
Besides the mTOR pathway, Akt also mediates glycogen synthase kinase 3 beta (GSK3β) signaling.
This key cellular pathway is involved in cellular apoptosis and alterations have been linked to various
diseases including diabetes mellitus and carcinomas and was found to be altered in response to
sports [64–67]. The role of GSK3 family in cardiac disease such as hypertrophy, aging, ischemic injury,
or fibrogenesis has been shown in many rodent studies and has been comprehensively reviewed by
Lal et al. [68]. Among this family: Akt; adenosine monophosphate-activated protein kinase (AMPK);
beta3-adrenergic receptor (β3-AR); B-cell lymphoma 2 (Bcl-2); Bcl-2-associated X protein (Bax);
CCAAT-enhancer-binding protein 1 (C/EBP1); cyclic guanosine monophosphate (cGMP); endothelial
nitric oxide synthase (eNOS); GSK3β; IGF-1; ischemia/reperfusion (I/R); left ventricular (LV); miR; matrix
metalloproteinase (MMP); mTOR; nitric oxide (NO); nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase (NOX); peroxisome proliferator-activated receptor gamma coactivator 1-alpha
(PCG-1α); PI3K; PPARα; protein kinase G (PKG); receptor tyrosine kinase (RTK); and especially GSK3β
seems to mediate positive effects in the context of ischemia/reperfusion injury which were found to be
at least partly mediated via PI3K/Akt signaling [51].
2.3.2. Neuregulin-1/ErbB-Signaling
The neuregulin-1/ErbB2/ErbB4 pathway is another key pathway which was found to be altered
in response to physical exercise and is connected with Akt/PI3K signaling underlining its cellular
significance. Activation of the tyrosine kinases ErbB2 and ErbB4 by neuregulin-1 in response to exercise
activates PI3K/Akt signaling and protects ventricular myocytes against apoptosis as demonstrated in a
myocardial infarction model in rats [69,70]. ErbB2 and its downstream cascades have been shown vital
in promoting mammalian heart regeneration, cardiomyocyte dedifferentiation, and proliferation [71].
In the past years this pathway has thus gained broad interest as potential therapeutic target in failing
and ischemic hearts.
Neuregulin-1 is a small cell adhesion molecule that, among other tyrosine kinase receptors, is able
to act on ErbB. It was shown to be a mediator of reverse cardiac remodeling in chronic heart failure [72].
In addition to its effects on ErbB receptors, neuregulin-1 induces paracrine secretion of cytokines in the
heart including interleukin-1α and interferon-γ as well as pro-reparative factors (such as angiopoietin-2,
brain-derived neurotrophic factor, and crypto-1), which have been demonstrated to contribute to cardiac
repair mechanisms [73]. Rats showed exercise-induced upregulation of neuregulin-1 at the mRNA and
protein level which was linked with physiological hypertrophy and cardiomyocyte proliferation [74].
Neuregulin-1 signaling can induce expression of transcription factor CAAT/enhancer-binding-protein
beta (C/EBPβ) which is known to be involved in exercise-induced cardiac growth and protection in the
context of pathological cardiac remodeling [21]. It has been further demonstrated that exercise activates
neuregulin-1/ErbB signaling and promotes cardiac repair after myocardial infarction in rats [70] which
shows its importance in cardiac regeneration in response to sports.
2.3.3. Nitric Oxide (NO) Signaling
Exercise has been shown to increase circulating catecholamines and consequently the expression
of β3 adrenergic receptors (β3-AR) [8,75]. β3-AR stimulation in turn mediates endothelial nitric oxide
synthase phosphorylation and increases cardiac NO metabolite levels (nitrite and nitrosothiols) which
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contribute to cardioprotective effects of exercise in ischemic hearts. Cessation of training in contrast
extenuated NO levels and cardioprotective effects [8].
Interestingly, Akt signaling again is able to activate eNOS phosphorylating at Ser1176, an activation
which has been shown to be critical for early ischemic preconditioning-induced cardioprotection [76].
NO has further been highlighted to inhibit ischemia/reperfusion injury, inflammation, and left
ventricular remodeling in the absence of reactive oxygen species. Exercise inhibits ROS generation and
promotes bioavailability of NO [77]. NO activates soluble guanylate cyclase, increases cGMP level,
and activates PKG. Dysregulation in NO/PKG signaling is known to be involved in heart failure with
enhanced calcium handling alterations, fibrosis, titin-based stiffness, pathological cellular hypertrophy,
and microvascular dysfunction [78]. PKG in contrast inhibits pressure-induced cardiac remodeling in
mice [79].
2.3.4. Other Pathways and Extracellular Vesicles
Physical exercise increases cardiac contractility to supply the raised demand of oxygenated blood.
In this context training improves aging-induced downregulation of thyroid hormone receptor signaling
mediated transcription of myosin heavy chain (MHC) and sarcoplasmatic reticulum Ca(2+)-ATPase
and contributes to an improvement in cardiac function and contractility in aged rat hearts [80].
Signaling via extracellular vesicles (exosomes, EVs) has gained interest recently since they act
as paracrine signaling mediators. They were found to be secreted by cardiac human progenitor
cells containing microRNAs (e.g., miR-210, miR-132) and consequently inhibit cardiac apoptosis and
improve cardiac function after acute myocardial infarction [81]. After three weeks of swimming
mice showed increased levels of EVs and were more resistant against cardiac ischemia/reperfusion
injury and demonstrated antiapoptotic effects by the activation of extracellular signal–regulated
kinases 1/2 (ERK1/2) and heat shock protein 27 (HSP27) signaling [82]. Induced pluripotent stem
cell (iPSC)-derived EVs seem to be more effective to induce cardiac repair mechanisms (including
maintained left ventricular function and vascularization, amelioration of apoptosis, and hypertrophy)
compared to iPSCs themselves [83].
3. MicroRNAs
MicroRNAs are small noncoding RNA molecules of approximately 22 nucleotides in length
modulating gene expression post-transcriptionally by binding to its target messenger RNAs promoting
their degradation [84]. Several animal and human studies have shown altered miR levels in cardiac diseases
such as hypertrophy, ischemic, and dilated cardiomyopathy, aortic stenosis, or arrhythmias [85–90].
As described above cardiac cell regeneration was thought to be a rare event in adult mammalian
hearts for a long time but recently different miRNA clusters have been linked to increased cardiomyocyte
proliferation and cardiac regeneration whereas others have been related to reduced cardiomyocyte
proliferation. Recently, however, animal studies revealed detailed insights in cardiac regeneration
processes including cardiomyocyte proliferation in failing hearts [91,92] and inducible regeneration
in adult cardiomyocytes [16–18]. Renewal of adult cardiomyocytes after acute injury of the heart is
therefore present yet insufficient [93]. MicroRNAs are directly linked to control this cardiomyocyte
regeneration, renewal, and proliferation. Many of these findings were obtained in exercise animal
studies and may further contribute to develop novel innovative therapeutic strategies for patients with
failing hearts in the future. Table 1 gives an overview of cardiac microRNAs changes in response to
physical activity.
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Table 1. Overview of microRNA levels altered in response to physical exercise and their contribution
to cardioprotection.

















miR-124 PI3K Cardiac hypertrophy Rats, swimming exercise [63]
miR-21 PTEN Cardiac hypertrophy Rats, swimming exercise [63,96]
miR-144 PTEN Cardiac hypertrophy Rats, swimming exercise [63]
miR-145 TSC Cardiac hypertrophy Rats, swimming exercise [63]
miR-126
Spred-1
Raf-1/ERK 1/2 signaling Cardiac angiogenesis Rats, swimming exercise [97]
miR-133
Calcineurin
PI3K/Akt signaling Cardiac hypertrophy Rats, swimming exercise [96,98]
miR-29c
Collagen I und III
TGFβ pathway Left ventricular compliance Rats, swimming exercise [99]
miR-29b MMP9 Fibrosis, matrix degradation Mice, treadmill running [100]
miR-455 MMP9 Fibrosis, matrix degradation Mice, treadmill running [100]
miR-199a PGC1α Cardiac hypertrophy Mice, treadmill running [101]
mi-R1 Bcl-2 Cardiac apoptosis Mice, swimming exercise [102]
miR-30 P53, Drp-1 Cardiac apoptosis Mice, swimming exercise [102]
miR-21 PDCD4 Cardiac apoptosis Mice, swimming exercise [102]
Extracellular signal–regulated kinases 1/2 (ERK1/2).
Several microRNAs have been discovered contributing to an improved cardiac repair after distinct
cardiac injury [103]. Among those, the miR-17-92 cluster seems to play an important role in regulating
cardiac growth, proliferation, hypertrophy, and survival in response to exercise [94]. This microRNA
family is known for regulatory influences on cell cycle, apoptosis and proliferation and has been linked
to enhanced proliferation and survival of colorectal cancer [104] as well as keratinocyte proliferation
and metastasis [105]. Shi et al. confirmed the role of miR-17-3p in cardiomyocyte hypertrophy and
proliferation in a rodent model of exercise: Inhibition of miR-17-3p in mice decreased exercise-induced
cardiac growth, cardiomyocyte hypertrophy and expression of markers of myocyte proliferation.
Furthermore, mice treated with a miR-17-3p agomir received protection against cardiac remodeling
after cardiac ischemia. The authors identified that miR-17-3p suppresses TIMP3, an inhibitor of
EGFR/JNK/SP-1, a pathway promoting cardiomyocyte proliferation [106], as well as PTEN which
antagonizes PI3K/Akt pathway [107], a pathway vital for cardiac hypertrophy [58] as elucidated above.
Samples of ventricular cardiomyocytes obtained in patients with dilated cardiomyopathy revealed
a downregulation of miR-17-3p, which confirms its important role in cardiac remodeling, growth,
and proliferation.
Exercise-induced activation of PI3K/AKT/mTOR signaling and subsequent left ventricular
physiological hypertrophy is not only mediated via disrupted miR-17 levels but also via other
miR-clusters as shown in a rat model [63]: Ma et al. found decreased miRNA-124 levels (targeting
PI3K) and increased miRNAs-21, -144, and -145 (targeting PTEN and TSC-2), all leading to an induced
activation of PI3K/Akt/mTOR signaling in cardiomyocytes. Furthermore swimming exercise and
application of recombinant human growth hormone (r-hGH) in rats altered cardiac PI3K/Akt/mTOR
signaling and miR-21 and miR-133 expression [96]. Reciprocal repression between miR-133 and
calcineurin is involved in regulating cardiac hypertrophy [98]. These findings emphasize the significance
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of PI3K/Akt signaling in cardiac proliferation and physiological hypertrophy and support the beneficial
effects of physical activity.
Importantly, miR-222 was identified as a key regulator of exercise-induced cardiomyocyte growth
and proliferation in mice as induced miR-222 expression in cardiomyocytes led to resistance against
adverse cardiac remodeling and ventricular dysfunction after ischemia [95]. These effects were
mediated via inhibition of p27, Hipk1, and Hmbox1. Inhibition of endogenous miR-199a was shown
to contribute to physiological cardiac hypertrophy probably due to the upregulation of PGC1α in
treadmill-trained mice [101]. In another promising study treatment with either miR-199a or miR-590
elevated cardiomyocyte proliferation in postnatal mice promoting cell-cycle re-entry, recovered cardiac
contractility, and decreased the levels of fibrosis after myocardial infarction [103].
In contrast miR-15 family attenuates heart regeneration through inhibition of postnatal
cardiomyocyte proliferation and acute inhibition of miR-15 in adult mice is associated with improved
contractile function after ischemic injury [108].
Physical activity also leads to altered miR clusters affecting increased cardiac angiogenesis in
animal models. Among those miR-15 is involved in controlling angiogenesis and downregulated
under hypoxic conditions [109]. Increased miRNA-126 expression is associated with exercise-induced
cardiac angiogenesis in response to changes in vascular endothelial growth factor (VEGF) pathway as
well as mitogen-activated protein kinase (MAPK) and PI3K/Akt/eNOS pathways in rats [97]. Decline
in cardiac microvascularization is a finding often obtained in aging and diabetes mellitus. Exercise
training in this context attenuated aging-induced downregulation of VEGF signaling cascades including
phosphorylation of Akt and eNOS proteins contributing to an improvement of angiogenesis in old age
rats [110].
Ventricular stiffness, increase in fibrosis and diastolic dysfunction often accompanies heart failure.
MiR-29c was found to be involved in improving ventricular compliance: Exercising rats showed
increased miRNA-29c expression correlating with a decrease in collagen I and III expression and
improved LV compliance [99]. Exercise-induced release of exosomes from cardiomyocytes containing
miR-29b and miR-455 downregulated matrix metalloproteinase 9 (MMP9) resulting in decreased
fibrosis and matrix degradation [100].
Swimming-trained mice showed decreased cardiac apoptosis via increased Bcl-2/Bax ratio, an effect
mediated via miR-1, miR-30b, and miR-21 [102].
Changes in miRNA expression found in animal studies seem to be at least in part transferable to
humans though their significance is still incompletely understood: Increases in circulating miR-126
have been also shown in healthy adults after endurance exercise [111]. miR-1, miR-133a, and miR-206
levels were significantly elevated after exercise and correlated with performance parameters such as
maximum oxygen uptake and anaerobic lactate threshold [112].
4. Metabolic and Mitochondrial Cardiac Changes
Exercising cardiomyocytes predominantly use glucose and fatty acids to generate energy.
The systemic usage of substrates is measured via respiratory exchange ratio (RER). A RER of 1.0
represents total usage of carbohydrates while a ratio of 0.7 represents fatty acid usage (values in
between represent a mixture). During exercise RER early approaches 1.0 but returns toward 0.7 in
extended workouts indicating a shift towards fatty acid oxidation after longer duration [113].
Different metabolic and mitochondrial alterations related to training have been identified. This
has high clinical implication for potential therapeutic targets as mitochondrial dysfunction is one
of the key findings in heart failure and as exercise is protective for cardiac mitochondria against
ischemia/reperfusion injury in mice [114]. Rather inconsistent data about changes in the proportion
of glucose and fatty acid oxidation in cardiac cells have been gained in the past years from rodent
models. Therefore, exact assignment of substrate utilization in response to chronic exercise remains
uncertain [115]. Clear changes have been found in metabolic gene expression and mitochondrial
pathways: Expression of genes involved in beta-oxidation of fatty acids and glucose metabolism in
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the heart differ between exercise-induced physiological cardiac growth and maladaptive pathological
cardiac growth. Genes involved in β-oxidation are downregulated in maladaptive cardiac hypertrophy
whereas they (including CD36, a fatty acid translocase and scavenger receptor) are found to be
upregulated in exercise-induced cardiac hypertrophy [116]. CD36 deficiency is directly linked to
insulin resistance and defective fatty acid metabolism in rats [117]. In contrast abnormal myocardial
fatty acid uptake via redistribution of CD36 from intracellular stores to the plasma membrane was
found in early stages of insulin resistance contributing to cardiac lipotoxicity [118]. The impact of CD36
on cardiac function is not entirely understood. CD36-deficient hearts were found not to be energetically
or functionally compromised and were not more vulnerable to ischemia as energy generation through
glucose oxidation was able to compensate for the loss of fatty acid-derived energy generation [119].
The transcriptional co-activators PGC-1α and PGC-1β regulate oxidative phosphorylation and fatty
acid oxidation gene expression and control number and size of mitochondria. Heart failure is associated
with repressed PGC-1α and PGC-1β gene expression [120]. In mice with diabetic cardiomyopathy
running prevented cellular apoptosis and fibrosis, improved mitochondrial biogenesis, prevented
diabetic cardiomyopathy-associated inhibition of PGC-1α, and activated Akt signaling [121].
Adenosine monophosphate-activated protein kinase is a serine/threonine kinase which participates
in regulating cellular energy supply [122]. Long-term activation of AMPK blocks cardiac hypertrophy
as well as NFAT, NF-kB, and MAPK signaling and thus preserves cardiac function in pressure-overload
rats [123]. AMPK deficiency, on the other hand, exacerbates LV hypertrophy in mice [124].
Swimming-trained rats showed activated AMPK levels with reduced cardiac fibrosis due to inhibition of
NADPH oxidase [125]. This finding has been confirmed as decreased AMPK activity by beta-adrenergic
activation exacerbated cardiac fibrosis [126]. This is interesting as exercise activates AMPK [127] and
consequently might be able to inhibit pathological hypertrophy and cardiac fibrosis.
The intrinsic mitochondrial apoptotic pathway is one of the most important mechanisms of
myocyte degeneration in the progression of heart failure [128]. Exercise induces a cardiac mitochondrial
phenotype that resists apoptotic stimuli increasing antioxidant enzymes [129]. The Bcl-2 pathway is
one of those proapoptotic mitochondrial-mediated pathways and has been demonstrated to be critical
in regulating apoptosis in aging patients [130]. Rat hearts showed 12 weeks after training attenuated
age-induced elevation in Bax/Bcl-2 ratio and consequently lower apoptotic rates and remodeling [131].
Another key metabolic pathway induced by exercise is the peroxisome proliferator-activated
receptors (PPAR)-pathway. PPAR are transcription factors mediating the development of cardiac
hypertrophy and regulating fatty acid metabolism [132]. Exercise increases PPAR-alpha levels
and decreases consequently inflammatory response including TNF-alpha and NF-kB levels [133].
This is important as PPAR-alpha stimulation downregulates inflammatory molecules and decreases
infarct size [134]. Aging processes decrease PPAR-alpha levels, a finding that could be attenuated
in swim-trained rat hearts which contributed to an improvement in fatty acid metabolic enzyme
activity [135].
5. Conclusions
Alterations in cellular pathways including Akt, ErbB, and NO signaling as well as various miR
clusters have been linked to cardiac disease such as heart failure. Physical exercise is known to
be cardioprotective and can partly compensate cardiac damage as demonstrated in various animal
models and patient studies. On a cellular level sports counteracts cardiac disease related alterations in
these cellular pathways and is able to improve cardiac function. Insights in cellular cardioprotective
pathways obtained from these exercise studies could contribute to the development of novel therapeutic
strategies in failing hearts due to toxic, infectious or ischemic injury, or aging in the future.
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